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Abstract
Chapter 2 discusses the synthesis of the arenearylpyrimidylmethanes (AAPMs) series
was investigated to further develop the structure activity relationships (SAR) of these
compounds as potential anti-chikungunya virus agents. 1-(4,6-Dichloropyrimidin-5-yl)2-methyl-1-(3-nitrophenyl)propan-1-ol was prepared in 50% yield. Subsequent
dehydration and amination gave the intermediate 4-amino-6-chloro-5-(2-methyl-1-(3nitrophenyl)prop-1-en-1-yl)pyrimidine in 90% yield, over two steps. Final amination
using either 1-amino-3-(diethylamino)propan-2-ol or N1,N1-diethylpentane-1,4-diamine
was attempted using several conditions, however, the desired final AAPM derivatives
were not obtained.
Further modification of the synthetic protocol was achieved through the replacement of
the 4,6-dichloropyrimidine with the less hindered 4-chloropyridine. The 4chloropyridin-3-yl alcohols were prepared in 42-52% yield. Subsequent dehydration
afforded the 4-chloropyridine alkenes in 62-85% yield. Final replacement of the
chlorine atom with the amine N1,N1-diethylpentane-1,4-diamine was attempted under
different conditions, however, the desired products were not obtained. Instead the 3(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline was isolated when using phenol
as a solvent for the amination reaction. Replacement of the N1,N1-diethylpentane-1,4diamine with the secondary amine morpholine gave 4-(3-(cyclopropylidene(3nitrophenyl)methyl)pyridin-4-yl)morpholine in 65% yield.

Chapter 3 discusses a development of a virtual screening computer model for the
Chikungunya virus (CHIKV) non-structural protein 3 (nsP3) macro domain, using the
ADP-ribose binding site as a possible druggable pocket for potential inhibitors. The
NCI diversity set III of 1990 compounds were screened against the nsP3 using
Autodock Vina as the virtual screening engine with 17 hits initially identified as
stronger ligands than the original co-crystallized ligand (ADP-ribose). The hits were
further screened in a second round docking using Autodock 4 where 7 hits were ranked
higher

than

ADP-ribose.

The

N1,N4-bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)

terephthalamide hit achieved a binding energy (ΔGbind) of -11.31 Kcal/mol and a
predicted inhibitory constant (Ki) value of 5.1 nM and was selected for further in silico
docking-based optimization. As a result, N1,N2-bis(3-(5-cyano-1H-benzo[d]imidazol-2vii

yl)phenyl)oxalamide was selected as an optimized ligand with ΔGbind of -13.12
Kcal/mol and Ki value of 0.239 nM, a more than 21 fold improvment in the combined in
silico binding profile to the nsP3 active site. This optimized ligand was chemically
accessed in three facile synthetic steps, starting with the synthesis of the 2-(3nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile. Subsequent reduction of the nitro
group afforded the 2-(3-aminophenyl)-1H-benzo[d]imidazole-5-carbonitrile in 80%
yield. Reaction with oxalyl chloride finally afforded the target optimized hit in 69%
yield. Compounds are under anti-chikugunya and cytotoxicity evaluation.

In chapter 4, a series of benzolactone-acid conjugates, benzolactone-tetrazole
conjugates and isatin-acid conjugates were prepared as mycophenolic acid derivatives to
be evaluated as potential inhibitors for the CHIKV. The benzolactones were synthesised
through the Pd catalysed cyclization of benzoic acids. The isatin cores were accessed
from

the

corresponding

aniline

derivatives.

Suzuki

coupling

with

3-(3-

boronophenyl)propanoic acid afforded the acid conjugates. The tetrazole conjugates
were accessed via two pathways: the formation of the acetonitrile intermediates via a
Suzuki reaction with either 3-(3-boronophenyl)propanoic acid or 2-(3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile,

with

subsequent

cycloaddition reaction with NaN3. The second pathway to access the tetrazole
conjugates was through a one step Suzuki reaction with the synthesized potassium 5((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol-1-ide.

The

synthesized benzolactones-acid conjugates, benzolactone-tetrazole conjugates and
isatin-acid conjugates have drug like qualities, as they are water soluble and have
LogD5.5 values in the range of 1-4. Therefore, this series could be further developed as
orally bioavailable compounds. These compounds are under anti-chikugunya
evaluation.

In chapter 5, the crystal structure of the CHIKV nsP2 (the viral protease) was
investigated for druggable binding sites for the development of possible inhibitors. Two
sites were detected, one within the proteolytic C domain, and one within the
NTPase/RTPase N domain. A computer virtual screening model was developed for each
site, where the Life Chemicals cysteine protease inhibitor library of 28,960 compounds
was screened in both sites using the FRED virtual screening engine. The interacting
viii

residues were determined for each hit. A second round of refining docking was
performed on the top FRED hits, using Autodock. The top 5 hits in each site were
recorded and purchased for anti-chikungunya evaluation.

Chapter 6 discusses the development of a virtual screening computer model to identify
novel binding sites for the chikungunya envelope glycoproteins. The model enabled the
identification of possible antagonists for these sites through virtual screening using two
successive docking scoring functions; FRED docking for fast precise screening, with
the top hits then subjected to a ranking scoring using the Autodock algorithm. Both the
immature and the mature forms of the chikungunya envelope proteins were included in
the study to increase the probability of finding positive and reliable hits. Some small
molecules were identified as good in silico chikungunya virus envelope proteins
inhibitors, representing templates for drug design targeting this virus.

In chapter 7, three facile synthetic steps were developed to synthesize analogues for the
lead N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2-fluorobenzenesulfonamide
that was discovered through a high throughput screening of 87,926 compounds (WEHI
2003) library against Trypanosoma brucei. The first step in the synthetic pathway was
the sulfonation of the secondary amine of the commercially available 7nitrotetrahydroquinoline using the appropriate sulfonyl chlorides. Subsequent reduction
using Raney Nickel and hydrazine hydrate afforded the 7-aminotetrahydroquinoline
intermediates which were reacted with the appropriate sulfonyl chlorides to afford the
final bis-sulfonamide analogues. Evaluation of the anti-trypanosoma activity of the
compounds revealed the activity of some analogues with the IC 50 values in the range of
2-4 µM, with good selectivity indices.
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CHAPTER 1: Introduction

1.1. Classification, History and Clinical Features
Chikungunya virus (CHIKV) is an emerging arthrogenic arbovirus that belongs to the
alphavirus genus, family Togaviridae. It has been responsible for major outbreaks of a
devastating human arthritis disease during the past five years.1 Chikungunya fever
caused by the virus was first described in 1952, 2 after an outbreak on the Makonde
Plateau (named after an ethnic group from East Africa), along the border between
Tanganyika and Mozambique. During this period, a high proportion of residents of all
ages were affected by a distinctive disease with a sharp onset of crippling joint pains,
severe fever, and a conspicuous rash.2 The elders of the Makonde tribes could not
remember any previous, similar epidemics with these symptoms, suggesting that this
was a new illness. The word ‘‘Chikungunya’’ translates to ‘‘that which bends up’’
relating to the stooped posture developed as a result of rheumatologic inflammation. 3
After that, only minor outbreaks occurred periodically in Africa, but some major
epidemics were reported in the 1960s and 70s in India and Southeast Asia.4 After the
1973 outbreak in India, only sporadic activities were detected over the next 30 years,
with no major recurrence until a large outbreak in Kenya in 2004.5 This outbreak
initiated a spreading epidemic that reached numerous islands of the Indian Ocean, India,
and parts of Southeast Asia, and was also detected in 18 countries throughout Asia,
Europe, and North America via imported infectious carriers. Over the course of five
years, an estimate of more than 2 million cases occurred, with outbreaks in several
countries where the virus had not been previously documented. 6 The first European
detection of CHIKV occurred in Italy in 2007.7,8
Nearly 40 countries have detected chikungunya virus infected cases so far
(Figure 1.1). The virus was listed in 2008 as a category C priority pathogen by the US
National Institute of Allergy and Infectious Diseases (NIAID) that include pathogens
which could be engineered for mass dissemination in the future, because of the high
morbidity and mortality rates and major health impact. 9,10 Recent epidemics were
reported in India (1.4 to 6.5 million cases in 2006-2007), 3,000 – 42,000 cases were
detected in 2009 in Malaysia and Thailand.11,12 The CHIKV mortality rate has been
1
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estimated to be 1 in 1000 and most of the deaths occur in neonates, adults with
underlying conditions and the elderly.10

Figure 1.1 Chikungunya virus Worldwide distribution, 10 figure used with permission
from NPG (Nature publishing group).

CHIKV can be transmitted through an urban cycle, man to mosquito to man, or
a sylvatic cycle, animal to mosquito to man.13 The virus is transmitted to humans by
mosquitoes of the Aedes genus (Aedes furcifer in Africa and Aedes aegypti in Asia),
similar to the dengue fever causing virus. However, the Ae. albopictus mosquito was
extensively implicated in CHIKV transmission during the 2005-2006 outbreak on
Reunion island.10
The switch of the CHIKV vector from Ae. aegypti to Ae. albopictus was caused
by the insufficient Ae. aegypti number for its transmission.14 A mutation in the E1
envelope protein, A226V, increased the CHIKV fitness in Ae. albopictus and improved
the transmissibility of the virus through Ae. albopictus to vertebrate species.15 Ae.
2
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albopictus has spread to Madagascar, the Indian Ocean nations, Africa, Southern
Europe and the USA.16,17 Virus transmission has been also reported as a result of
maternal-foetal transmission in recent epidemics. 18

Chikungunya fever (CHIKF): The symptoms of CHIKF infection generally start 4–7
days after the mosquito bite. Infection tends to present in two phases, the first stage is
acute, while the second stage is persistent (chronic), causing disabling polyarthritis.19
Acute infection lasts 1–10 days and is characterized by a painful polyarthralgia, high
fever, asthenia (weakness), headache, vomiting, rash, and myalgia (muscle pain). Rash
is the least reliable symptom, presenting in as few as 19% of patients. When a rash is
present, it is typically maculopapular in nature, but recent studies have also noted
vesiculobullous lesions with desquamation. 20 The persistent chronic CHIKF phase is
characterized by polyarthralgia (aches in the joints, joint pains) that can last from weeks
to years beyond the acute stage.21 Eighteen months after disease onset, 40% of patients
are found to still have anti-CHIKV immunoglobulin M (IgM).22
CHIKV attacks fibroblasts, explaining the involvement of muscles, joints, and
skin connective tissues. The high number of nerve endings within the joints and muscle
tissues explains the pain associated with CHIKF. Neurological manifestations have also
been reported during the most recent epidemics. In India, some neurological disorders
such as encephalitis, peripheral neuropathy, myelopathy, myeloneuropathy and
myopathy were reported.23 Moreover some cases with multi-organ failure have also
been reported.24 Eye infection (Chikungunya neuroretinitis) has also been reported
where patients suffered from a sudden, painless diminution of vision in both eyes. 25,26 It
has been also reported that CHIKV can infect the cornea and can be transmitted via the
ocular route.27

1.2. Virology of the CHIKV
The CHIKV genome (Figure 1.2) is a positive sense, single stranded RNA genome of
about 11.8 Kb in size. It consists of two open reading frames (ORFs),28 one in the 5`
end encoding the non-structural protein (nsP) precursors:
 nsP1: involved in viral mRNA capping via its guanine-7-methyltransferase and
guanylyltransferase enzymatic activities,
3
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 nsP2: acts as protease and helicase,
 nsP3: part of the replicase unit and an accessory protein involved in RNA synthesis,
 nsP4: RNA-dependent-RNA polymerase,
The nsP123 precursor and nsP4 function in a complex for viral negative-strand
RNA synthesis. The 3` end ORF encodes the structural proteins, the capsid (C),
envelope glycoproteins E1 and E2 and two small cleavage products (E3, 6K). The
untranslated junction region (J) (Figure 1.2) contains its internal promoter, a conserved
sequence of 21 nucleotides, for transcription of the sub-genomic mRNA in other
alphaviruses (sindbis virus).29

Figure 1.2 Schematic representation for The CHIKV genome showing the RNA
sequence ORFs.

The CHIKV surface consists of 80 trimeric spikes composed of heterodimers of
the envelope glycoproteins (E1 and E2) in the lipid bilayer. Similar to other members of
the alphaviruses, the CHIKV starts its life cycle (Figure 1.3) by entering the target cells
by pH dependent endocytosis in clathrin coated vesicles via receptor mediated
interaction,30 but the exact mechanism by which it does so remains unclear. CHIKV has
been shown to replicate in a large number of cell types including epithelial, endothelial
and fibroblast cells as well as monocyte derived macrophages. 30 A recent study
identified prohibitin (PHB) as a microglial cell expressed CHIKV binding protein. 31
PHB is an evolutionarily conserved and ubiquitous protein that consists of two highly
homologous proteins of different molecular weights. PHB1 has a mass of approximately
4
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30 kDa while PHB2 is approximately 37 kDa. The two proteins oligomerize, and
hetero-oligomerization is essential for protein stability. 32 PHB has been shown to be
present in multiple cell compartments including the mitochondria, cytoplasm and
nucleus in addition to its expression on the cell surface.33 PHB1 was confirmed as a
CHIKV E2 binding protein, but not PHB2.31 PHB1 was found to be involved in the
internalization process either on its own or as part of a complex, further suggesting that
a PHB-virus interaction may be mediated by the specific PHB molecule that interacts
with the virus. Experimental down-regulation of PHB1 significantly reduced the level
of infection in tested cell lines. However, it is believed that this mechanism might be
only one pathway by which CHIKV can enter the susceptible cells, as in case of other
enveloped viruses.31

Figure 1.3 Schematic representation of the Chikungunya virus life cycle.

After entering the cell, the endosome acidic environment triggers conformational
changes, the viral envelope proteins (E1 and E2 complex) reorganizes, leading to
5
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dissociation of the E2-E1 heterodimers, and the formation of E1 homotrimers. E1
trimerizes and inserts into the target membrane with the hydrophobic fusion peptide
(fusion loop) and refolds to form a hairpin-like structure. Exposure of the E1 fusion
peptide mediates virus host cell membrane fusion, releasing the nucleocapsid into the
cytoplasm.34,35 This process depends on low pH and cholesterol, which is also required
for budding during alphavirus infection.36,37
Two non-structural protein precursors are translated from the viral mRNA, and
then are cleaved generating nsP1, 2, 3 and 4. During translation, nsP123 binds to free
nsP4 and with some cell proteins, forming the replication complex,38,39 which
synthesizes a full-length negative-strand RNA intermediate required for replication.
When nsP123 concentration increases, it is cleaved into nsP1, nsP2, nsP3 and nsP4
which forms, along with host cell proteins, the positive strand replicase, which produces
the 26S sub-genomic positive strand RNAs and genomic (49S) RNAs. 39 Promoters
present in the negative strand initiate the transcription of 26S sub-genomic positive
stranded RNA which encodes the structural protein precursors. The later is cleaved by a
serine protease to yield the capsid (C) which remains in the cytoplasm (Figure 1.3),
pE2, 6K and E1.40 The C protein might be responsible for such autoproteolytic activity
as it has few conserved sequences which have similar activity, and are common in other
alphaviruses.41
pE2 and E1 are translated in the endoplasmic reticulum (Figure 1.3) and
processed in the Golgi, and are moved to the plasma membrane, where pE2 is cleaved
by furin-like protease activity in the host cell into E2 and E3. 42 The assembly of virions
begins in the cytoplasm of the cell, where the formation of the nucleocapsid with 120
dimers of the C protein starts to occur.43 The assembled particle buds at the cell
membrane as spherical particles of 65 to 70 nm in diameter, composed of genomic RNA
molecules and the capsid proteins and enveloped in a host-derived lipid membrane.
1.3. The Development of CHIKV Vaccine
There is an urgent need to control the spreading CHIKV, however, there is little
understanding of the interaction between the chronic CHIKV infection and the immune
system in defending the body against any subsequent reinfection.10 The immune
responses are strongly accepted to induce autoimmunity, by cross reactivity between
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viral and host antigens. The B cells and T cells might respond to CHIKV and this may
contribute to the long-term joint disease experienced by many convalescent patients. 44
Thus far, there is no licensed CHIKV vaccine. Some vaccine preparations that
involved either formalin inactivation or Tween-ether extracts of virus45 showed high
immune responses without any adverse effects. In 2000, the US Army carried out a
Phase II clinical trial examining a live attenuated CHIKV vaccine. 46,47,48 The vaccine
was formulated from human MRC-5 cell line. In this study, subjects that received the
vaccine developed neutralizing antibodies, with few subjects showed mild joint pain
compared to those who did not.48
In 2009, one study reported a vero cell adapted formalin inactivated prototype
vaccine with alhydrogel as adjuvant that was prepared using an Indian CHIKV strain
implicated in the 2006 epidemic. The humoral immune response was characterized by
high titer antibodies that have been confirmed through microcytotoxicity assay and in
vivo neutralization tests. Therefore, this could be a promising, safe and effective vaccine
that can elicit long lasting protective immune response. 49
A live CHIKV vaccine was developed in 2011 that elicits a protective immune
response with no detectable disease in mice. It is also unable to infect mosquito vectors,
which is an important safety feature for a live virus vaccine that could be used in non
endemic areas to immunize travellers or laboratory personnel. However, this vaccine
candidate is still under evaluation in nonhuman primates, before evaluation in humans.50
Other promising CHIKV vaccine candidates that depend on virus-like particles are in
early stages of preclinical development. 51,52 A successful virus-like particle vaccine
based on viral structural proteins was tested on nonhuman primates and was found to
produce neutralizing antibodies that protect against viremia after high-dose challenge.
When these antibodies were transferred into an immunodeficient host (a mouse), the
host was protected indicating a passive immunity.53
With the ongoing vaccine development research against the CHIKV, the world
remains under the threat of rapidly spreading CHIKV infections, emphasizing the
importance of developing chemotherapeutics targeting the virus.
1.4. Emerging novel CHIKV targets
As previously mentioned, the CHIKV genome is formed from 2 ORFs, one in the 5` end
coding for nsP1, nsP2, nsP3 and nsP4. The 3` end ORF encodes capsid (C), envelope
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proteins E1, E2, E3 and 6k (Figure 1.2). These proteins, which mediate essential steps
in the lifecycle (Figure 1.3) of the virus,10 could be possible targets for drug design.
1.4.1. Non-Structural Proteins
1.4.1.1. Non-structural protein 1
Like in other alphaviruses, CHIKV nsP1 is a palmitoylated 535 amino acid protein. The
N-terminal region is a methyltransferase and guanylyltransferase involved in capping
and methylation of the newly formed viral genomic and subgenomic RNAs. 54 In early
2013, it was shown that CHIKV nsP1 acts as antagonist for the bone marrow stromal
antigen 2 (BST-2).55 BST-2 is one of the host cell defensive mechanisms, and is
induced by interferon (INFα). BST-2 expression results in retaining viruses at the
surface of the infected cells.56 BST-2 was found to co-localize with CHIKV E1 and
nsP1, but only nsP1 is able to down-regulate BST-2 expression and therefore, inhibiting
the virus tethering on cell surface. 55 This activity of the CHIKV nsP1 is similar to that
of the HIV-1 Vpu protein56 in that both repress BST-2. This discovery will help in
developing BST-2 mediated therapeutics targeting the nsP1.
1.4.1.2. Non-structural protein 2
The non-structural protein 2 (nsP2) of alphaviruses is a multifunctional protein.57,58,59,60
The proteolytic domain has been allocated to its C-terminal section which forms a
papain like cysteine protease (also known as thiol protease). 57,61 The nsP2 proteolytic
activity is critical for virus replication and is responsible for cleavage of the nonstructural polyprotein complex.62,63
The proteolytic activity of the CHIKV nsP2 has been demonstrated, 64 and the
enzymatic activities within the N-terminus have been investigated recently. It was found
to have RNA triphosphatase activity that performs the first of the viral RNA capping
reactions. It was also found to have a nucleotide triphosphatase (NTPase) activity,
fueling the RNA helicase activity performed by the C-terminal domain.65 CHIKV-nsP2
also has 5`-triphosphatase (RTPase) activity that removes the γ-phosphate from the 5`
end of RNA. Both NTPase and RTPase activities are completely dependent on Mg 2+
ions.65
Both N and C domains are composed of α-helices and β-strands (Figure 1.4).
The N terminus is dominated by α-helices, whereas the C-terminal domain contains
8
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helices and strands. The central β-sheets are flanked by α-helices. The crystal structure
of CHIKV nsP2 protease has been solved and comprises 324 residues. Being a cysteine
protease, the catalytic mechanism involves a nucleophilic cysteine thiol in a catalytic
dyad.66 Analysis of the CHIKV nsP2 crystal structure shows 6 cysteine residues, three
in the N-terminus (Cys1013, Cys1057 and Cys1121) and three in the C-terminus
(Cys1233, Cys1274 and Cys1290) as shown in Figure 1.4. Since the proteolytic activity
is isolated in the C-terminus,64 one of the three cysteine residues in the C-domain might
contribute as the catalytic thiol.

Figure 1.4 CHIKV nsP2 crystal structure showing the N- and C-terminal domains,
cysteine residues shown in yellow balls and stick form (PDB code: 3TRK67, no citation
was found for the crystal structure).

The first step in the mechanism of cysteine proteases catalysis is usually the
deprotonation of a thiol group within the enzyme active site by an adjacent amino acid
containing a basic side chain, often a histidine residue.68 Among the three cysteine
residues in the C-terminus (Figure 1.5), the Cys1274 residue is less likely to be involved
in the catalytic mechanism because only one His residue (His1314) is nearby, whereas
the other cysteine residues, four His residues, His1222, His1228, His1229 and His1236
could be associated in the deprotonation mechanism (Figure 1.5).
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Figure 1.5 Schematic representation of the CHIKV nsP2 C-Domain showing the
positions of the cysteine residues (yellow) and histidine residues (green). Distances (Å)
shown in red, generated from the crystal structure PDB file code: 3TRK.

In 2012, Singh Kh et al. reported the development of a homology model of
CHIKV nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan
equine encephalitis virus (VEEV),69 in order to locate the active site of the protease. The
critical residues in nsP2 were identified by docking three different peptides in order to
identify the residues responsible for non-structural protein cleavage, nsP1-2, nsP2-3 and
nsP3-4 peptides. These three peptide sequences represent the substrates for the nsP2
proteolytic processing with a remarkable preference of nsP3-4>nsP1-2>nsP2-3.70
The active site was investigated and was found to lie in the C-terminal domain69
(Figure 1.5). The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222,
Lys1239, Ser1293, Glu1296 and Met1297 were found to interact with the nonstructural
protein sequence complex to be cleaved, and were considered an individual functional
unit. Only two residues are located in the N-domain, Gln1039 and Lys1045, all the
other residues are located in the C-domain. Similar work by Bassetto et al.71 reported
the development of a homology model for the nsP2 protease active site within the Cdomain.
The predicted active site by Singh Kh et al.69 and Bassetto et al.71 matches with
the abovementioned explanation concerning the poisoning the active site within the C10
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domain, especially, they found that His1222 residue to be lying within the predicted
active site pocket. Analysis of the enzyme surface shows that the predicted active site is
located in a major surface groove as shown in Figure 1.6, the major cavity on the
enzyme surface is more likely to accommodate the substrate polyprotein sequence to be
cleaved.

Figure 1.6 Electrostatic potential surface of the CHIKV nsP2 and its active site pocket
within the C-domain, a) The active enzyme surface front view showing the active site as
a transparent red sphere surrounding the active site with the Cys1233 and His1222
residues lying within the sphere. b) Side view of the enzyme (rotated left by 90º about
the vertical axis from the view in a) showing the major accessible cavity to the active
site with a part of the sphere protruding toward the outer surface, generated from the
PDB file 3TRK.

This major enzyme groove (Figure 1.6b) may act as the enzyme mouth holding
the protein to be processed. Therefore, targeting the residues specified above, 69 as well
as the residues within the active site, would be an applicable strategy to inhibit the
enzyme function and consequently inhibiting the virus replication.
Moreover, the alphaviruses nsP2 proteins have been described as virulence
factors responsible for the transcriptional and translational shutoff in infected host cells
and the inhibition of interferon (IFN)-mediated antiviral responses contributing to the
controlling of translational machinery by viral factors.72,73 This controlling comes
through interactions with cellular RNA binding proteins, including heterogeneous
nuclear ribonucleoproteins (hnRNPs), ribosomal protein S6 (RpS6), and cellular
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filament components. Recently, 22 cellular components were hypothesized to interact
with nsP2 or nsP4 contributing to the CHIKV replication, mainly, heterogeneous
nuclear ribonucleoprotein K (hnRNP-K) and ubiquilin 4 (UBQLN4). Also, it was noted
that the interaction of nsP2 with the tetratricopeptide repeat protein 7B (TTC7B) plays a
significant role in the cellular machinery control induced by the CHIKV infection. 74
1.4.1.3. Non-structural protein 3
The function of alphaviruses nsP3 has remained unknown, although mutations can
affect different steps of the viral replication machinery. 75 It is constructed of two
domains, the first is a unique macro domain in the conserved N-terminal region. The Cterminal region is less conserved and is phosphorylated in about 16 positions on serines
and threonines.76,77 The function of phosphorylation is not understood, but it was found
that deletion of these phosphorylated residues decreases the RNA synthesis level. 78
Interestingly, viral pathogenicity of Semliki Forest virus (SFV), another alphavirus, is
decreased in the absence of phosphorylation on nsP3, and the absence of the C terminus
alters SFV neurovirulence.79
The N-terminus of nsP3 contains a macro domain (known also as X domain),
which binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose1``- phosphate,80,81 a side product of cellular pre-tRNA splicing. Therefore, it is
believed to control the metabolism of ADP-ribose 1``- phosphate and/or other ADPribose derivatives which have regulatory functions in the cell. The ADP ribose–binding
site within the nsP3 macro domain is solvent-exposed and points away from the other
domains in the nsP23 polyprotein. Based on sequence conservation in alphaviruses, it
has been shown that residues just after the nsP3 macro domain play a role in positioning
of the nsP23 complex cleavage site. 82 It can be inferred from the crystal structure of the
nsP23 precursor protein of the closely related alphaviruses, SINV, that the nsP2 is
connected to the nsP3 through the macro domain of the nsP3.83 The nsP23 cleavage site
is located in a narrow cleft formed between nsP2 and nsP3 that is inaccessible for
proteolysis, and all the nsP2 noncytopathic mutants lie at the interface between nsP2
and nsP3.83 The inaccessibility of the nsP23 cleavage site indicates that access is tightly
regulated. It is believed that the activator segment is located in the amino-terminus of
the nsP2 which becomes exposed after cleavage from the nsP12 precursor poly
protein.84
12
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In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was
solved80 (Figure 1.7). It is formed of 672 residues and contains six-stranded β sheets
with three α helices. The intermolecular interactions between the residues in the binding
pocket of the enzyme and the ADP-ribose,85 as analysed from the crystal structure, are
shown in Figure 1.8.

Figure 1.7 Crystal structure of the CHIKV macro domain with the bound ADP-ribose
(yellow colour), generated from the PDB file code: 3GPO.

Figure 1.8 2D representation of the interaction of ADP-ribose inside the nsP3 macro
domain binding pocket showing the other residues inside the active site (Generated
from the PDB file: 3GPO)
As shown in Figure 1.8, the key binding residues are: Arg144, Asp10, Ile11
Thr111, Gly112, Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding
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complex is formed from 10 H-bonds and one π-cation interaction.85 The PO42− moiety
showed the strongest interactions with these residues in the enzyme pocket. Also, the
ribose (with Thr111) and the diphosphate (with Val 33, Ser110, Gly112, Val113,
Tyr114) units were found to play major roles in the CHIKV nsP3 ADP-ribose
complex.85
Understanding this binding interaction of the ADP-ribose to the macro domain
of the CHIKV could therefore be a useful element to further assist in drug design and
development of inhibitors for this virus. Bound inhibitors to the ADP-ribose binding
pocket will alter the function of the nsP3 either cleaved or in a polyprotein complex,
and consequently will alter the function of the viral replication machinery.
Recently, more insights on the molecular function of the nsP3 revealed
interesting findings, it was reported that the nsP3 of CHKV, as with other alphaviruses,
use a conserved proline-rich motif to interact with the Src-homology-3 (SH3) domain of
amphiphysin-1 and amphiphysin-2 proteins of the host cell, two related member
proteins of the BAR (Bin-Amphiphysin-Rvsp) protein superfamily implicated in several
cellular functions.86
More recently,87 the nsP3 has been shown to be the inhibitor of stress granule
assembly by recruiting G3BP into cytoplasmic foci. The conserved nsP3 SH3 domainbinding motif (the proline-rich motif) is essential for both nsP3-G3BP interactions and
viral RNA replication. G3BP (Ras GTPase-activating protein-binding protein) is an
enzyme in human cells and a member of the heterogeneous nuclear RNA-binding
proteins.88 This protein plays a major role during infection and in the assembly of stress
granules. Stress granules are membranous cytoplasmic focal structures (foci) that
immediately aggregate in response to cellular stress, this last action leads to impaired
translation of most mRNAs.89 These stress granules may have antiviral activity that is
inhibited by CHIKV replication by the nsP3 SH3 domain-binding motif.87
1.4.1.4. Non-structural protein 4
The

non-structural

protein

4

was

identified

as

the

RNA-dependent-RNA

polymerase,29,90 and recently was found to suppress the host cell unfold protein response
(UPR), also named as endoplasmic reticulum (ER) stress response. 91 The UPR is a
mechanism that maintains the cellular protein homeostasis and prevents over-loading of
unfolded protein in the lumen of the ER during normal and diseased cellular conditions.
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The UPR involves some steps and some contributing proteins, including the PKR-like
ER kinases (PERK).92 During the UPR, PERK activates by self-dimerization and
phosphorylation; this activated PERK in turn, phosphorylates the serine 51 position of
the eukaryotic translation initiation factor 2, alpha subunit (eIF2α), an essential factor
for protein synthesis. Phosphorylated eIF2α inhibits the general protein synthesis, and
consequently, will inhibit the pathogen protein replication. The CHIKV nsP4 was found
experimentally to significantly reduce the phosphorylation (serine 51) of eIF2α, and
thus ensuring the translation of the viral protein. 91 This discovery can be exploited as a
possible target for anti-CHIKV intervention.
1.4.2. Structural Proteins
The invasion of susceptible cells by the CHIKV is performed by two viral
glycoproteins, E1 and E2. Both carry the basic antigenic determinants and form the
icosahedral shell of the virion particle. E2 and E3 are produced from furin cleavage of
p62 (also known as PE2, see Figure 1.2) precursor. E2 is responsible for receptor
binding whereas E1 mediates the membrane fusion. 10 E3 contains the 64-aminoterminal residues of p62.93
E1 and p62 peptide are type I membrane proteins and are derived from a
structural polyprotein precursor. They are translated in the infected cell endoplasmic
reticulum, into a p62–E1 heterodimer and processed by the Golgi (Figure 1.3), E3
protects the E2-E1 heterodimer from premature fusion with cellular membranes. 94 The
heterodimers trimerize forming the viral spikes. Cleavage of p62 into E3 and E2 during
transport to the cell surface prepares the spikes for the fusogenic activation to enter the
cell. At the plasma membrane, the formed virions bud through interactions between E2
and genome-containing viral nucleocapsids in the cytoplasm. 95
In a recent study, the roles of four amino acid residues (G91, V178, A226, and
H230) in the CHIKV E1 protein have been linked to the E1 and cell fusion process. 96
The study revealed that the highly conserved amino acid residues, G91 and H230, are
important for membrane fusion functionality. The glycine residue (G91) is critical for
the fusion process whereas any mutation or substitution in this residue leads to complete
loss of E1 fusion ability. The E1 histidine 230 is located outside of the fusion sequence,
but is still critical for the fusion. Other structural proteins also affect the E1 fusogenic
capacity. E2 protein facilitates both E1 folding and regulates E1 fusogenic properties.
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This process is pH and cholesterol dependent. 96 As an alphavirus family member, the
hydrophobic fusion peptide of the CHIKV was found to be a trimer of hairpins
composed of β-sheets in the post fusion state (type II fusion proteins). 97,98 Figure 1.9
shows the crystal structure of the CHIKV fusion peptide, 99 consisting of 18 amino acid
residues, residues 84−101 in the full-length E1 glycoprotein.95

Figure 1.9 Hydrophobic surface view of the CHIKV fusion peptide showing the residue
G91 in red label located at the back side (generated from the crystal structure of the
fusion peptide, PDB file code: 2RSW99).

The crystal structures of the CHIKV p62-E1 (immature) and the E3-E2-E1
(mature) glycoprotein complexes have been recently solved (Figures 1.10-1.12). E1 is
folded into three domains I, II and III (Figure 1.11) that are rich in β-sheets. E2 is an
immunoglobulin β protein, with three domains (A, B and C). Domain A is at the centre,
domain B is at the membrane upper end whereas domain C is towards the viral
membrane. The later binds to domain II of E1 by hydrogen bonding due to the
hydrophilic contact area between them (Figure 1.10). The long β – ribbon of E2 makes
most of the connection with E3 (Figure 1.12). Furin loop (Figure 1.10) is the E2E3
junction in the immature complex, and this junction contains a functional proprotein
convertase motif which is cleaved by the cellular proteases, furin-like proprotein
convertases, during the maturation (Figure 1.3) of the glycoproteins.42 Variations within
this junction site among the different CHIKV isolates greatly affect the cleavage
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susceptibility by furin proteases. The amino acid His60 (residue 56 in the crystal
structure PDB file: 3N40) is the critical residue that determines the spectrum of furin
and furin-like convertases that process the E2E3 glycoprotein complex.100 It can be
inferred from the comparison between the structures of the immature and the mature
glycoprotein complex,95 that the short peptide sequence (Pro59, His60, Arg63, Glu64,
Ser65, Thr66, Lys67 and Asp68) is cleaved form the immature complex after furin
cleavage.

Figure 1.10 Crystal structure of the immature envelope glycoprotein complex of
Chikungunya virus, E1 formed of domains I, II and III. E2 contains domains A, B and
C, generated from the PDB file code: 3N40.95 E3 stabilizes the E2 β–ribbon connector94
being associated with domain A of E2 and domain II of E1, allowing domain B to
protect the fusion loop.

The U shaped fusion loop of E1 is inserted in a cavity that lies between E2
domains A and B that is stabilized by hydrogen bonds (Figure 1.13) with E2 histidine
side chains.95 At neutral pH, E3 maintains the relative orientation of the E2 domain B
and the domain A, creating the cavity space accommodating the E1 fusion loop. This
orientation by E3 protects the virus from premature fusion with other cellular
membranes.95,101 The fusogenic activity of the E1 fusion peptide is therefore, highly
dependent on pH change. The histidine residues of E2 act as the pH sensor for the
activation of the fusion protein at lower pH95 due to the increased probability of
histidines to become positively charged at lower pH values (acidic endosome), based on
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the fact that the imidazole ring of the histidine residue is the only amino acid side chain
whose apparent dissociation constant from protons (pKa; acid dissociation constant at
logarithmic scale) falls within the physiological range.

Figure 1.11 Crystal structure of E1 glycoprotein formed of 393 residues (residue 402residue 794 within the whole complex structure), separated from the complex for
visualization, generated from the PDB file code: 3N40.95

Figure 1.12 Crystal structure of E2, E3 glycoprotein complex formed of 401 residues
(residue 1-residue 401 within the whole structural protein complex), separated from the
complex for visualization, generated from the PDB file code: 3N40.95

Some important locations (transitional epitopes) were identified in both E1
(domain III) and E2 (domain B) of alphaviruses: these locations become accessible
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upon exposure to heat or low pH.102,103 These locations are also accessible upon the
contact of the virions with the susceptible cells. This contact leads to conformational
changes related to cell binding,104 e.g. domain B moves out in relation to domain A
opening the cavity, and the fusion loop now becomes free to release.95 This occurs
without a full dissociation of the E2–E1 heterodimer. Other residues in domain B of E2
are believed to be associated with cell recognition assuming that several sites on the
virus surface can interact with different cell receptors and therefore, these residues may
be involved in the attachment and entry of the virus.94

Figure 1.13 Crystal structure of the CHIKV mature envelope glycoprotein complex. E1
is viewed as hydrophobic surface with the critical amino acid residue Gly91 99 of the
fusion loop labelled in black. E2 and E3 are viewed as solid ribbon, with histidine
residues on E2 viewed as stick structures in red surrounding the fusion loop and acting
as the pH sensors95, generated from the PDB file code: 3N42.95

1.5. Highlights for the CHIKV emerging targets
With the recent growing knowledge and available structural information about the
CHIKV genome, drug design of particular inhibitors targeting individual viral proteins
has become more real. The most promising targets from a chemical and biological
standpoint would be the viral protease (nsP2) and the viral envelope proteins. The first
protein has a complete crystal structure for the protein N and C domains, while the
critical residues for the proteolytic activity have already been investigated. This nsP2
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protein also functions through the N domain, and therefore, it would be interesting for
medicinal chemists to investigate all possible options to inhibit the function of this viral
protein within the two domains. The challenge here is the lack of a tool to validate the
inhibitory effects of the designed protein antagonists, rather than whole cell assay
protocols. Therefore, extensive efforts should be devoted to investigate the use of the
nsP2 as an applicable target for the structure based drug design. The second promising
protein target is the viral envelope proteins, with several residues identified to be
essential for the viral fusion process such as the Gly91 and His230 residues. Designing
specific inhibitors targeting the viral fusion process would be valuable for the inhibition
of the alphaviruses in general. The viral nsP3 also represents a possible drug design
target, with the structure of the conserved macro domain already known. However, this
target requires further investigation, such as the complete protein structure as well as a
tool to validate the inhibitory activity of the designed antagonists.
1.6. Development of chemotherapeutics against CHIKV: new medicinal chemistry
leads
There is currently no recognised single antiviral treatment for chikungunya. During the
recent outbreaks that occurred in the Indian Ocean nations, only surface treatments were
available, based on non-steroidal anti-inflammatory, non-salicylate analgesics and
fluids. Mild physical exercise is believed to decrease the joint stiffness, but heavy
exercise may increase the rheumatic pain. During the chronic CHIKV infection,
corticosteroids may be used to help decrease the inflammation.105 The status of drug
discovery for the CHIKV is still in the early stages with no drugs currently in clinical
trials. The first mouse model to study the pathophysiology of the resulting disease was
developed in 2008,106 after which several animal models were developed to aid the
understanding of the drug-disease interactions that would facilitate the development of
an effective therapy.107
1.6.1. Protease inhibitors
Targeting the CHIKV nsP2 protease activity within the C-domain, would have an
inhibitory effect on viral replication. Using the developed homology model for the
nsP2, Singh and coworkers screened, in silico, a library of compounds to identify
potential hits for the predicted active site. Four compounds (1-4) shown in Figure 1.14,
were identified as potential in silico inhibitors for the nsP2 protease.69 Ideally, binding
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to this active site will block the protein function and will stop the replication cycle.
However, the actual antiviral activity of these hits (1-4) has not yet been investigated.

Figure 1.14 Chemical structure of the four identified in silico CHIKV nsP2 inhibitors.
In similar work, Bassetto et al.71 reported the identification of in silico CHIKV
nsP2 inhibitors through virtual screening of a large compound library using the
developed homology model for the CHIKV nsP2. One of the hits, compound 5 (Figure
1.15) was predicted to bind to the central portion of the nsP2 protease active site, with
its hydrazone group placed in the region defined by the catalytic dyad. The in vitro
activity of this hit compound was assessed and it was found to inhibit the virus at EC 50
value of 5 µM and selectivity index (SI) value of 14, through the inhibition of the virusinduced cytopathic effect.71 The central cyclopropyl and the hydrazone moieties were
found, through a structure activity relationship study, to be important for the antichikungunya activity. A series of derivatives were also designed based on these
identified pharmacophores of (5). When the cyclopropyl group was replaced with a
trans-ethenylic moiety maintaining length and geometry of the original linker (6, Figure
1.15), the antiviral activity was slightly improved. Compound (6) displayed EC50 value
of 3.2 µM and selectivity index (SI) of 32. The binding modes of both compounds (5, 6)
inside the nsP2 pocket were similar.71
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Figure 1.15 Chemical structure of the CHIKV inhibitors identified from the in silico
screening, red circles indicates the only difference in the structures responsible for the
activity change.

1.6.2. Furin inhibitors
Infection by alphaviruses can be inhibited in vitro by blocking the intracellular furinmediated cleavage of viral envelope glycoproteins: the E2E3 or p62 precursors. This
blocking was demonstrated by showing the inhibitory effect of an irreversible furininhibiting peptide, decanoyl-RVKR-chloromethyl ketone (dec-RVKR-cmk, 7, Figure
1.16) on in vitro CHIKV infection.100 This peptide significantly reduces the processing
of E3E2 CHIKV glycoproteins in infected myoblast cultures and led to the formation of
immature viral particles and impaired viral spreading among cells, but not the
replication in the already infected cells. 100 Therefore, the chemical structure of the furininhibiting peptide (7) could be a starting point for generating novel generations of active
peptidomimetics using the ligand based drug design techniques, targeting the
intracellular furin cleavage step.

Figure 1.16 Chemical structure of the furin-inhibiting peptide (7).
22

Chapter 1

Introduction

1.6.3. Chloroquine and Quinine
The in vitro antiviral activity of chloroquine (8, Figure 1.17) was first reported more
than 35 years ago and has been successfully used as anti-malarial drug.108,109
Concerning the alphaviruses, chloroquine was found to be effective in vitro,110,111,112 but
a few years later, a mouse model revealed that chloroquine may enhance viral
replication in vivo leading to aggravation of the disease. 113 Regarding the CHIKF,
chloroquine and chloroquine phosphate have been used in the treatment of chronic
chikungunya arthritis,114 only for the anti-inflammatory properties of the molecule (used
in chronic rheumatologic diseases) rather than for the antiviral effect. Some studies
suggest that chloroquine might interact with the endosome-mediated internalisation
process during the infection cycle, stating that chloroquine might be classified as an
entry inhibitor. Chloroquine 8 entered phase 3 clinical trials in France as a therapy for
the CHIKV in 2006, however, these studies were terminated in 2007 without promising
results.

Figure 1.17 Chemical structures of chloroquine (8) and quinine (9).

In one clinical study, the effect of chloroquine 8 on CHIKF patients was
investigated using another placebo treated group of patients, and at the conclusion of the
study period, there was no statistical difference between the chloroquine and the
placebo treated groups regarding the mean duration of febrile arthralgia or the decrease
of viraemia (viral count in plasma). However, these contradicting results casts serious
doubt as to the effectiveness of chloroquine as an effective chemotherapeutic against
CHIKV and until resolved, it should be treated with caution as a drug lead.105
Another anti-malarial drug, quinine (9, Figure 1.17), also inhibits the virus in
vitro in a concentration less than that of chloroquine (IC50 = 0.1 µg/ml for quinine, 1.1
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µg/ml for chloroquine). Also, quinine is suggested to affect the nsP1 as mutations in this
protein occur upon growing the virus in a high concentrations of quinine. 105
1.6.4. Ribavirin and 6-Azauridine
The antiviral ribavirin (10, Figure 1.18), is well known to inhibit many RNA viruses in
vitro, by different mechanisms.115 It is being used either alone for treatment of
Respiratory Syncytial virus, or in combination with alpha-interferon in the treatment of
hepatitis C virus (HCV) infection. This combination showed a synergistic in vitro
inhibition of the CHIKV.116 A combination of alpha-interferon, at a concentration of 3.9
IU/ml, and ribavirin at a concentration of 18.75 µg/ml, inhibited CHIKV replication by
50%, whereas ribavirin 10 alone without interferon, inhibited CHIKV with EC50 value
of 83.3 µg/ml. However, there is no evidence supporting the clinical efficacy of
ribavirin 10 on CHIKV, and the combination with interferon should be subjected to
clinical trials for the treatment of CHIKV infections. 105 Furthermore, the exact
mechanism of ribavirin is still unclear as it may change from one virus to another,
however, it is believed that ribavirin can interact with the intracellular viral RNA
production.

Figure 1.18 Chemical structures of ribavirin (10) and 6-azauridine (11).

The broad-spectrum anti-metabolite, 6-azauridine (11, Figure 1.18) inhibits both
DNA and RNA virus replication, and the activity might be through the inhibition of
orotidine monophosphate decarboxylase, an enzyme involved in the de novo
biosynthesis of pyrimidine, cytidine and thymidine. 117 It showed a significant inhibition
of CHIKV at a low concentration (0.2 µg/ml) and was more effective against the
CHIKV compared to ribavirin 10.116 6-Azauridine 11 is not approved for human use
and therefore was not included in a combination study with alpha-interferon. However,
24

Chapter 1

Introduction

6-azauridine triacetate is used for treatment of different diseases without notable
adverse effects.118 Therefore, 6-azauridine should be evaluated in vivo as CHIKV
inhibitor.116
1.6.5. Arbidol
The antiviral drug arbidol (12, Figure 1.19) was originally developed 20 years ago at the
Russian Research Chemical and Pharmaceutical Institute. 119 Since 1990, it has been
used in Russia for acute respiratory infections including influenza. So far, arbidol shows
a wide range of activity against many RNA, DNA, enveloped and non-enveloped
viruses.120 This broad spectrum of activity may be attributed to the different modes of
action including the inhibition of virus mediated fusion, 121 and blocking of the viral
entry into the target cells through inhibition of glycoprotein conformational changes that
are essential for the fusion process, as in the case of influenza virus and hepatitis C
virus.122,123
In 2011, arbidol 12 and two derived metabolites (Figure 1.19), HZ1 13 and HZ3
14, were tested in vitro on the chikungunya virus using two cell lines, and in different
conditions, pre- and post-infection treatments. Arbidol was the only active compound
with an IC50 value that was much lower than the toxic concentration (IC50 = 12.2 µM,
CC50 > 200 µg/ml).124 HZ1 13 and HZ3 14 were assumed to be responsible for the antiviral properties of arbidol, however in this study, HZ1 and HZ3 showed only weak
effects on CHIKV replication.

Figure 1.19 Chemical structures of arbidol (12), HZ1 (13) and HZ3 (14).

Arbidol 12 was found not to be viricidal, rather, it blocks the earliest stages of
the viral replication, virus attachment and/or virus entry as previously reported.120 For
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CHIKV, it works by targeting the cellular membrane (E2 viral envelope protein) which
was confirmed by the use of arbidol resistant CHIKV strain (mutation in the E2 protein,
G407R).124 However, all these studies were performed in vitro and in vivo studies are
required to validate the activity of arbidol on CHIKV.
1.6.6. Mycophenolic acid (MPA)
Mycophenolic acid (15, Figure 1.20) was isolated about one hundred years ago.125 It is
an inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in
the de novo biosynthesis of guanine nucleotide. It has a very good anti-proliferation
activity and has been established as an anticancer, 126 antiviral agent and as an
immunosuppressant.127

Figure 1.20 Chemical structures of mycophenolic acid (15) and trigocherrin A (16).

Recently, MPA was shown to inhibit the CHIKV replication and virus induced
cell death. The IC50 value was 0.2 µM with a selectivity index of 150.128 Mycophenolic
acid was found to induce CHIKV apoptosis. When the treated CHIKV infected cells
were provided with exogenous guanosine (GMP), MPA could no more prevent the
CHIKV induced cell death, indicating that it works by inhibiting IMPDH enzyme. It has
also been suggested that MPA increases the mutation rate during the viral replication.128
Considered as a good lead compound, the in vivo activity of mycophenolic acid on
CHIKV should be investigated as it is well known that mycophenolic acid suffers from
a metabolic drawback associated with rapid conjugation of the C-7 phenolic hydroxyl
group with glucuronic acid.129,130
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1.6.7. Trigocherrin A
Trigocherrin A (16, Figure 1.20), is a highly oxygenated and chlorinated daphnane
diterpenoid orthoester, that had been isolated from the bark of Trigonostemon cherrieri
Veillon (Euphorbiaceae), a tree collected in the sclerophyllous forest of New-Caledonia.
This genus comprises about 80 species occurring in tropical Asia, from India and Sri
Lanka to New Guinea.131 These diterpenoids have been shown to have cytotoxic132,133
and antiviral134,135 properties. Recently, this natural product was tested against CHIKV
and was found to inhibit virus-induced cell death in a virus-cell-based assay with an
EC50 of 1.5 μM and only caused a significant antimetabolic effects at a concentration
(CC50) of 35 μM, and the selectivity index (SI) value was 24. Different concentrations
of 16 were able to protect the host cells from the virus cytopathic effect without any
adverse effects. Also, it was found to be more potent than the reference compound used
in this study (chloroquine, 8).136,137 The assay protocol suggests that this compound
might inhibit the viral replicase functions, however, for the drug discovery process, the
in vivo activity, the precise mode of action as well as the total synthesis of this lead
compound should be investigated.
1.6.8. Trigowiin A, Prostratin and 12‑O‑Tetradecanoylphorbol 13-Acetate
In a recent study (2012), an extract of the bark of Trigonostemon howii (Euphorbiaceae
species) from central Vietnam was tested against the CHIKV. 138 A new tigliane
diterpenoid, trigowiin A (17, Figure 1.21) was isolated and was found to be structurally
closely related to the tigliane diterpenes (Figure 1.21), prostratin (a promising adjuvant
for anti-HIV therapy)139 18 and 12-O-tetradecanoylphorbol 13-acetate (TPA, 19).138

Figure 1.21 Chemical structures of trigowiin A (17), prostratin (18) and TPA (19).
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In the CHIKV assay, trigowiin A 17 showed weak antiviral activity, with an
EC50 of 43.5 ± 12.8 μM whereas TPA 19 and prostratin 18 proved to be the most potent
inhibitors, with low EC50 values and higher selectivity indices (SI), for TPA 19, EC50 =
0.0029 ± 0.0003 μM and SI = 1965 while EC50 for prostratin 18 was 2.6 ± 1.5 μM and
SI = 30.3 showing that TPA 19 was 65 times more potent than prostratin 18.138 At the
same time, these compounds did not show activity against Sindbis virus (SINV) nor
Semliki forest virus (SFV) which indicates an excellent selectivity for inhibition of the
CHIKV. The authors138 believe that this selectivity might be due to a specific
mechanism of virus inhibition through the activation of the signal transduction enzyme
protein kinase C (PKC), similar to the proposed mechanism of HIV replication
inhibition140 for TPA 19. However, TPA 19, is currently one of the most potent tumorpromoting agents known to date,141 therefore, the less potent prostratin 18 is more likely
to be further investigated as a potential candidate, as it does not exhibit 142 a tumorpromoting activity. The exact mode of action of these compounds is as yet unknown
and needs further investigation.
1.6.9. Lupenone and β-amyrone
In the continuous effort to identify novel inhibitors of Chikungunya from natural
sources, a phytochemical study on the leaves of Anacolosa pervilleana (Madagascan
plant) was performed in a virus-cell-based assay for CHIKV.143 Two triterpenoids with
a moderate anti-CHIKV activity were isolated and identified (Figure 1.22), lupenone 20
with EC50 = 77 μM and β-amyrone 21 with EC50 value of 86 μM.143 However, the weak
activity of these natural compounds should be improved by medicinal chemistry
optimization processes before being considered as lead compounds.

Figure 1.22 Chemical structures of lupenone (20) and β-amyrone (21), Me refers to
methyl groups, simplified to fit within the ring structure.
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1.6.10. Harringtonine
Harringtonine (22, Figure 1.23) is an alkaloid from Cephalotaxus harringtonia trees,
which is native to Japan. The natural product has known antitumor activity and inhibits
the first cycle of the elongation phase of eukaryotic translation. 144 Recently, the antiCHIKV activity of harringtonine was investigated. 145 It displayed potent inhibition of
CHIKV infection (EC50 = 0.24 μM) with minimal cytotoxicity, through the inhibition of
the early stages of infection after cellular endocytosis. Also, it was found to affect the
CHIKV RNA production inside the infected cell, as well as viral protein expression
such as the nsP3 and the E2 proteins.145 The in vivo studies of harringtonine are still
ongoing which could make harringtonine a promising lead towards the discovery of
anti-CHIKV drugs.

Figure 1.23 Chemical structures of harringtonine (22).

1.6.11. Purine based inhibitors
In 2012, D’hooghe et al. reported the design and synthesis of a new series of purine-βlactam hybrids and purine-aminopropanol hybrids and their evaluation as potential
antiviral candidates depending on the antiviral templates purines and β-lactams.146
These new scaffolds were screened against nine different viruses including the
chikungunya virus. Two purine-β-lactam hybrids and one purine-aminopropanol hybrid
(Figure 1.24) were found to possess promising activity and cytotoxicity profiles, the
purine-β-lactam 23 with EC50 = 17.11 μM and SI > 5.75, the purine-β-lactam 24 with
EC50 = 13.01 μM and SI > 4 and the purine-aminopropanol 25 with EC50 = 11.51 μM
and SI > 6, which displayed relatively stronger inhibition compared to the β-lactam ring
29

Chapter 1

Introduction

analogues, indicating that the β-lactam ring is not essential.146 The mode of action has
not been investigated. The synthesis of this class of compounds is already established
and therefore, they represent good subject for further medicinal chemistry optimization.

Figure 1.24 Chemical structures of the purine-β-lactams (23, 24) and the purineaminopropanol (25) compounds.

1.6.12. Polyinosinic acid
Polycytidylic acid [Poly (I:C)] (26, Figure 1.25), a synthetic double-stranded RNA
(dsRNA) analogue, is an immunostimulant that acts as an inducer for the most potent
interferon (IFN) via interaction with toll-like receptor 3 (TLR3).147 It can induce IFNα/β production and natural killer (NK) cell activation in vivo after intraperitoneal
injection.148 Activation of the TLR3 contributes to an innate immune response against
many viruses.149 In CHIKV infection, the virus was found to be sensitive to the innate
immune response induced by Poly (I:C). This sensitivity was noticed as a decreased
cytopathic effect and inhibition of the virus replication in the infected cell lines. This
sensitivity has been explained to be a result of the overstimulation of the TLR3 as well
as the other anti-viral genes by Poly (I:C).150
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Figure 1.25 Chemical structures of polycytidylic acid (26).

1.6.13. Gene silencers
New trends in the CHIKV treatment trials are the use of genes silencers targeting
specific viral proteins (capsid protein, E1, nsP1 and nsP3). Silencing the target viral
genes will consequently lead to shutdown of the protein expression process, and thereby
stopping viral replication. After viral infection, the exogenous small interfering RNA
(siRNA) induces RNA interference mechanism, resulting in the assembly of RNAinduced silencing complex (RISC) which inhibits subsequent protein expression. Using
the siRNA targeting CHIKV E1 and nsP3, was effectively used in suppression of in
vitro CHIKV replication.151 Similarly, a plasmid based small hairpin RNA (shRNA)
against CHIKV replication targeting the capsid, E1 and nsP1 proteins has been used.
Simply, the plasmid is first introduced to cell, expressed inside the nucleus, smallhairpin RNA (shRNA) is formed and processed by cytoplasmic Dicer enzyme to
siRNAs, leading to activation of the RNA silencing machinery. This silencing
machinery recognizes and degrades the target CHIKV single strand RNA, consequently
stopping viral protein expression.152 However, clinical studies should be able to prove
the applicability of these trends in developing effective anti-CHIKV therapeutics.
1.7. Highlights for CHIKV inhibitors
Several molecules have been tested against the emerging CHIKV with weak to
moderate activities. Those included drugs already in the market, being used for other
diseases, such as chloroquine 8, ribavirin 10, arbidol 12 and mycophenolic acid 15. The
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challenge here would be in finding similar compounds that are structurally unique with
improved potency and other drug like qualities, also avoiding the metabolic draw backs
when present. The protease inhibitors 5, 6 that were developed based on an in silico
study, would be attractive candidates for further development, however, the challenge
here is to develop a more specific inhibitory assay protocol to confirm the selectivity for
the inhibition of viral proteins. Protein crystallization with the inhibitor would be a
useful element to validate such studies. Some of the tested compounds represent
complex natural products and have good enough activity as antiviral agents, such as
Trigocherrin A 16, prostratin 18, TPA 19 and harringtonine 22. It will be an arduous
task to chemically access these structures and to simplify these chemical skeletons to
more drug like molecules with acceptable ADME properties.
The anti-CHIKV activity of the tested molecules ranged from strong to weak
inhibition depending on the type of the assay used, with the TPA 19 being the strongest
inhibitor with EC50 = 0.0029 μM and β-amyrone 20 which displayed the weakest
activity with EC50 = 86 μM, similar activity to that of ribavirin 10, EC50 = 83.3 μM. It is
worth noticing that the active agents, TPA 19 and the less active Trigocherrin A 16,
shared a common structural feature, the substituted benzo[e]azulene derived structure,
(Figure 1.26). The TPA structure 19 is simpler than that of Trigocherrin A 16, lacking
the extra phenyl rings, two chlorine atoms, four oxygen bridges and the alkene side
chain (Figure 1.26), however, TPA 19 on the other hand has a characteristic long
tetradecanoic ester moiety which was responsible for the activity over Trigowiin A 17
and Prostratin 18, two derivatives that were even less active than Trigocherrin A 16.
These highlights will guide further investigations toward the development of CHIKV
inhibitors based on that substituted benzo[e]azulene skeleton.
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Figure 1.26 Chemical structures of TPA (19) and Trigocherrin A (16), common
skeleton is highlighted in bold red colour, unique groups to TPA (19) are shown in
green while the excess groups of Trigocherrin A (16) are shown in blue colour.
1.8. Concluding remarks
Chikungunya virus (CHIKV) is an emerging arbovirus virus that has had devastating
effects in recent years in many areas in the world. Chikungunya virus infection can
develop into an arthritis disease that remains with the patient for years. The mutations in
the viral envelope protein genes increased the fitness of the virus in another mosquito
vector, Ae. albopictus which was responsible for cases reported in temperate zones.
With no licensed vaccine for immunization against this virus, disease control is
currently non-existent, and the treatment would be through the development of
chemotherapeutics. Some promising lead compounds have been discovered recently and
could be starting points towards effective treatments. The discovery of these leads was
mostly based on random screening of drugs already on the market, newly discovered
natural products or the antiviral evaluation of synthetic compounds. Also, in the last two
years, the molecular functions as well as the crystal structures of a number of critical
enzymes involved in the virus life cycle are being reported, with no known inhibitor
thus far. Some in silico models targeting these viral proteins have been developed, with
some active compounds identified, to initiate the search for effective and selective
therapy such as targeting the viral protease. This will help the drug discovery and
development process through designing inhibitors against those targets. The virus has
been considered neglected for many years and this emphasizes the importance of
developing highly potent and safe inhibitors.
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1.9. Project aims
At the outset of this project (2010), there were no lead compounds reported (including
those previously mentioned in this chapter 1-26), except for some contradicting
arguments about the efficacy of chloroquine 8, with limited evidence suggesting the
efficacy against the chikungunya virus. There were no crystal structures available for
any of the viral proteins. Therefore, the main aim of the project was to find a hit
compound that could be taken further via a hit to lead discovery study. The main
strategies investigated during this project were:


Random screening, through the synthesis and evaluation of anti-microbial class
of compounds that were driven from the current projects within our research
group.



Continuous screening of the literature for emerging viral proteins to develop a
structure-based drug design approach.



Continuous screening of the literature for active lead compounds to conduct a
ligand-based drug design approach.
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CHAPTER 2: The Search for Anti-CHIKV Lead Compounds

2.1. Introduction
At the outset of this project (2010), there were no lead compounds reported, except
some contradicting arguments about the efficacy of chloroquine 8 against the
chikungunya virus, as was referred to in chapter 1. Therefore, the goal of this project
was to search for new lead compounds. Finding a lead compound usually starts with the
random screening of a compound library against the target virus. One active program
within our group was the investigation of new structural motifs as potential nonnucleoside inhibitors of HIV-1 reverse transcriptase (HIV RT)153 and developing in
silico models for the identification of structurally unique inhibitors. While 15
compounds tested from this in silico screening of these models were inactive against
HIV RT,154 seven possessed good anti-malarial activity. Of these seven compounds, the
arylarenepyrimidylmethane (AAPM) compound 27 (Figure 2.1) was chosen for further
investigation as an anti-malarial lead, where it showed an IC50 of 0.88 µM against P.
falciparum.155,156 The developed synthetic strategy utilized for the synthesis of
compound 27 is shown in Figure 2.1.

Figure 2.1 The synthesis of the AAPM derivative, compound 27.
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When compound 27 was synthesized, no similar derivatives were investigated to
study structure activity relationships for the anti-malarial activity, nor an optimization
strategy for the synthetic pathway used to obtain more derivatives. Therefore, our
research group had focused on developing this series, not only to further develop the
synthetic methodology, but also accessing analogues to investigate the structure activity
relationship.
An attempt to derivatise compound 27 in our laboratory had been performed,
and only one derivative, the unsubstituted AAPM compound 34 (Figure 2.2) was
synthesized, due to the difficulties in the synthesis, even after several trials of
optimization.157

Figure 2.2 The unsubstituted AAPM compound 34, and the two AAPM modified
derivatives 35, 36 displaying inhibitory activity against the dengue virus close to 50% at
25 μM.

During the optimization157 process, some modified AAPM derivatives (without
the diethylamino-propanol side chain) were synthesized and were tested against dengue
virus.157 The AAPM derivatives 35, 36 showed weak to moderate activity against the
dengue virus (Figure 2.2). Dengue virus belongs to the family Flaviviridae, and is
transmitted through the Aedes aegypti mosquito,158 the same vector which transmits the
chikungunya virus. Therefore, this family of heterocycles may also inhibit the CHIKV.
With an established synthetic strategy, the generation of analogues for testing against
the CHIKV makes a viable line of research seeking new leads. Consequently, the
synthesized derivatives would enrich the AAPM library giving strength to the scope of
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developing novel anti-microbial agents in general, and especially, with respect to the
anti-malarial program.
2.2. Synthesis of the meta-nitro AAPM derivative
The synthetic strategy for this AAPM derivative was similar to the procedures described
in Figure 2.1 replacing the ketone 29 with 38.
2.2.1. Nitration of isobutyrophenone 37
The synthesis started with the nitration of isopropyl phenyl ketone 37 under the standard
nitration conditions of dropwise addition of the cold nitrating mixture to a cold solution
of the ketone 37 in conc. sulphuric acid (Scheme 2.1). The isopropyl 3-nitro-phenyl
ketone 38 was isolated in 52% yield, as a yellow oil.

Scheme 2.1 The synthesis of the isopropyl 3-nitrophenyl ketone 38.

2.2.2. Addition of the isobutyrophenone 35 to 4,6-dichloropyrimidine 28
The next step in the synthetic pathway was the addition of the 4,6-dichloropyrimidine
28 to the nitro derivative 38. Therefore, a fresh solution of lithium diisopropylamide
(LDA) solution was prepared by the dropwise addition of n-BuLi solution in hexanes to
a solution of diisopropyl amine (DIPA) in tetrahydrofuran (THF), pre-cooled to -78 ºC
(Scheme 2.2), and the solution was allowed to stir at -78 ºC for 45 min to allow the
complete formation of LDA. A solution of 4,6-dichloropyrimidine 28 in THF, precooled to -78 ºC, was then added dropwise to the LDA solution, producing an instant
orange colour change which was attributed to the formation of the pyrimidyl anion 39,
and the solution was stirred at -78 ºC for 45 min. The solution was then cooled to -116
ºC, and a solution of nitro derivative 38 in THF, pre-cooled to -116 ºC, was added
dropwise. The mixture was left for 45 min to allow complete addition. The reaction was
then quenched by addition of NH4Cl. After acidic aqueous workup, the desired alcohol
40 was isolated in 50% yield as pale yellow crystals, the unreacted starting ketone 38
was recovered with the remaining outcomes of this reaction being polymeric products
as analysed from the baseline material on thin layer chromatography (TLC) analysis.
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The analysis of the 1H NMR spectrum of 40 showed a broad singlet peak at 3.38 ppm,
asssigned to the OH group, and two doublet peaks resonating at 1.11 and 0.93 ppm, that
were assigned to the two methyl groups.

Scheme 2.2 Addition of 4,6-dichloropyrimidine 28 to the nitro derivative 38, forming
the alcohol 40.

The proposed mechanism for this reaction starts with the nucleophilic attack of
LDA onto the 5-pyrimidyl proton resulting in the lithiated dichloropyrimidine anion 39,
which nucleophilically attacks the electrophilic carbonyl of the ketone 38, to give the
alcohol after a protic workup (Scheme 2.3).

Scheme 2.3 The proposed mechanism for the formation of alcohol 40.

This reaction (Scheme 2.2) required ultra dry conditions, with all the glassware
oven dried for at least 12 h prior to reaction, and all the reactants dried overnight under
vacuum. The 4,6-dichloropyrimidine 28 was crystallized from water. Previous work157
reported the purification of 28 by bulb-to-bulb distillation, however, in this work,
simple crystallization was effective. The previous best reported yields157 of similar
reactions in our group was 38-47% yield. In this work (Scheme 2.2), the yield was
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optimized to 50%. The notable increase in yield was attributed to the ultra dry
conditions, as this reaction was found to be very sensitive to moisture, including from
the N2 atmosphere used during the reaction. Therefore, in this reaction (Scheme 2.2),
the needle supplying N2 to the reaction flask, was filled with pre-dried CaCl2 to ensure
the dry atmosphere inside the reaction flask. The slow rate of addition of the
electrophile 38, as well as the pre-cooling (-116 ºC) of the electrophile 38 solution prior
to addition, were found to be important factors for improving the yield (Scheme 2.2).
2.2.3. Dehydration reaction of the alcohol 38 to the form the alkene 41
The next synthetic step was the dehydration of alcohol 40. Previous work157 facilitaed a
similar transformation by reacting the alcohols with four molar equivalents of thionyl
chloride (SOCl2) and four molar equivalents of phosphorus pentaoxide (P2O5) in
dichloromethane with stirring at 50 ºC for 12 h. In this work, when this method was
carried out on the alcohol 40, the yield of the alkene derivative 41 was low (24%), with
substantial quantities of un-reacted alcohol (Scheme 2.4), even with the continued
heating for 48 h at 70 ºC.

Scheme 2.4 Dehydration reaction of the alcohol 40 to the alkene 41, using SOCl2 and
P2O5 in CH2CH2.

The reaction was then performed using neat pre-distilled SOCl2, by heating the
alcohol 40 with SOCl2 at reflux under a N2 atmosphere for 48 h (Scheme 2.5). After
basic aqueous workup, the alkene 41 was isolated in 70% yield. Analysis of the 1H
NMR spectrum of the alkene 41 showed the disappearnce of two peaks at 3.38 ppm and
3.64-3.58 ppm from 40, indicating the loss of the alcohol functionality. Analysis of the
13

C NMR spectra showed a shift of the propanol C1 of 40 (81.7 ppm) to 140.1 ppm for

the propene C1 in 41, indicating the formation of the double bond.
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Scheme 2.5 Dehydration of the alcohol 40 using neat SOCl2.

The proposed dehydration mechanism of the reaction begins with the
nucleophilic attack of the alcohol to the sulfonylchloride. Elimination of HCl results in
the chlorosulfite intermediate which eliminates to yield SO2 and a second mole of HCl
and the alkene 41 as shown in Scheme 2.6.

Scheme 2.6 The proposed dehydration mechanism of the alcohol 40 to form 41.

The difference in the yield of the alkene 41 obtained in this work (70%) from the
yield obtained by the previous other derivatives156,157 is attributed to the difference in
the electronic environment of the aromatic ring carrying the deactivating nitro group 40.
The electron withdrawing nitro group on the alcohol 40 may be responsible for slowing
the rate of the reaction (Scheme 2.6), especially the last elimination step of the HCl and
SO2 in the proposed mechanism.
The yield of the alkene 41 using SOCl2 dehydration mechanism was
satisfactory, however, the reaction required 48 h. Therefore, an alternative dehydration
40
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method was investigated. Conc. sulphuric acid is a well know dehydrating reagent for
primary alcohols via an E2 mechanism, and secondary and tertiary alcohols via an E1
mechanism, to give the corresponding alkenes in both cases.159 This sulphuric acid
dehydration reaction was performed on the alcohol 40 by adding the later, portion-wise,
to conc. H2SO4 and allowing the mixture to stir at room temperature (Scheme 2.7). The
reaction was allowed to stir until all the alcohol 40 was consumed. After workup, the
alkene 41 spot was found to be present in trace (not changing) compared to the major
product,

which was

found

to

be

4-chloro-6,6-dimethyl-5-(3-nitrophenyl)-5,6-

dihydrofuro[2,3-d]pyrimidine 42 derivative (Scheme 2.7). Analysis of the 1H NMR
spectrum showed a singlet peak resonating at 4.55 ppm integrating for one proton,
which was assigned to H5 of the furo-pyrimidine skeleton. Analysis of the HRMS
spectrum showed a peak at 306.0648 m/z which was assigned to the molecular formula
C14H13ClN3O3 (MH+), indicating that the alcohol oxygen atom was still present in the
structure

Scheme 2.7 Dehydration reaction of the alcohol 40 using H2SO4, producing the furopyrimidine 42.

The proposed mechanism for the formation of the furo[2,3-d]pyrimidine 42 was
attributed to the rearrangement of the carbocation produced after the E1 elimination step
(Scheme 2.8), where the positive charge is transferred to carbon 2 of the propyl chain
(through a hydride shift). The planarity of the benzylic carbocation with the benzene
and the pyrimidine ring might be responsible for such a rearrangement. This later
carbocation is further attacked by water giving another tertiary alcohol on C2 of the
propyl chain. SN2 attack of the OH group to Cl gave the cyclised product 42. This
reaction (Scheme 2.7) is considered as a new convenient two step synthesis of the
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furo[2,3-d]pyrimidine heterocycle, which is rarely reported in the literature. Existing
methods for the synthesis of this scaffold require more harsh synthetic160,161 conditions.

Scheme 2.8 The proposed mechanism of the formation of furo[2,3-d]pyrimidine
derivative 42.

2.2.4. Mono-amination of the alkene 41
The nucleophilic substitution of ammonia onto the pyrimidine ring of the alkene 41 has
been previously optimized on similar scaffolds using a microwave assisted reaction. 157
Therefore, the alkene 41 was suspended in ammonia solution (25%), and the mixture
heated and irradiated in a microwave reactor at two stages; the first stage involved
heating the mixture at 120 ºC for 50 min, followed by a slight increase in the
temperature to 130 ºC, for a 30 min (Scheme 2.9). These conditions maximized the
production of the mono-amino substitution product 43 and minimized the production of
the di-amino product 44. Analysis of the 1H NMR spectrum of 43 showed a broad peak
at 5.27 ppm, which was assigned to the NH2 group. Analysis of the ESI-MS spectrum
showed a peak at 307 m/z for the molecular ion (M+,
of one Cl atom in the alkene 41 by an amino group.

42
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Scheme 2.9 Selective amination of the dichloro-pryrimidine 41.

The reaction proceeded via a SNAr mechanism where the lone pair of electrons
of ammonia attacked C4 of the pyrimidine ring followed by rearomatisation of the ring
displacing the chlorine atom resulting in the formation of 43.
2.2.5. Final amination of 43 for the final AAPM derivative
The final amination of the amino alkenes had been a challenge in the synthesis of this
series, in this work as well as the previous work. 157 Only the lead compound, the chloroAAPM 27, and the unsubstituted AAPM 34 were synthesized previously in our group,
with multiple attempts to generate more derivatives.156,157
The previous synthesis of the AAPM 27 utilised the reaction between the
racemic, highly viscous, propylamine side-chain 33 in a solvent free reaction with the
aminochloropyrimidine 32 to give the desired AAPM 27 (Figure 2.3) in 40%
yield.155,156

Figure 2.3 The synthesis of the AAPM 27 from the aminochloropyrimidine 32.

When this synthetic strategy was used previously in our group for the synthesis
of the unsubstituted AAPM 34, the reaction failed with no evidence for the formation of
the AAPM 34, even after conventional heating of the reactants at 200 ºC for 5 h (Figure
2.5).157 Instead, further investigation of the reaction mixture indicated the
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polymerization of the poly aminic side chain 33.157 However, access to the AAPM 34
was achieved through an optimization process previously investigated in our group, 157
using a microwave irradiation method (Figure 2.4), with a poor yield (21%).157

Figure 2.4 Reactions of the aminopyrimidine 45 with the amine 33 for the synthesis of
the AAPM 34.

Therefore, the aminochloropyrimidine 43 was heated with the amine 33 under
microwave irradiation at 150 ºC for 5 min (Scheme 2.10). The reaction cycle was
repeated 5 times until the complete disappearance of the starting aminochloropyrimidine
43 as indicated by the TLC analysis (90% ethyl acetate in petroleum spirit). Further
analysis of the reaction revealed the presence of polymeric baseline material and the
absence of material resembling the AAPM 46. This indicated the disintegration of the
heterocyclic structure. Although harsh conditions are required to overcome the steric
barrier of the reaction, prolonged periods of heating result in the destruction of the
material. Therefore, lower temperature were investigated, Table 2.1 summarises the
series of microwave reactions attempted using the aminochloropyrimidine 43 and the
amine 33.

Scheme 2.10 Attempted synthesis of the AAPM 46 using the microwave irradiation.
Table 2.1 Attempted microwave reactions of 43 with 33.
44

Chapter 2

New Leads

Entry Microwave

Reaction

Yield (%)

temp. (ºC)

time (min)

of 46

1

120

50

0

2

130

30

0

3

140

40

0

For all entries (Table 2.1), TLC analysis was performed to gauge the outcome of
each reaction. For entry 1, the staring material 43 was the major spot, with the
additional appearance of the polymeric baseline material. Mass spectrometric analysis
of the crude reaction mixture did not show any peaks that could be assigned to the
formation of the AAPM 46. Increasing the temperature to 130 ºC (entry 2) and 140 ºC
(entry 3) did not produce any differences from the results from entry 1, with the
exception of increased decomposition.
The next attempt to synthesise 46 used solvent in order to solubilise the highly
viscous amino side chain 33, and for the ease of recovery of the aminochloropyrimidine
43. In the previous optimized process of the synthesis of AAPM 34, dichlorobenzene
(DCB) was used, however, it was demonstrated not to improve the reaction, nor the
recovery of the un-reacted starting material.157 Therefore, the reaction was attempted
here using water as a solvent, because of the amino side chain 33 solubility in water
reduced the high viscosity of the amine 33 allowing a greater chance of reaction with
the aminochloropyrimidine 43. Water was also selected as it had been successfully used
for many microwave assisted reactions.162 Therefore, the aminochloropyrimidine 43
was heated with amino side chain 33 in a microwave tube at 100 ºC for 5 min. TLC
analysis (90% ethyl acetate in petroleum spirit) indicated the presence of the starting
materials with polymeric baseline material. The temperature was increased to 150 ºC
and the reaction was held at this temperature for 10 min. TLC analysis after the 10 min
at 150 ºC indicated that the concentration of the starting material was decreasing and the
concentration of the baseline material increased. Furthermore, low resolution mass
spectrometric analysis did not show any evidence indicating the formation of the
desired AAPM 46. The aminochloropyrimidine 43 was recovered in 60%.
The difficulties in the synthesis of the AAPM derivatives along with the
previous attempts157 were attributed to the polymerization of the amino side chain 33 at
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the reaction temperatures. The electronic effect of the substituents on the phenyl ring
(Cl in AAPM 27, H in AAPM 34 and NO2 in the unformed AAPM 46) is also believed
to play a role in the amination reaction, where the Cl atom might activate the amination
and the NO2 group may deactivate the amination reaction. No investigations were
performed at this point to confirm this hypothesis either in the previous work or in this
work.*
2.3. Modification in the amine side chain of the AAPM derivatives
An alternative amine side chain, N1,N1-diethylpentane-1,4-diamine 47† was selected as a
replacement for the polymeric side chain 33, as it is identical to the amino side chain of
the antimalarial chloroquine 8. Furthermore, the amine 47 is a liquid with low viscosity
compared to the amine 33. Therefore, it was thought that it would react more easily with
the aminochloropyrimidine 43. The later was reacted with amine 47 in different
conditions (Scheme 2.11) using either conventional heating or microwave irradiation
(Table 2.2).

Scheme 2.11 Attempted reaction of the aminochloropyrimidine 43 with the amine 47.

*

Personal communication with Andrew Stevens (ref 157), who synthesized the AAPM 34, and attempted
in other AAPM derivatives.
†
Was purchased from Aldrich and further distilled under N2 at 70 ºC to provide a colourless liquid.
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Table 2.2 Attempted reaction conditions for the synthesis of the target compound 48.
Heating

Reaction

method

temp. (ºC)

time

of 48

1

Microwave

150

3 min

0

2

Microwave

150

10 min

0

3

Microwave

170

5 min

Trace

4

Microwave

200

3 min

Trace

5

Microwave

200

12 min

0

6

Conventional

150

12 h

0

7

Conventional

200

48 h

0

Entry

Reaction Yield (%)

From Table 2.2, the first attempt of the reaction (Scheme 2.11) used microwave
irradiation (entry 1); this method resulted in no change as indicated by TLC and mass
spectrometric analyses. Increasing the reaction time to 10 min (entry 2) did not produce
any change in the reaction. The temperature was then increased to 170 ºC (entry 3) and
the reaction was held for 5 min. The mass spectrum of the reaction mixture showed a
weak peak at 427 m/z, indicating a trace of the product 48. Increasing the temperature to
200 ºC for 3 min (entry 4) to push the reaction to completion did not improve the
production of 48 but still the weak 427 m/z peak in the mass spectrum could be
observed. When the hold time was increased to 12 min (entry 5), the weak 427 m/z peak
of the product 48 could not be seen indicating the decomposition or polymerization of
the product. In entries 1-4, 70-73% of the starting material was recovered indicating that
little reaction had taken place, while in entry 5, no starting material was recovered from
the reaction mixture. The reaction (entry 4) was then repeated on fresh starting
materials, the content was then subjected to preparative TLC (PTLC) using 10% water
in acetonitrile, the baseline band was isolated. Analysis of the mass spectrum of this
band revealed the presence of the 48 peak at 427 m/z and the amine peak 47 at 158 m/z.
However, analysis of the 1H NMR spectrum of this fraction showed mainly complex
polymeric protons in the aliphatic region (0.6-2.5 ppm) and the compound 48 was not
separated.
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When the reactants were heated using the conventional heating method (entries
6, 7), no evidence for the formation of 48 was detected by either mass spectrometric or
NMR analysis, and the starting aminochloropyrimidine 43 was completely decomposed.
2.4. Decreasing the steric hindrance of the dimethyl groups
The poor reactivity of the aminochloropyrimidine 43 with either the amine 33 (Scheme
2.10) or the amine 47 (Scheme 2.11) argued for the difficulties in the reaction being due
to the steric clashes with the dimethyl group. Therefore, the dimethyl groups in 43 were
replaced with a cyclopropyl group, in an attempt to give the aminochloropyrimidine 51.
The cyclopropyl group was selected in order to tether the dimethyl groups together and
minimize the steric hindrance. The attempted access to 51 was performed in a similar
synthetic pathway (Scheme 2.12) as that used for 41, using cyclopropylphenyl ketone
49.

Scheme 2.12 Attempted synthesis of the alkene 51 through the alcohol 50.

The alcohol 50 was isolated in 37% yield compared to 50% of the alcohol 40.
Analysis of the 1H NMR spectrum of 50 showed a broad peak at 2.83 ppm, assigned to
the OH substituent. The ESI-MS spectrum showed a peak at 295.1 m/z assigned to the
(M+,

35

Cl) of the alcohol 50. However, the alcohol 50 was found to be unstable, with

decomposition occurring immediately after column chromatography (80% ethyl acetate
in petroleum spirit), as indicated by TLC analysis. These unstable by-products could not
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be separated and identified. Therefore, the dehydration reaction was carried out
immediately after the isolation of 50 from the column. Stirring the alcohol 51 with
SOCl2 at room temperature, or at 80 ºC, caused only charring of the alcohol 51. The
dehydration reaction using conc. H2SO4, that was carried out on alcohol 40 (Scheme
2.7), was also attempted on alcohol 50 to investigate the possibility of forming the
alkene 51, or the furopyrimidine 52 product (Scheme 2.13). However, charring was also
observed after 5 min of stirring, with no formation of 51 or 52.

Scheme 2.13 Attempted conc. H2SO4 reaction on the alcohol 50.

Compared to alcohol 40, alcohol 50 does not contain a nitro group in the phenyl
ring. The next investigation was to check whether the presence of the nitro group on the
phenyl ring of 50 would stabilize the alcohol or not. Therefore, the cyclopropylphenyl
ketone 49 was first nitrated using conc. H2SO4/HNO3 at -10 ºC to afford the
cyclopropyl(3-nitrophenyl)methanone 53 in 70% yield (Scheme 2.14).

Scheme 2.14 Nitration of cyclopropylphenyl ketone 49.

The phenone 53 was then subjected to the LDA addition reaction with the 4,6dichloropyrimidine 28 (Scheme 2.15). Despite subjecting the substrates to identical
reaction conditions previously used for the synthesis of the alcohols 40 and 50, the
alcohol 54 was not formed and the starting phenone 53 was recovered (50%). The
percentage consumed from the phenone 53 indicated that the reaction may have
occurred but the product was unstable, and immediately decomposed.
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Scheme 2.14 Attempted LDA addition reaction of the phenone 53 with the 4,6dichloropyrimidine 28.

These investigations into the synthesis the AAPM 46, compound 48 and the
alcohol 54, as well as the instability of the alcohol 50, argued for the importance of
decreasing the steric hindrance around the Cl atom to be substituted with the amine, and
also argued for the need of further simplification of the AAPM structure.
2.5. Replacing the 4,6-dichloropyrimidine with 4-chloropyridine
One strategy to simplify the core structure of the AAPM precursors involved replacing
the

bulky

4,6-dichloropyrimidine

28

(Scheme

2.2)

with

the

simpler

4-

chloropyridine.HCl 55. Lithiation of the meta position of 4-chloropyridine 55, with
subsequent addition of aldehydes has been previously reported,163 where the
electrophilic addition was performed at -78 ºC without the need to cool the reaction to 116 ºC.163 This change of the addition temperature would be advantageous, compared to
the example of 4,6-dichloropyrimidine 28, in avoiding the difficulty of maintaining the
reaction temperature at -116 ºC. During this modification, the nitro group was kept on
the phenyl rings of the reacting phenones, ketones 38, 53 and the nitrocyclobutylphenyl
ketone 57 were investigated in this modification step.
2.5.1. Synthesis of the nitrocyclobutylphenyl ketone 57
Ketone 57 was accessed through the nitration of the precursor phenone 56 using a
nitrating mixture of conc. H2SO4/HNO3 at -15 ºC (Scheme 2.15). After completion of
the reaction and the aqueous workup, the oil left was subjected to column
chromatography using 30% ether in petroleum spirit. The desired meta isomer
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cyclobutyl(3-nitrophenyl)methanone 57 was isolated in 27% yield, and the ortho isomer
cyclobutyl(2-nitrophenyl)methanone 58 in was isolated 10% yield.

Scheme 2.15 Nitration of the cyclobutylphenyl ketone 56.

The ortho nitration of ketones carrying bulky groups has been previously
observed as in case of adamantyl bearing aromatic ketones.164 Therefore, in the presence
of the bulky cyclobutyl ring, the formation of the ortho derivative 58 was also possible,
and could be explained by formation of the nitronium or proton complex with the
carbonyl of cyclobutylphenyl ketone 56 and establishment of pre-equilibrium included
both this form and its mutual competition. The increase of the nitronium-carbonyl
complex concentration leads to an increase of the amount of ortho nitro regioisomer 58
(Figure 2.5) by the nucleophilic attack of the benzene ring from the ortho position.
Optimization of this reaction (Scheme 2.15) could be investigated by changing the
reaction conditions, however, this was out of the scope in this work.

Figure 2.5 Proposed mechanism for the nitration of 56 and the formation of 58.164
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2.5.2. Addition reactions of ketones to the 4-chloropyridine.HCl 55
The first step in the addition reaction was the lithiation of the 4-chloropyridine 55 using
a freshly prepared LDA solution at -78 ºC as previously discussed (Scheme 2.2). The
prepared LDA solution was then transferred to the solid 4-chloropyridine HCl 55, and
the solution was left to react at -78 ºC and to form the lithiated pyridinyl anion (Scheme
2.16). The completion of the reaction was indicated by the disappearance of the solid 4chloropyridine HCl 55, which took almost 45 min. To this anion solution, was added
dropwise a solution of the appropriate ketone (38, 53 or 57) in dry THF at -78 ºC. The
reaction temperature was kept at -78 ºC for 45 min, after which the reaction mixture was
allowed to warm up to room temperature over 12 h. After quenching the reaction and an
acidic work up, the alcohols 59-61 were obtained after column chromatography in 4852% yield. The same dry reaction conditions discussed previously (Scheme 2.2) were
also utilized. Addition of the ketones at -78 ºC (Scheme 2.16) rather than at -116 ºC
(Scheme 2.2), was advantageous and could be more easily controlled. Moreover, the
acidic workup conditions in case of the pyridine based alcohols 59-61 facilitated the
isolation of relatively pure products. This was indicated by the improved yield and less
side products observed by TLC analysis, compared to the results obtained before when
using pyrimidine (Scheme 2.2). Analysis of the 1H NMR spectrum of alcohol 59
showed a broad peak at 3.25 ppm assigned to the OH substituent, whereas the EI-MS
spectrum showed a peak at 306 m/z which was assigned to the (M+, 35Cl).

Scheme 2.16 Addition of the ketones (38, 53, 57) to the 4-chloropyridine HCl 55.
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The reaction was attempted using 2 molar equivalents of the prepared LDA
solution, however, this was insufficient to react with the 1 molar equivalent of 4chloropyridine HCl 55 and some of the solid remained undissolved. On addition of the
electrophile (ketones 38, 53 and 57), the reaction proceeded, however, the isolated
yields were lower than those obtained in Scheme 2.16, due to the presence of a lower
concentration of the lithiated pyridinyl anion (Scheme 2.16). Using 2.5 molar
equivellents of LDA was found to completely react with 4-chloropyridine HCl 55.
2.5.3. Dehydration of the alcohols 59-61
The first attempted dehydration reaction used the conc. H2SO4 method. Therefore, a
mixture of the appropriate alcohol (59-61) and conc. H2SO4 was stirred at room
temperature for 24 h and the reaction was monitored by TLC analysis at 1 h time
intervals (Scheme 2.17). Although the reactions were clean and complete by TLC
analysis, in the case of the alcohol 59 and the cyclopropyl alcohol 60, the cyclobutyl
alcohol 61 underwent charring after 30 min of stirring with conc. H 2SO4. The dimethyl
alkene analogue 62 and the cyclopropyl alkene 63 were isolated after aqueous basic
workup conditions as yellow oils in 85% and 62% yield, respectively. Analysis of the
1

H NMR spectrum of the alkene 62 showed the disappearance of the OH substituent of

the alcohol that was resonating at 3.25 ppm, and the adjacent proton that was resonating
as a multiplet peak at 3.12-3.09 ppm in 59, indicating the formation of the double bond.
Analysis of the 13C NMR spectrum showed a shift of the propanol C1 in 59 (79.7 ppm)
to 138.5 ppm for the propene C1 of 62 .Analysis of the EI-MS spectrum of 62 showed a
peak at 288 m/z, which was assigned to M+.

Scheme 2.17 Dehydration of the alcohols (59-61) using conc. H2SO4.
Upon the workup of the charred solution in case the alcohol 61, neither the
alcohol nor the alkene 64 were detected, instead, a polymeric dark line was present by
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TLC analysis. Therefore, the SOCl2 dehydration method was attempted, where the
alcohols 60 or 61 were added to neat SOCl2, and the solutions were heated at 80 ºC
under N2 atmosphere for 24 h and 36 h, respectively (Scheme 2.18). Upon cooling the
reactions, ice was added, and the solutions were neutralized with 2 M KOH. After
CH2CH2 extraction and column chromatography, the oily alkenes 63 and 64 were
isolated in 75% and 69% yield, respectively. The yield of the alkene 63 was slightly
improved over using the conc. H2SO4 method (Scheme 2.17).

Scheme 2.18 Dehydration of the alcohols 60 and 61 using neat SOCl2.

2.5.4. Final amination of the alkenes 62-64
The amine 33 was avoided in this trial based on the results previously discussed
(Scheme 2.10). The amine 47 was selected for the amination reaction on the alkenes 6264 and a series of reactions, using different conditions, were carried out on the alkenes
62-64 depending on the availability of each. The alkene 62 was mixed neat with the
amine 47 and the mixture was placed in a microwave tube, followed by irradiation
under different conditions (Scheme 2.19, Table 2.3).

Scheme 2.19 Attempted microwave reaction of the alkene 62 with the amine 47.
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Table 2.3 Microwave reaction conditions of the alkene 62 with the amine 47.
Microwave

Reaction

temp. (ºC)

time (min)

of 65

of 66

1

135

10

0

0

2

150

10

0

0

3

170

20

0

0

4

200

5

0

0

5

250

20

0

0

6

280

20

0

trace

7

280

60

0

trace

Entry

Yield (%) Yield (%)

After each entry (1-7, Table 2.3), a sample of the reaction mixture was taken for
TLC and low resolution mass analysis. In entries 1-5, TLC analysis indicated no change
in the reactants. Furthermore, the analysis of EI-MS spectra of the samples showed
peaks at 288 m/z (M+ of 62) and the amine 47 peak at 158 m/z. The stability of the
alkene 62 at 250 ºC was encouraging to increase the temperature to 280 ºC. When the
alkene 62 was heated with the amine 47 at 280 ºC for 20 min (entry 6), TLC analysis
indicated no change, however, EI-MS spectrum showed a new peak at 269 m/z, which
corresponded to the (M+) of the amine 66. When the reaction was heated further at 280
ºC for 60 min (entry 7), the alkene 62 disappeared and the the peak at 269 m/z (amine
66) was still present in the EI-MS spectrum. TLC analysis of the reaction mixture of
entry 7 presented a polymeric baseline long spot and the amine 66 was not isolated.
Formation of the amine 66 at high temperature not only indicated the decomposition of
the amine 47 releasing the NH2 nucleophile, but also indicated the weak reactivity
(electrophilicity) of the alkene 62 towards the amine 47. This lack of reactivity towards
47 and the reactivity with the released nucleophile NH2, can be explained based on
steric hindrance with the amine 47 being hindered from replacing the 4-chloro on the
pyridine ring of 62.
The instability of the amine 47 and the lack of reactivity of the alkene 62 under
the normal SNAr conditions required a different strategy. Therefore, the use of a catalyst
such as palladium [Pd(0)], in mild conditions was attempted to facilitate the reaction
and to avoid the degradation of the amine 47. The amine 47 was reported to react with
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4-chloroquinoline 67 in the presence of palladium acetate (4 mol%), DPEphos* (8
mol%) and potassium phosphate (K3PO4, 2.5 equivalent) and the mixture was heated in
1,4-dioxane for 18 h at 85 ºC, where the final product 68 was isolated in 93% yield
(Figure 2.6).165

Figure 2.6 Reported amination165 reaction using the amine 47 with 4-chloroquinoline
67 using a Pd catalyst.

The presence of the chlorine atom in position 4 of the quinoline 67, makes it
analogous to the case in the alkene 62, however, there is no steric hindrance around the
chlorine atom in 67. Therefore, the alkene 62 was placed with the amine 47 in a sealed
tube, to which was added palladium acetate (4 mol%), DPEphos (8 mol%) and K3PO4
(2.5 equivalent), and the tube was degassed for 10 min using N 2, the tube was sealed
and then heated at 18 h at 85 ºC (Scheme 2.20). Upon TLC analysis of the mixture, no
change was observed. Therefore, the content of the tube was transferred to a microwave
tube and the reaction was irradiated with microwave at 100-160 ºC for 10 min to 1 h.
No change in the reaction was detected until reaching 160 ºC for 1 h, where the
reactants decomposed as indicated by the TLC analysis where several minor spots (>7)
appeared that were difficult to separate.

*

(oxydi-2,1-phenylene)bis(diphenylphosphine).
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Scheme 2.20 Attempted Pd catalysed amination of the alkene 62 using the amine 47.

The failure of the above reactions (Schemes 2.19, 2.20) argued for the difficulty
of the reactions in the presence of the steric hindrance induced mainly by the methyl
groups in both 62 and 47. Therefore, the less hindered, alkene 63, with the cyclopropyl
chain instead of the two methyl groups in 62, was reacted with the amine 47 using the
same Pd catalysed conditions (Scheme 2.21). At the same time, the alkene 63 was
reacted with the amine 47 using a conventional heating method in a sealed tube, to test
the reactivity without the Pd catalyst (Scheme 2.21).

Scheme 2.21 Attempted reactions of the cyclopropyl alkene 63 with the amine 47, using
the Pd catalysed amination and the free SNAr reaction.

Using the Pd catalysed conditions, the product 69 was not detected and only the
alkene 63 was recovered. Using the thermal heating method, the reaction was heated
until the starting material disappeared. No characteristic peaks were identified in the EIMS/ESI-MS spectra, therefore, the excess amine 47 was then removed by distillation
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under vacuum at 120 ºC. Further analysis of the EI-MS and 1H NMR spectra of the oily
residue did not provide any evidence indicating the formation of 69, instead, a
polymeric material was detected that had complex multiplicity in the aliphatic regions
(1-3 ppm) with no aromatic protons.
Another SNAr reaction of the amine 47 with 9-chloroacridine 70 was reported in
2009, utilizing phenol as a solvent and heating the reaction at 100 ºC for 15 min, with
the product 71 isolated in 65% yield166 (Figure 2.7).

Figure 2.7 Reported SNAr reaction of the 9-chloroacridine 70 with the amine 47 using
phenol as a solvent.166

Therefore, the alkene 64 was placed in a sealed tube, phenol was added and
then, the amine 47 was added. The tube was sealed and the reaction was heated at
100 ºC for 5 min (Scheme 2.22). A sample of the reaction was taken for TLC analysis,
which indicated no change. The tube was then heated at 120 ºC for 10 min and 140 ºC
for 1 h, after which, no change was observed in the reaction. Finally, the tube was
heated at 160 ºC for 14 h. The tube was then cooled and the content was adsorbed onto
silica and subjected to a flash column chromatography and eluted with 10% methanol in
CH2Cl2 to give 3-(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline 72 as a
colourless oil in 43% yield. Analysis of the EI-MS spectrum showed a peak at 328 m/z
that was assigned to the M+. Analysis of the 1H NMR spectrum showed a broad peak at
3.55 ppm which was assigned to the NH2 group. The IR spectrum of 72 showed the
disappearance of the NO2 group absorption bands at 1527 and 1340 cm-1 from 64, and
showed an absorption band at 3256 cm-1 indicating the presence of an amino group,
confirming the reduction of the nitro group on the phenyl ring of 64.
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Scheme 2.22 Reaction of the alkene 64 with the amine 47 using phenol as a solvent.

The nucleophilic substitution reaction of the chlorine atom by the phenol is a
known reaction for the preparation of ethers (Ullmann ether synthesis), where the
nucleophile (phenol) is heated with a chlorated substrate at elevated temperatures, in the
presence of a base and copper metal, as in case of 4-phenoxypyridine 74, which was
prepared via reacting 4-chloropyridine HCl 55 with phenol in the presence of cesium
carbonate (Cs2CO3), and Cu-source (Figure 2.8).167 The same reaction can also occur in
the absence of the copper metal, where the 4-chloropyridine HCl 55 could be heated
with phenol at 150 ºC for 15 h (Figure 2.8).168

Figure 2.8 Reported reaction of 4-chloropyridine HCl 55 with phenol, forming 4phenoxypyridine 74.167,168

In our reaction (Scheme 2.22), two transformations are taking place, the solvent
phenol first serves as a nucleophile and undergoes an SN2 reaction, replacing the Cl
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leaving group, producing the ether 72. This was surprising because the phenol is a
weaker nucleophile than the NH2 group of amine 47 or its decomposition product, the
NH2 nucleophile, as previously noted (Scheme 2.19). This can be explained based on
the steric hindrance, by the adjacent sp3 carbon in 47, which prevents the nucleophilic
attack of the amine 47 to give the product 72. At the same time, the amine 47 or its
decomposition product (at 160 ºC), might serve as base to mediate the reaction of the
phenol with the alkene 64, as the case mentioned in Figure 2.8.
The second transformation that occurred (Scheme 2.22) was the reduction of the
nitro group of 64 to give the aniline 72. No metal catalyst was present in the reaction to
catalyse such a reduction, however, the catalyst free reduction of the aromatic nitro
group is possible and has been reported previously,169 where aromatic nitro compounds
can be heated with a hydrogen source at 110 ºC for 24 h, in a solvent like water or
water/DMSO mixture.169 Amines and hydrazines are well known sources of hydrogen
in reduction reactions,170,171 and therefore, the amine 47 or its decomposition products
are proposed to be the hydrogen source for the reduction of the nitro group in 64 to the
amino group in 72, when heated at 160 ºC for 14 h in a sealed tube. The sealed tube also
provided the pressure required for such a reduction reaction. However, because the
product 72 is out of the scope in this work, the reaction was not repeated on the other
alkene 62 or 63, to investigate the scope of this reduction.
2.5.5. Amination of the alkenes 62-64 using morpholine 75
Replacing the amine side chain 33 and the amine 47 by morpholine 75 was an
applicable strategy that was previously used. 157 The AAPM 36 carrying the morpholine
side chain (Figure 2.2), displayed a weak to moderate activity against the dengue virus
(64% inhibition at 25 µM).157 The synthesis of the AAPM 36 was also achieved in 62%
yield.157 Therefore, the alkenes 62-64 were reacted with neat morpholine 75, by heating
the mixture at reflux for 48 h (Scheme 2.23). Excess morpholine 75 was then removed
by distillation under vacuum, leaving oily residues. Only the cyclopropyl analogue 77
was isolated after being subjected to alumina column chromatography. Analysis of the
ESI-MS (negative ionization) spectrum of 77 showed a peak at 336.9 m/z which
corresponded to [M-H+]-. Analysis of the

13

C NMR spectrum of 77 showed a peak at

66.8 ppm assigned to the morpholine C2 and C6, and two carbon resonating at 53.4
ppm assigned to C3 and C5 of the morpholine ring in 77.
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Scheme 2.23 Amination reaction of the alkenes 62-64 with morpholine 75.

In case of the alkenes 62 and 64, no reaction was detected and the alkenes were
fully recovered after the reaction time (Scheme 2.23). The ability of the alkene 63 to
react with morpholine 75 was related to the less hindrance, in comparison with the more
hindered alkenes 62 and 64. Therefore, harsher conditions were employed on alkenes 62
and 64. Neat morpholine 75 was heated with either alkene 62 or alkene 64, in a
microwave tube (Scheme 2.24). The maximum heat applied was 240 ºC (using the
maximum microwave power), and the reaction was held for 1 h. The reaction was
cooled with compressed air for 10 min. TLC and low resolution mass analysis indicated
no change in the reactants.

Scheme 2.24 Attempted microwave reaction of the alkenes 62, 64 with morpholine 75.

The failure to synthesise 76 and 78 was mainly attributed to the steric hindrance
by the dimethyl groups in case of alkene 62, and the bulky cyclobutyl of the alkene 64.
However, the alkenes 62, 64 were found to be stable after heating at 240 ºC for 1 h, and
were fully recovered.
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2.6. Concluding remarks
This chapter presented the attempted trials to synthesise the nitro AAPM derivative 46,
starting from the nitro-isobutyrophenone 38. The sequence of the reaction sequence
proceeded well until the final amination step with the racemic side chain amine 33.
Different conditions were tried for this amination, however, the polymerization of the
side chain and the loss of the starting material, the aminochloropyrimidine 43, provided
additional difficulties in repeating the reaction. During the optimization of the
dehydration reaction for the alcohol 40, using conc. H2SO4, a new furopyrimidine 42
was obtained in an excellent yield. This is considered a novel short synthetic pathway to
access the furopyrimidine skeleton which has been rarely reported in the literature.
The racemic amine 33 was then replaced by the amine 47, which contains
features present in the anti-malarial chloroquine 8. Final amination using 47 was not
successful due to the instability of 47, decomposing and releasing NH2 as a nucleophile,
and also due to the steric hindrance caused mainly by the two methyl groups in the
aminochloropyrimidine 43. One way to decrease the steric hindrance was by tethering
the two methyl groups by using the less hindered cyclopropyl group. The replacement
took place, and the alcohol 50 was isolated, however, it was found to be unstable, and
the conversion to the alkene 51 was not successful. Another possibility is to use a less
hindered analogue of 47 that does not have the methyl germinal to the NH2 group.
A modification of the AAPM structure was then achieved by replacing the 4,6dichloropyrimidine 28 by the simpler 4-chloropyridine HCl 55. The addition and
dehydration reactions proceeded well and three alcohols 59-61 and the corresponding
alkenes 62-64 were obtained in good yields. However, the final amination with the
amine 47 was not successful with any of the alkenes, including the Pd catalysed
amination chemistry. Instead, the ether-aniline product 72 was obtained when trying the
amination with the alkene 64, using phenol as a solvent. This product showed that the
nucleophilic substitution on the alkenes 62-64 was possible, although steric hindrance
prevented the addition of the amine 47 in the desired position. Product 72 showed also
the instability of the amine 47 when placed in harsh conditions which might be required
for such nucleophilic substitution reactions, as can be noted by the reduction of the nitro
group on alkene 64 to an amino group in 72, depending on the amine as a hydrogen
source.
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Finally, the amination with the secondary amine, morpholine 75, was performed
on the alkenes 62-64, however, only the cyclopropyl analogue 77 was isolated in good
yield. This confirmed the difficulties in performing such reactions in the presence of
hindered systems.
In conclusion, the alkene 63, with the less hindered cyclopropyl group,
represents the most promising alkene to perform more amination reactions under
moderate conditions. The synthesized compounds, not only represent milestones in the
optimization process of the AAPM derivative syntheses, but also provide new scaffolds
for testing against the CHIKV as well as against malaria, to identify new hit
compounds.
Some alternative routes to the AAPM derivatives are to be considered. The
synthesized new furopyrimidine 42 can be considered for the amination reaction, as it is
less stericaly hindered than the corresponding alkene 41 (Scheme 2.25). The furan ring
can then be open using POCl3160 to give the final aminated products.

Scheme 2.25 Alternative synthesis of the AAPM 46, 48 and 81 using the
furopyrimidine 42 intermediate.
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CHAPTER 3: Modelling Study of the CHIKV nsP3 as a Possible
Drug Development Target

3.1. Introduction
The function of alphaviruses nsP3 has remained unknown, although mutations can
affect different steps of the viral replication machinery. 75 It is constructed of two
domains, with the first being a unique macro domain in the conserved N-terminal
region. The C-terminal region is less conserved and is phosphorylated in about 16
positions on serines and threonines.76,77 The function of phosphorylation is not
understood, but it was found that deletion of these phosphorylated residues decreases
the RNA synthesis level in infected cells.78
The N-terminus of nsP3 contains a macro domain (known also as X domain),
which binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose1"- phosphate,80,81 a side product of cellular pre-tRNA splicing. Therefore, it is believed
to control the metabolism of ADP-ribose 1"-phosphate and/or other ADP-ribose
derivatives which have regulatory functions in the cell. The ADP ribose-binding site
within the nsP3 macro domain is solvent-exposed and points away from the other
domains in the nsP23 polyprotein. Based on sequence conservation in alphaviruses, it
has been shown that residues just after the nsP3 macro domain play a role in positioning
of the nsP23 complex cleavage site. 82 It can be inferred from the crystal structure of the
nsP23 precursor protein of the closely related alphaviruses, SINV, that the nsP2 is
connected to the nsP3 through the macro domain of the nsP3. 83
In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was
solved80 (Figure 3.1). It is formed of 672 residues and contains six-stranded β sheets
(cyan colour in Figure 3.1) and three α helices (red colour in Figure 3.1). The 2D
intermolecular interactions between the residues in the binding pocket of the enzyme
and the ADP-ribose,85 as analysed from the crystal structure, are also shown (Figure
3.2).
As shown in Figure 3.2, the key binding residues are: Arg144, Asp10, Ile11
The111, Gly112, Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding
complex is formed of 10 H-bonding and one π-cation interaction.85 The PO42− moiety
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showed the strongest interactions with these residues in the enzyme pocket. Also, the
ribose (with Thr111) and the diphosphate (with Gly112, Ser110, Tyr114, Val113, Val
33) units were found to play major roles in the CHIKV nsP3 ADP-ribose complex.85
The nsP3 of CHKV uses a conserved proline-rich motif to interact with the Srchomology-3 (SH3) domain of amphiphysin-1 and amphiphysin-2 proteins, of the host
cell, which are related members of the BAR (Bin-Amphiphysin-Rvsp) protein
superfamily implicated in several cellular functions. 86

Figure 3.1 Crystal structure of the CHIKV macro domain with the bound ADP-ribose,
generated from the PDB file code: 3GPO,80 β sheets are shown in cyan, while the three
α helices are shown in red colour.

Figure 3.2 2D representation of the interaction of ADP-ribose inside the nsP3 macro
domain binding pocket showing the other residues inside the active site (Generated
from the PDB file: 3GPO80).
65

Chapter 3

CHIKV nsP3

It was recently87 found that the nsP3 acts as an inhibitor of stress granule
assembly by recruiting G3BP into cytoplasmic foci. The conserved SH3 domainbinding motif in nsP3 (the proline-rich motif, not included in the crystal structure) is
also essential for both nsP3-G3BP interactions and viral RNA replication. G3BP (Ras
GTPase-activating protein-binding protein) is an enzyme in human cells and a member
of the heterogeneous nuclear RNA-binding proteins.88 This protein plays a major role
during infection and in the assembly of stress granules. Stress granules are membranous
cytoplasmic focal structures (foci) that immediately aggregate in response to cellular
stress; this last action leads to impaired translation of most mRNAs. 89 These stress
granules may have antiviral activity that is inhibited by CHIKV replication by the nsP3
SH3 domain-binding motif.87
The crystal structure of the CHIKV nsP3 macro domain represents only one
domain of the whole protein, however, the main function of the CHIKV nsP3 is located
within this X domain, through the ADP-ribose binding site. Moreover, like other
alphaviruses, the nsP2 is connected to the nsP3 through the macro domain of the
nsP3.83 Therefore, targeting the binding site of this domain will have effects on both the
functions of the whole nsP3 itself, and also, will impair the functions of the polyprotein
complex (nsP23 cleavage site). Therefore, impairing the functions of the nsP3 macro
domain would either affect the functions of the whole protein (nsP3) as an individual
functioning unit, or would impair the functions of the polyprotein complex before being
cleaved by the protease activity of the nsP2. In either case, the viral replication
machinery will be impaired.
This chapter describes the investigation of using of the CHIKV nsP3 as a
potential drug target by utilizing the ADP-ribose binding site to perform virtual
screening of a compound library. In this structure-based search approach, the cocrystallized ligand (ADP-ribose) was used as a control. Ligands which showed higher
scores within the pocket were considered as potential competitive inhibitors, and
ligands which showed lower affinities were discarded.
3.2. Results and discussion:
3.2.1. The data set library used in the search
The freely available NCI diversity set III was selected for this virtual screening. The
diversity set was derived from almost 140,000 compounds available in plates for high
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throughput screening approaches. Only available compounds were considered. The
71,756 compounds meeting this criterion were filtered using the program Chem-X
(Oxford Molecular Group). Chem-X uses defined centres (hydrogen bond acceptor,
hydrogen bond donor, positive charge, aromatic, hydrophobic, acid, base) and defined
distance intervals to create a particular finite set of pharmacophores. 3-Point
pharmacophores were used resulting in almost 1,000,000 possible pharmacophores. The
Chem-X diverse subset generating function reads through a set of structures and
determines the acceptable conformations. For each acceptable conformation, it
determines all the possible pharmacophores. The pharmacophores for the current
structure are compared to the set of all pharmacophores found in structures already
accepted into the diverse subset. If the current structure has more than a preset number
of new pharmacophores, it is added to the diverse subset. The requirements were set as
5 new pharmacophores and, additionally, 5 or fewer rotatable bonds. This procedure
resulted in the selection of 1990 compounds. *

3.2.2. Virtual screening with the CHIKV using Autodock Vina
In this chapter, Autodock Vina (Vina)172 was used to perform virtual screening of the
NCI Diversity Set III into the ADP-ribose binding site within the CHIKV nsP3 macro
domain crystal structure (pdb: 3GPO80). Vina is freely available to the academic
community. It is two orders of magnitude faster than Autodock 4.0 (Autodock173). Vina
performs well relative to Autodock; while Autodock is slightly better at predicting the
energy of binding (standard error of 2.2 kcal.mol-1 versus 2.8 kcal.mol-1 for Vina), Vina
more accurately reproduces cocrystallized ligand poses.172,174 Vina has been used
successfully for virtual screening with reliable results. 175
Table 3.1 shows the top 17 ranked docked poses that achieved lower binding
energies (ΔGbind) than the co-crystallized ligand (ADP-ribose), with the binding
energies (Kcal/mol), interacting residues and calculated log (ClogP). The validation of
the docking accuracy was achieved by docking the native co-crystallized ligand (ADPribose) into its binding site of nsP3 macro domain. The result was satisfactory where the
docked ligand was exactly superimposed on the native co-crystallized ligand with a
RMSD value of 0.34 Å, and a binding free energy of -10.4 kcal/mol. The top 10
compounds were selected for in vitro antiviral evaluation against the CHIKV.
*

The diversity set III definition and the preparation procedures were extracted from the NCI website.
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Table 3.1 Autodock Vina top ranked molecules which scored higher than ADP-ribose,
binding affinity (ΔGbind), interacting residues and calculated logP (ClogP).
ΔGbind
Entry

Structure

Interaction Residues

ClogP*

Kcal/mol
Leu108 (H bond, 1.99 Å),
-12.0

1

Ser110 (H bond, 2.26 Å),

2.94

Arg144 (cation-π)

Trp148 (π-π),
-11.9

2

2.41
Leu108 (H bond, 2.2 Å)

Arg144 (H bond, 2.15 Å),
Ser115 (H bond, 2.01 Å),
-11.5

3

6.77
Thr111 (H bond, 2.18 Å),
Trp148 (π-π)
Asn24 (H bond, 2.24 Å),
Cys34 (H bond, 2.08 Å),
Val113 (H bond, 1.83 Å),

-11.4

4

Leu108 (H bond, 2.47 Å),

6.75

Arg144 (H bond, 1.84 Å),
Ile11 (H bond, 2.42 Å),
Tyr142 (H bond, 2.30 Å)

-11.3

5

Ile11 (H bond, 2.42 Å)

3.01

Trp148 (π-π),
-11.1

6

Val113 (H bond, 2.03 Å),
Asp31 (H bond, 2.39 Å)

*

Calculated using ChemBioDraw Ultra 13.0 (2012).
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Arg144 (cation-π, H bond, 2.09 Å),
Ile11 (H bond, 2.27 Å),
-10.9

7

Tyr142 (H bond, 1.88 Å),

3.43

Thr111 (H bond, 2.19 Å),
Gly112 (H bond, 2.02 Å)

Thr111 (2 H bond, 1.81, 2.48 Å),
-10.8

8

4.72
Gly112 (H bond, 2.26 Å)
Trp148 (π-π),
Arg144 (H bond, 1.91 Å),

-10.7

9

3.54
Thr111 (H bond, 1.83 Å),
Gly112 (H bond, 2.40 Å)

-10.7

10

Agr144 (cation-π)

4.51

Arg144 (H bond, 2.13 Å),
Asp145 (H bond, 2.29 Å),
-10.7

11

2.09
Thr111 (H bond, 1.89 Å),
Gly112 (H bond, 2.22 Å)

-10.6

12

Asp31 (H bond, 1.90 Å)

4.91

Arg144 (cation-π, H bond, 2.48 Å),
Thr111 (H bond, 2.09 Å),
-10.6

13

4.39
Gly112 (H bond, 2.17 Å),
Val33 (H bond, 2.36 Å)
Leu108 (H bond, 1.93 Å),
Tyr142 (H bond, 2.15 Å),

-10.6

14

3.78
Thr111 (H bond, 1.79 Å),
Gly112 (H bond, 2.33 Å),
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Leu108 (H bond, 2.44 Å),
-10.6

15

Val113 (H bond, 2.32 Å),

6.94

Tyr114 (H bond, 2.33 Å)
Val33 (H bond, 2.47 Å),
Thr111 (2 H bond, 1.70, 1.88 Å),
-10.6

16

3.51
Gly112 (H bond, 2.24 Å),
Arg144 (cation-π)
Asn24 (H bond, 2.19 Å),
Thr111 (H bond, 2.16 Å),

-10.4

17

6.88
Val113 (H bond, 2.23 Å),
Arg144 (cation-π)

From Table 3.1, it can be seen that all the top ranked poses could interact with
the key residues inside the CHIKV nsP3 pocket, which interact with ADP-ribose
(Figure 3.2). The results also revealed the participation of new residues within the
pocket, where the amino acid Leu108 was found to either accept H-bonds through the
carbonyl group, or donate H-bonds through the NH group with poses 1, 2, 4, 14 and 15
(Figure 3.3). The Leu108 residue is located inside the pocket close to the key residues
Ser110, Thr111, Gly112 and Val113. Interactions with these residues were found to be
important for the binding of the ADP-ribose ligand.85 Therefore, interactions with
Leu108, should also strengthen the interactions within this site of the pocket. This
would stabilizes the ligand-enzyme complex at this site, therefore, competing well with
ADP-ribose (did not show interactions with Leu108) to fit within the pocket inside the
CHIKV nsP3 macro domain.
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Figure 3.3 Leu108 (red colour) interactions within the nsP3 pocket with entries 1, 2, 4,
14 and 15 (poses are shown in green colour). Leu108 can either accept H-bonds through
the backbone CO or donate H through the backbone NH group.

Another common residue, Trp148 which is lying on the pocket floor, was found
to have π-π stacking interactions with entries 2, 3, 6 and 9 (Table 3.1). These poses were
found to position aromatic systems against the indole ring of Trp148, giving stability of
the aromatic residues against the pocket mouth (Figure 3.4). The amino acid residue
Asp145 was also found to form a H-bond only with entry 11 (Table 3.1). Ser115 was
also found to form a H-bond only with entry 3.

Figure 3.4 Trp148 π-π interactions with the aromatic rings of entries 2, 3, 6 and 9.
Trp148 is shown in blue colour within the transparent surface of the nsP3 pocket. The
π-π interactions are shown as orange lines.
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3.2.3. Ranking of the Autodock Vina output using Autodock
To select the hit to be optimized, the hit list obtained by Autodock Vina (Table 3.1) was
subjected to ranking using the Autodock algorithm, which was then used for the in
silico optimization. Re-docking of the hits using Autodock was performed to re-score
the list with the Autodock scoring function, using the native ligand (ADP-ribose) as a
control, and excluding those hits which are ranked below the score of ADP-ribose.
Table 3.2 shows the re-docking results. Autodock 4 results for the ADP-ribose: binding
energy (ΔGbind = -11.07 Kcal/mol) and predicted inhibition constant (Ki = 7.74 nM).

Table 3.2 Hits which passed the Autodock re-ranking, achieving scores higher than
(ADP-ribose), their binding energies (ΔGbind), predicted inhibitory constant (Ki) and
interacting residues. Entries of the table are the same as in Table 3.1.
Entry

12

Structure

ΔGbind
Kcal/mol

Predicted
Ki (nM)

Interaction residues

-12.66

0.528

Asp31 (H bond, 1.74 Å)

Asn24 (H bond, 2.32 Å),
Asp31 (H bond, 2.15 Å),
-12.01

6

1.56

Leu108 (H bond, 1.90 Å),
Val113 (H bond, 2.01 Å),
Tyr142 (π-π)
Leu108 (H bond, 1.97 Å),

-11.71

1

2.59

Thr111 (H bond, 2.21 Å),
Arg144 (cation-π)
Ala22 (H bond, 2.09 Å),
Cys34 (H bond, 1.71 Å),

-11.37

17

4.62

Gly112 (H bond, 2.16 Å),
Val113 (sigma-π),
Arg144 (H bond, 2.06 Å)
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Leu108 (H bond, 2.09 Å),
Val113 (H bond, 2.16 Å),
-11.35

15

4.75
Tyr114 (H bond, 2.10 Å),
Tyr142 (π-π)
Ala22 (H bond, 2.36 Å),
Gly112 (H bond, 2.48 Å)

-11.31

3

5.1

Val113 (H bond, 2.11 Å),
Arg144 (2 cation-π, H
bond 1.97 Å)
Asp31 (H bond, 2.38 Å),
Val33 (H bond, 1.78 Å),
Leu108 (H bond, 1.74 Å),
Thr111 (H bond, 2.27 Å),

-11.14

16

6.81
Gly112 (H bond, 2.09 Å),
Val113 (H bond, 2.18 Å),
Tyr114 (H bond, 2.01 Å),
Agr144 (H bond, 2.23 Å)

Table 3.2 showed that the amino acid residue Asp31 is critical for the ligandenzyme interaction complex as demonstrated by entries 12 and 6, where both ere
predicted to form H-bonding with Asp31 with predicted distances of 1.74 Å and 2.15 Å,
respectively. Entry 12 also achieved shape matching and therefore was predicted to
have the highest ΔGbind value. Entry 16 showed the ability to form a H-bonding with
Asp31 with a predicted distance of 2.38 Å, a greater distance from those observed in
entries 12 and 6. Although ranked the last pose (Table 3.2), entry 16 showed 8 H-bonds
with key binding residues within the pocket, ranging from 1.78 to 2.38 Å.
Entry 3 (benzimidazole derivative) was selected for the docking based
optimization due to its easy chemical access, high scoring in the first Autodock Vina
screening, highly optimizable structure and it showed the ability to form 2 cation-π
interactions with Arg144 (similar to ADP-ribose). It was also selected in order to
validate the efficacy of the optimization process (optimizing a lower ranked hit rather
than a higher ranked one).
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3.2.4. In silico optimization of entry 3
Hit 3 (Table 3.2) showed interaction within the CHIKV nsP3 pocket (ΔGbind = -11.31
Kcal/mol, predicted Ki = 5.1 nM). Figure 3.5 shows the 2D representations of the
interaction of entry 3 with the nsP3 residues. This hit can be described as two
benzimidazol-2-yl phenyl units connected to a central phenyl ring through amide
linkages. One of the benzimidazol-2-yl phenyl forms important interactions with the
key amino acid residue Arg144, where the benzimidazole moiety forms the π-cation
stacking interaction with the cationic side chain of Arg144 via the benzo moiety, and
another π-cation interaction with the phenyl ring, whereas one N atom of the imidazole
moiety accepts a H-bond from one of the Arg144 NH2 (Figure 3.5). The other
benzimidazole moiety can donate a H-bond, through the imidazole moiety to the
backbone carbonyl group of Ala22. One of the amide carbonyl (Figure 3.5) accepts two
H-bonds from the backbone amide NH of the key residues Gly112 and Val113.

Figure 3.5 2D representations of the interaction of entry 3 within the CHKV nsP3.

Therefore, the important moieties for hit 3 (Table 3.2) appear to be the
benzimidazol-2-yl phenyl moieties and the amide linkages. The ClogP for this hit is
6.77, which is due to the presence of 5 phenyl rings in the structure. Removal of the
central phenyl ring was the first modification performed on hit 3, producing pose_3_1
(Figure 3.6) which suggested more positive interactions with active site residues (ΔGbind
= -11.44 Kcal/mol, predicted Ki = 4.08 nM), a slight improvement in the Autodock
score compared to hit 3. ClogP for pose_3_1 is 4.97, lower than that of the original hit
3.
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Figure 3.6 2D representations of the pose_3_1 within the CHIKV nsP3.
Figure 3.6 shows that pose_3_1 has the same predicted interactions with the key
residue Arg144. However, Gly112 also interacted, not through a H-bond as in case of
hit 3 (Figure 3.5), but through a sigma-π stacking interaction (Figure 3.6). Two amino
acid residues participated in new H-bonds, the key residue Tyr142 (1.82 Å) and the
backbone NH of Leu108 (1.88 Å). The other terminal benzimidazole N did not donate a
H-bond to Ala22 as in hit 3, instead, a H-bonding interaction with the key residue
Asp31 (Figure 3.6) was predicted. The 3D model of pose_3_1 suggested further
possibilities of H-bonds with the polar hydrogens of the key amino acid residue Asn24
(Figure 3.7), through one of the benzimidazole rings. Such H-bond formation will
require the presence of an acceptor on the terminal benzo moiety of the benzimdazole
close to Asn24 (Figure 3.7). Moreover, the presence of an acceptor on the other
benzimidazole moiety (which forms interactions with Arg144), would make possible a
H-bond with the polar hydrogens of Lys35 (Figure 3.7).
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Figure 3.7 3D representation of pose_3_1 within the nsP3 pocket. Asn24 and Lys35
polar hydrogens are shown as yellow spheres.

Therefore, the next modification was to insert an acceptor group on the terminal
benzimidazole rings. This acceptor was to be added on both benzimidazole rings, to
achieve the two possible interactions with Asn24 and Lys35. Several acceptor groups
such as NH2, OH, COOH and NO2 could be added on the desired position, however, the
nitrile group (CN) was selected as an acceptor to be added on the benzimidazole ring. It
was selected because it is able to form relatively strong H-bonds with the receptor
residues,176 and also, the presence of the carbon atom would act as a spacer, bringing the
N closer to the receptor residues. 177 Therefore, pose_3_1 was optimized to give
Pose_3_2. This modification, not only represented a better in silico binding profile
(ΔGbind = -13.12 Kcal/mol, predicted Ki = 239.69 pM), but also, it showed interactions
with 9 key residues within the nsP3 binding pocket (Figure 3.8). Furthermore, the
ClogP for pose_3_2 was brought down to be 3.84 compared to 6.77 of the original hit 3.
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Figure 3.8 Pose_3_2 within the CHIKV nsP3 pocket. a) 3D representation, b) 2D
representation. H-bonds are shown as green dashes, cation-π and sigma-π interactions
are shown as orange lines.

As predicted, the nitrile group introduced on the benzimidazole rings, not only
accepted a H-bond from Asn24 (1.90 Å), but also accepted another H-bond from the
key residue Cys34 (2.19 Å). The nitrile group on the other benzimidazole ring also
accepted a H-bond from Lys35 (2.35 Å) as predicted. It is envisaged that such
interactions with Cys34 and Lys35 residues would stabilize the pose within the pocket
cavity openings (Figure 3.8a). The pocket central residues Gly112, and Val113 were
able to form sigma-π stacking interactions with a phenyl ring, and the imidazole moiety,
respectively (Figure 3.8b). The molecular weight of pose_3_2 is 522.5, with ClogP
value of 3.84, and these drug-like properties made it an attractive candidate for
synthesis and testing against the CHIKV.
3.3. Synthesis of pose_3_2 (86)
The retrosynthetic analysis of pose_3_2 (Figure 3.9) suggested that it could be accessed
through three synthetic steps; the synthesis of the nitro-benzimidazole, which can be
then reduced to the amino derivative, and reacted in a final step with oxalyl chloride
(Figure 3.9) to give the bis-product.
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Figure 3.9 The retrosynthetic analysis for the synthesis of pose_3_2 (86).

The synthesis of the benzimidazole nucleus can be achieved by a variety of
methods. The synthesis can involve the reaction between the phenylene diamine
derivatives with aldehydes,178 carboxylic acids179 or acid chlorides,180 utilizing a variety
of different solvents and catalysts. In this work, the benzimidazole 84 was synthesized
via the reaction of the 3,4-diaminobenzonitrile 82 with 3-nitrobenzaldehyde 83 in
solvent free conditions, where the two solids were mixed together (1:1 molar ratio) and
the mixture was heated with vigorous stirring at 90 ºC. Both solids melted, giving a dark
brown oil mixture (Scheme 3.1). After a few minutes of stirring the dark oil at 90 ºC,
the mixture solidified as a dark brown solid. At this stage, the first step of the reaction
occurred which was the condensation reaction of the aldehyde 83 with one of the
amines in 82 giving the Schiff base intermediate (Scheme 3.1). Increasing the
temperature to 145 ºC initiated the cyclization step, where the 2nd amine attacked the
electron deficient azomethene carbon, where the dark brown solid condensation
intermediate melted again giving a dark red oily mixture. Stirring continued for about 3
min, after which the mixture solidified again as a dark red solid (Scheme 3.1). The solid
was then extracted into boiling ethanol, and crystallized from a mixture of methanol,
1,4-dioxane and water to afford the benzimidazole 84 as a yellow crystalline solid.
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Scheme 3.1 The synthesis of the benzimidazole 84.

Analysis of the ESI-MS spectrum of 84 showed a peak at 264.1 m/z that
corresponded to (M+). The 1H NMR spectrum showed a broad singlet peak resonating
at 13.8 ppm which was assigned for the NH. This solvent free conditions enabled the
access to the desired benzimidazole in a short time (less than one hour) and relatively
good yield (70%).
The next synthetic step was the reduction of the nitro group in 84. Therefore, the
benzimidazole 84 was suspended in methanol, and Raney Nickel catalyst was added
under N2 atmosphere with vigorous stirring. The hydrogen source for the reduction was
hydrazine monohydrate in methanol, which was added dropwise. During the addition of
hydrazine hydrate, hydrogen gas was evolved and upon cessation, the reaction was
heated to 80 ºC for 2 h (Scheme 3.2). The mixture was then filtered through celite while
hot, and methanol and excess hydrazine hydrate were removed under reduced pressure
to give the amine 85 as a dark yellow solid.

Scheme 3.2 Reduction of the benzimidazole 84 to the amino derivative 85.

The analysis of 1H NMR spectrum of the product 85 showed a broad peak
resonating at 5.37 ppm which was assigned as the NH2 group. ESI-MS (negative
ionization) showed a peak at 233.0 which was assigned for (M-1).
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The final synthetic step was the dimerization of the amine 81 using oxalyl
chloride. The amine 85 was dissolved in dry THF in the presence of TEA, and the
mixture was stirred under N2 atmosphere at 0 ºC. A solution of oxalyl chloride in dry
THF was then added dropwise with vigorous stirring. After addition, the mixture was
left to warm to room temperature with stirring for 2 h (Scheme 3.3) after which the
mixture became turbid. The reaction was then quenched with chilled water and a solid
precipitated immediately. The solid was filtered and washed with water and methanol,
recrystallised from DMF to afford the final pose_3_2 (86) in 69% yield. The 13C NMR
spectrum of the product showed a peak at 158.8 ppm which was assigned to the CO
groups. The 1H NMR spectrum showed a peak at 11.08 ppm which was assigned for the
two oxalamide NH groups. The IR spectrum also showed a band at 2219 cm-1 that was
assigned for the nitrile group.

Scheme 3.3 Reaction of the amino benzimdazole 85 with oxalyl chloride to afford the
final compound 86.

In this reaction (Scheme 3.3), only the primary amine NH2 group was involved
in the reaction with oxalyl chloride. The benzimidazole NH is reactive and might react
with acid chlorides, however, it is known that N-acylbenzimidazoles undergo hydrolysis
to the free NH again in the presence OH groups or water.181 The rate of this hydrolysis
increases if the imidazole or benzimidazole carries electron withdrawing groups such as
the nitro group.182 The electron withdrawing nitrile group of 85 is therefore believed to
achieve similar effect, deactivating the acylation of the benzimidazole NH.
3.4. Concluding remarks
This chapter discussed the use of the macro domain (domain X) of the CHIKV nsP3 as
a possible target for the drug design against that virus. The nsP3 is a multifunctional
viral protein, with the macro domain being the domain which regulates the ADP-ribose
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substrates within the cellular process. Furthermore, the ADP-ribose binding site within
the macro domain is close to the connection site with the nsP2. Therefore, occupying
the ADP-ribose binding pocket with an exogenous ligand (inhibitor) should affect the
function of the nsP3 either in a polyprotein complex or as an individual functioning
protein. In this chapter, a virtual screening process of the NCI diversity set III, a library
that carries drug-like molecules, was performed using the ADP-ribose pocket as the
target binding site. Autodock Vina, a fast and reliable virtual screening engine, was
used and 17 hits were identified as potentially stronger enzyme binders compared to the
original ligand (ADP-ribose) which may serve as inhibitors for the CHIKV nsP3
functions. The search revealed that the hits made interactions with the identified key
residues within the pocket, and also with new residues that tended to stabilize the
ligand-receptor complex, such as Leu108, Trp148, Ser115 and Val22. The top 17 hits
(Table 3.1) were obtained from the NCI and are currently under antiviral evaluation (at
Griffith University).
The top hits were then subjected to re-ranking against the original ligand (ADPribose) using Autodock 4. This re-ranking resulted in 7 hits achieving higher scores than
the ADP-ribose. One hit, hit 3 (Table 3.2) was selected for further docking based
optimization. This optimization resulted in pose_3_2 (86) which showed a significantly
improved in silico profile compared to the original hit (Figure 3.10).
a) Hit 3

b) Pose_3_2 (optimized hit 3, 86)

ΔGbind = -11.31 Kcal/mol

ΔGbind = -13.12 Kcal/mol

Ki = 5.1 nM

Ki = 0.239 nM

ClogP = 6.77

ClogP = 3.84

Figure 3.10 Comparison between (a) hit 3 and (b) the optimized structure 86.
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The optimized structure 86 was then accessed through three facile synthetic
steps. This optimized hit 86 represents an early stage towards the discovery of a lead
compound, based on the structure-based approach, which can be further optimized using
in silico and in vitro in-depth studies.
The virtual screening hits 4 and 17 (Tables 3.1, 3.2) have the same linear
skeleton and showed good interactions with the CHIKV nsP3 ADP-ribose pocket. If
these molecules were demonstrated to be promising in activity, different derivatives can
be accessed through one step reaction (Figure 3.11), and therefore, they might be a
subject of both in silico and in vitro optimizations.

Figure 3.11 Possible access of different analogues for hits 4 and 17.

The inhibitor discovery status for the CHIKV nsP3 is still in the very early
stages. Thus fare, the enzyme is not even available as a testing kit to validate the
potential inhibitors. Efforts should be devoted to develop such validation techniques.
Protein crystallization with the inhibitor would enhance the drug design approach for
this virus.
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CHAPTER 4: Synthesis of Mycophenolic Acid Analogues as
Inhibitors of the Chikungunya Virus

4.1. Introduction
Mycophenolic acid (15, Figure 4.1) was isolated about one hundred years ago
from the cell culture of Penicillium brevi-compactum.125 It acts as an inhibitor for the
inosine monophosphate dehydrogenase (IMPDH) enzyme which is involved in the de
novo biosynthesis of guanine nucleotide. It has good anti-proliferation activity and has
been established as an anticancer126 and antiviral agent,

as well as an

immunosuppressant properties.127

Figure 4.1 Chemical structures of mycophenolic acid 15.

Recently, MPA was shown to inhibit the CHIKV replication and virus induced
cell death with an IC50 value of 0.2 µM and a selectivity index value of 150 (compared
to vero cell lines),128 and it was found to induce CHIKV apoptosis. It works by
inhibiting IMPDH, and when the CHIKV infected cells were provided with exogenous
guanosine (GMP), MPA was prevented from inducing the CHIKV cell death.128
Considered as a good lead compound, the in vivo activity of MPA acid against CHIKV
should be investigated as it is well known that mycophenolic acid suffers from a
metabolic drawback associated with rapid conjugation of the C-7 phenolic hydroxyl
group with glucuronic acid.183,184,129,130
MPA as a lead: Mycophenolic acid 15 has good drug like properties with a molecular
weight of 320.3, calculated logP (clogP *) value of 2.92, calculated LogD† value of 3.56
*
†

Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA, LogD is a pH dependent
distribution coefficient version of the logP. It represents the drug permeability (lipophilicity) at a certain
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(pH=1-2), 0.67 (pH=7.4) and 2.52 (pH=5.5) indicating good blood solubility and oral
bioavailability (oral drug absorption occurs in the small intestine at pH ~ 5.5185,186).
With the good CHIKV activity (IC50 = 0.2 µM), MPA 15 is a promising template for
developing anti-CHIKV drugs, with the metabolic drawbacks to be avoided for better
bioavailability properties.183,184,129,130 The structure of CHIKV IMPDH enzyme is not
yet available and therefore the structure based drug design for inhibitors is not a
possibility. Instead, a ligand based drug design approach can be used starting with MPA
15 as a lead compound.
4.2. Design of MPA analogues
Mycophenolic acid consists of three major components (Figure 4.2), an aromatic head
(the 3-oxo-1,3-dihydroisobenzofuran moiety), a rigid linker (the alkene connection) and
an acidic tail (the carboxylic acid group). The aromatic head carries two major hydrogen
bond acceptors (the carbonyl group and the oxygen atom of the lactone ring). The
aromatic benzo moiety carries a hydroxyl group, a methoxy group and a methyl group.
In this study, the three components of MPA 15 were investigated as optimizable
components that could be changed with a variety of similar systems, starting from
simple cores such as benzoic acids and anilines. Figure 4.2 shows the possible access to
MPA 15 analogues starting from such derivatives. Both the acids and anilines could be
converted into the aromatic head groups carrying H-bond acceptor capacity, and then
could be connected through simple C-C coupling, to the other two cores, the linker and
the acidic tail. R groups on the acids and anilines were selected to give a similar
environment as in 15.

physiological pH. Oral drugs to be able to be absorbed by passive diffusion through the gut wall, should
have their lipophilicity within a given range between 1 and 4 on LogD scale. Note that LogD = LogP at
neutral pH, therefore LogD describes the actual LogP values at different pHs.

84

Chapter 4

MPA Analogues

Figure 4.2 Design of MPA 15 analogues starting from benzoic acids and aniline
derivatives. The red circles indicate the HBA groups, the blue boxes indicate the rigid
linker and the green circle refers to the acidic tail moiety which could be either COOH
or the bioisostere tetrazole.

4.2.1. Design Strategy
The design of alternative and similar cores to MPA 15 was based on:
1. Changing the aromatic head: the aromatic head was either kept as a
benzolactone or changed to an isatin moiety (Figure 4.2). The use of benzolactones as
the aromatic head groups would highlight the importance of this functionality for the
anti-CHIKV activity. Isatins were also selected as alternative possible replacements for
the aromatic head group; as they have been showed to possess various pharmacological
and biological properties including anticholinesterase, anticonvulsant, antiinflammatory,
antihypertensive, antihypoxic, antimicrobial, and antiviral properties. 187,188 Furthermore,
the isatin moiety has been found in nature, e.g. as a component of the secretion from the
parotid gland of Bufo frogs,187 and in humans as a metabolic derivative of adrenaline. 189
Isatin is also found in the brain. 190 The structure of isatin participates in the activity,
where the two carbonyl groups (red circles, Figure 4.2) could accept H-bonds from
residues in the target receptors, and the NH can donate a H-bond to acceptor
residues.191,192 The aromatic core π-system of isatin was also found to participate
through aromatic interactions with some target receptor residues. 193 Therefore, replacing
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the benzolactone head of MPA 15 with isatin, would have some structural similarities,
with possible similar interactions with the yet unknown viral receptor.
2. Replacing the rigid linker alkene with the rigid phenyl ring (blue boxes, Figure
4.2) would be an applicable strategy for obtaining a rigid linker between the aromatic
head and the acidic tail of MPA analogues. Utilizing the C-C cross coupling
chemistry194,195,196 could facilitate such facile access to the biphenyl system. This phenyl
aromatic linker may also provide a π-electron system for interaction within the yet
unknown target site.
3. The acidic tail was kept as either a carboxylic group or changed to the
bioisosteric tetrazole197 moiety (green, Figure 4.2). The carboxylic group is highly polar
and can ionize and hinder absorption. The tetrazole ring has similar physiochemical
properties but offers some advantages over carboxylic acids. Like COOH groups,
tetrazole rings have an ionisable acidic proton at pH 7.4. They are also planar in
structure, however, the tetrazole anion is 10 times198 more lipophilic than the
carboxylate anion and this can enhance drug absorption as a result. Tetrazole rings are
also resistant to many of the metabolic reactions that occur to the carboxylic
groups.199,198
This chapter discusses the different synthetic strategies undertaken for the access to
the aromatic head groups (benzolactones and isatins) and the C-C coupling reactions
utilized to tether the synthesized head groups to the linker and acidic tails (either COOH
groups or tetrazoles) producing different conjugates. It also discusses the calculated
physicochemical properties of the synthesized target compounds as templates for
developing drug-like candidates.
4.3. Synthesis of the Aromatic Heads
4.3.1. Synthesis of the isobenzofuran-1(3H)-one (benzolactones)
Many procedures have been reported for the synthesis of the isobenzofuran-1(3H)-one
ring system including from 2-formylbenzoic acid,200 phthalaldehyde,201 1,2phenylenedimethanol202 and from benzoic acids.203
In this study, benzoic acids were used as starting materials.203 Therefore, a
mixture of benzoic acid derivatives 87-89, palladium acetate, dipotassium phosphate
and dibromomethane as the solvent and carbon donor was heated in a sealed tube at 140
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ºC under a N2 atmosphere for 36 h (Scheme 4.1). After dilution of the reaction with
CH2CH2, filtration through celite, washing with acid and evaporation of the solvent, the
lactones 90-62 were obtained in 38-58% yield. The obtained compounds were easily
purified through either flash column chromatography or recrystallization from a mixture
of chloroform/hexane mixture (1:3, v/v). Analysis of the 1H NMR spectra of the
isobenzofuran-1(3H)-ones 90-92 showed a new singlet peak resonating at 5.17-5.23
ppm that was assigned to the newly formed lactone CH2 group. Analysis of the

13

C

NMR spectra showed one carbon resonating at 68.2-86.7 ppm that was assigned to the
newly added methylene carbon.

Scheme 4.1 The synthesis of the isobenzofuran-1(3H)-one heads 90-92.

The reaction proceeds via a Pd(II)-catalysed C–H activation where the
coordination of the cation with the carboxylate group forces the Pd(II) centre to chelate
in the proximity of the C-H bond ortho to the acid substituent (Figure 4.3), a geometry
that facilitates C-H cleavage.203 The alkylation attacks the less hindered ortho position
to the carboxylic acid group.

Figure 4.3 Mechanism of benzolactone formation from benzoic acid. 203

This synthetic procedure was applied either on the brominated benzoic acids,
which provided the 6-bromobenzolactones with the coupling handles already intact, e.g.
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90

and

the

6-bromo-7-

methylisobenzofuran-1(3H)-one 91, or was applied on the benzoic acid derivative
without the bromo substituent, which required further attachment of a coupling handle
for the next step, e.g. 5,7-dimethoxyisobenzofuran-1(3H)-one derivative 92.
Addition of coupling handle (bromine) to 92: The presence of the coupling handle
(bromine) on C6 of the 5,7-dimethoxyisobenzofuran-1(3H)-one 92 was previously
described using a different benzolactone synthesis procedure, starting from either 4,6dibromo-5,7-dimethoxyisobenzofuran-1(3H)-one204

or

from

methyl

3-bromo-6-

(bromomethyl)-2,4-dimethoxybenzoate (93, Figure 4.4).205 In both cases, the
benzolactone skeleton was synthesized with the bromine already attached in the desired
position, prior to the cyclization step.

Figure 4.4 Example of the synthesis of the 6-bromo-5,7-dimethoxyisobenzofuran1(3H)-one 94 from methyl 3-bromo-6-(bromomethyl)-2,4-dimethoxybenzoate 93, with
the bromine atom already intact prior to cyclization. 205

However, the regioselective bromination on C6 of the unsubstituted phthalide 97
(benzolactone) has been previously described in acidic medium, using a mixture of
sulphuric acid and trifluoroacetic acid.206 The selective iodination at C6 was also
previously reported.207 Position 6 in 5,7-dimethoxyisobenzofuran-1(3H)-one in 92 is
more activated than that of the unsubstituted phthalide 97, however, it is more sterically
hindered by the methoxy groups. In this work, due to the crowding of C6 by the two
methoxy groups, a different method was used to access the 6-bromo derivative for this
benzolactone 94 from the corresponding benzolactone 92. A solution of 5,7dimethoxyisobenzofuran-1(3H)-one 92 in glacial acetic acid was cooled in an ice bath
before a solution of bromine in glacial acetic acid was added dropwise and the mixture
was then stirred at room temperature for 4 h (Scheme 4.2). The resulting solid was
filtered and subjected to flash column chromatography (60% CH2 Cl2 in hexane) to
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afford the benzofuran 94, which was recrystallised from 1,4-dioxane. The
isobenzofuran-1(3H)-one 94 was obtained in 84% yield with a melting point of 190 ºC
(Lit.205 m.p 206 ºC). The 1H NMR spectrum of 94 showed the disappearance of the C6
aromatic proton which resonated at 6.42 ppm in

1

H NMR spectrum of the

isobenzofuran-1(3H)-one 92. The EI-MS spectrum of 94 showed also a peak at 272 m/z
which was assigned to the molecular ion (M+,

79

Br). The addition of the bromine

solution was carried out at 0 ºC to minimize the production of the 4-bromo isomer 95
and the 4,6-dibromo derivative 96 side products. These side products were not separated
due to overlapping bands on the TLC plates, and low mass recovery of this mixture. The
EI-MS spectrum of the mixture showed peaks at 272 m/z (79Br) that was assigned to the
4-bromo isomer 95 and at 352 m/z (79Br,

81

Br) that was assigned to the 4,6-dibromo

derivative 96. The reported melting point for the 4,6-dibromo derivative 96 is 136 ºC204,
and that for the 4-bromo isomer 95 is 245 ºC205.

Scheme 4.2 The synthesis of 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 90.

The 2D 1H NMR NOESY experiment of 94 showed a correlation between the
aromatic proton H4 with a methoxy group. The methoxy groups appear as singlets
resonating at 4.02 ppm and integrate for 6 protons*. No correlation was seen between
the aromatic H4 proton and the CH2 in the NOESY experiment. However, the big
difference in the melting points of 94 and 95 argued the bromination of C6.
Access to the unsubstituted benzofuran 100: The synthesis of 6-bromoisobenzofuran1(3H)-one 100 was performed following the reported short procedure206 initially using
N-bromosuccinimide (NBS) in the H2SO4/TFA mixture and stirring for 3 days (Scheme
4.3). However, this procedure gave a mixture of the multi-brominated phthalide rather
*

Different NMR solvents were used to get better resolution of the methoxy groups, however, they always
appeared as a singlet peak.
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than the 6-bromo derivative 100. Therefore, in an alternative procedure208 (Scheme 4.3),
phthalide 97 was treated with a nitrating mixture of H2SO4/HNO3 to afford 6nitroisobenzofuran-1(3H)-one 98 in 81% yield. Subsequent reduction with iron209 in a
mixture of ethanol, water and acetic acid, followed by standard diazonium formation
and then treatment with CuBr gave the 6-bromoisobenzofuran-1(3H)-one 100 in 74%
yield,210 which was recrystallised from methanol.

Scheme 4.3 The synthesis of 6-bromoisobenzofuran-1(3H)-one 100.

4.3.2. Synthesis of the isatin aromatic heads
The desired isatin heads were prepared from the corresponding aniline derivatives with
or without the bromine coupling handles.
Access to the bromodimethoxy isatin 103: The synthesis of 4,6-dimethoxyindoline-2,3dione 103 (Scheme 4.4) was undertaken using the Stolle procedure. 211 Therefore, the
aniline 101 was reacted with oxalyl chloride to form an intermediate chlorooxalylanilide
with spontaneous cyclization, in the absence of Lewis acid, to yield dimethoxyisatins
102 in 80% yield.212
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Scheme 4.4 The synthesis of 5-bromo-4,6-dimethoxyindoline-2,3-dione 103.
Mono selective bromination of isatins at C5 can be achieved on small scale
reactions by using N-bromoacetamide in acetic acid medium.213 Therefore, a solution of
the isatin 98 in glacial acetic acid was cooled in an ice bath followed by portion wise
addition of the NBS at 0 ºC, and the mixture was then left to warm to room temperature
with stirring for 8 h. The yellow solid was filtered, washed with saturated NaHCO3
solution, and then with a water/ethanol mixture and then vacuum dried. The residue was
then recrystallised from 1,4-dioxane to afford the bromoisatin 103 in 60% yield. The EIMS spectrum of 103 showed a peak at 287 m/z that was assigned to (M,81Br)+ ion. The
1

H NMR spectrum showed only one aromatic proton peak resonating at 6.36 ppm

assigned to H7. This proton correlated to only one methoxy group in the 2D NMR
(HMBC and NOESY) experiment. This is only possible when the proton is on C7. The
proton in position 5 must show correlation to both methoxy groups which was not
observed in 103. This confirmed that the bromination occurred at position 5 of the isatin
ring.
Access to the 7-methylisatin 106: The synthesis of 5-bromo-7-methylindoline-2,3-dione
106 was achieved using Sandmeyer214 methodology, starting from 4-bromo-2methylaniline 104 which was reacted with chloral hydrate and hydroxylamine
hydrochloride in aqueous sodium sulphate to form an isonitrosoacetanilide 105 (Scheme
4.5), which presented as a gummy solid that was difficult to isolate. This gummy solid
was dried and taken directly to the next cyclization step using concentrated sulphuric
acid. The mixture was heated gradually to 80 ºC for 10 min. After cooling to room
temperature, the mixture was poured onto crushed ice and stirred for 1 h, whereby a
solid precipitated and was filtered. The desired compound was isolated in 75% yield
over 2 steps. The synthesis of the isatin 106 was previously reported by a different
method,215 where the isatin core was synthesized first, and then was brominated using
bromine solution.215
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Scheme 4.5 The synthesis of 5-bromo-7-methylindoline-2,3-dione 106.

Access to methoxymethylisatin 111: The structure of MPA 15 (Figure 4.1) has one
methyl group in the para position to the OH group on the aromatic head. The isatin 4methoxy-7-methylindoline-2,3-dione 111 was selected as a similar derivative with the
OH group masked as a methoxy functionality, to avoid the metabolic drawback of MPA
15. The synthesis of this derivative started from the commercially available 4-methyl-3nitrophenol 107 which was methylated using methyl iodide216 in DMSO with NaOH as
a base to give 4-methoxy-1-methyl-2-nitrobenzene 108 in 80% yield (Scheme 4.6). The
5-methoxy-2-methylaniline217 109 was then obtained by reducing the nitro group of 108
over Raney Nickel and using hydrazine monohydrate as hydrogen source, and heating
in methanol, to afford the aniline 109 in 91% yield. Reaction of the aniline 109 with
oxalyl chloride in benzene gave the intermediate chlorooxalylanilide 110, without
spontaneous cyclization as in the case of the dimethoxy derivative 102 (Scheme 4.4).
This was due to the lower reactivity of the monomethoxy intermediate 110. Therefore,
the intermediate 110 was directly suspended in dichloroethane (DCE) and aluminium
chloride was then added as a Lewis acid to promote the cyclization step. Acidic workup,
followed by extraction with ethyl acetate and concentration of the solvent gave an
orange residue that was subjected to column chromatography and elution with 30%
ethyl acetate in petroleum spirit afforded the isatin 111 in 30% yield. The IR spectrum
of the product showed strong amide absorption peak at 1635 cm-1 assigned to the CO
group. The EI-MS spectrum showed a peak at 191 assigned to the molecular ion mass
(M+). Analysis of the 13C NMR spectrum of 111 showed two additional carbons peaks
resonating at 180.9 and 160.1 ppm assigned to the two carbonyls C2 and C3,
respectively.
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Scheme 4.6 The synthesis of 4-methoxy-7-methylindoline-2,3-dione 111.

Addition of the coupling handle (bromine) on 111 for the next synthetic step was
easily achieved as there was only one dominant bromination site at C5. Therefore, 4methoxy-7-methylindoline-2,3-dione 111 was reacted with bromine in glacial acetic
acid (Scheme 4.7) at 0 ºC to room temperature for 10 h. The resulting solid was
collected, washed with NaHCO3, water and then recrystallised from acetic acid to yield
the desired isatin 112 in 84% yield. Analysis of the 1H NMR spectrum of the product
showed the disappearance of the H5 that resonated at 6.61 ppm, and the EI-MS
spectrum of 112 showed a peak at 271 that was assigned to the (M, 81Br)+ ion.

Scheme 4.7 The synthesis of 5-bromo-4-methoxy-7-methylindoline-2,3-dione 112.
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4.4. Coupling of the Aromatic Head groups
4.4.1. Coupling with the isobenzofuran-1(3H)-one
4.4.1.1. Coupling to the linker and COOH tail
Linking of the aromatic head to the acidic tail was accessed utilizing Suzuki C-C cross
coupling chemistry,194,195,196 to access the biphenyl rigid system (Figure 4.2). This facile
one step synthesis gave the three main components of the MPA designed analogues: the
aromatic head, the rigid linker (phenyl) and the acidic tail (COOH). The chosen boronic
acid was the commercially available 3-(3-boronophenyl)propanoic acid 113. Suzuki
cross coupling for the 6-halo-isobenzofuran-1(3H)-one derivatives was previously
described206 using a diphasic medium of toluene and water as a solvent, disodium
carbonate as a base and tetrakis(triphenylphosphine)palladium(0) as palladium catalyst
and heating at reflux temperature.
In this work, 1,2-dimethoxyethane (DME) was initially used as a solvent
because of its lower boiling point (~85 ºC) compared to that of toluene (~110 ºC) to
retain the stability of the lactone ring when heating with water at refluxing temperatures.
Therefore, the 6-bromo-isobenzofuran-1(3H)-ones 90, 91, 94 and 100 were reacted with
3-(3-boronophenyl)propanoic

113,

potassium

phosphate

and

tetrakis(triphenylphosphine)palladium(0) in DME/H2O mixture and the reaction was
heated in a sealed system at 85 ºC for 8-14 h. After the specified reaction time, the
solvent was concentrated and the obtained solids were suspended in HCl and were then
extracted with ethyl acetate. After evaporating the solvent, the resulting residues were
subjected to PLC (10% methanol in CH2 Cl2, 0.5% acetic acid) to afford the acid
conjugates 114-117. The reaction worked well, however the isolated yields of the final
product were modest (30-35%). This was due to the poor solubility of the benzolactones
(90, 91, 94, 100) in DME. Interestingly, replacing the DME with 1,4-dioxane and
keeping the temperature at 85 ºC (Scheme 4.8), greatly improved the yields up to 78%.
Table 4.1 shows the optimized reaction conditions. The IR spectra of the obtained
benzolactone-acid conjugates 114-117 showed broad OH absorption bands at 29722989 cm-1 accompnied by C=O absorption bands at 1699-1755 cm-1 indicating the
presence of the COOH functional group. Analysis of the 1H NMR spectrum of 3-(3-(4methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 114 showed a
peak at 10.54 ppm that was assigned to the COOH group, and the two propanoic CH 2
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groups appeared as two triplets resonating at 2.99 and 2.68 ppm. The purity of the
compounds 114-117 was found to be >95% as analysed by normal-phase HPLC using
isopropanol with 0.1% TFA in hexane as the developing solvent. The calculated
physiochemical properties of this series are shown in Table 4.2.

Scheme 4.8 Coupling procedures for the isobenzofuran-1(3H)-one 90, 91, 94 and 100
with the boronic acid 113.

Table 4.1 Optimization conditions of the isobenzofuran-1(3H)-ones 114-117 coupling
reaction with the boronic acid 113.
Solvent

Reaction time (h)

Yields (%)

DME/H2O

8-14

30-35

Dioxane/H2O

4-6

54-78

The Suzuki coupling is a robust technique for the synthesis of biaryl bonds
commonly utilising an aryl boronic acid and an aryl halide. The reaction mechanism of
the Suzuki coupling (Figure 4.5) proceeds in 3 key steps; oxidative addition of the Pd(0)
complex to the aryl bromide to give the Pd(II) complex, transmetallation of the aryl
boronate complex to the Pd(II) complex, and reductive elimination to give the biaryl
and restore the Pd(0) catalyst.
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Figure 4.5 The mechanism of the Suzuki reaction to produce the biaryls.

Table 4.2 Physiochemical properties of the benzolactones-carboxylic acid conjugates
114-117.

Compound

R

Mwt

clogP

*

LogD† at pH
1

4-OCH3

312.32 1.96±0.59 2.98 1.97 0.14

115

4-CH3

296.32 2.83±0.52 2.85 2.08 0.34

117

†

4,6-(OCH3)2 342.35 1.67±0.60 2.82 1.84 0.01
H

282.29 2.37±0.52 2.89 1.90 0.07

Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA
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The introduction of the rigid linker (the phenyl ring) was proposed to increase
the lipophilicity of the compounds compared to the lead mycophenolic acid which has a
LogD value of 0.67 at blood pH. Table 4.2 shows that all the synthesized benzolactonecarboxylic conjugates 114-117 have drug like qualities. This series can ionize in the
different pH values as can be seen from the change in the LogD values. In acidic pH
(stomach), they show similar LogD values around 2.85 as the ionization will be
minimum (unionized), and therefore, 114-117 could be in the absorbable form (can
cross the lipid layer). At the blood pH (7.4), the acid conjugates showed low LogD
values indicating good blood solubility, and therefore, may present siutable properties
for absorbtion from the stomach and distribution through the body with the circulating
blood. At the intestine pH 5.5, where the oral bioavailable drugs are absorbed,186 the
ionization shifts towards the lipophilic character without returning to the full unionized
state, where the synthesized compounds have good lipophilicity scale (1.84-2.08, lower
than that of the lead MPA 15 at the same pH), and therefore, the designed compounds
might show good oral bioavailability properties.

4.4.1.2. Coupling to the linker and tetrazole tail
The first synthesis of the tetrazole ring used the acetonitrile intermediates which
can then be cyclised to tetrazoles. Therefore, the commercially available boronic acid,
3-(3-boronophenyl)propanoic acid 118 was utilized in the coupling reaction with the
bromobenzolactones. Due to the high cost of 118, the ester 2-(3-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile 119 was also synthesized as an alternative
to 118 and was used in the coupling reaction (Scheme 4.9). The same coupling
conditions were used: 1,4-dioxane/H2O mixture, potassium phosphate as a base and
tetrakis(triphenylphosphine)palladium(0) as a catalyst, and the mixture was heated
under a N2 atmosphere for 7-15 h. The solvent was then evaporated and the resulting
residues were suspended in HCl, and extracted with ethyl acetate. After evaporating the
solvent and subjecting the residues to flash column chromatography, the acetonitrile
intermediates 120 and 121 were obtained in 50% and 76%, respectively. Analysis of the
1

H NMR spectra of 120 and 121 showed the CH2 protons adjacent to the CN group,

resonating as a singlet peak at 4.83 ppm. The IR spectra of these derivatives 120 and
121 showed strong absorption bands at 2165-2169 cm-1 assigned to the CN group.
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Scheme 4.9 The synthesis of the acetonitrile intermediates 120 and 121.

Synthesis of 119: The boronic ester 119 was synthesized starting from the
commercially available 3-iodophenol 122 where it was dissolved in DMF with NaOH
and the mixture was stirred until a pale brown solution was obtained (Scheme 4.10).
Alkylation of the OH group was then achieved using the dropwise addition of 2chloroacetonitrile 123 at room temperature and the mixture was stirred for 18 h. The
mixture was then poured onto ice, where the resulting oil was extracted. Washing the oil
extract with water and brine, and trituration with charcoal and concentration gave 2-(3iodophenoxy)acetonitrile 124 in 80% yield. Analysis of the 1H NMR spectrum of the
intermediate 124 showed a singlet peak at 4.68 ppm assigned to the CH 2. Analysis of
the EI-MS spectrum showed a peak at 259 m/z assigned to the molecular ion (M+).

Scheme 4.10 The synthesis of the acetonitrile boronic ester 119.
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The intermediate 2-(3-iodophenoxy)acetonitrile 124 was then converted to the
boronic ester using Miyaura borylation218 reaction, using bis(pinacolato)diboron 125,
potassium acetate and PdCl2(dppf)* catalyst in THF and the mixture heated at reflux for
24 h. The solvent was then evaporated, ethyl acetate was added and the resulting residue
was sonicated for 10 min and filtered. The filtrate was triturated with MgSO 4 and
charcoal, filtered through celite and then concentrated under vacuum. The resulting
residue was recrystallised from ethyl acetate/hexane (3:2) to give the boronic ester 119
as a pink solid in 95% yield. Analysis of the 1H NMR spectrum of 119 showed a singlet
peak resonating at 1.26 ppm integrating for 12 protons assigned to the four methyl
groups. Analysis of the

13

C NMR spectrum showed one peak resonating at 83.7 ppm

integrating for two carbons assigned to the dioxaborolan, and another peak at 25.2 ppm
(four carbons) that was assigned to the methyl groups.
The Miyaura borylation reaction proceeds via the oxidative addition of the alkyl
iodide to the palladium catalyst (Figure 4.6). The acetoxy anion from the base then
reacts with the palladium complex replacing the iodide ion and forming the
(acetate)palladium(II) complex. Transmetalation with the bis(pinacolato)diboron and
subsequent reductive elimination then occurs to afford the boronic ester 119 and
releasing the ligand complex.

*

[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
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Figure 4.6 Borylation mechanistic pathway using PdCl2(dppf) for the synthesis of the
boronic ester 119.218

The tetrazole ring synthesis: The benzolactone acetonitrile intermediates 120 and 121
were then used in the tetrazole synthesis step, utilizing the [2 + 3] cycloaddition of
azides. The nitriles 120 and 121 were allowed to react with 4 equivalents each of NaN3
and NH4Cl in DMF and the mixture was heated at reflux for 48 h. DMF was then
evaporated and the resulting residue was dried under vacuum. Ethanol was then added
to the dry residue and the mixture was sonicated for 10 min, filtered and ethanol was
concentrated and the residues were subjected to PLC using 90% CH 2Cl2, 10% ethanol
and 0.1% TFA. The isolated yields of the tetrazoles 126 and 127 were below 30%. Acid
catalysis219 for this cycloaddition significantly reduced the reaction time (Scheme 4.11).
However, the improvement in the yield was not significant (35%). The purity of the
isolated tetrazoles were analysed by HPLC and was found to be >95%.
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Scheme 4.11 The synthesis of the tetrazoles 126 and 127 from the acetonitrile
derivatives 116 and 117.

Himo et al.219 reported different mechanisms of tetrazole formation using azide
salts in the presence of ammonium salts. The reaction can either proceed via the known
[2 + 3] cycloaddition (pathway A, Figure 4.7) or by a two-step sequence where the
azide, as a nucleophile, attacks the nitrile carbon giving an intermediate compound
(pathway B, Figure 4.7), followed by ring closure through simple 1,5-cyclization. The
second mechanistic pathway B depends of the substituent adjacent to the nitrile group
(A in Figure 4.7), the more electron-withdrawing group, the intermediate in pathway B
becomes more stable and mechanism B is more favourable based on calculated energy
barriers219 for the transition states. Also, the presence of a proton in the reaction
medium can act as an activator to the nitrile group to be attacked. This mechanism is
similar to the known mechanisms of acid-catalyzed nitrile hydrolysis and the Pinner
synthesis,220 with the difference being that the nucleophile in this case (Figure 4.7) is an
azide.
The key to this mechanistic pathway (B) is that the nitrile is activated by a
proton, provided by the ammonium salts as well as other proton sources. In this reaction
(Scheme 4.11), the addition of acetic acid catalyst may have provided sufficient
concentrations of the activating proton, and the reaction proceeded via pathway B, and
that was the reason for shortening the reaction time (48 h without acid and 12-24 h in
presence of acid).
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Figure 4.7 Mechanistic pathways for the tetrazole formation. 219

Access to the tetrazole via an alternative strategy: The modest yields (35%) of the
tetrazole formation described above (Scheme 4.11) were not appropriate for the
synthesis of other tetrazole derivatives. Another synthetic strategy was therefore
designed to synthesize these derivatives in which the tetrazole moiety was attached to
the boronic ester, prior to the coupling reaction with the 6-bromobenzolactones. The
previously synthesized 2-(3-iodophenoxy)acetonitrile 124 was used to access the
intermediate 128 utilizing the azide tetrazole formation discussed above. Therefore, 124
was mixed with NaN3 and NH4Cl in DMF containing a few drops of glacial acetic acid
and the mixture was heated at reflux for 14 h under a N 2 atmosphere (Scheme 4.12).
The solvent was then concentrated and the resulting residue was dried. Ethanol was
added, and the mixture was sonicated for 10 min, filtered and ethanol was evaporated to
yield a white fluffy solid of the tetrazole intermediate 128 in good yield (80%). The EIMS spectrum for this tetrazole intermediate 128 showed a peak at 302 m/z assigned to
the molecular ion (M+). This 5-((3-iodophenoxy)methyl)-1H-tetrazole 124 was then
converted to the boronic ester using the same borylation method discussed in Scheme
4.10. Therefore, 128 was reacted with bis(pinacolato)diboron 125, potassium acetate
and PdCl2(dppf) catalyst in THF and the mixture was heated at reflux temperature for
18 h under a N2 atmosphere (Scheme 4.12). The solvent was then concentrated and
ethanol was added to the resulting residue and the mixture was further heated at reflux
for 10 min, filtered hot and concentrated under vacuum to afford a white solid of
potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol102
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1-ide 129 (Scheme 4.12). Analysis of the 1H NMR spectrum of this boronic ester 129
showed a singlet peak resonating at 1.90 ppm and integrating 12 protons assigned to the
four methyl groups. These four methyl carbons appeared also as a singlet peak in the
13

C NMR spectrum, resonating at 22.6 ppm. ESI-MS spectrum showed a peak at 301.1

m/z that was assigned to the anion [m-K+]-.

Scheme 4.12 The synthesis of the tetrazole boronic ester intermediate 129.

The tetrazole synthesis: The synthesized boronic ester-tetrazole conjugate 129 was then
reacted in the same optimized coupling conditions, using 1,4-dioxane/water mixture,
with 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 94 and 6-bromoisobenzofuran1(3H)-one 100 (Scheme 4.13). The tetrazole rings are known to be stable198 in such
mild coupling conditions as well as many other chemical conditions. Therefore, the
mixture was heated at 85 ºC for 20-24 h, the solvent then was concentrated and a
solution of NaHCO3 was added to the resulting residue and sonicated for 15 min. The
resulting turbid solution was then washed with CH2Cl2 and the aqueous layer was
filtered, cooled to 0 ºC and neutralized with 2 M HCl. The resulting white solid was
collected by filtration, washed with chilled methanol and dried under vacuum to afford
the tetrazoles 130 and 131 in 53% and 57% yield, respectively (Scheme 4.13). The
HPLC analysis of this series indicated purity >95%.
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Scheme 4.13 Alternative route to access the tetrazole conjugates 130 and 131 via
reaction with the boronic ester-tetrazole intermediate 129.

Interestingly, using this alternative route (Scheme 4.13) not only allowed the use
of mild reaction conditions, thereby avoiding unwanted side products, but also
improved the yield of the final tetrazole conjugate (from 35% in Scheme 4.11 to 56% in
Scheme 4.13) without further optimization. This reaction (Scheme 4.13) was clean
compared to the above mentioned cycloaddition tetrazole formation method (Scheme
4.11) as judged by less side products spots upon TLC analysis.
For all the tetrazole conjugates obtained by the two methods, the sodium azide
cycloaddition, 126 and 127 (Scheme 4.11) and the coupling with the tetrazole-boronic
ester intermediate, 130 and 131 (Scheme 4.13), the purity was analysed using the
normal phase HPLC, utilizing a mixture of isopropanol with 0.1% TFA in hexane. This
system was developed after the failure with the reverse phase HPLC where the tetrazole
conjugates were eluted first within two minutes, with poor resolution. Table 4.3 showed
the calculated physiochemical properties for the synthesized tetrazoles.
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Table 4.3 Physiochemical properties of the benzolactones-carboxylic acid conjugates.

Compound

R

Mwt

clogP

LogD† at pH

*

1
126

5-OCH3

127

5-CH3

130
131

5.5

7.4

338.32 0.68±0.70 2.33 1.55 -0.16
322.32 1.55±0.68 2.85 2.08

0.34

5,7-(OCH3)2 368.35 0.39±0.72 2.20 1.42 -0.29
H

308.30 1.09±0.68 2.47 1.69 -0.03

It can be inferred from table 4.3 that the designed and synthesized benzolactonetetrazoles conjugates 126, 127, 130 and 131 have good ionization profiles when present
at physiological pH. Like the synthesized carboxylic acid analogues 114-117, the
tetrazole conjugates 126, 127, 130 and 131 are nearly non-ionizable in the acidic pH of
the stomach, however, their LogD values lie in the acceptable scale range (1-4).186 The
noticed increase in the lipophilicity compared to the carboxylic acid conjugates 114117, was related to the introduction of the more lipophilic tetrazole moiety. After
absorption, the tetrazole conjugates 126, 127, 130 and 131 would tend to be strongly
ionisable in the blood pH as can be indicated by the low LogD values. The methyl
substituent 127 was the only derivative with a positive LogD value at pH 7.4. This
argues for the increased blood solubility and also the possibility of conjugation with
blood soluble proteins. However, at the intestine pH 5.5, the conjugates have relatively
good LogD values (1.42-2.08), very similar to the carboxylic acid conjugates 114-117
(Table 4.2), which indicates the possible oral bioavailability of these compounds.
Synthesis of a β-lactam derivative: During the synthesis of the benzolactone
derivatives, it was also of interest to synthesize one benzolactone derivative with an
amino group (NH2) replacing the OH group, which is responsible for the metabolic
*
†

Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA

105

Chapter 4

MPA Analogues

drawback of the lead MPA 15 (Figure 4.1). Therefore, the synthesis of this amino
analogue

started with the

2-amino-3-bromo-5-methylbenzoic acid

132.

The

benzolactone formation reaction (Scheme 4.1) required protection of the NH 2 group in
the presence of palladium catalyst, and heating at elevated temperature for a long time
would produce undesired side products that might involve the NH2 group, and therefore,
a base stable group such as the acetyl or the pivaloyl group, was required. Initial trials
with mild conditions such as TMA in CH2CH2 were used, however, this method ended
up with the full recovery of the unprotected amino benzoic acid 132. Instead, an
alternative method was used (Scheme 4.14) using pivaloyl chloride, excess n-BuLi as
the base, in THF at -78 ºC. This method was previously described221 for the protection
of the unsubstituted 2-aminobenzoic acid. Therefore, the amino benzoic acid 132 was
dissolved in THF and the solution was cooled to -78 ºC and was stirred for 20 min.
Pivaloyl chloride was then added dropwise at -78 ºC and the reaction was allowed to
warm to room temperature and was stirred for 3 h. The reaction mixture was then
diluted with ethyl acetate and water and the organic layer was separated and washed
with water and brine. The combined organic layers were concentrated under vacuum to
yield a colourless oil (Scheme 4.14).

Scheme 4.14 Attempted reaction to synthesize the protected amino benzoic acid 134.

Surprisingly, analysis of the resulting oil showed that the amino-protected
compound 134 was not formed, instead, the β-lactam product 133 was obtained in 47%
yield. The remaining of the reaction mixture was un-reacted starting material 132. The
EI-MS spectrum showed a peak at 295 m/z assigned for M+ of 133, rather than a peak at
313 m/z for 134. This 18 amu unit difference (as H2O) in the molecular ions was an
indication of the formation of the β-lactam ring system. The HRMS spectrum for the β106
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lactam formula C13H15BrNO2 (calculated; 296.0286 m/z), showed the ion peak at
296.0294 m/z, confirming the molecular formation of 133.
This reaction proceeded via nucleophilic attack of the N atom on the carbonyl of
the carboxylic acid group, forming the β-lactam ring. Figure 4.8 shows suggested
mechanistic pathways for such reaction. Pathway (A) is the formation of the mixed acid
anhydride, then the nucleophilic attack of the amino group on the carbonyl group,
forming the closed ring, and then the less nucleophilic amidic NH attacked another
pivaloyl group giving the final product 133. The alternative pathway (B) is the
protection of both functional groups, followed by the nucleophilic attack of the nitrogen
on the electrophilic carbonyl and ring closure.

Figure 4.8 Suggested mechanistic pathways for the formation of the β-lactam product
133.

A similar reaction was reported for the synthesis of such β-lactam (Figure 4.9)
where the reaction occurred after protecting the NH2 with the pivaloyl group.222 Such
evidence might suggest that the second pathway (B) might be the mechanism that
occurred for 132, especially the reaction (Scheme 4.14) occurred in the presence of
excess base.
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Figure 4.9 Reported reaction showing the formation of the β-lactam product 136.222

It was interesting to utilize this β-lactam derivative 133 in the coupling reactions
with the different boronic acids, especially it has already the coupling handle (bromide)
attached. Therefore, 133 was heated with 3-(3-boronophenyl)propanoic acid 113,
tetrakis(triphenylphosphine)palladium(0) and potassium phosphate in dioxane/water
mixture, at 85 ºC for 18 h (Scheme 4.15). The solvent was then concentrated and the
flask was cooled to 0 ºC, chilled HCl solution was added dropwise with stirring, the
resulting solid was extracted with ethyl acetate, washed with water, brine and dried
(MgSO4), and the solvent was concentrated under vacuum. The resulting residue was
subjected to a flash column chromatography using 50% CH 2Cl2, 50% ethyl acetate and
1% acetic acid to afford 3-(3-(3-methyl-8-oxo-7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5trien-5-yl)phenyl)propanoic acid 137 as an oil in 60% yield. Analysis of the 1H NMR of
137 showed a singlet peak at 8.56 ppm assigned to the COOH group. EI-MS spectrum
showed a peak at 365 assigned to the molecular ion (M+). This oily product was found
to be > 98% pure by HPLC analysis, with a retention time of 27.9 min.

Scheme 4.15 Coupling reaction of the β-lactam derivative 133 with the boronic acid
113.
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This β-lactam acid conjugate 137 has a LogD* value of 3.85 (at pH = 1), 2.83 (at
pH = 5.5) and 0.99 (at pH = 7.4). The relatively unionized (clogP † = 3.75±0.65) form in
the stomach indicated good lipid solubility that the compound can be found in the
absorbable form. In the blood, 137 has the tendency to ionize providing good solubility
and therefore, good distribution within the body. The slight ionization state in the
jejunum (pH=5.5) makes 137 also a possible orally bioavailable candidiate.
The reaction of the β-lactam intermediate 133 with the boronic acid (3(cyanomethoxy)phenyl)boronic acid 118 was undertaken utilizing the same coupling
conditions (Scheme 4.16). The coupling reaction occurred, forming the biphenyl
system, and the β-lactam was open to give a benzoic acid derivative 138. The IR
spectrum of 138 showed a broad peak at 3328 cm-1 assigned to the NH group. Analysis
of the 1H NMR spectrum showed a peak resonating at 8.61 ppm that was assigned to the
COOH group. The found mass by the HRMS was 367.1656 that corresponded to the
formula C21H23N2O4 (MH+; calculated, 367.1658).

Scheme 4.16 Reaction of the β-lactam 133 with (3-(cyanomethoxy)phenyl)boronic acid
118.

The difference between this reaction (Scheme 4.16) and the previous one
(Scheme 4.15) was only during the workup, which was the same except the HCl was not
pre-cooled and was added at room temperature. It is believed that during this thermally
uncontrolled procedure, the β-lactam ring was hydrolysed to give the COOH group of
138. The LogD profile for this compound is shown in Table 4.4.
*
†

Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA
Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
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Table 4.4 Calculated logP and LogD for the open β-lactam product 138.
LogD†

*

clogP (unionized)
4.14±0.74

pH 1 pH 5.5 pH 7.4
4.6

3.13

1.30

The presence of a carboxylic acid group within the structure is responsible for
the unionized state of the compound in acidic pH environment (stomach), and therefore,
would be present as a lipophilic state that can pass the gut wall. After reaching the blood
(pH 7.4), the compound ionizes providing blood solubility. At pH 5.5 (jejunum), where
absorption occurs, the LogD value is within the acceptable range (1-4)186 for orally
bioavailable drugs.

4.4.2. Coupling with the isatin aromatic head groups
4.4.2.1. Coupling to the linker and COOH tail
Synthesis of the 5-aryl isatin derivatives starting from the corresponding 5-haloisatin via the cross-coupling Suzuki reaction has been previously described,223,224 using
tetrakis(triphenylphosphine)palladium(0) as a catalyst and potassium phosphate as a
base. Therefore, the 5-bromoisatin derivatives (103, 106, 112 and the 5-bromoindoline2,3-dione 139) were reacted with the 3-(3-boronophenyl)propanoic acid 113,
tetrakis(triphenylphosphine)palladium(0) and potassium phosphate (Scheme 4.17) in
either DME or diethylene glycol dimethyl ether (diglyme) based on the solubility of the
5-bromoisatin used: in case of 5-bromo-4,6-dimethoxyindoline-2,3-dione 103 and 5bromo-4-methoxy-7-methylindoline-2,3-dione 112, the solvent used was diglime. The
reaction was then heated at 85 ºC under nitrogen atmosphere for 4-6 h. After cooling to
room temperature, the solvent was concentrated and HCl solution was added, and the
resulting suspended solid was either collected by filtration or extracted with ethyl
acetate. The combined residues were then dissolved in ethanol and were subjected to
PLC (10% methanol in CH2Cl2, 0.5% acetic acid) to yield the isatin-acid conjugates
140-143.
*
†

Analysis of the

1

H NMR spectrum for

Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA
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yl)phenyl)propanoic acid 143 showed two triplets resonating at 2.88 and 2.59 ppm, both
integrating for two protons that were assigned to the two CH 2 groups introduced from
the boronic acid. Analysis of the IR spectrum of 143 showed an absorption band at 2989
cm-1 assigned to the OH of the COOH group. The purity of this series was >95% as
analysed by HPLC, with retention times 5.34-35.84 min.

Scheme 4.17 The synthesis of the isatin-acid conjugates 140-143.

Table 4.5 shows the calculated physical properties of this series of compounds
140-143. For all the derivatives, the ionization increases as the pH increases, the LogD
values at pH 5.5 ranges from 1.13 to 1.71, a good range for oral bioavailability.
However, the increased solubility in the blood pH, as indicated by the negative LogD
values, might argue the chance of binding with the blood soluble proteins.
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Table 4.5 Physiochemical properties of the isatin-carboxylic acid conjugates

Compound

R

Mwt

clogP

LogD† at pH

*

1

5.5

7.4

140

4,6-(CH3)2

355.35 1.49±0.82 2.14 1.13 -0.70

141

7-CH3

309.32 2.40±0.37 2.53 1.55 -0.28

142
143

4-OCH3-7-CH3 339.35 2.06±0.80 2.70 1.71 -0.12
H

295.29 1.94±0.37 2.17 1.19 -0.64

3.4.2.2. Coupling to the linker and tetrazole tail
In order to obtain the isatin-tetrazole conjugates, the acetonitrile derivatives
were synthesized by reacting the 5-bromoisatin derivatives (103, 106, 112 and 139)
with (3-(cyanomethoxy)phenyl)boronic acid 118 using diglyme/water mixture as a
solvent in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium
phosphate and the mixtures were heated at 85 ºC for 5-9 h (Scheme 4.18). The solvent
was then concentrated and 1 N HCl solution was added, and the suspended solids were
either collected by filtration or extracted with ethyl acetate. The combined residues were
adsorbed onto silica and subjected to flash column chromatography (40% ethyl acetate
in petroleum spirit) to yield the acetonitrile intermediate 144-147 in 35-60% yield. The
IR spectrum of 2-(3-(2,3-dioxoindolin-5-yl)phenoxy)acetonitrile 147 showed an
absorption band at 2166 cm-1 that was assigned to the CN group. Analysis of the 1H
NMR spectrum of 147 showed a peak resonating at 5.21 ppm and integrating for two
protons that was assigned to the CH2 group.

*
†

Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada)
Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA
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Scheme 4.18 The synthesis of the isatin-acetonitrile intermediates 140-143.

Among the isatin-acetonitrile intermediates 144-147, 2-(3-(4,6-dimethoxy-2,3dioxoindolin-5-yl)phenoxy)acetonitrile 144 was not isolated from the crude mixture due
to product instability. The EI-MS spectrum of a sample taken from the reaction mixture
showed a peak at 338 that assigned to the molecular ion (M+). The HRMS spectrum
showed a peak at 339.0980 m/z that was assigned to the formula C18H15N2O5 for (MH+;
calculated, 339.0981 m/z). The reaction for 144 was repeated several times in order to
isolate a pure compound, however, once the solid was separated from the reaction
mixture, it was found to decompose to many overlapping spots on the TLC plate.
Subjecting the solid to a flash column chromatography was not successful and analysis
of the EI-MS spectra of the isolated fractions did not show any indications of 144.
Conversion to tetrazoles: The reaction of the isatin-acetonitrile derivatives 145-147
with sodium azide and ammonium chloride was attempted to afford the isatin-tetrazole
conjugates (Scheme 4.19). Several attempts were made using different molar ratios of
the azide/amonium chloride up to 10 equivalents, and heating at elevated temperatures
for longer times up to 72 h with and without acid catalysis, however, the tetrazole
conjugates 148-150 were not formed. Upon workup and separation of the oily gummy
material from the reaction, TLC analysis showed that the starting material disappeared
and just a polar polymeric spot was found. No evidence indicating the formation of the
tetrazole conjugate was observed in the mass spectra of these polymerized residues.
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Scheme 4.19 Attempted access to the isatin-tetrazole conjugates 148-150 via the
cycloaddition reaction with sodium azide/ammonium salts.

Such reaction of the isatin derivatives with the sodium azide has not been
previously reported. The nucleophilicity of the sodium azide and the electrophilic C3 of
isatin might be involved in such reaction, however, no evidence was found in the mass
spectra to support this hypothesis. This reaction was attempted before the design of the
alternative coupling reaction (Scheme 4.13) with the synthesized tetrazole-boronic ester
salt 129, and therefore, it would be interesting to try to access the isatin-tetrazole
conjugates 148-150 utilizing such coupling reaction, in which the electrophilicity of the
isatin C3 will not interfere with the reaction as in the case of sodium azide.

4.5. Concluding remarks
This chapter discussed the synthesis of a series of benzolactone-carboxylic acid
conjugates 114-117, benzolactone-tetrazole conjugates 126, 127, 130, 131 and isatincarboxylic acid conjugates 140-143 as analogues of the lead compounds mycophenolic
acid 15. The designed and synthesized analogues carry the same features as the parent
lead compound in that they all have the three components: the aromatic head, the rigid
linker and the acidic tail. All of the synthesized compounds showed good
physiochemical properties such as the low molecular weight and good LogD profiles,
having a range of 1-4 in the pH 5.5. Therefore, this series can be further developed as
promising leads against CHIKV depending on the activities in the preliminary antichikungunya testing. The formation of isatin-tetrazole conjugates 148-151 might be
possible using the coupling with the designed and synthesized boronic ester 129
(Scheme 4.20).
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Scheme 4.20 Possible coupling reaction to access the isatin-tetrazole conjugates 148151 via reaction with the boronic ester 129.
A facile and applicable synthetic strategy was developed to access different
analogues for the mycophenolic acid 15 via the introduction of the widely used cross
coupling reactions. The obtained carboxylic acid conjugates can be further derivatised
via the carboxylic acid reactions such as formation of esters or amides as prodrugs. The
tetrazole conjugates can also be further derivatised via the substitution on the tetrazole
NH by different alkylation/arylation reactions. The isatin conjugates can also be further
derivatised utilizing the different nucleophilic reactions on C3 or ring expansion
reactions (Figure 4.10). This will allow the further investigate the structure activity
relationship of this series against the CHIKV.
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CHAPTER 5: Computational and Modelling Studies of the CHIKV
nsP2 as a Possible Drug Development Target

5.1. Introduction
The CHIKV non-structural protein 2 (nsP2) is a significant enzyme that plays an
important role during the viral replication cycle. It consists of 324 residues with two
domains; the N and C domains that have different cellular functions. The nsP2 of
alphaviruses is a multifunctional protein.57,58,59,60 The N-terminus (amino terminal) was
found to be the RNA triphosphatase that performs the first of the viral RNA capping
reactions and a nucleotide triphosphatase (NTPase) that fuels the RNA helicase activity
performed by the other domain.65 It also performs 5`-triphosphatase (RTPase) activity
that removes the γ-phosphate from the 5` end of RNA. Both NTPase and RTPase
activities are completely dependent on Mg2+ ions.65 The proteolytic domain has been
allocated to its C-terminal (carboxy terminal) section which forms a papain like cysteine
protease (also known as thiol protease).57,61 The nsP2 proteolytic activity is critical for
virus replication and responsible for the cleavages of the non-structural polyprotein
complex during the viral life cycle.62,63
During the life cycle, and after entering the host cell, two non-structural protein
precursors are translated from the viral mRNA, and are then cleaved generating nsP1, 2,
3 and 4. During translation, nsP123 binds to free nsP4, with some cell proteins forming
the replication complex,38,39 which synthesizes a full-length negative-strand RNA
intermediate required for replication. When the nsP123 concentration increases, it is
cleaved into nsP1, nsP2, nsP3 and nsP4 which form, along with host cell proteins, the
positive strand replicase, which produces the 26S sub-genomic positive strand RNAs
and genomic (49S) RNAs.39 The proteolytic activity of the CHIKV nsP2 is responsible
for the cleavage of the replication machinery into individual working proteins. The
alphaviruses nsP2 proteins have also been described as virulence factors responsible for
the transcriptional and translational shutoff in infected host cells and the inhibition of
interferon (IFN)-mediated antiviral responses contributing to the controlling of
translational machinery by viral factors. 72,73,225 This controlling comes through
interactions with cellular RNA binding proteins, including heterogeneous nuclear
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ribonucleoproteins (hnRNPs), ribosomal protein S6 (RpS6), and cellular filament
components. Recently discovered, 22 cellular components are believed to interact with
nsP2 or nsP4, contributing to the CHIKV replication, such as heterogeneous nuclear
ribonucleoprotein K (hnRNP-K) and ubiquilin 4 (UBQLN4). It was also noted that the
interaction of nsP2 with the tetratricopeptide repeat protein 7B (TTC7B) plays a
significant role in the cellular machinery control induced by the CHIKV infection. 74
These critical functions are associated with nsP2 C domain protease and also the N
domain that controls some metabolic processes of some cellular substrates, and
therefore, this enzyme represents an important target in developing drugs against the
CHIKV virus.
Both N and C domains are composed of α-helices and β-strands (Figure 5.1).
The N terminus is dominated by α-helices (red spirals in Figure 5.1) whereas, the Cterminal domain contains helices and strands (cyan colour in Figure 5.1). The central βsheets are flanked by α-helices. The crystal structure of CHIKV nsP2 protease was
solved in 2012. Being a cysteine protease enzyme (within domain C), the catalytic
mechanism involves a nucleophilic cysteine thiol in a catalytic dyad.66 Analysis of the
CHIKV nsP2 crystal structure shows 6 cysteine residues; three in the N-terminus
(Cys1013, Cys1057 and Cys1121) and three in the C-terminus (Cys1233, Cys1274 and
Cys1290) as shown in Figure 5.1. Since the proteolytic activity is isolated in the Cterminus,64 one of the three cysteine residues in the C-domain might be the catalytic
head.

Figure 5.1 CHIKV nsP2 crystal structure showing the N- and C-terminal domains,
cysteine residues shown in yellow balls and stick form (PDB code: 3TRK67, no
reference cited thus far).
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Generally, the first step in the mechanism of cysteine protease catalysis is the
deprotonation of a thiol group within the enzyme active site by an adjacent amino
acid containing a basic side chain, usually a histidine residue.68 Among the three
cysteine residues in the C-terminus (Figure 5.2), the Cys1274 residue is less likely to be
involved in the catalytic mechanism as only one His residue (His1314) is nearby,
whereas for the other cysteine residues, four histidine residues (His1222, His1228,
His1229 and His1236) are nearby and could be associated in the deprotonation
mechanism (Figure 5.2).

Figure 5.2 Schematic representation of the CHIKV nsP2 C-Domain showing the
positions of the cysteine residues (in yellow) and histidine residues (in green), generated
from the crystal structure PDB file code: 3TRK.

For the nsP2 protease activity, the enzyme must hold its substrate at the catalytic
site to start the cysteine cleavage mechanism. This site can be described as the enzyme
“mouth”, and will be critical for the enzyme’s function. Blocking this site, will
therefore, antagonise the enzyme function and will interfere with the viral replication
cycle inside the infected host cell.
In 2012, Singh Kh et al. reported the development of a homology model of
CHIKV nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan
equine encephalitis virus (VEEV),69 before the release of the actual nsP2 crystal
119

Chapter 5

CHIKV nsP2

structure. The critical residues in nsP2 were identified by docking three different
peptides in order to identify the residues responsible for non-structural protein cleavage;
nsP1-2, nsP2-3 and nsP3-4 peptides. These three peptide sequences represent the
substrates for the nsP2 proteolytic processing with a remarkable preference of nsP34>nsP1-2>nsP2-3.70 The active site was investigated and was found to lie in the Cterminal domain.69 The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222,
Lys1239, Ser1293, Glu1296 and Met1297 were found to interact with the nonstructural
protein sequence complex to be cleaved, and were considered an individual functional
unit. Only two residues are located in the N-domain; Gln1039 and Lys1045; all the
other residues are located in the C-domain. In similar work, Bassetto et al.71 reported
the identification of in silico CHIKV nsP2 inhibitors based also on a homology model
of CHIKV nsP2 protein, not the actual crystal structure.
Blocking the protease activity will be an applicable strategy for designing
inhibitors for that particular enzyme. However, the reported studies 69,71 only included
the C domain as the main target site for the enzyme. They also did not describe the
active proteolytic site in sufficient detail, nor did they discuss the possibility of targeting
sites in the N domain. Herein, we describe the protease active site revealing some
important criteria for the future design of inhibitors. We also describe here for the first
time the binding site within the nsP2 N domain. Blocking the later site might not only
block the multiple functions of the N domain,65 but could affect the C protease domain
through an allosteric effect, invoking indirect inhibition of the C domain.
5.2. Results and discussion
The possible druggable sites at both the C and N domains of the CHIKV nsP2
were investigated. These sites were then used for the identification of possible inhibitors
through virtual screenings.
5.2.1. Protease active site (domain C)
From the CHIKV nsP2 crystal structure analysis, one major cavity can be
detected within the enzyme surface lying as a central region between domains C and N.
It also blocks the access through the two of the cysteine residues within domain C;
Cys1233, Cys1290. Therefore, this cavity is more likely to be the protease active site
(Figure 5.3), where the protein holds the peptide segment to be cleaved.
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Figure 5.3 Crystal structure of the CHIKV nsP2 showing the enzyme mouth cavity in
green space filling lying in the centre between domain N and C.

A closer inspection of the binding site revealed that the cavity looks as a Ushaped cavity or tunnel (hereafter called site_1) that extends inward from the enzyme
surface and opens and widens towards the outer surface of the enzyme (Figure 5.4). The
tunnel itself is narrow and is surrounded by side walls and floor on the exterior side of
the enzyme.

Figure 5.4 Site_1 U-shaped cavity that is lying between the nsP2 domains N and C. It
has the two openings on the enzyme surfaces. The cavity mouth is wide and surrounded
by hydrophobic side wall and a floor.
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Site_1 makes contact with the residues: Gln1039, Ala1040, Lys1045-Tyr1047,
Gly1176, Pro1191, Leu1192, Tyr1201, Asn1202, Leu1203, Glu1204, His1222,
Thr1223, Pro1224, Arg1226, Asp1235, Mes1238, Lys1239, Leu1243. The cavity is
mainly hydrophobic due to the presence of the residues Ala, Tyr, Gly, Pro and Lys, with
some amino acids able to form H-bonds such as His, Tyr, Gln, Glu as well as the polar
part of Lys. The central blue bridge (Figure 5.4) in the middle of the cavity is a
hydrophilic bridge that is formed by the polar heads of the N domain Lys1045 and the C
domain Lys1239. Domain C residue Cys1233 is buried in one of the α-helices behind
this cavity and closer to domain N, confirming the hypothesis that this mouth cavity
might be the access to the catalytic proteolytic activity of the enzyme. Therefore,
blocking this cavity might block the proteolytic activity of the enzyme and consequently
inhibit viral replication.
5.2.2. N domain binding site
Lying on the opposite side of the enzyme surface is another hydrophobic pocket
that extends within the N domain of the enzyme before the junction with domain C
(Figure 5.5).
a

b

Figure 5.5 Hydrophobic pocket within the N domain of the CHIKV nsP2 a) Front view
of the pocket, b) side view of the pocket, divided into 3 sections; the narrow linker
cavity which open towards site_1 side, a middle section and a wide terminal mouth.
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This pocket (hereafter called site_2) extends under the N domain β-sheet and
ends with a small cavity that opens on the domain C side surface, just above site_1
(Figure 5.6).

Figure 5.6 Electrostatic surface of the CHIKV nsP2 showing site_1, site_2 and the
linker cavity that opens from site_2 towards site_1

Site_2 is mainly lined by residues: Asn1011, Cys1013, Trp1014, Ala1046,
Tyr1047, Ser1048, Glu1050, Val1077, Tyr1079, Asn1082, Trp1084, Gly1090,
Lys1091, Leu1205 and Mse1242. It is also a hydrophobic cavity due to the presence of
hydrophobic residues with some amino acids able to form H-bonds such as Ser, Tyr,
Trp, Gln, and also the polar moiety of Lys. Targeting this site by inhibitors, might not
only block the NTPase and RTPase N domain functions, but may also act as an
allosteric site for the protease binding site on the opposite C domain side of the enzyme;
small molecules bound to this site may alter the function of the enzyme or change the
enzyme conformation and consequently block the enzyme function, stopping the viral
replication.
5.3. Virtual screening with the CHIKV nsP2
A virtual screening study was performed on both sites (site_1, site_2) using the Life
chemicals cysteine protease inhibitors library (28,960 compounds). This library was
designed using a ligand based approach – first, a set of 585 compounds active in assays
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related to cysteine proteases was assembled. This Life Chemicals collection was
searched for compounds similar to the reference dataset using MDL public keys and the
Tanimoto similarity cut-off of 85% to generate a library of 28,960 compounds.
The virtual screening was performed using two successive docking scores,
FRED (fast rigid exhaustive docking) for fast precise screening, with the top hits then
subjected to a ranking scoring using the AUTODOCK algorithm. The important
residues within both sites have been identified. Some in silico inhibitors were also
predicted that could be developed as selective CHIKV nsP2 inhibitors. The results of
the first Fred screening and the second Audodock re-ranking on both sites are shown in
tables 5.1-5.6.
Table 5.1 The top 25 compounds docked by Fred in nsP2_site_1 and their interacting
residues. Numbering is based on Fred output list (visualised by VIDA*).
Entry
†

1

Structure
2+

Mg

H-bonding

Other interacting

residues

residues

-

-

Lys 1239

π-cation Lys 1045

Asp 1235
2

3 x π-cation Lys 1239
3

Lys 1045

Lys 1239

4

*

VIDA is a visualising software developed by Openeye (OpenEye Scientific Software, Santa Fe,
NM. http://www.eyesopen.com)
†
Mg ion within the crystal structure
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π-cation Lys 1239
π-sigma Lys 1239
5

2x π-cation Lys1239

6

Leu 1203

π-cation Lys 1239
π-sigma Lys 1239

7

π-cation Lys 1045
π-cation Lys 1239
π-sigma Lys 1239
8

Lys 1045 x2

π-cation Lys 1239 x 2

Asp 1235

π-sigma Lys 1239

9

π-cation Lys 1239 x 3

10
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π-cation Lys 1239 x 2
π-sigma Lys 1239
π-cation Lys 1045
11

π-cation Lys 1239 x 2
π-sigma Lys 1239
12

Lys 1045

π-sigma Ile 1221
π-cation Lys 1045
π-cation Lys 1239

13

π-sigma Lys 1239
π-sigma Ala 1040
Lys 1045

π-cation Lys 1239 x 2

14

π-cation Lys 1239
π-sigma Lys 1239
15

π-cation Lys 1239
π-sigma Lys 1239
16
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π-cation Lys 1239 x 2
π-sigma Lys 1239

17

π-cation Lys 1239 x 2
π-sigma Lys 1239
18

π-π His 1222
π-cation Lys 1239

19

π-sigma Lys 1239

Lys 1045 x2

π-cation Lys 1239 x 3

20

π-cation Lys 1239 x 3
π-sigma Lys 1239
21

22

127

Asn 1202

π-cation Lys 1239 x 2

Lys 1045

π-sigma Pro 1191
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His 1222

π-cation Lys 1239
π-cation Lys 1045

23

Glu 1204

π-sigma Pro 1191

Asn 1202

π-sigma Lys 1239

24

π-cation Lys 1239 x 3
π-sigma Glu 1204
25

π-sigma Lys 1239 x 3

26
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Table 5.2 Autodock output for the nsP2_site_1 Fred hit list. Cluster analysis was
performed on docked results, with a root-mean-square tolerance of 1.0, 2.0 and 3.0 Å.
Entry*
2

&

Binding Energy

Predicted Ki

Kcal/mol

nM

-11.36

4.72
3

Number of clusters&

Lowest energy
cluster poses

4

14

3

-7.26

4.79 × 10

8

13

4

-9.83

61.92

13

16

3

5

-7.22

5.12 × 10

9

7

6

-10.5

19.96

7

28

7

-9.46

116.7

7

22

8

-10.0

46.58

7

21

9

-8.68

435.31

17

20

10

-8.39

709.36

4

10

11

-9.88

57.32

7

16

21

5

1

50

21

4

12

-7.13

5.9 × 10

13

-10.16

35.58

14

-9.03

241.5

3

3

15

-7.69

2.29 × 10

5

28

16

-9.37

134.58

10

16

17

-8.45

644.95

4

22

18

-9.03

240.22

4

1

19

-9.18

185.76

2

48

20

-9.9

55.24

11

15

21

-9.75

71.74

20

5

3

22

-7.92

1.57 × 10

6

20

23

-8.3

822.33

2

44

24

-8.63

472.65

41

1

25

-9.89

56.66

7

12

26

-10.24

30.98

10

25

Predicted docked poses are grouped together according to their root-mean-square (RMS) values

compared to the input ligand structure. Poses that have similar RMS values (within the tolerance value
selected) are grouped in one cluster.

*

Entries are the same as in Table 5.1, entry 1 was assigned for the Mg ion.
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Table 5.3 The top 5 poses for the nsP2_site_1 based on Autodock ranking, their ClogP,
calculated binding energies, Ki values and interacting residues.

Entry

Structure

2

clogP*

4.08±0.69

6

5.13±0.97

26

5.88±0.94

13

6.07±0.88

8

5.67±1.05

Binding
energy
Kcal/mol

-11.36

-10.50

-10.24

-10.16

-10.0

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).
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Predicted Ki
(nM)

4.72

19.96

30.98

Interaction residues

Lys 1045 (Hb, 1.9 Å)
Lys 1239 (2Hb, 1.9, 2.5 Å)
Lys 1239 (π-cation)
Leu 1192 (π-sigma)

Glu 1043 (2Hb, 2.1, 2.2 Å)
Lys 1239 (Hb, 1.7 Å)
Lys 1239 (π-cation) x 3

Glu 1043 (Hb, 1.9 Å)
Lys 1239 (Hb, 1.7 Å)
Lys 1239 (π-cation)
Lys 1239 (π-sigma)

35.58

Lys 1045 (Hb, 2.4 Å)
Lys 1239 (Hb, 2.1 Å)
Pro 1191 (π-sigma)
Lys 1045 (π-cation)
Lys 1239 (π-cation)

46.58

Lys 1045 (2Hb, 2.1, 2.2 Å)
Lys 1239 (Hb, 1.8 Å)
Lys 1045 (π-cation)
Lys 1239 (π-sigma) x 2
Lys 1239 (π-cation)
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Table 5.4 The top 25 compounds docked by Fred in nsP2_site_2 and their interacting
residues. Numbering is based on Fred output list (visualised by VIDA).
Entry

Structure

H-bonding

Other interacting

residues

residues

Trp 1084

π-cation Lys 1091

Gln 1241
1

Ser 1048

π-cation Lys 1091

2

Trp 1084 x 2
Asn 1202
3

Ser 1048
Trp 1084
4

Trp 1084
Asn 1202

5

Trp 1084
Gln 1241
6
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Trp 1084

7

Trp 1084 x 2
Asn 1202
8

Trp 1084 x 2

π-sigma Ala 1046

9

Asn 1202
Trp 1084 x 2
10

Trp 1084

π-cation Lys 1091

Gln 1241
11

Ser 1048
12

Trp 1084

Trp 1084

13

132

π-cation Lys 1091
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Trp 1084

π-sigma Mse* 1242

Trp 1084

π-cation Lys 1091

14

Gln 1241
15

Trp 1084 x 2
16

Ser 1048
Trp 1084
17

Trp 1084
18

Asn 1202

Trp 1084

19

Asn 1082

20

*

Selenomethionine
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Ser 1048

π-sigma Trp 1084

Trp 1084

21

Asn 1202
Trp 1084
22

23

Trp 1084 x 2

π-cation Lys 1091 x

Ser 1048

2

Trp 1084
Ser 1048
24

Gln 1241
Tyr 1047
25
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Table 5.5 Autodock output for the nsP2_site_2 Fred hit list. Cluster analysis was
performed on docked results, with a root-mean-square tolerance of 1.0, 2.0 and 3.0 Å.
Binding Energy

Predicted Ki

Kcal/mol

nM

1

-8.32

799.94

13

7

2

-9.74

72.63

3

42

3

-9.24

167.47

3

31

4

-8.97

264.9

11

16

5

-8.8

353.41

5

2

6

-7.65

2.47 × 103

9

8

7

-9.23

170.77

6

10

8

-9.8

65.79

2

48

9

-9.76

70.47

4

30

10

-9.28

156.76

4

20

11

-8.42

667.9

7

16

12

-9.9

55.69

3

31

13

-8.38

722.18

9

20

14

-8.8

355.69

7

25

15

-8.88

312.02

10

14

16

-8.72

404.11

7

28

17

-8.45

636.79

7

25

18

-8.82

345.39

6

19

19

-9.4

129.44

7

27

20

-8.23

929.53

9

13

21

-9.67

81.91

1

50

22

-9.2

180.54

6

36

23

-8.68

431.68

9

2

24

-8.15

1.06 × 103

7

16

25

-8.53

562.66

12

5

Entry*

*

Entries are the same as in Table 5.4.
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Table 5.6 The top 5 poses in the nsP2_site_2 based on Autodock ranking, their ClogP,
calculated binding energies, Ki values and interacting residues.

Entry

Structure

clogP*

Binding
energy
Kcal/mol

Predicted Ki
(nM)

Interaction residues

12

4.57±0.65

-9.90

55.69

Ser 1048 (Hb, 1.6 Å)
Tyr 1079 (Hb, 2.1 Å)
Trp 1084 (Hb, 1.8 Å)
Gln 1241 (Hb, 2.4 Å)
Lys 1091 (π-cation)

8

4.13±0.68

-9.80

65.79

Trp 1084 (Hb, 1.7 Å)
Lys 1091 (Hb, 1.8 Å)

9

3.28±1.00

-9.76

70.47

Glu 1050 (Hb, 2.3 Å)
Tyr 1079 (Hb, 2.3 Å)
Trp 1084 (2Hb, 2.1, 2.2 Å)
Lys 1091 (Hb, 1.9 Å)

2

6.12±0.49

-9.74

72.63

Ser 1048 (Hb, 1.7 Å)
Trp 1084 (Hb, 2.2 Å)
Lys 1091 (π-cation)

21

4.86±1.49

-9.67

81.91

Trp 1084 (Hb, 1.8 Å)
Lys 1091 (π-cation) x2

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).

5.3.1. Analysis of the C domain virtual screening results
The CHIKV nsP2 plays an important role during the replication life cycle, and is
composed of two domains. Domain C, which is the proteolytic machinery, processing
the non-structural protein complex into individual functional proteins, and the N
domain, which performs regulatory cellular functions through the NTPase and RTPase
activities. These vital roles of the enzyme with the availability of a crystal structure,
makes it an attractive target for the drug design for this virus. We investigated both
domains for the possible binding sites. Within domain C which contains 3 cysteine
residues (Figure 5.2) that might be involved in the proteolytic mechanism, access to
these residues is most likely to occur through the site_1 (Figure 5.4), a possible site for
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holding the protein to be cleaved by the protease activity. The site extends between
domains N and C with residues from both lining the site_1 tunnel. The tunnel opens to
the outer surface as a wide mouth lined mainly by residues from domain C. Our
hypothesis is that bound small molecules to this site, not only freezes both domains
together, preventing its function, but also blocks the sites through π-stacking
interactions, mostly, hydrophobic/aromatic interactions. Our study did not reveal the
participation of the cysteine residues (Cys1233, Cys1290), however, other residues have
been found to strongly participate in the interactions in this site. Figure 5.7 shows the
3D and the 2D representations of the docked poses.
Pose 2

Pose 6
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Pose 26

Pose 13

Pose 8

Figure 5.7 Three and two dimensional representations of the top 5 ranked poses (Table
5.3) inside the nsP2 site_1 pocket.
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Figure 5.7 shows that compounds 2, 13 and 8 were able to insert at least a
phenyl ring inside the U-shaped tunnel whereas poses 6 and 26 were found to prefer the
outer surface of the cavity (the outer mouth cavity). All compounds were able to bind to
Lys1045 or Glu1043 from the N domain and to Lys1239 from the C domain. These
interactions with residues in the two domains N and C make the compounds good
possible ligands for this pocket. When bound to the pocket in the predicted way,
compounds will be able to freeze domain N in relation to domain C, blocking the
protease cavity of the enzyme, rendering the access to the cysteine residues for the
catalytic cleavage not possible.
Poses 2 and 13 were able to form π stacking interactions with the side wall of
the pocket via interactions with Leu1192 and Pro1191, respectively (Figure 5.7). This
pocket side wall represents the enzyme outer surface, with this part of the enzyme
surface being close to the linker cavity of site_2 (see Figure 5.6).
Poses 2 and 13 were able to orient in such way that they have aromatic rings
relaxing before the side wall of the pocket forming interactions with Leu1192 and
Pro1191, respectively. This unique ability for the two ligands (2 and 13) was related to:
a) the presence of a relatively smaller linear terminal phenyl-furan sequence, such that
this moiety can insert inside the tunnel, being stabilized by H-bonds with the tunnel
hydrophilic bridge, b) the flexibility of the other terminal phenyl ring; in the docked
pose 2, the terminal phenyl is attached to the relatively flexible non-aromatic piperazine
moiety whereas in the docked pose 13, the terminal phenyl is attached to rigid aromatic
central moiety via a flexible CH2 linker. This flexibility enables the terminal phenyl
rings to find the right position for interaction with the amino acid residues Leu1192 and
Pro1191. These two classes of compounds can be described as relatively small rigid
aromatic head groups linked in a linear manner through relative flexible joints to small
aromatic tails. This orientation allows the insertion inside the tunnel forming stacking
interactions with the cavity residues.
Poses 6 and 26 are derivatives of the main skeleton of N-aryl-2-((4-oxo-3-aryl4,5-dihydro-3H-pyrimido[5,4-b]indol-2-yl)thio)acetamide, with different aryl groups.
The 3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one head is important in this class of
compounds as it forms a strong π-stacking interaction with the C domain central
Lys1239 (Figure 5.7), and is able to insert one the terminal phenyl rings inside the right
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opening of the tunnel (on the right hand side when looking to front Figure). In both
derivatives, the 2-mercaptoacetamide linker is important; the carbonyl oxygen can
accept H-bond from the polar head of Lys1239 of the tunnel central bridge, and the NH
participates in H-bonding with the N domain Glu1043. The aromatic tail; the relatively
more flexible benzo[1,4]dioxane in compound 6 and the rigid naphthalene moiety in
compound 26 blocked the access of the left opening of the tunnel (on the left hand side
when front looking to the Figure). These three segments, bulky aromatic head,
mercaptoacetamide linker and the aromatic tail were responsible for the orientation of
this class in such a way that they block the entrance of the U-shaped tunnel from the
two openings, and therefore, can be developed as selective blockers for this site. Figure
5.8 shows the superimposition of compound 6 and 26 inside site_1.

Figure 5.8 Superimposition of pose 6 (violet) and pose 26 (yellow) inside the
nsP2_site1 binding pocket.

The mercaptoacetamide linker was also important in pose 8 where it connected
the bulky head the phenylthieno[3,2-d]pyrimidin-4(3H)-one to the tail of the
tetrahydroquinoline. The terminal phenyl substituent of the head was inserted inside the
right hand side opening of the tunnel and was stabilized by interaction with the N
domain tunnel bridge residue Lys1045 (Figure 5.7), whereas the main thieno[3,2d]pyrimidin-4(3H)-one moiety was stabilized by interaction with the C domain tunnel
bridge residue Lys1239 (Figure 5.7). The mercaptoacetamide linker forms H-bonds
with both residues of the bridge tunnel residues. The benzo moiety of the tail forms an
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interaction with Lys1045 blocking the left tunnel opening. In comparison with poses 6
and 26 where the linker is attached to the rigid benzo moiety of the head groups, the
linker in pose 8 is attached to the relatively flexible moiety of the rigid tail where certain
flexibility might allow such stabilizing interaction with the tunnel bridge. Such
stabilization was not possible in case of 6 and 26.
5.3.2. Analysis of the N domain virtual screening results
Site_2 is located within the N domain and lies as a channel that is partially
covered by two of the N domain β-sheets. It represents the main pocket within domain
N that might be important for the N domain functions. This pocket can also lead to
access to the cysteine residues within C domain. Therefore, the hypothesis is that
blocking the pocket will inhibit the enzymatic functions of this domain, and secondly, it
might be an allosteric site for blocking the enzymatic activity of domain C. Figure 5.9
shows the 3D and 2D representations of the top ranked docked poses (Table 5.6) within
the nsP2 site_2 N domain pocket.
Pose 12

Pose 8
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Pose 9

Pose 2

Pose 21

Figure 5.9 Three and two dimensional representations of the top 5 ranked compounds
(Table 5.6) inside the nsP2 site_2 pocket.
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Site_2 can be divided into 3 sections (Figure 5.5), the narrow linker cavity
which opens towards site_1 side, a middle section and a terminal wide mouth. Two
important interactions emerged in the top ranked poses, one strong H-bond with
Trp1084 (in the range of 1.7-2.2 Å) which is located in the middle section and another
interaction with Lys1091 in the terminal wide mouth section (Figure 5.9, the snapshots
were taken with the wide mouth component in the front). This later interaction was
either through H-bonds with the polar part of Lys1091 as in poses 8 and 9, or through πcation stacking interaction with the positively charged head of Lys1091 as in
compounds 12, 2 and 21. In poses 12, 8, 9 and 2, the terminal hydrophobic/aromatic
moiety was inserted inside the narrow linker cavity of the pocket (Figure 5.9, the rear
part of the snapshots).
All compounds interacted with residues within domain N without interacting
with domain C except pose 12, which forms a strong H-bond (2.4 Å, Figure 5.9) with
the Gln1241 residue, located in one of the α-helices of domain C. This unique
interaction was responsible for the better binding profile compared to the other docked
poses as can be inferred from Table 5.6 where pose 12 was predicted to bind to the
pocket with a binding energy of -9.90 kcal/mol with a predicted inhibition constant (Ki)
of 55.69 nM.
The presence of the bi-heterocyclic system in the middle of the pocket, namely
the benzo[d]thiazole moiety, in poses 12 and 9 was responsible for H-bond formation
through the sulfur atom with the N domain β-sheet Tyr1079 residue; this β-sheet
extends outwards like an umbrella over the pocket.
The presence of a sulfoxide group in the third wide mouth pocket section (front
view of the snapshots taken in Figure 5.9) is favourable as both oxygens of this group
can accept H-bonds from the N domain Ser1048 (around 1.6 Å, Table 5.6) as in case of
poses 12 and 2, or with the near by amino acid Glu1050 (2.3 Å) in case of pose 9.
Poses 12, 8 and 9 can insert hydrophobic tails within the linker cavity that opens
on site_1 side. This indicates that this site may affect the other protease site somehow
through this linker cavity. Figure 5.10 shows a 3D representation of the nsP2 surface
with pose 12 (Table 5.3, within site_1) and pose 8 (Table 5.6, within site_2). It shows
the possible clashes between the compounds in the linker cavity. It also shows the
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possible allosteric effect of ligands in site_2 on the protease active site. This opens other
possible investigations into using two inhibitors together as an effective inhibitory
mechanism for that critical enzyme in the viral life cycle.

Figure 5.10 Pose 2 (Table 5.3) within the nsP2 site_1, shown in red colour. Pose 8
(Table 5.6) within the nsP2 site_2, shown in yellow colour. The hydrophobic tail of
pose 8 within site_2 is protruding through the linker cavity towards pose 2 in site_1.

5.4. Concluding remarks
We have examined the CHIKV nsP2, a critical enzyme for the viral life cycle, for
potential druggable pockets that could be targeted by small molecules. Two major
pockets where identified within the N and C domains. The hypothesis described here
investigated the possibility of inhibiting the enzyme multi-functions through blocking
the active sites of the two domains. A database search on the two hydrophobic pockets
was performed and this search detected the residues important for significant bindings
as well as the preferred pharmacophores of the potential in silico inhibitors. Within
domain C proteolytic site, Lys1239 and Lys1045 were found to interact with most of the
identified ligands. Both residues represent a hydrophilic bridge in the C domain
hydrophobic pocket that can form H bonds through their polar heads and stacking
interactions through their side chains. Within domain N, Trp1084 and Lys1091 were
found to be interacting with all of the docked poses, with the possibility for interaction
with the C domain Gln1241. Some small molecules were also identified for each site
that look promising in silico (nano-molar) inhibitors that might be starting points for
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lead development targeting this enzyme. Another hypothesis is the possibility of using
dual inhibitors for the enzyme, targeting both domains at the same time by a
combination therapy. The CHIKV nsP2 enzyme is unfortunately not available for direct
binding assays, therefore, the identified compounds were purchased and currently are
being evaluated for their anti-chikungunya activities. This represents the first study in
understanding the CHIKV nsP2 enzyme as well as identifying some selective potential
inhibitors, and this computer model can be further used for screening large libraries to
identify more hits. Depending on the activities, a retro-synthetic analysis can be
designed for the active compounds, allowing in-depth in silico with in vitro
optimization studies that might lead to the discovery of potent selective inhibitor for the
virus.
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CHAPTER 6: Structure Based Design towards the Identification of
Novel Binding Sites and Inhibitors for the Chikungunya Virus
Envelope Proteins

6.1. Introduction
The CHIKV genome is approximately 11.8 Kb in size and consists of a single stranded,
positive sense RNA genome with two open reading frames (ORFs), 28 one in the 5` end
which encodes two polyproteins, the precursors of the non-structural proteins. The
second ORF at the 3` end encodes the structural proteins, the capsid (C), envelope
glycoproteins E1 and E2 and two small cleavage products (E3, 6K). Like the other
members of the alphaviruses, the CHIKV starts the life cycle by entering the target host
cells by pH dependent endocytosis via a receptor mediated interaction.30 A recent study
identified prohibitin1 (PHB1) as a microglial cell expressed CHIKV binding protein. 31
After entering the cell, the endosome acidic environment triggers conformational
changes in the viral envelope complex made of E1 and E2 proteins, resulting in
dissociation of the E2-E1 heterodimers and E1 homotrimers are formed. The E1 trimer
inserts into the target cell membrane via its hydrophobic fusion peptide (fusion loop)
and refolds to form a hairpin-like structure. Exposure of the E1 fusion peptide leads to
releasing of the nucleocapsid into the host cell cytoplasm. 34,35 During the replication
cycle inside the host cell, the capsid protein is released, and the pE2 and E1
glycoproteins are translated in the Golgi and are moved to the plasma membrane, where
pE2 is cleaved by furin-like protease activity into E2 and E3.42
Glycoprotein E2 is responsible for receptor binding whereas E1 is responsible
for membrane fusion.10 E3 contains the 64-amino-terminal residues of p62 and mediates
proper folding of pE2 and its subsequent association with E1.93 E3 also protects the E2E1 heterodimer from premature fusion with cellular membranes. 94 Furin maturation of
p62 into E3 and E2 during transport to the cell surface primes the spikes for subsequent
fusogenic activation for cell entry. Mature virions bud at the plasma membrane via
interactions between E2 and genome-containing viral nucleocapsids present in the
cytoplasm,95 ready for infecting new cells. The crystal structures of both the immature
and the mature glycoprotein complexes have recently been solved, 95 (Figure 6.1).
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Figure 6.1 Crystal structure of the immature envelope glycoprotein complex of
Chikungunya. Generated from the PDB file: 3N40.95

E1 is folded into three β-sheet rich domains (I, II and III). E2 is an all β protein
belonging to the immunoglobulin superfamily, with three domains A, B and C. Domain
B is at the membrane upper end and domain C is towards the viral membrane: Domain
A is at the centre while domain C binds to the adjacent domain II of E1. The long β –
ribbon of E2 makes most of the connection with E3. Furin loop is E2-E3 junction in the
immature complex; this junction contains a functional proprotein convertase motif
which is cleaved by the cellular porteases; furin-like proprotein convertases during the
maturation of the glycoproteins.42 The amino acid His60 in this junction is the critical
residue that determines the spectrum of furin and furin-like convertases that process E2E3 glycoprotein complex.100 The U shaped fusion loop of E1 is inserted in a groove
between E2 domains A and B being stabilized by hydrogen bonds with E2 histidine side
chains.95 In the neutral pH, E3 maintains E2 domain B in an orientation with respect to
domain A in such way that it creates the groove accommodating the E1 fusion loop,
protecting the virus from premature fusion with other cellular membranes. 95,101 Some
residues in domain B of E2 are believed to be associated with cell recognition. 94 The
fusogenic activity of the E1 fusion peptide is highly dependent on pH change. The
histidine residues of E2 are believed to be involved as the pH sensor for the activation
of the fusion protein at lower pH95 due to the increased probability of histidines to
become positively charged at lower pH values, based on the fact that the imidazole ring
of the histidine residue is the only amino acid side chain whose apparent dissociation
constant from protons (pKa) falls within the physiological range. Within the E1 fusion
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peptide sequence, the glycine residue (Gly91) is critical for the fusion process. Also, it
was found that one histidine residue at E1 230, which is located outside of the fusion
sequence, is also critical for the fusion. 96
Blocking the in vitro CHIKV infection in the host cells targeting the envelope
proteins has been demonstrated by blocking the intracellular furin-mediated cleavage of
viral envelope glycoproteins (E2E3 or p62 precursors), this blocking was achieved by
an irreversible furin-inhibiting peptide which significantly reduce the processing of
E3E2 CHIKV glycoproteins. This led to the formation of immature viral particles and
impaired viral spreading through other uninfected cells. 100 This reflects the importance
of considering the envelope glycoproteins as an attractive target for selective drug
development.
The usage of the three-dimensional structure of the target proteins (crystal
structures) in the virtual screening (in silico) of chemical libraries has been a powerful
approach to identify lead compounds with some successful examples in a number of
systems.226, 227 Such structure based drug design techniques, including the identification
of new binding sites and virtual screening search, have been successfully used for
identification of lead compounds for the dengue virus envelope protein (E protein).228,
229

Dengue virus is also an arbovirus and is transmitted by the same vector mosquito of

the CHIKV. Herein, we report for the first time the novel binding sites in the CHIKV
envelope glycoproteins that can be used as sites for inhibitors that could alter the
function of the envelope proteins and consequently, inhibit the virus fusion function. To
increase the chances of possible hits, we examined both the immature and the mature
glycoprotein crystal structures for possible binding sites. Two sites were chosen that
were common in both the immature and the mature proteins based on their locations and
functions. We then used virtual screening combining two different docking algorithms
with a number of chemical databases to identify suitable compounds predicted to bind
in these sites. FRED (fast rigid exhaustive docking) was used for fast and precise
screening using multiple scoring functions, followed by re-docking ranking of the top
hits using AUTODOCK scoring function. This led to the identification of favoured hits
that have suitable binding profiles to the CHIKV glycoproteins. This hypothesis
represents a new strategy for inhibiting this particular virus by targeting the envelope
proteins which will lead to impaired protein function and thus inhibiting the virus, and
will help the further synthetic development and optimization of selective inhibitors, as
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previously and successfully achieved for the dengue virus envelope protein
inhibitors.229, 230
6.2. Results and discussion
6.2.1. Identification of novel binding sites
Both the crystal structure of the immature complex (PDB file: 3N40 95) and the mature
complex (PDB file: 3N4295) were used. Binding sites within the receptors were detected
using the Discovery Studio 3.5 software (Accelrys Software Inc.: San Diego, CA,
2012). The algorithm is based on a grid search and "eraser" algorithm which derives
binding sites from cavities in the structure of the receptor. The binding site found is
displayed as a set of points. The volume of each cavity is defined as the product of the
number of site points and the cube of the grid spacing. Six main sites were detected in
both the immature and the mature crystal structures and only one site was detected in
the mature crystal structure that is not present in the immature form (Figure 6.2). Table
6.1 shows the identified sites. Suitable cavities were then checked further based on
functionality, presence of hydrophobic residues, presence of charged residues and
solvent accessibility.

Figure 6.2 Crystal structure of (a) the immature glycoproteins (generated from file pdb:
3N40) and (b) the mature glycoproteins (generated from the file pdb: 3N42) showing
the identified binding cavities as solid filled surface.
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Table 6.1 The identified receptor cavities in the immature (3N40) and mature (3N42)
crystal structures, grid coordinates x, y and z, cavity volumes, points count and location
for each cavity site.
3N40

3N42

(immature structure)

(mature structure)

x, y, z

-15.381, -1.269, 16.434

-15.687, 2.019, -19.939

Volume

687.25

651.375

Points count

5498

5211

x, y, z

-30.631, 17.481, 33.684

-33.937, -18.731, -31.939

Volume

395

357.375

Points count

3160

2859

x, y, z

-30.631, 4.981, 37.934

-33.437, -6.731, -33.189

Volume

157.625

156.125

Points count

1261

1249

x, y, z

-38.131, 31.481, 24.934

-42.937, -28.731, -22.939

Volume

126.25

183.875

Points count

1010

1471

x, y, z

-44.631, 14.731, 23.184

-44.437, -14.731, -23.439

Volume

93.125

124

Points count

745

992

x, y, z

-57.631, 16.731, 36.184

-16.187, -18.231, -36.439

Volume

29.5

20.5

Points count

236

164

Location

Site 1 (red)

Site 2 (light green)

Site 3 (dark green)

Site 4 (blue)

Site 5 (black)

Site 6 (yellow)

x, y, z
Site 7 (orange)

Volume
Points count

-59.187, -15.731, -26.189
Does not exist

Between
E1
domain II and E2
domain C

Between
E1
domain II and the
β–ribbon of E2

Adjacent to site 2

Behind the fusion
loop, between E3,
E2 domain B, E2
domain A
between the β–
ribbon of E2 and
E3

Within E3 cavity

Replacing the furin
loop

22.25
178

6.2.2. Virtual screening with the CHIKV envelope proteins
Two chemical compounds libraries were used; The NCI set library of 265,242
compounds and the Life Chemicals protein-protein interactions inhibitors library of
31,143 compounds. The databases were filtered with the drug-likeness-index; limit the
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range for Molecular Weight < 500, calculated octanol–water partition coefficient (clogP
< 5), and hydrogen bond donors, and acceptors (OH’s and NH’s < 5; N’s and O’s <
10),231

using

Filter

v2.0.2

(OpenEye

Scientific

Software,

Santa

Fe,

NM. http://www.eyesopen.com), producing 55,841 compounds from the NCI library
and 4,124 compounds from the Life Chemicals library. Fast exhaustive virtual screening
was performed using FRED v2.2.5 (OpenEye Scientific Software, Santa Fe,
NM. http://www.eyesopen.com), which is a fast and effective docking application
whose performance is significantly more reliable, i.e. lower variance, than most other
programs.232, 233 FRED performs a systematic, exhaustive, nonstochastic examination of
all possible poses within the protein active site, filters for shape complementarily 234 and
pharmacophoric features before selecting and optimizing poses using the Chemgauss
scoring function. Omega2 (Systematic high-throughput conformer generation, OpenEye
Scientific Software, Santa Fe, NM. http://www.eyesopen.com),235,

236

was used to

generate multiple conformers for each compound in the database libraries using the
default settings. Omega2 takes into account the ﬂexibility of a molecule by generating
all representative conformers. For the NCI library, 2,312,012 conformers were
generated, and 334,064 conformers were generated from the Life Chemicals
compounds. The work-flow diagram is shown in (Figure 6.3), the life chemical library
was screened on site 2 (light green colour in Figure 6.2) in both of the immature and the
mature glycoproteins. The NCI set compounds were screened on site 4 (blue colour in
Figure 6.2) of the two envelope protein forms. The binding sites were prepared for
docking using Fred receptor setup software (OpenEye Scientific Software, Santa Fe,
NM. http://www.eyesopen.com). The grid boxes were determined based on the x, y and
z co-ordinates given in Table 1. After the docking calculations, the poses returned were
scored and ranked with a Gaussian shape function independently by the five available
scoring functions (PLP, Chemgauss3, Chemscore, OEChemscore, and Screenscore) and
by a consensus of all. The top ranked poses from the exhaustive docking were then
optimized using systematic solid body optimization by chemgauss3. VIDA v4.2.0
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com) was used to
visualise the docked poses within the receptor active site, and to inspect the critical
interacting residues in each pocket with the individual docked poses. Top 20 hits were
then recorded for each of the four sites (Tables 6.2, 6.5, 6.8, 6.11).
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The top 20 docked poses ranked in each of the four binding sites were then
extracted as PDB files, and were processed with Autodock Tools 1.5.6rc3 (ADT)
graphical interface.173 The Gasteiger charges were calculated and the nonpolar hydrogen
atoms were merged, torsion angles were defined, they were then saved as pdbqt files for
Autodock calculations. Crystal structures (3N40, 3N42) were used by Autodock Tools
1.5.6rc3 to setup the receptor binding sites. The grid box co-ordinates in each site were
determined based on the co-ordinates in Table 1. AutoGrid 4.2 algorithm was used to
evaluate the binding energies between the inhibitors and the enzyme and to generate the
energy maps for the docking run. Fifty runs were generated using Autodock 4.2
Lamarckian genetic algorithm173 for the searches. Cluster analysis was performed on
docked results, with a root-mean-square tolerance of 2.0 Å, the docked poses were
ranked according to the binding energies and ligand efficiencies, and finally the five
lowest energy poses (Tables 6.3, 6.4, 6.6, 6.7, 6.9, 6.10, 6.12, 6.13) were selected as the
resultant complexes with the enzymes. Compounds are commercially available and
have drug like qualities and also can be accessed through chemical syntheses for further
optimization process.

Figure 6.3 Work-flow diagram of the virtual screening procedures used for CHIKV
envelope proteins.
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Table 6.2 Fred output virtual screening top 20 hits and their target residues, for the
immature glycoprotein receptor (3N40) site_2.
Entry

Structure

H-bonding

Other interactions

E1 Lys 52
E1 Thr 53

1

E2 Tyr 301
π–sigma (E1 Val 54)
2

π–sigma (E2 Arg 100)

3

E1 Thr 53

π–cation (E1 Lys 52)

E1 Ile 55
4

Lys 52

E1 Ile 55

π–sigma (E1 Val 54)

E1 Val 231

π–cation (E1 Lys 52)

5

E1 His 230
6

E1 Ile 55

E1 His 230
E1 Val 231
7
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E2 Tyr 301

π–cation (E2 Arg 100)

8

E1 Ile 55 (2 Bonds)
9

E2 Tyr 301 (2 Bonds)

10

E1 Thr 53, Ile 55
E2 Arg 100, Tyr301
11

π–cation (E1 Lys52)
12

E2 Glu 232

13

E1 Val 231, His 230
14

E1 Tyr 301
15
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E1 Ile 55 x 2

16

17

18

E1 Val 54, Thr 53
E2 Tyr 301

19

E2 Tyr 301 x 2

20
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Table 6.3 Autodock output for the immature glycoprotein receptor (3N40) site_2 Fred
hit list, Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 2.0, 3.0 Å.
Binding Energy

Predicted Ki

Kcal/mol

(nM)

1

-8.37

734.41

6

24

2

-8.23

930.55

12

19

3

-8.38

721.49

2

41

Entry

Lowest energy
cluster poses

4

-7.67

2.39 × 10

5

24

5

-9.43

121.87

10

10

6

-10.06

42.15

10

15

7

-8.99

255.48

8

19

3

8

-8.04

1.29 × 10

13

9

9

-8.3

819.29

6

31

10

-9.36

138.19

6

9

11

-8.8

354.66

16

3

12

-9.18

187.59

14

3

13

-8.19

987.11

1

50

16

3

14

156

3

Number of clusters

-7.91

1.6 × 10

3
3

15

-7.85

1.75 × 10

4

23

16

-8.8

357.02

7

11

17

-8.7

416.95

7

18

18

-8.43

657.11

4

22

19

-8.97

267.05

5

33

20

-8.98

263.45

9
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Table 6.4 Top 5 hits identified for site 2 using the immature glycoprotein receptor
(3N40), showing the molecular weights, calculated logP (clogP), predicted binding
energies, inhibitory constants (Ki) and the interaction residues.

Structure

Molecular
weight

*

clogP

Binding
energy

Predicted
Ki (nM)

Interaction
residues

Kcal/mol
E1 Lys52
E1 Ile55
1

396.47

0.31±0.89

-10.06

42.15

E1 Thr53
E2 Tyr301
E2 Arg100
E1 Lys52
E1 Ile55

2

411.91

3.43±0.66

-9.43

121.87

E1 Thr53
E2 Tyr301
E2 Arg100
E1 Lys52
E1 Ile55

3

392.52

3.60±0.43

-9.36

138.19
E2 Tyr301
E2 Glu232
E1 Lys52
E1 Ile55

4

372.46

2.93±0.44

-9.18

187.59

E2 Tyr301
E2 Glu232
E2 Arg100
E1 Lys52
E1 Ile55

5

327.36

3.47±0.71

-8.99

255.48
E2 Tyr301
E2 Arg100

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).
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Table 6.5 Fred output virtual screening top 20 hits and their target residues, for the
mature glycoprotein receptor (3N42) site_2.
Entry

Structure

H-bonding

Other interactions

E1 Ile 55, Lys 52

π–cation (E2 Arg 36)

E2 Tyr 237, Arg 36

π–cation (E1 Lys 52)

E1 Ile 55, Lys 52,

π–cation (E1 Lys 55)

Glu112

π–cation (E2 Arg 36)

E2 Tyr 237, Glu 66

π–sigma (E2 Ile 167)

E1 LYS 52 x 2

π–sigma (E1 Val 54)

1

2

3

E1 Lys 52
E2 Tyr 237
4

E1 Ile 55, Lys 52

π–cation (E1 Lys 52)

E2 Glu 35, Tyr 237

5

E1 Lys 52
E2 Glu 35
6

E1 Ile 55

π–sigma (E1 Val 54)
π–cation (E1 Lys 52)

7
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E1 Lys 52

π–sigma (E2 Arg 36)
π–cation (E1 Lys 52)

8

E1 Ile 55

π–cation (E1 Lys 52)

E2 Tyr 237 x 2

π–cation (E2 Arg 36)

E1 Ile 55, Val 231

π–cation (E1 Lys52)

9

10

E2 Tyr 237

E1 Ile 55, Lys 52 x 2

π–sigma (E1 Val 54)

E1 Lys 52

π–sigma (E1 Val 54)

E2 Tyr 237

π–cation (E1 Lys 52)

11

12

13

E1 Ile 55

14

E1 Lys 52

15
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E1 Lys 52

π–cation (E2 Arg 36)

E1 Lys 52 x 2

π–sigma (E1 Val 54)

E1 Lys 52 x 2

π–cation (E2 Arg 36)

16

17

π–cation (E1 Lys 52)

18

E1 Lys 52

19

E1 Lys 52

π–cation (E1 Lys 52)
π–cation (E2 Arg 36)

20
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Table 6.6 Autodock output for the mature glycoprotein receptor (3N42) site_2 Fred hit
list, Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 2.0, 3.0 Å.
Binding Energy

Predicted Ki

Kcal/mol

(nM)

1

-8.8

357.4

8

15

2

-8.51

581.05

10

23

3

-7.63

2.57 × 103

14

11

4

-9.36

138.07

8

30

5

-9.17

190.7

18

2

6

-9.98

48.38

8

22

7

-9.26

163.4

7

23

Entry

161

3

Number of clusters

Lowest energy
cluster poses

8

-8.05

1.25 × 10

5

13

9

-8.98

262.77

16

15

10

-9.71

75.78

8

14

3

11

-7.83

1.81 × 10

10

12

12

-7.97

1.44 × 103

9

28

13

-8.65

454.1

8

2

14

-8.29

842.46

8

9

15

-8.53

554.46

5

22

16

-8.36

741.07

7

23

17

-9.12

207.45

4

22

3

18

-8.16

1.05 × 10

7

28

19

-8.19

993.62

6

25

20

-8.88

311.61

6

31
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Table 6.7 Top 5 hits identified for site_2 using the mature glycoprotein receptor
(3N42), showing the molecular weights, calculated logP (clogP), predicted binding
energies, inhibitory constants (Ki) and the interaction residues.

Structure

Molecular
weight

Binding
*

clogP

energy
Kcal/mol

Predicted

Interaction

Ki (nM)

residues#
E1 Lys52
E1 Thr53

1

376.50

2.37±0.60

-9.98

48.38

E1 Ile55
E2 Arg36
E2 Glu168
E1 Lys52
E1 Ile55

2

354.43

4.12±0.64

-9.71

75.78

E2 Arg36
E2 Glu168
E2 Tyr237

3

376.50

3.90±0.72

-9.36

138.07

E1 Lys52
E1 Ile55
E2 Tyr237
E1 Lys52
E1 Thr53

4

390.50

3.03±0.75

-9.26

163.4

E1 Ile55
E2 Arg36
E2 Tyr237
E1 Lys52
E1 Thr53

5

350.39

2.83±0.90

-9.17

190.7

E1 Ile55
E2 Arg36
E2 Tyr237

#

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). Numbers of E2
residues in the mature form are different than the corresponding residues in the
immature form.
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Table 6.8 Fred output virtual screening top 20 hits and their target residues, for the
immature glycoprotein receptor (3N40) site_4.
Entry

1

Structure

H-bonding

Other interactions

E1 Val 229 x 2

Sigma–π (E2 His 93, x

E2 Leu 305

2)
π–sigma (E2 Leu 80)

E2 His 82, Leu 305

π– π (E2 His 93)

2

π–sigma (E2 Leu 80)
3

E2 Gln 300,
E1 Fusion Loop Trp 98

4

5

E1 Fusion Loop Phe 87,

π–sigma (E1 fusion

Val 229

loop Met88)

E2 His 82

E1 Leu 305
6

E1 Fusion Loop Phe 87
E2 His 82, His 93 x 2

7

163

π–sigma (E2 Leu 80)
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E1 Val 229 x 2

π–sigma (E2 Leu 80)

E2 Leu 305 x 2
8

E1 Val 229, Gly 227,
Fusion Loop Phe 87

9

E2 His 82
E2 His 93

Cation– π (E2 His93)
π–sigma (E1 fusion
loop Met88)

10

π–π (E1 fusion loop
Trp 89)
π–sigma (E2 Leu 80)
E1 Fusion Loop Phe 87
E2 His 82 x 2

11

E2 His 82, Asn 136

12

E2 Leu 305, His 82
E1 Fusion Loop Phe 87 x
13

164

2

π–sigma (E2 Leu 80)
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Shape Fitting

14

E1 Thr 228, Fusion Loop
Trp 89
15

E1 Fusion Loop Phe 87 x
2, Gly 227
16

E2 His 82 x 2

E1 Gly 227, Fusion Loo
17

Phe 87 x 2
E2 His 82, His 93
E2 Leu 305

18

E1 Fusion Loop Trp 89,

π–sigma (E2 Leu 80)

Fusion Loop Phe 87, Val
229
19

20
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E2 His 93

E1 Fusion Loop Trp 89,

π–sigma (E2 Leu 80)

Val 229

π–sigma (E1 fusion
loop Met 88)
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Table 6.9 Autodock output for the immature glycoprotein receptor (3N40) site_4 Fred
hit list, Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 2.0, 3.0 Å.
Binding Energy

Predicted Ki

Kcal/mol

(nM)

1

-9.47

114.55

8

29

2

-10.07

41.32

3

44

3

-11.23

5.91

4

45

4

-9.78

67.42

16

6

5

-9.79

66.16

3

23

6

-11.2

6.19

4

47

7

-10.03

44.5

4

42

8

-8.64

465.62

2

49

9

-8.39

704.34

3

30

10

-9.64

85.29

6

31

11

-10.45

21.98

5

42

12

-9.49

110.32

6

35

Entry

166

3

Number of clusters

Lowest energy
cluster poses

13

-7.31

4.39 × 10

10

23

14

-10.69

14.49

5

33

15

-10.15

36.19

5

26

6

32

3

16

-7.78

2.0 × 10

17

-7.61

2.62 × 103

8

15

18

-11.3

5.18

6

41

19

-7.42

3.64 × 103

10

17

20

-9.2

181.14

1

50
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Table 6.10 Top 5 hits identified for site 4 using the immature glycoprotein receptor
(3N40), showing the molecular weights, calculated logP (clogP), predicted binding
energies, inhibitory constants (Ki) and the interaction residues.

Structure

Molecular
weight

*

clogP

Binding
energy

Predicted
Ki (nM)

Interaction
residues

Kcal/mol
E1 Val229
E2 His82
1

361.89

4.76±0.54

-11.30

5.18

E2 His93
E2 Leu80
E2 Leu305
E1 Val229
E2 His82

2

361.89

4.71±0.48

-11.23

5.91

E2 His93
E2 Leu80
E2 Leu305
E1 Val229
E2 His82

3

341.47

4.49±0.47

-11.20

6.19

E2 His93
E2 Leu80
E2 Leu305
E2 His82

4

337.41

3.42±0.34

-10.69

14.49

E2 His93
E2 Leu80
E1 Phe87
E2 His82
E2 His93

5

379.39

1.83±0.90

-10.45

21.98
E2 Ser91
E2 Leu80
E2 Leu305

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).
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Table 6.11 Fred output virtual screening top 20 hits and their target residues, for the
mature glycoprotein receptor (3N42) site_4
Entry

Structure

H-bonding

Other interactions

E2 His 18, His 29

1

E2 Leu 16, Leu 241
2

π–sigma (E2 Leu 16)

E1 Fusion Loop
Trp 89
E2 Arg 13, Thr 175,

π–sigma (E2 Leu16)

Leu 16 x 2
3

E1 Fusion Loop
Trp 89

E1 Fusion Loop
4

π–cation (E2 His 29)

Phe 87 x 2
E2 His 18, His 29
E1 Fusion Loop

5

π–sigma (E2 Thr 175)

Trp 89
E2 Arg 13, Leu 16,
His 18
E2 His 29

Cation–π (E2 His 29)

6

E2 Arg 13, His 18,
7

His 29
E1 Val 229
E2 His 18, Leu 241

8
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π–cation (E2 His 18)
π–π (E2 His 29)
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E2 Arg 13, Gln
236, Leu 16, E2 His
29
9

E1 Fusion Loop
Trp 89

E2 Arg 13 x 2,
10

Gln236, Thr 175

E2 His 18, Leu 241

π–cation (E2 His 18)
π–π (E2 His 29)
π–sigma (E2 Leu 16)

11

12

E2 Leu 16

π–sigma (E1 fusion

E2 Arg 13

loop Met 88)

E2 Arg 13, Gln 236

π– sigma (E1 fusion
loop Met 88)

13

E1 Val 229 x 2

π–sigma (E2 Leu 16)

E2 His 29, Leu 241

π–sigma (E1 fusion
loop Met 88)

14

Cation–π (E2 His29)

E2 His 29, Thr 228

π–cation (E2 His 29)

E2 Arg 13, Leu

π–sigma (E2 Thr 175)

15

241, Leu 16
16

169
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E2 Arg 13, Gln 236

π–sigma (E2 Leu 16)

E1 Fusion Loop

π–sigma (E2 Leu 16)

17

18

Trp 89
E2 Leu 241, Leu 16
E2 Arg 13

π–sigma (E2 Thr 175)
π–cation (E2 His 73)

19

π–cation (E2 His 29)

E2 Leu 16

π–cation (E2 His 18)
π–cation (E2 His 29)

20

170
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Table 6.12 Autodock output for the mature glycoprotein receptor (3N42) site_4 Fred
hit list, Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 2.0, 3.0 Å.
Binding Energy

Predicted Ki

Kcal/mol

(nM)

1

-9.62

88.92

13

17

2

-8.42

678.5

2

45

3

-9.58

95.8

3

47

4

-10.25

30.49

5

36

5

-8.96

270.32

4

37

6

-8.76

380.09

10

21

7

-8.78

368.52

4

31

8

-9.98

48.35

4

43

9

-9.63

87.87

1

50

10

-8.54

551.47

1

50

11

-10.0

46.61

6

39

12

-7.75

2.09 × 103

2

49

13

-8.78

366.14

1

50

14

-9.48

112.05

7

23

15

-10.91

10.03

Entry

171

Number of clusters

Lowest energy
cluster poses

3

43

3

16

-7.87

1.72 × 10

4

38

17

-7.32

4.29 × 103

1

50

18

-7.51

3

3.13 × 10

2

2

19

-9.88

57.61

2

42

20

-8.89

302.63

5

17
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Table 6.13 Top 5 hits identified for site 4 using the mature glycoprotein receptor
(3N42), showing the molecular weights, calculated logP (clogP), predicted binding
energies, inhibitory constants (Ki) and the interaction residues.

Structure

Molecular
weight

*

clogP

Binding
energy

Predicted
Ki (nM)

Interaction
residues#

Kcal/mol
E1 Thr228
E1 Gly229
1

358.46

3.64±0.39

-10.91

10.03
E2 His18
E2 His29
E1 Phe87
E2 His18
E2 His29

2

379.39

1.83±0.90

-10.25

30.49
E2 Ser27
E2 Leu16
E2 leu241
E1 Val229
E2 His18

3

361.89

4.98±0.48

-10.00

46.61
E2 His29

E1 Val229
E2 His18
4

361.89

4.98±0.48

-9.98

48.35
E2 His29

E1 Trp89
E2 His18
5

352.36

2.47±1.22

-9.88

57.61
E2 His29
E2 Leu16

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). #Numbers of E2
residues in the mature form are different than the corresponding residues in the
immature form.
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6.3 Analysis of the docking calculations
The essential role of the CHIKV envelope protein in the fusion process, its location on
the surface of the mature virus (spikes) and the availability of the crystal structures
make it a suitable target for structure-based drug design. The CHIKV glycoprotein
exists in two forms, the immature form and the mature form. The immature form
represents the early stages of the envelope protein after the replication cycle, translated
in the endoplasmic reticulum and processed in the Golgi for maturation, moved to the
plasma membrane, where it is cleaved by furin-like protease activity in the host infected
cell into E2 and E3.42 The furin cleavage occurs at the furin loop, which represents the
junction between E2-E3. The difference between the two crystal structures is the
removal of the furin susceptible peptide motif that resulted in slight changes in the
volumes of the predicted binding sites. We searched for possible binding sites within
both the immature and the mature crystal structures. Six common sites were detected in
both structures (Table 1). Among the detected sites, site 2 (the light green colour in
Figure 6.2) and site 4 (the blue colour in Figure 6.2) were interesting. Site 2 represents a
surface cavity that lies between the E1 domain II and E2 β–ribbon that connects E2
domain A to E2 domain C; it also extends downwards as a channel between E1 domain
II and E2 domain A. E2 domains A and B move relative to each other in the pre- and
post-fusion structures. Therefore, small molecules that bind to this site may stabilize the
E1-E2 heterodimer and prevent their dissociation during the fusion process. Another
hypothesis is that it may also stabilize the orientation of E2 domain A with respect to
domain B in a way that inhibits the exposure of the fusion peptide in conditions of low
pH in the endosome, preventing the fusion process. Moreover, being a groove in this
area looking like the enzyme mouth (Figure 6.4), bound small molecules in this site
might act as indirect allosteric inhibitors for the furin susceptible peptide motif, and
therefore, might impair the cleavage step by the furin proteases. The indirect allosteric
inhibition mechanism might be through the inhibition of the interaction between the
CHIKV envelope protein, and hence the furin susceptible motif (furin loop), and the
acting protease (therefore, the Life Chemicals protein-protein inhibitors library was
used here), or through trapping the glycoprotein conformation in one inactive form
(relative to the furin cleavage step), which does not interact with the acting proteases.
The site 2 volume in the immature form is 9.5% bigger than that in the mature form.
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Therefore, both structures were included in the virtual screening study in an attempt to
find positive hits for this site.

Figure 6.4 Surface representation of the location of site 2 (green), parts of E2 and E3
are shown in orange where the furin loop takes a greyish orange at the top, E1 domain II
surface is shown in grey. Site 2 is located in a mouth like cavity that might interact
during the furin cleavage. Generated from the PDB file: 3N40.95

Site 2 makes close contact with residues from E1 and E2. The E1 residues are:
Glu50-Val60, Val229-Pro237; the E2 residues are: Ala97-Arg102 (corresponds to
Ala33-Arg38 in the mature form), Gln300-Arg308 (Gln236-Arg244 in the mature
form). Hydrogen bonding within these residues involve E1 Lys52, Thr53, Ile55,
Val231, His230, and E2 Tyr301 (Tyr237 in the mature form), Glu232 (Glu168 in the
mature form), and Arg100 (Arg36 in the mature form). Val54, Lys52, Arg100, Ile167
are able to form other types of strong noncovalent molecular interactions. Generally,
valine, alanine and proline amino acids within this pocket are also able to participate in
the hydrophobic interactions.
Surprisingly, we could not find a common hit ligand that fits in site 2 in both the
immature and the mature forms. However, inspection of the top 5 docked poses in each
site reveals that they have the common sequence: heterocycle-S-CH2-CO-N, the amidic
nitrogen in this sequence might be NH, and also can be a part of another ring system.
Figure 6.5 shows the 2D representations of the top docked poses in site 2 for both the
immature and the mature forms of the envelope glycoproteins. The presence of an
electron rich system results in strong noncovalent molecular interactions such as the π174
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cation interaction with E2 Arg100 (Arg36 in the mature form) and with E1 Lys52. The
heterocyclic ring adjacent to the sulphur in most of the top ranked poses can accept Hbonding with E1 Lys52, Ile55, and Thr53. Being able to bind to residues in both E1 and
E2, the ligands identified for this site are most likely to confirm our hypothesis and
stabilize the E1-E2 heterodimer and prevent the dissociation.

Figure 6.5 2D representation of the docked poses within the binding site 2. (a) Top
ranked pose (number 1 in Table 6.4) within the immature glycoprotein complex site 2.
(b) Top ranked pose (number 1 in Table 6.7) within the mature glycoprotein binding
site 2. H-bonds are shown in green and blue dashes, while π interactions are shown as
orange lines.

Site 4 (blue colour in Figure 6.2) can be described as a narrow channel
extending just behind the fusion loop and surrounded by both E2 domains A and B.
Comparison between the two sites in the immature and the mature forms indicates that
the site volume is 31.3% bigger in the mature form (Figure 6.2), and looks like an
umbrella above this site in the immature form. Small molecules binding to this narrow
channel will have significant effects; this might not only freeze the relative movement
of E2 domains A and B, but might also freeze the fusion loop through stabilizing
interactions, and consequently, prevent the exposure of the fusion loop. The fusion loop
is stabilized by the histidine residues of E2, which act as the pH sensors for the
activation of the fusion protein at lower pH. 95 This site cavity lies in contact with
several histidine residues of E2. Therefore, blocking this site may also impair the pH
sensor activation mechanism. All the identified hits were found to bind to both E1 and
E2 residues, involving the histidine residues of E2, moreover, two hits were found to
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bind to the fusion loop amino acids, confirming the ability of freezing the fusigenic
activity of the envelope proteins.
Site 4 forms close contact with the E1 fusion loop residues Pro86-Gly91, E1
Gly227-His230. The fusion loop Gly91 and His230 (outside of the fusion sequence)
were found to be critical for the fusion. 96 This emphasizes the importance of our
hypothesis that binding to this site will impair the fusion process. From E2, residues
Arg77-His82 (Arg13-His18 in the mature form), Ser91-Val96 (Ser27-Val32 in the
mature form) and residues Leu305-Ala310 (Leu241-Ala246 in the mature form) form
close contacts with the binding site.
Interestingly, a common hit ligand was found in both the blue sites (ranked 5 in
Table 6.10, and ranked 2 in Table 6.13). It shows the same interactions within the two
binding pockets and more importantly, it forms two H-bonds (5.4, 6.3 Å) with E1 fusion
loop amino acid Phe87 backbone carbonyl, three amino acids away from Gly91, the
critical96 residue for the fusion process. It also binds to E2 His82, His93 (His18, His29
in the mature form) via H-bonding and π-cation interactions (Figure 6.6). Moreover, the
predicated binding affinity and inhibitory constant (Ki, in the nano molar range), along
with the acceptable clogP value of 1.8 (Tables 6.10, 6.13), make it a very attractive
candidate for developing anti-chikungunya drug targeting the envelope proteins.
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Figure 6.6 3D representation of the predicted docking pose of compound 2 (Table 6.13)
within site 4 binding pocket (transparent surface) of the mature chikungunya envelope
protein showing the H-bonding (green dashes) with the fusion loop amino acid Phe87
(shown in orange colour).

A further interesting observation is the presence of same chiral skeleton; the (S)1-(2-hydroxy-3-phenoxypropyl)-4-phenylpiperazin-1-ium in a series of compounds (1,
2 and 3 in Table 6.10) and (3, 4 in Table 6.13). The compounds only differ in the
substituents on the terminal phenyl rings. The chirality of this series indicates the
selectivity of the compounds and reflects the importance of the stereochemistry in
designing inhibitors for this site. The enantiomers of these compounds (within the
library) did not pass the first FRED virtual screening. Within the immature narrow
binding pocket (site 4), these series were able to form H-bonds with the E1 Val229, E2
His82, E2 Leu305. However, in case of the 31.3% bigger pocket of the mature site 4,
this series was able to achieve the H-bonding with E1 Val229, E2 His29 whereas it
failed to form H-bonds with the E2 Leu241, but was still able to achieve the π stacking
interaction with E2 His18 and His29 (Figure 6.7). The importance of this stereoselectivity in inhibiting the envelope protein, was also noticed recently in the inhibitors
of the dengue virus envelope proteins mediated fusion, where compounds with certain
stereochemistry of the OH group (the (S) enantiomers) were shown to have
stereospecific effects on the activities.237 The importance of the (S) configuration of the
compounds (Figure 6.7) can be related to the ability of the OH groups of the compounds
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to achieve H-bonds with the E2 histidine residues (His82 of the immature form and
His29 of the mature form), whereas these H-bonds might not be possible with the other
enantiomers. Superimposition of the two compounds (number 1 in Table 6.10 and
number 3 in Table 6.13) within the binding pockets (site 4 in both enzyme forms)
revealed the positioning of the docked poses in a similar way with slight changes in the
orientation of the hydroxyl groups and the central piperazinium moiety (Figure 6.8). It
is also clear that the chlorine atoms seem not essential for interactions. This
superimposition not only indicates the reliability of the interactions of this class of
compounds with the residues within this site in the two forms of the enzyme, but also
confirms our hypothesis that this series might be developed as selective CHIKV
envelope protein inhibitors.

Figure 6.7 2D representation of the docked poses within the binding site 4. (a) Top ranked
pose (number 1 in Table 6.10) within the immature glycoprotein complex site 4. (b) Top
ranked pose (number 3 in Table 6.13) within the mature glycoprotein binding site 4. Hbonds are shown in green and blue dashes, while π interactions are shown as orange lines.
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Figure 6.8 Superimposition of compound 1 (in Table 6.10) within the immature
glycoprotein site 4 (compound and residues are shown in violet colour) and compound 3
(in Table 6.13) within the mature glycoprotein binding site 4 (compound and pocket
residues are shown in green colour). Slight differences can be observed for the orientation
of the hydroxyl groups and the central piperazinium ring.

Although ranked 5 in Table 6.13, this ligand shows extraordinary H-bonding
(2.41 Å) with the fusion peptide amino acid Trp89 backbone (Figure 6.9), just one
amino acid away from Gly91, the critical96 amino acid for the fusion process, The pose
is also stabilized inside the pocket by the interactions with the E2 His18, His29 and
Leu16 (Table 6.13). This also emphasizes the possibility of inhibiting the fusion process
through designing ligands for this pocket.
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Figure 6.9 Pose 5 (Table 6.13) within the mature glycoprotein binding site 4, showing
the 2.4 Å H-bond interaction (yellow line) with Trp89. Gly91 is shown in orange.

6.4. Concluding remarks
Thus far, the CHIKV envelope protein has not been investigated as a possible target for
the drug design against the virus. Therefore, we have investigated for the first time the
possible binding target sites within the immature and the mature forms of the CHIKV
envelope proteins. We managed to identify two sites that look critical to the protein
functions; mainly the fusion process, based on the functionality and the location of the
sites. A virtual screening search was performed on the two sites in both forms of the
enzymes to increase the chances of finding reliable positive hits. Five hits for each site
in both forms of the CHIKV envelope proteins were identified revealing some
important features for further developing antagonists for these proteins. To test our
hypothesis, the identified hits need to be evaluated against the CHIKV, which is
currently under investigation. Our study represents a good template for designing
selective inhibitors for the chikungunya virus envelope proteins via in silico and in vitro
optimization process. This developed computer model can be further used for screening
larger database libraries such as the FDA approved drugs libraries that would facilitate
the identification of effective therapies against the CHIKV. Our hypothesis might also
be a useful tool for inhibiting other alphaviruses such as Sindbis virus and Semliki
Forest virus as well as other fusion mediated viruses.
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7.1. Introduction
Trypanosoma brucei gambiense and T. b. rhodesiense are the causative agents of the
Human African Trypanosomiasis (HAT), also known as sleeping sickness. Anothere
neglected disease as the Chikungunya virus, the major topic of this thesis. Trypanosoma
brucei rhodesiense is found in Eastern and Southern Africa, whereas Trypanosoma
brucei gambiense occurs in Western and Central Africa and is responsible for over 90%
of all reported cases of infection.238 This disease threatens about 60 million people
living in sub-Saharan Africa and causes an estimated 25,000 deaths per year.239 It has a
major impact on the affected nations causing suffering and poverty and if left untreated,
the disease is usually fatal.240 The lack of full-scale screening programmes and poor
diagnostic tools has led to under-reporting of cases, which is likely to be at least
threefold higher than the measured value.241
Both subspecies are transmitted by the bite of the infected tsetse fly. T. b.
gambiense HAT is primarily a chronic human disease whereas T. b. rhodesiense HAT is
primarily zoonotic with a huge animal reservoir, causing the acute form of sleeping
sickness. After the bite, the parasite starts to multiply in the blood (phase I, febrile
illness with flu-like symptoms, which can last for several weeks or months). During this
phase, the parasite lives within the bloodstream and subsequently migrates to other
areas of the human body, such as the lymph nodes, spleen, and spinal fluid, causing
symptoms similar to those caused by malaria (rash, fever, shaking chills, body aches,
and general fatigue). If phase I is left untreated, the parasite then crosses the blood brain
barrier attacking the central nervous system (phase II) and neurological symptoms start
to appear, causing progressive mental deterioration, sleep disturbances, long lasting
coma (disruption of the sleep/wake cycle and psychological effects) and finally death if
not treated.242
Unfortunately, vaccines are not available for this disease. The unavailability of
vaccines is mainly due to the high degree of antigenic variation expressed by the
glycoprotein forming their surface coat.243 Therefore, the main defence against the
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parasite would be chemotherapeutics. The treatment options are limited with only few
drugs available. The four registered drugs to treat HAT, are suramin 152 and
pentamidine 153 for early stage infections, whereas melarsoprol 154 (contains arsenic)
and eflornithine 155 are for the late-stage treatment (Figure 7.1).244,245 All these drugs
were developed approximately 30 years ago and suffer high toxicity, the emergence of
resistance and lack of efficacy. Melarsoprol 154 is the most toxic and causes reactive
encephalopathy in 5−10% of treated patients, with 1−5% mortality.246

Figure 7.1 Older generation of African sleeping sickness treatment drugs.

Recently, there has been some progress in the treatment of HAT, 247 with the
nifurtimox 156−eflornithine 155 (Figure 7.1) combination (NECT) chemotherapy
developed to reduce resistance frequency.248,249 However, these options are still under
investigation due to inactivity against some trypanosome species or phases of the
infection, as well as toxicity, the parenteral mode of administration, and the emergence
of resistance.250,251
Other trypanocidal agents that are active against the first stage of HAT and are
orally bioavailable are pafuramidine 157252 and fexinidazole 158253 (Figure 7.2).
182

Chapter 7

African Sleeping Sickness

Although it was used in phase III clinical trials in 2007, pafuramidine 157 use was
terminated in 2008 because of hepatic toxicity. More recently, the novel boroncontaining molecule 159 (Figure 7.2) emerged as an orally active drug candidate that
completed preclinical studies in 2011.254 It showed promising activity against the blood
and the brain parasite. The mechanism by which compound 159 acts as a trypanocidal
agent is still unknown. It entered phase I clinical trials in France in 2012 for evaluation
against phase 1 and phase 2 HAT. The present treatment options indicate that new
therapeutics with acceptable efficacies and safety profiles are urgently needed new
therapeutic opportunities.255

Figure 7.2 New generation of African sleeping sickness treatment promising agents.

High throughput screening (HTS) is one approach that can be used to identify
new lead compounds for such neglected diseases. Therefore, in a previous work,256 the
HTS library of 87,926 compounds (WEHI 2003) 256 was tested against the related
trypanosome subspecies, Trypanosoma b. brucei and against a mammalian cell line
HEK293, to determine a selectivity index for each compound. Cluster analysis,
considering chemical alerts such as toxicophores, the likelihood of CNS penetration,
and drug-like structural features yielded a subset of twelve compounds as promising
medicinal chemistry starting points for drug development. A consortium of Australian
medicinal chemists was formed among different Australian universities, to optimize the
obtained hits, and some of these hits were introduced to our group for optimization.
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This chapter discusses the synthesis and anti-trypanocidal activity of new
analogues for the bis-sulfonamide hit, WEHI-1203255 (160, Figure 7.3), which showed
an IC50 1.3 µM, with a selectivity index (SI) of >32. This hit compound 160 has
excellent physiochemical properties, good calculated aqueous solubility of 100 µM, an
acceptable polar surface area of 84 Å2, and an acceptable CLogP value231 of 2.5. The
analogues were synthesized and tested for their ability to inhibit the growth of T. brucei
limiting the changes to the two sulfonamide moieties to study the preliminary structure
activity analysis. The cytotoxicity profiles of the compounds were evaluated using
(HEK293) cell line and selectivity index was estimated for each analogue. The SI of the
compounds was determined where possible by directly comparing the IC 50 values from
the T. b. brucei and (HEK 293) assay. If this was not possible, an estimated IC50 value
was calculated by comparing the dose at which the compound was active >50% in the
T. b. brucei assay and the highest dose at which there was no activity (<50%) in the
(HEK 293) assay.

Figure 7.3 Lead compound 160 (WEHI 1203255), IC50= 1.3 µM.

7.2. Results and discussion
7.2.1. Synthesis of the bis-sulfonamide analogues
The retro-synthetic analysis of the lead compound 160 (Figure 7.4) revealed that
it could be accessed through three facile synthetic steps: the sulfonation of the
commercially available 7-nitrotetrahydroquinoline 161, followed by the reduction of the
nitro group to afford the aminotetrahydroquinoline 163. A second sulfonation of the
amino group would result in the final bis-sulfonamide compound 160 (Figure 7.4). This
strategy enabled us to access 26 separate derivatives in a short timeframe, reliable yields
and at reasonable cost.
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Figure 7.4 The retro-synthesis analysis for the access of the lead compound 160.

The first step in the synthetic pathway was the sulfonation of the secondary
amine of commercially available 7-nitrotetrahydroquinoline 161 using the appropriate
sulfonyl chloride. The reaction (Scheme 7.1) was initially attempted using CH2CH2 as a
solvent in the presence of TEA as a base and stirring the reaction mixture at room
temperature for 24 h, however, the yields of the isolated compounds were less than
40%, with the remaining being un-reacted starting 7-nitrotetrahydroquinoline 161.
Pyridine behaves as a better solvent and a stronger base for the tetrahydroquinoline
sulfonation,257,258 and was therefore used throughout in this reaction. Therefore, the 7nitrotetrahydroquinoline 161 was dissolved in anhydrous pyridine, and the mixture was
then stirred at 0 ºC. The appropriate sulfonyl chloride (liquid) was then added dropwise
and the mixture was stirred for 24 h (Scheme 7.1). The reaction mixture was then
quenched with cold water, after which the resultant oil or solid was extracted using
ethyl acetate. Column chromatography afforded the desired sulfonamides 162, 164-166
in 70-88% yield. Analysis of the 1H NMR spectrum of 1-(ethylsulfonyl)-7-nitro-1,2,3,4tetrahydroquinoline 162 showed quartet peak integrating for two protons and resonating
at 3.22 ppm, and another triplet peak, integrating three protons, resonating at 2.95 ppm.
These peaks were assigned to the ethyl CH2 and CH3 groups, respectively. Analysis of
the EI-MS spectrum of 162 showed a peak at 270 m/z corresponding to the molecular
ion (M+).
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Scheme 7.1 Sulfonation of the tetrahydroquinoline 161 to afford intermediates 162-165.

The nitro group of the sulfonamides 162, 164-166 was then reduced, initially
using the reduction methodology developed in our lab, where the sulfonamides 162,
164-166 were dissolved in a mixture of acetic acid, ethanol and water in the presence of
iron powder as a catalyst, with sonication at 30 ºC,209 however, under these conditions,
yields of the reduced products were under 50%. Therefore the Raney nickel catalysed
reduction was performed by dissolving the nitro derivatives in methanol, followed by
the addition of Raney Nickel (as a suspension in water) under a N 2 atmosphere. The
mixture was then vigorously stirred (Scheme 7.2) and hydrazine monohydrate, as a
hydrogen source, dissolved in methanol was then added dropwise resulting in the
production of H2 gas. After the H2 gas evolution ceased, the mixture was heated at
reflux, filtered hot through celite, and the methanol and excess hydrazine hydrate were
removed, affording the aniline derivatives 163, 167-169 in 80-90% yields, which were
easily purified by recrystallization from either methanol or toluene. Analysis of the EIMS spectrum of 7-amino-1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinoline 163 showed a
peak at 240 m/z which was assigned for the molecular ion (M+). Analysis of the 1H
NMR spectrum of 163 showed a broad singlet peak resonating at 3.62 ppm that was
assigned for the NH2.
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Scheme 7.2 Reduction of the nitrotetrahydroquinolines 162, 164-166.

The amino groups in the sulfonamides 163, 167-169 were then reacted with the
appropriate sulfonyl chloride (the second sulfonation) in pyridine at room temperature
(Scheme 7.3). After aqueous workup, extraction, washing with HCl and evaporation of
the solvents, the bis-sulfonamides compounds 160 and 170-194 were isolated and were
purified using column chromatography to afford the final analogues in 70-80% yield.
Analysis of the EI-MS spectrum of N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7yl)-2-fluorobenzenesulfonamide 160 showed a peak at 398 m/z that was assigned as the
molecular ion (M+). Analysis of the 13C NMR spectrum of 160 showed a doublet peak
at 159.6 ppm (J = 254.9 Hz) that was assigned to the carbon attached to the F atom
(compound 160, Figure 7.4). HPLC analysis of these bis-sulfonamides showed a purity
range > 95% for all the synthesized derivatives.

Scheme 7.3 The synthesis of the bis-sulfonamides 160, 170-194 (see Table 7.1 for R1
and R2).
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7.2.2. Trypanocidal activity and structure activity relationship (SAR)
The results for the testing against Trypanosoma b. brucei, the calculated ClogP and the
selectivity index are listed in Table 7.1. The initial activity was screening at 1 µM and
10 µM and derivatives that showed significant activity were then tested to obtain the
IC50 values. The first series of derivatives examined the changes in the aromatic sulfonyl
moiety where the lead compound 160 has a fluorine atom in the ortho position. This
lead compound was also resynthesised and tested with IC50/SI= 4.1/>20, confirming the
initial activity results from the (WEHI 2003) compounds library. Changing the orthofluoro substituent to the para (compound 170) and meta (compound 171) positions, did
not improve the activity where the IC50/SI profile was 7.8 µM/>10 for both derivatives,
indicating decreased trypanocidal activity and increased toxicity. Increasing the number
of the fluorine atoms had a negative effect on the activity, where the addition of a
second fluoro substituent into the adjacent ortho position (compound 172) resulted in a
decreased activity (82% activity at 10 µM) as did the presence of five fluoro
substituents (compound 173, 40% activity at 1 µM). This implied the importance of the
mono-fluoro atom only in the ortho position, with no advantages with the presence of
the extra fluorine atoms.
The fluorine atom is the smallest halogen size, therefore, it was interesting to
test the presence of other halogen atoms. The addition of a bromo substituent at the
para position (compound 174) resulted in increased toxicity and did not improve the
activity (IC50/SI= 9.9 µM/>8).
Replacing the benzene moiety with its bioisostere thiophene259,260 (compound
175) resulted in a similar activity (IC50/SI= 4.0 µM/>20) compared to the lead 160. The
same activity profile of 160 and the simpler 175 might be attributed to the lipophilic
nature thiophene ring in 175 that might have the same effect as the fluorine atom in 160.
The addition of another halogen to this thiophene (Br, compound 176) showed
improved trypanocidal activity (IC50/SI= 2.6 µM/>7), however, the selectivity index
value was reduced compared to the unsubstituted thiophene analogue 175. Interestingly,
replacement of the bulky bromo substituent in 176 by a chloro substituent (compound
177) was not tolerated, as the activity decreased (IC50/SI= 13.1 µM/>6). The activity of
177 was 3 fold less than that of 175 and 5 fold less than that of 176.
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Table 7.1 R1, R2, molecular weight, ClogP, IC50 and Selectivity index for compounds
160, 170-19.

Compound

R1

R2

Mwt

ClogP*

IC50 (µM)

S.I.

160

398.47

2.48±0.82

4.1±0.643

20.2

170

398.47

2.98±0.82

7.8±2.695

10.7

171

398.47

3.09±0.82

7.8±2.155

10.6

172

416.46

2.33±0.87

82% @ 10 µM

173

470.43

3.37±1.07

40% @ 1 µM

174

477.36

3.50±0.88

9.9±3.319

8.4

175

386.50

2.27±0.79

4.0±0.625

20.5

176

465.40

3.49±0.87

2.6±2.573

>7

177

420.95

3.28±0.88

13.1±4.344

6.3

178

394.50

3.13±0.77

3.4±0.910

24.4

179

332.43

1.57±0.76

IN

-
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180

386.41

2.82±0.96

IN

-

181

408.53

3.66±0.77

4.7

>18

182

436.58

4.54±0.77

3.9

>22

183

470.60

4.85±0.79

13.0

>6.6

184

412.49

3.01±0.82

10.0

>8

185

400.53

2.80±0.79

IN

-

186

408.53

3.66±0.77

IN

-

187

408.53

3.66±0.77

IN

-

188

422.56

4.12±0.77

16.0

>5

189

422.56

4.12±0.77

IN

-

190

464.64

5.50±0.78

11.4

>7

191

440.57

2.26±0.83

IN

-

192

448.57

3.12±0.81

3.1±0.893

2.45

190
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448.57

3.12±0.81

7.6±2.552

1.5

194

456.57

3.99±0.79

3.9±0.887

1.9

*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).

Replacing the aromatic moiety with aliphatic chains as in compounds 179 and
180 completely abolished the activity which indicates the importance of the aromatic
ring in that position for the trypanocidal activity. The π system of the aromatic ring may
be involved in the interaction site, whereas with aliphatic side chains, such interactions
don’t exist. Interestingly, the introduction of a small hydrophobe such as a methyl group
on the para position on the phenyl ring of the aromatic sulfonyl moiety (compound 178)
improved the activity slightly (IC50/SI= 3.4 µM/>24), mostly due to the increased
difference between the effective and toxic concentrations compared to 160. As the mode
of action and the target of the compounds are not yet known, the role of this hydrophobe
methyl group cannot be confirmed, however, it might be involved in a hydrophobic
interaction within the target site.
Addition of another hydrophobe (a methyl group) on the ethyl side chain of the
other sulfonyl group (second changeable moiety) as in compound 181, was also
tolerated (IC50/SI= 4.7 µM/>18) where no significant difference in the activity
compared to 178 was observed with a

slight narrowing of the selectivity index

compared to 178. In the case of compound 185, this extra hydrophobe on the ethyl side
chain was not tolerated and activity dropped. When the p-tolyl group of 181 was
replaced by a thiophene ring (compound 185), the activity was completely abolished
due to this extra hydrophobic methyl (the propyl aliphatic group), compared to 175.
The para position of the methyl hydrophobe in 181 was important for activity as
can be indicated by the inactivity of compounds 186 (ortho position) and 187 (meta
position). The weak activity of 188 and 190 and inactivity of 189 (no p-methyl group)
also gives indications about the importance of the para position, with no advantages
with the presence of the extra hydrophobic methyl groups. Figure 7.5 shows the SAR
for this series of bis-sulfonamides.
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Figure 7.5 Structure activity relationship for the bis-sulfonamides.

Addition of the hydrophobic methyl groups on either the ethyl side chain or on
the aromatic sulfonyl moieties seemed to act as a tuner for the activity. Compound 185
was completely inactive whereas compound 184 showed similar activity (IC50/SI= 3.1
µM/>8) compared to the lead 160, with a narrowing in the selectivity index observed.
Increasing the bulkiness of compound 181 to 182 (replacing the small methyl
hydrophobe with the more bulky isopropyl group) resulted in an improved activity
profile and decreased the toxicity (IC50/SI= 3.9 µM/>22). Increasing the bulkiness by
replacing the isopropyl in 182 by a phenyl ring (compound 183) decreased the activity
(IC50/SI= 13 µM/>7) by 3 fold compared to 182, but did not completely abolish the
activity. This difference can be attributed to the difference of the electronic effect; the
methyl and isopropyl group have a positive inductive effect on the benzene ring while
the phenyl ring at the para position has a negative inductive effect. This also confirms
that the π system of the aromatic ring (directly attached to the sulphonamide group)
might be involved in the activity.
When the aliphatic sulfonyl side chain (sulfonyl group attached to the
tetrahydroquinoline N) was replaced with aromatic ring, the activity was either
completely abolished as in case of compound 191 or toxicity was increased as in
compounds 192-194. Interestingly, compound 192 carrying the para methyl group was
the best in this series (IC50/SI= 3.1 µM/>2), confirming the importance of the para
192
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position on this aromatic moiety. The aliphatic sulfonyl groups directly attached to the
tetrahydroquinoline ring is important for activity rather than an aromatic replacment.
7.3. Concluding remarks
In this chapter, we synthesized 26 bis-sulfonamide analogues of the lead compound
160, which had good physiochemical properties and was discovered during the high
throughput screening (HTS) of the WEHI 2003 library of 87,926 compounds. The
analogues were accessed through three facile synthetic steps. Some of the analogues
displayed good activity profile ranging from 2 to 4 µM. The preliminary structure
activity relationship revealed that the presence of an aliphatic side chain on the
tetrahydroquinoline 160 is important for activity and should not be replaced by aromatic
groups.

The

second

sulfonation

of

the

amino

group

of

the

sulfonated

tetrahydroquinoline 166-169 must be with aromatic sulfonyl groups, as when aliphatic
groups were used, activity was completely abolished. The bis-sulfonamide 176 with the
bromo-thiophene group, displayed IC50 value of 2.6 µM with a selectivity index >7. The
para position of the aromatic ring on the bis-sulfonamides 178, was found to be critical
for tuning the activity, where the activity changed with changing the size of the
hydrophobe substituents in that position. Small hydrophobe groups were favoured over
the bulky aromatic groups in that para position. Therefore, this position should be
investigated more with a variety of possible substitutions. The target site and mode of
action of the bis-sulfonamides are still yet unknown, and need further investigations.
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8.1. Chapter 2: The Search for Anti-CHIKV Lead Compounds
8.1.1. Conclusions
The modifications in the AAPM series (Figure 8.1) were advantageous in decreasing the
steric hindrance around the exchangeable chloro substituent, and also in simplification
of the synthetic steps required throughout the synthesis. The alkene 63, with the less
hindered cyclopropyl group, represents the most promising alkene to perform more
amination reactions under moderate conditions, as can be indicated by the formation of
the morpholine analogue 77.

Figure 8.1 Modifications of the AAPM series by simplification and decreasing the
steric hindrance.

Different conditions were investigated to synthesize the AAPM with the amines
33 or 47, however, all attempts failed due to the polymerization of 33 and the
decomposition of 47 under the reaction conditions. The degradation of 47 was observed
during the attempted synthesis of 65 (Figure 8.2) where the amine 66 peak was
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observed in the mass analysis. Furthermore, during the synthesis of 72, the amine 47 is
believed to decompose providing the hydrogen source for the reduction reaction to
occur giving the NH2 group in 72 (Figure 8.2).

Figure 8.2 The un-synthesized AAPM 65, the decomposition product 66 and compound
72 that was produced in a reaction with the amine 47.

8.1.2. Future directions
Some alternative access routes to the AAPM derivatives are to be considered. The
synthesized new furopyrimidine 42 can be considered for the amination reaction with
the original pyrimidine core, as it is less stericaly hindered. The furan ring can then be
open using POCl3160 to give the final aminated products (Scheme 8.1).
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Scheme 8.1 Alternative synthesis of the AAPM series using the furopyrimidine 42
intermediate.

Using the pyridine core, an alternative synthesis method to access the AAPM
derivatives can be investigated (Scheme 8.2). The suggested synthesis starts with the
reaction of the aminopyridine 196 with the amino-acid chloride 197 to afford the amide
198. Subsequent addition reaction with the ketone 38 using n-BuLi and N,N,N′,N′196
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tetramethylethylenediamine (TMEDA)261 at -70 ºC would afford the alcohol 199.
Finally, a dehydration reaction would afford the alkene 200 as the AAPM derivative.

Scheme 8.2 An alternative synthetic route for the AAPM derivatives starting from
aminopyridine 196.

8.2. Chapter 3: The CHIKV nsP3
8.2.1. Conclusions
The CHIKV nsP3 protein represents an attractive target for developing selective
inhibitors for the virus. This was illustrated by the virtual screening of the NCI set
library of 1990 compounds, using the available crystal structure of the macro domain of
the nsP3. The hits that achieved higher scores than the co-crystallized ligand (ADPribose) were selected for further refining using a second round of docking and scoring.
This resulted in 7 hits that scored higher than the co-crystallized ligand. Pose_3 (Figure
8.3) was in silico optimized giving pose_3_2, which achieved higher scoring and
improved interactions inside the nsP3 macro domain binding pocket. The optimized
pose_3_2 also has improved drug-like qualities and fits more to Lipinski’s guidelines. 231
The optimized hit was the accessed through three facile chemical synthesis steps. The
compounds are still under antiviral evaluations and the accuracy of the model
predictions would depend on the biological activity of the compounds.
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Figure 8.3 The virtual screening hit pose_3 that was in silico optimized and
synthesized.

8.2.2. Future directions
The parallel virtual screening, in silico optimization and in vitro evaluation of the
obtained hits, would be an applicable structure-based approach for the drug design of
selective inhibitors for the CHIKV. Molecular dynamic simulation would also help in
optimizing the developed computer model, assisting in obtaining more reliable hits.
Based on the in vitro activity of the compounds, the retro-synthesis analyses can
be investigated for the active hits, allowing the generation of more analogues which
would represent good templates for the discovery of a lead compound, and developing
the medicinal chemistry against the CHIKV.

8.3. Chapter 4: Mycophenolic acid analogues
8.3.1. Conclusions
A series of benzolactone-acid conjugates 114-117, benzolactone-tetrazole conjugates
126, 127, 130, 131 and isatin-acid conjugates 140-143 was synthesized as
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mycophenolic acid analogues as inhibitors for the CHIKV (Figure 8.4). Two side
products were obtained; the β-lactam ring structure and the open β-lactam product. All
the synthesized analogues have drug-like qualities. The access to the isatin-tetrazole
conjugates was attempted using the cycloaddition reaction with NaN 3, however, no
compounds were obtained due to the reactivity of the isatin core which is believed to
interfere with the tetrazole ring formation reaction.

Figure 8.4 Mycophenolic acid derivatives, the coloured features represent the main
moieties used in the analogues design.

8.3.2. Future directions
The access to the isatin-tetrazole conjugates could be achieved through the Suzuki
coupling

with

potassium

5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

yl)phenoxy)methyl)tetrazol-1-ide 129. The synthesized conjugates are currently under
anti-chikungunya evaluation, and based on the derived structure activity relationship,
further medicinal chemistry derivatisation could be achieved such as formation of esters
or amides as prodrugs.
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The analogues were designed as mycophenolic acid analogues and are assumed
to inhibit the IMPDH enzyme. Therefore, it would be interesting to evaluate these
analogues as inhibitors for this enzyme in specific enzyme inhibition tests. Furthermore,
a number of crystal structures of the IMPDH enzymes with mycophenolic acid are
available within the protein data bank. Therefore, the ability of the analogues to bind to
the active site of the enzyme could be in silico evaluated, giving more impact to the
rational drug design of this series of compounds as spicific enzyme inhibitors.

8.4. Chapter 5: The CHIKV nsP2
8.4.1. Conclusions
The CHIKV protease (nsP2) is critical for the viral replication cycle and therefore,
represents an attractive target for drug design. The druggable binding pockets within the
nsP2 crystal structure were investigated where two hydrophobic pockets were observed,
one within the protease C domain and one within the N domain (Figure 8.5). A
computer virtual screening model was developed combining two virtual screening
algorithms, FRED and Autodock. The model was used to screen a library of protease
inhibitors within the two domains and resulted in favoured hit list for each pocket.
Domain C pocket

Domain N pocket

Figure 8.5 The druggable pockets within the CHIKV nsP2.
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Within domain C druggable site, Lys1239 (from domain C) and Lys1045 (from
domain N) were found to interact with most of the identified ligands, stabilizing them
within the U-shaped pocket, blocking the protease function. Within domain N pocket,
Trp1084 and Lys1091 were found to be interacting with all of the docked ligands, with
the possibility for interaction with the C domain Gln1241. Ligands for this pocket
would block the enzyme NTPase/RTPase functions, and might act as allosteric
inhibitors for the domain C protease site.

8.4.2. Future directions
The anti-CHIKV evaluation of the identified hits is still ongoing. The results of these
assays would be used evaluate the prediction accuracy of the model. The ongoing
testing is based on whole cell assays and the ability of the compounds to inhibit the viral
induced cytopathic effect and viral replication. The CHIKV nsP2 enzyme is not
available as a testing kit for evaluating the direct binding with the model hits, and this
would need further investigations and collaborations.
Based on the derived model prediction accuracy, it could be used for screening
more compound libraries, with the in vitro evaluation of the identified hits. Molecular
dynamic simulation studies on the developed model should reveal more insights for the
precise molecular interactions with the bound ligands, allowing improved structurebased drug design approach.

8.5. Chapter 6: The CHIKV envelope proteins
8.5.1. Conclusions
The binding sites within the CHIKV envelope proteins (mature and immature
forms) were identified with two binding sites found common in the two enzyme forms.
A virtual screening computer model combining two successive docking algorithms was
developed for these proteins. This model was used for the screening of two chemical
libraries within the identified sites in the two enzyme forms. The top 5 hits in each
pocket were selected as promising in silico inhibitors. The green pocket (Figure 8.6)
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represents a surface cavity that lies between the E1 domain II and E2 β–ribbon that
connects E2 domain A to E2 domain C, it also extends downwards as a channel
between E1 domain II and E2 domain A. The blue pocket (Figure 8.6) is a narrow
channel extending just behind the fusion loop and surrounded by both E2 domains A
and B. These pockets make contact with residues from E1 and E2 and therefore, ligands
for these pockets can affect the relative movement of E1 and E2 domains in the pre- and
post-fusion states. Furthermore, the blue pocket makes contact with the fusion loop
residues, and therefore, designing antagonists for this pocket would be an applicable
strategy to block the fusion function. 262

Figure 8.6 Possible druggable cavities within the CHIKV envelope proteins (parts of
the whole protein), the blue and the green pockets. E1 is coloured in violet, E2 is
coloured in orange and E3 is shown in red.

8.5.2. Future directions
The anti-CHIKV activity of the compounds is to be investigated to evaluate the
prediction accuracy of the model. To get more insights into the accuracy of the model,
molecular dynamic simulations are to be developed for these models. This developed
structure-based computer model can be further used for screening larger database
libraries such as the FDA approved drugs libraries that would facilitate the
identification of lead compounds against the CHIKV.
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Based on the structural similarities of the CHIKV envelope proteins with the
other members of alphaviruses, this developed computer model as well as the
discovered hits could be also evaluated against other viruses.

8.6. Chapter 7: New Leads for African Trypanosomiasis
8.6.1. Conclusions
A bis-sulfonamide lead compound was discovered during the high throughput screening
(HTS) of the WEHI 2003 library of 87,926 compounds that were tested against
Trypanosoma brucei. 256 A series of 26 bis-sulfonamides were synthesized through three
facile synthetic steps (Scheme 8.3) and were evaluated against Trypanosoma brucei and
the cytotoxicity profiles of the compounds were evaluated using the HEK293 cell line.
The lead compound was resynthesized and re-evaluated confirming the activity.

Scheme 8.3 The three facile synthesis steps designed for the synthesis of the bissulfonamides 160, 170-194.
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A structure activity relationship was developed for this series based on the
activities, with some of the analogues displaying good activity profile ranging from 2 to
4 µM with acceptable selectivity indices from the medicinal chemistry prospective.
8.6.2. Future directions
To further assess the structure activity relationship, another possible derivatisation is the
use of amides instead of the sulfonyl linkages (Figure 8.7) giving a series of compounds
with the general formula A. Another possibility is the change of the core ring, to
investigate the importance of the tetrahydroquinoline ring, for example to the indoline
ring, giving a series of compounds with the general formulas B and C, taking into
account the preliminary structure activity relationship results. These changes will give a
full picture for the requirements of activity for this class of the bis-sulfonamide based
skeleton. More biological evaluation are required to assess the mode of action and the
target sites for these molecules.

Figure 8.7 Possible derivatisation of the bis-sulfonamide class of compounds.
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9.1. Chemistry
9.1.1. General experimental
Unless otherwise stated, chemicals were purchased from Sigma Aldrich (Australia).
1,2,3,4-Tetrahydro-7-nitroquinoline was purchased from Shanghai Xunxin Chemical
Co., Ltd. (China). (3-(Cyanomethoxy)phenyl)boronic acid was purchased from CombiBlocks, Inc., USA. All 1H, 13C and 19F NMR spectra were recorded at 500, 125 and 282
MHz, respectively on a Varian Inova 500 MHz spectrometer. Chemical shifts () are
reported in parts per million relative to TMS using CDCl3 as a solvent unless otherwise
noted. The solvents used for

13

C NMR were the same used for the 1H NMR unless

otherwise noted. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are
reported as singlet (s), broad (br), doublet (d), doublet of doublets (dd), doublet of
doublets of doublets (ddd), doublet of triplet (dt), multiplet (m), pentet (p), sextet (sex)
or septet (sp). Electron impact (EI) and electrospray (ES) mass spectra (MS) were
recorded on a Shimadzu QP-5000 spectrometer and high resolution (HR) on a VG
AutoSpec spectrometer. Electrospray (ESI) mass spectra were recorded on a Micromass
Platform LCZ spectrometer and high resolution on a Micromass QTOF2 spectrometer.
Ion mass to charge (m/z) values are stated with their relative abundances as a percentage
in parentheses. Peaks assigned to the molecular ion are denoted by M+ or M- (when
using the ESI-). Thin Layer Chromatography (TLC) was performed using Merck Silica
Gel F254 aluminium sheets. Column chromatography purifications were performed
using flash Silica gel (0.04-0.06 mm, 230 – 400 mesh). Infrared (IR) spectra were
recorded on a (Shimadzu FT-IR spectrometer) fitted with a Smart Omni-Sampler
germanium crystal accessory. All IR spectra were recorded as neat samples. In the IR
spectra, strong, medium and weak peaks are assigned as s, m and w, respectively.
Melting points were determined using a Gallenkamp (Griffin) melting point apparatus.
Temperatures are expressed in degrees Celsius (ºC) and are uncorrected. Microwave
reactions were performed using a Discover CEM Focused Microwave Synthesis System
in 10 mL closed vessels. HPLC purity check was performed using Waters 1525 HPLC
pump, WatersTm 486 absorbance detector (using the wavelength, 254 nm) and Nova205
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Pak® Silica 3.9x150 mm C18 column. HPLC solvents used in this work: solvent A was
hexane, solvent B was isopropanol containing 0.1% TFA, solvent C was isopropanol
and solvent D is ethyl acetate. Retention times in minutes for the HPLC results are
expressed as Rt. Reactions performed at -78 °C and -116 °C were cooled using N2
(l)/EtOAc

and N2 (l)/EtOH slush baths, respectively. The concentration of n-BuLi was

determined by titration using phenanthroline and 2-butanol in toluene (ca. 1 M). Known
compounds were synthesized either according to the reported procedure (references are
provided) or using new methods which were described in detail, and the spectral data
collected for these reported intermediates matched those reported in the literature. The
assignments of the protons and carbons in the spectra were based on the given
nomenclatures, unless otherwise stated.

9.1.2. Experimental for chapter 2
2-Methyl-1-(3-nitrophenyl)propan-1-one 38

To conc. H2SO4 (25 mL) cooled to -20 ºC, was added dropwise pre-cooled 2-methyl-1phenylpropan-1-one 37 (20 g, 0.135 mol), and the mixture was stirred for 10 min at -20
ºC. A pre-cooled nitrating mixture of conc. H2SO4 (15 mL) and conc. HNO3 (8.3 g) was
added dropwise at a rate that the temperature remained at -10 to -5 ºC. After complete
addition, the reaction mixture was stirred for 1 h at 0 ºC. It was then poured onto
crushed ice, and extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were
washed with water (50 mL) and brine (50 mL), dried (MgSO4) and concentrated under
reduced pressure. The oily residue was then subjected to flash column chromatography
and elution with 40% CH2Cl2 in petroleum spirit gave the meta-nitro compound 38
(13.5 g, 52%) as a yellow oil; IR (cm-1): υ 1667 (s, C=O), 1528 (s, NO2), 1355 (s, NO2).
1

H NMR (CDCl3): δ 8.75 (t, J = 1.8 Hz, 1H, phenyl_2 H), 8.40 (ddd, J = 8.3, 2.3, 1.1

Hz, 1H, phenyl_4), 8.27 (d, J = 7.9 Hz, 1H, phenyl_6 H), 7.68 (t, J = 8.0 Hz, 1H,
phenyl_5 H), 3.57 (sp, J = 6.8 Hz, 1H, propanone_2 H), 1.17 (d, J = 7.2 Hz, 6H,
(CH3)2). 13C NMR, δ: 202.4 (CO), 149.3 (phenyl C3), 137.7 (phenyl C1), 134.2 (phenyl
C6), 130.2 (phenyl C5), 127.4 (phenyl C4), 123.4 (phenyl C2), 36.0 (C2), 19.1 (2 CH3).
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EI-MS m/z 193 (M+, 26), 176 (9), 150 (100%), 134 (19), 121 (22), 104 (70). HRMS
(ESI) calcd for C10H12NO3 (MH+), 194.0817; found, 194.0823.

1-(4,6-Dichloropyrimidin-5-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 40

Under a N2 atmosphere, a fresh solution of LDA was prepared by dropwise addition of
n-BuLi (1.56 mL of 2 M solution, 3.11 mmol) to a solution of diisopropyl amine (314.7
mg, 3.11 mmol) in a pre-cooled (-78 ºC) dry THF (20 mL), and the mixture was stired
for 30 min at -78 ºC. To this solution, was added dropwise, a solution of 4,6dichloropyrimidine 28 (385.9 mg, 2.59 mmol) in dry THF (10 mL), also pre-cooled to 78 oC, and the mixture was allowed to stir for 45 min at -78 oC. The solution was then
cooled to -116 oC and the mixture was allowed to stir for 10 min, after which, a solution
of 2-methyl-1-(3-nitrophenyl)propan-1-one 38 (500 mg, 2.59 mmol) in dry THF (10
mL), pre-cooled to -116 oC, was added dropwise over 10 min period. After complete
addition, the resulting solution was allowed to stir for a further 45 min at -116 to -100
o

C. The reaction was then quenched with a saturated solution of NH 4Cl (25 mL). To the

resulting biphasic mixture was added H2O (20 mL) before the organic layer was
partitioned from the reaction mixture. The aqueous layer was further extracted with
CH2Cl2 (3 x 50 mL) and the combined organic layers were washed with 1 M HCl (25
mL), dried (MgSO4) and the solvent concentrated under reduced pressure. The resulting
crude oil was subjected to flash column chromatography and elution with 15% ethyl
acetate

in

petroleum

spirit

gave

1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-

nitrophenyl)propan-1-ol 40 (442.8 mg, 50%) as pale yellow crystals, mp: 141-142 ºC;
IR (cm-1): υ 3354 (w, OH), 1556 (w, NO2), 1375 (s, NO2). 1H NMR (CDCl3): δ 8.63 (s,
1H, pyrimidine_2 H), 8.41 (t, J = 1.0 Hz, 1H, phenyl_2), 8.16 (ddd, J = 8.4, 2.1, 1.0 Hz,
1H, phenyl_4 H), 7.80 (ddd, J = 7.8, 2.0, 0.8 Hz, 1H, phenyl_6 H), 7.52 (t, J = 8.1 Hz,
1H, phenyl_5 H), 3.64-3.58 (m, 1H, propanol_2 H), 3.38 (br, OH), 1.11 (d, J = 6.6 Hz,
3H, CH3), 0.93 (d, J = 6.6 Hz, 3H, CH3). 13C NMR, δ: 161.4 (pyrimidine C4, C6), 155.1
(pyrimidine C2), 148.0 (phenyl C3), 145.4 (phenyl C1), 136.3 (pyrimidine C1), 132.5
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(phenyl C6), 129.1 (phenyl C5), 122.8 (phenyl C4), 121.8 (phenyl C2), 81.7 (propanol
C1), 34.9 (propanol C2), 18.1 (CH3), 17.1 (CH3). EI-MS m/z 342 (M+,

35

Cl2, 5), 302

(20), 300 (70), 298 (100%), 284 (15), 282 (20). HRMS (ESI) calcd for C14H1435Cl2N3O3
(MH+), 342.0407; found, 342.0397.

4,6-Dichloro-5-(2-methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyrimidine 41

A solution of 1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 40
(315 mg, 0.963 mmol) in SOCl2 (10 mL) was heated at reflux for 48 h under a N2
atmosphere. The mixture was then cooled to room temperature, quenched by the
dropwise addition of cold H2O (20 mL), and neutralised with 2 M KOH, and was
extraced with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (MgSO 4),
the solvent concentrated under vacuum and the resulting residue was subjected to flash
column chromatography (50% CH2Cl2 in petroleum spirit) to yield the alkene 41 (220
mg, 70%) as a pale yellow crystaline solid, mp: 93-94 °C; IR (cm-1): υ 2986 (w, C-H
aliphatic), 1506 (s, NO2), 1349 (s, NO2). 1H NMR (CDCl3): δ 8.74 (s, 1H, pyrimidine_2
H), 8.17 (s, 1H, phenyl_2 H), 8.14 (d, J = 8.0 Hz, 1H, phenyl_4 H), 7.60 (d, J = 7.5 Hz,
1H, phenyl_4 H), 7.50 (t, J = 7.5, 1H, phenyl_5 H), 1.94 (s, 3H, CH3), 1.73 (s, 3H,
CH3).

13

C NMR, δ: 162.2 (pyrimidine C4, C6), 157.1 (pyrimidine C2), 148.3 (phenyl

C3), 141.2 (phenyl C1), 140.1 (propene C1), 135.8 (phenyl C6), 134.2 (pyrimidine C5),
129.4 (phenyl C5), 126.0 (propene C2), 124.8 (phenyl C4), 122.6 (phenyl C2), 22.5
(CH3), 21.8 (CH3). EI-MS m/z 327 (M+
35

37

Cl2, 10), 325 (M+

35

Cl37Cl, 65), 323 (M+

Cl2, 100%) 278 (6), 276 (10), 205 (15). HRMS (ESI) calcd for C14H1235Cl2N3O2

(MH+), 324.0302; found, 324.0298.
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4-Chloro-6,6-dimethyl-5-(3-nitrophenyl)-5,6-dihydrofuro[2,3-d]pyrimidine 42

A solution of 1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 40
(50 mg, 0.147 mmol) in conc. H2SO4 (5 mL) was stirred for 4 h at room temperature.
The mixture was then poured onto crushed ice, and a saturated solution of Na 2CO3 was
added dropwise until no more CO2 gas evolved. The mixture was then extracted with
CH2Cl2 (2 x 20 mL) and the combined organic layers were washed sequentially with
water (20 mL) and brine (20 mL) and then dried (MgSO4). The solvent was
concentrated under reduced pressure and the residue was subjected to flash column
chromatography and elution with 40% ethyl acetate in petroleum spirit gave 42 (38 mg,
85%) as a pale yellow oil, IR (cm-1): υ 2922 (w, C-H aliphatic), 1522 (s, NO2), 1350 (s,
NO2), 1238 (m, C-O). 1H NMR (CDCl3), δ: 8.16 (s, 1H, pyrimidine_2 H), 8.22 (d, J =
7.5 Hz, 1H, phenyl_4 H), 7.90 (s, 1H, phenyl_2 H), 7.59 (t, J = 7.9 Hz, 1H, phenyl_5
H), 7.29 (d, J = 7.6 Hz, 1H, phenyl_6 H), 4.55 (s, 1H, C_5 H), 1.73 (s, 3H, CH 3), 1.15
(s, 3H, CH3).

13

C NMR, δ: 174.1 (pyrimidine C2), 159.8 (O-C-N), 157.8 (phenyl C3),

148.3 (pyrimidine C4), 138.9 (phenyl C1), 134.1 (phenyl C6), 130.2 (phenyl C5), 123.5
(phenyl C4), 123.4 (phenyl C2), 119.1 (CCl-C), 90.5 (CH(CH3)2), 55.2 (C5), 29.9
(CH3), 24.9 (CH3) ppm. EI-MS m/z 305 (M+ 35Cl, 50), 288 (100%), 270 (30), 248 (20),
230 (17). HRMS (ESI) calcd for C14H1335ClN3O3 (MH+), 306.0645; found, 306.0648.

4-Amino-6-chloro-5-(2-methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyrimidine 43

A suspension of the alkene 41 (100 mg, 0.306 mmol) in NH4OH (25%, 2 mL) was
added to a 10 mL microwave reaction vessel, sealed and heated to 120 °C in a
microwave reactor with a maximum pressure of 15 Bar using a power of 50 W,
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allowing 10 min (ramping) and then held for 50 min. At this time, the pressure regularly
dropped below the 15 Bar maximum and the temperature was increased to 130 °C for a
further 30 min. After cooling, the resulting suspension was extracted with ethyl acetate
(2 x 25 mL), the combined organic layers were washed with brine (25 mL), dried
(MgSO4) and concentrated under vacuum before being subjected to flash column
chromatography (80% ethyl acetate in petroleum spirit) to give 4-amino-6-chloro-5-(2methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyrimidine 43 (84.5 mg, 90%) as a yellow
crystalline solid, mp: 144-145 °C; IR (cm-1): υ 3329 (w, NH2), 1562 (s, NO2), 1347 (s,
NO2). 1H NMR (CDCl3): δ 8.31 (s, 1H, pyrimidine_2 H), 8.13-8.11 (m, 2H, phenyl_2,4
H), 7.57 (d, J = 7.5 Hz, 1H, phenyl_6 H), 7.49 (t, J = 8.0 Hz, 1H, phenyl_5 H), 5.27 (br,
NH2), 2.17 (s, 3H, CH3), 1.97 (s, 3H, CH3).

13

C NMR (CDCl3), δ: 162.0 (pyrimidine

C6), 159.0 (pyrimidine C4), 157.3 (pyrimidine C2), 148.2 (phenyl C3), 141.1 (phenyl
C1), 140.5 (propene C1), 135.3 (phenyl C6), 129.3 (phenyl C5), 125.3 (propene C2),
124.1 (phenyl C4), 122.3 (phenyl C2), 116.7 (pyrimidine C5), 22.3 (CH 3), 21.9 (CH3).
ESI-MS m/z 307 (M+

37

Cl), 305 (M+

35

Cl). HRMS (ESI) calcd for C14H1435ClN4O2

(MH+), 305.0799; found, 305.0799.

Cyclopropyl(4,6-dichloropyrimidin-5-yl)(phenyl)methanol 50*

Under a N2 atmosphere, a fresh solution of LDA was prepared by dropwise addition of
n-BuLi (1.64 mL of 2.5 M solution, 4.109 mmol) to a solution of diisopropyl amine
(415.8 mg, 4.109 mmol) in dry THF (20 mL) pre-cooled to -78 ºC, and the mixture was
stirred for 30 min at -78 ºC. To this solution was added dropwise at -78 oC, a solution of
4,6-dichloropyrimidine 28 (510 mg, 3.424 mmol) in dry THF (10 mL) and the mixture
was allowed to stir for 45 min at -78 oC. The solution was then cooled to -116 oC and
allowed to stir for 10 min, after which a pre-cooled (-116

o

C) solution of

cyclopropyl(phenyl)methanone 49 (500 mg, 3.424 mmol) in dry THF (10 mL) was
*

Numbers on the structure correspond to the cyclopropyl ring, not related to the compound name.
Compound was unstable for HRMS or IR.
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added dropwise over a 10 min period. After complete addition, the resulting solution
was allowed to stir for a further 45 min at -116 to -100 oC, then quenched with a
saturated solution of NH4Cl (25 mL). To the resulting biphasic mixture was added H 2O
(20 mL) before the organic layer was partitioned from the reaction mixture. The
aqueous layer was further extracted with CH2Cl2 (3 x 50 mL) and the resulting organic
layers were combined and washed with 1 M HCl (25 mL). The organic layer was then
dried (MgSO4) and the solvent concentrated under reduced pressure. The resulting crude
oil was subjected to flash chromatography and elution with 15% ethyl acetate in
petroleum

spirit

gave

the

alcohol,

cyclopropyl(4,6-dichloropyrimidin-5-

yl)(phenyl)methanol 50 (373 mg, 37%) was obtained as a yellow solid, mp: 146-147
°C; 1H NMR (CDCl3), δ: 8.61 (s, 1H, pyrimidine_2 H), 7.38 (d, J = 7.0 Hz, 2H,
phenyl_2,6 H), 7.35-7.31 (m, 3H, phenyl_3,4,5 H), 2.83 (s, br, OH), 2.06 (p, J = 7.0 Hz,
1H, C1_H), 0.90 (q, J = 7.0 Hz, 1H, C_3 H), 0.77 (t, J = 6.5 Hz, 2H, C_3 H, C_2 H),
0.57 (q, J = 6.5 Hz, 1H, C_2 H).

13

C NMR, δ: 161.9 (pyrimidine C4, C6), 155.3

(pyrimidine C2), 145.9 (phenyl C1), 138.1 (pyrimidine C5), 128.9 (phenyl C2, C6),
128.3 (phenyl C3, C5), 126.2 (pyrimidine C4), 78.3 (methanol C), 20.1 (C1), 4.1 (C3),
2.3 (C2) ppm. ESI-MS m/z 295.1 (M+ 35Cl), 297.0 (M+ 37Cl).

Cyclopropyl(3-nitrophenyl)methanone263* 53

Cyclopropyl(phenyl)methanone 49 (1.0 g, 6.849 mmol) was added dropwise to a precooled mixture of conc. H2SO4 (10 mL) and conc. HNO3 (10 mL) at -15 ºC, over 10
min. The mixture was then allowed to stir at -10 ºC for 2 h before being poured onto
crushed ice, and extracted with ether (2 x 30 mL). The combined organic layers were
washed sequentially with water (20 mL), and brine (20 mL) and then dried (MgSO4).
The solution was passed through short pad of silica gel, and the eluent was evaporated
to leave a pale yellow oil of cyclopropyl(3-nitrophenyl)methanone 53 (915 mg, 70%).
IR (cm-1): υ 1662 (s, C=O), 1526 (s, NO2), 1350 (s, NO2). 1H NMR (CDCl3), δ: 8.84 (s,
*

This reference reports only the elemental analysis of 53.
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1H, phenyl_2 H), 8.42 (d, J = 8.1 Hz, 1H, phenyl_4 H), 8.33 (d, J = 7.8 Hz, 1H,
phenyl_6 H), 7.70 (t, J = 7.8 Hz, 1H, phenyl_5 H), 2.74-2.69 (m, 1H, CO-CH), 1.32 (t,
J = 3.7 Hz, 2H, CH2-CH2), 1.16 (p, J = 3.7 Hz, 2H, CH2-CH2).

13

C NMR, δ: 198.4

(CO), 139.1 (phenyl C3), 133.9 (phenyl C1), 130.6 (phenyl C6), 129.8 (phenyl C5),
126.9 (phenyl C4), 122.9 (phenyl C2), 17.5 (cyclopropyl CH), 12.5 (cyclopropyl CH2CH2) ppm. EI-MS m/z 191 (M+, 20), 150 (100%), 104 (70), 77 (75). HRMS (ESI) calcd
for C10H10NO3 (MH+), 192.0661; found, 192.0654.

Nitration of Cyclobutyl(phenyl)methanone 56, formation of 57 and 58
Cyclobutyl(phenyl)methanone 56 (5 g, 31.25 mmol) was added to a round bottom twoneck flask fitted with a magnetic stirrer and a thermometer, containing conc. H 2SO4 (20
mL) and the mixture was cooled to -15 ºC in ice/salt bath. A pre-cooled nitrating
mixture of H2SO4 (10 mL) and conc. HNO3 (10 mL) was added dropwise in a rate that
the mixture temperature did not exceed 0 ºC. After complete addition, the mixture was
stirred for 1 h at 0 - 5 ºC. The mixture was then poured onto crushed ice, and extracted
with CH2Cl2 (2 x 30 mL). The combined organic layers were then washed with a
saturated solution of NaHCO3 (20 mL), water (20 mL), and brine (20 mL) and then
dried (MgSO4) and concentrated under reduced pressure. The resulting oil was then
subjected to flash column chromatography and elution with 30% ether in petroleum
spirit gave:
Cyclobutyl(3-nitrophenyl)methanone 57 (1.73 g, 27%) as a pale yellow oil,

IR (cm-1): υ 2989 (w, C-H aliphatic), 1675 (s, C=O), 1527 (s, NO2), 1350 (s, NO2). 1H
NMR (CDCl3), δ: 8.69 (s, 1H, phenyl_2 H), 8.39 (d, J = 7.9 Hz, 1H, phenyl_4 H), 8.23
(d, J = 7.5 Hz, 1H, phenyl_6 H), 7.67 (t, J = 7.5 Hz, 1H, phenyl_5 H), 4.04 (p, J = 8.3
Hz, 1H, CO-CH), 2.46-2.33 (m, 4 H, cyclobutyl), 2.19-2.10 (m, 1H, cyclobutyl), 1.991.93 (m, 1H, cyclobutyl).

13

C NMR, δ: 198.8 (CO), 148.7 (phenyl C3), 137.1 (phenyl

C1), 134.1 (phenyl C6), 130.1 (phenyl C5), 127.4 (phenyl C4), 123.4 (phenyl C2), 42.5
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(CO-CH), 25.2 (CH2-CH2-CH2), 18.3 (CH2-CH2-CH2) ppm. EI-MS m/z 205 (M+, 5),
188 (10), 150 (100%). HRMS (ESI) calcd for C11H12NO3 (MH+), 206.0817; found,
206.0810.
Further elution afforded:
Cyclobutyl(2-nitrophenyl)methanone 58 (640 mg, 10%) as a yellow oil.

Yellow oil, IR (cm-1): υ 2990 (w, C-H aliphatic), 1675 (s, C=O), 1528 (s, NO2), 1350 (s,
NO2). 1H NMR (CDCl3), δ: 8.09 (d, J = 8.1 Hz, 1H, phenyl_3 H), 7.70 (t, J = 7.6 Hz,
1H, phenyl_5 H), 7.59 (t, J = 8.0 Hz, 1H, phenyl_4 H), 7.38 (d, J = 7.6 Hz, 1H,
phenyl_6 H), 3.66 (p, J = 8.5 Hz, 1H, CO-CH), 2.45-2.38 (m, 2H, cyclobutyl 2H), 2.232.17 (m, 2H, cyclobutyl 2H), 2.05-1.93 (m, 2H, cyclobutyl 2H).

13

C NMR, δ: 204.1

(CO), 146.3, (phenyl C2), 137.3 (phenyl C1), 134.3 (phenyl C5), 130.7 (phenyl C4),
128.0 (phenyl C6), 124.6 (phenyl C3), 45.6 (CO-C), 25.6 (CH2-CH2-CH2), 18.1 (CH2CH2-CH2) ppm. EI-MS m/z 205 (M+, 5), 188 (5), 169 (7), 150 (100%). HRMS (ESI)
calcd for C11H12NO3 (MH+), 206.0817; found, 206.0809.

1-(4-Chloropyridin-3-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 59

Under a N2 atmosphere, diisopropyl amine (400 mg, 3.953 mmol) was added to dry
TFH (20 mL) in an oven dried 50 mL flask. The flask was then sealed with a rubber
cap, and the flask was degassed by applying vacuum and flushing with N2 gas. The
solution was cooled to -78 ºC before n-BuLi (2.47 mL of 1.6 M solution, 3.953 mmol)
was added dropwise by a syringe, and the mixture was allowed to stir at -78 ºC for 40
min (Flask A). In a separate oven dried 50 mL flask, 4-chloropyridine.HCl 55 (230 mg,
1.554 mmol) was added and the flask was sealed with a rubber cap and the flask was
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flushed with N2 for 10 min and then sealed; the flask was then cooled to -78 ºC (Flask
B). The LDA solution formed in Flask A was then transferred (under N2) through a
double sided needle to Flask B, and the resultant mixture was stirred at -78 ºC for 45
min, where the solution became dark yellow in colour and the 4-chloropyridine.HCl 55
was completely dissolved as can be indicated from the disappearance of the solid. A
pre-cooled solution (-78 ºC) of 2-methyl-1-(3-nitrophenyl)propan-1-one 38 (300 mg,
1.554 mmol) in dry THF (10 mL) was added slowly under N 2 to Flask B, using a double
sided needle, and the reaction was stirred at -78 ºC for another 45 min. The mixture was
allowed to warm up to room temperature (over 12 h) and was then quenched with a
mixture of water/THF. The mixture was then acidified with 2 M HCl (20 mL). The
aqueous acidic layer was separated and the organic layer was further extracted with 2 M
HCl (2 x 25 mL). The combined acidic extracts were washed with ether (25 mL). The
acidic extract was then cooled to 0 ºC and conc. ammonia solution was added dropwise
to give a slightly basic solution (pH paper). The mixture was then extracted with
CH2Cl2 (2 x 30 mL), the combined organic layers were dried (MgSO4), and then
concentrated under reduced pressure. The residue was subjected to a flash column
chromatography and elution with 40% ethyl acetate in petroleum spirit gave 1-(4chloropyridin-3-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 59 (200 mg, 42%) as a pale
yellow solid, mp: 132-133 ºC; IR (cm-1): υ 3180 (w, OH), 1525 (s, NO2), 1352 (s, NO2).
1

H NMR (CDCl3), δ: 9.12 (s, 1H, pyridine_2 H), 8.40 (d, J = 5.1 Hz, 1H, pyridine_6

H), 8.13 (s, 1H, phenyl_2 H), 8.09 (d, J = 7.8 Hz, 1H, phenyl_4 H), 7.69 (d, J = 7.8 Hz,
1H, phenyl_6 H), 7.47 (t, J = 7.8 Hz, 1H, phenyl_5 H), 7.21 (d, J = 5.1 Hz, 1H,
pyridine_5 H), 3.25 (s, br, OH), 3.12-3.09 (m, 1H, propanol_2 H), 1.01 (d, J = 6.6 Hz,
3H, CH3), 0.95 (d, J = 6.9 Hz, 3H, CH3).

13

C NMR, δ: 149.7 (phenyl C3), 149.6

(pyridine C6), 149.4 (phenyl C1), 147.9 (pyridine C2), 146.2 (pyridine C3), 142.4
(pyridine C4), 137.6 (phenyl C6), 133.3 (phenyl C5), 128.8 (pyridine C5), 126.4
(phenyl C2), 122.2 (phenyl C4), 79.7 (propanol C1), 32.9 (propanol C2), 17.6 (CH3),
17.4 (CH3) ppm. EI-MS m/z 306 (M+

35

Cl, 5), 263 (100%), 217 (50), 182 (20), 140

(90). HRMS (ESI) calcd for C15H1635ClN2O3 (MH+), 307.0849; found, 307.0838.
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(4-Chloropyridin-3-yl)(cyclopropyl)(3-nitrophenyl)methanol 60

Under a N2 atmosphere, in an oven dried 50 mL flask, a solution of diisopropyl amine
(397.4 mg, 3.926 mmol) in dry TFH (20 mL) was prepared, and the flask was then
sealed with a rubber cap, and the solution was degassed by applying vacuum and
flushing with N2 gas. The solution was cooled to -78 ºC. n-BuLi (2.62 mL of 1.5 M
solution, 3.926 mmol) was added dropwise by a syringe, and the mixture was allowed to
stir at -78 ºC for 40 min (Flask A). In another oven dried 50 mL flask, 4chloropyridine.HCl 55 (235 mg, 1.571 mmol) was added and the flask was sealed with a
rubber cap and flushed with N2, and the flask was then cooled to -78 ºC (Flask B). The
LDA solution formed in Flask A was then transferred (under N2) through a double sided
needle to Flask B, and the mixture was stirred at -78 ºC for 45 min, where the solution
became dark yellow in colour and the 4-chloropyridine.HCl 55 dissolved completely. A
pre-cooled solution (-78 ºC) of cyclopropyl(3-nitrophenyl)methanone 53 (300 mg,
1.571 mmol) in dry THF (10 mL) was added slowly under N2 to the content in flask B,
using a double sided needle, and the reaction was stirred at -78 ºC for another 45 min.
The mixture was allowed to warm up to room temperature (over 12 h), and was then
quenched with a mixture of water/THF. The mixture was then acidified with 2 M HCl.
The aqueous acidic layer was separated and the organic layer was further extracted with
2 M HCl (2 x 25 mL). The combined acidic extracts were washed with ether (25 mL).
The acidic extract was then cooled to 0 ºC and conc. ammonia solution was added
dropwise to give a slightly basic solution (pH paper). The mixture was then extracted
with CH2Cl2 (2 x 30 mL), dried (MgSO4) and evaporated under reduced pressure. The
residue was subjected to a flash column chromatography and elution with 40% ethyl
acetate

in

petroleum

spirit

gave

(4-chloropyridin-3-yl)(cyclopropyl)(3-

nitrophenyl)methanol 60 (248 mg, 52%) as a yellow solid, mp: 138-139 ºC; IR (cm-1): υ
3100 (w, OH), 1525 (s, NO2), 1348 (w, NO2). 1H NMR (CDCl3), δ: 9.28 (s, 1H,
pyridine_2 H), 8.50 (d, J = 5.0 Hz, 1H, pyridine_6 H), 8.24 (s, 1H, phenyl_2 H), 8.07
(d, J = 8.0 Hz, 1H, phenyl_4 H), 7.57 (d, J = 8.0 Hz, 1H, phenyl_6 H), 7.48 (t, J = 8.0
Hz, 1H, phenyl_5 H), 7.28 (d, J = 5.4 Hz, 1H, pyridine_5 H), 2.98 (s, OH), 1.74 (m,
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1H, cyclopropyl_CH), 0.81-0.64 (m, 4H, cyclopropyl_CH2). 13C NMR, δ: 150.1 (phenyl
C3), 149.8 (pyridine C6), 148.4 (pyridine C2), 148.1 (phenyl C1), 143.1 (pyridine C4),
133.9 (phenyl C6), 132.1 (pyridine C3), 129.4 (phenyl C5), 129.1 (phenyl C2), 122.6
(pyridine C5), 121.0 ( phenyl C4), 89.4 (methanol C), 20.6 (cyclopropyl CH), 2.4
(CH2), 2.1 (CH2) ppm. ESI-MS m/z 304.8 (MH+

35

Cl). HRMS (ESI) calcd for

C15H1435ClN2O3 (MH+), 305.0693; found, 305.0679.

(4-Chloropyridin-3-yl)(cyclobutyl)(3-nitrophenyl)methanol 61

Under a N2 atmosphere, diisopropyl amine (333.2 mg, 3.293 mmol) was added to dry
THF (20 mL) in an oven dried 50 mL flask. The flask was then sealed with a rubber
cap, and the flask was degassed by applying vacuum and flushing with N2 gas. The
solution was cooled to -78 ºC. n-BuLi (2.35 mL of 1.4 M solution, 3.293 mmol) was
added dropwise by a syringe, and the mixture was allowed to stir at -78 ºC for 40 min
(Flask A). In another oven dried 50 mL flask, 4-chloropyridine.HCl 55 (197 mg, 1.317
mmol) was added and the flask was sealed with a rubber cap and flushed with N 2, and
the flask was then cooled to -78 ºC (Flask B). The LDA solution formed in flask A was
then transferred (under N2) through a double sided needle to flask B, and the mixture
was stirred at -78 ºC for 45 min, where the solution became dark yellow in colour and
the 4-chloropyridine.HCl 55 dissolved completely. A pre-cooled solution (-78 ºC) of
cyclobutyl(3-nitrophenyl)methanone 57 (270 mg, 1.317 mmol) in dry THF (10 mL),
was added slowly under N2 to Flask B, using a double sided needle, and the reaction
was stirred at -78 ºC for another 45 min. The mixture was allowed to warm up to room
temperature (over 12 h), and then was quenched with a mixture of water/THF. The
mixture was then acidified with 2 M HCl. The aqueous acidic layer was separated and
the organic layer was further extracted with 2 M HCl (2 x 25 mL). The combined acidic
extract was washed with ether (25 mL). The acidic extract was then cooled to 0 ºC and
conc. ammonia solution was added dropwise to give a slightly basic solution (pH
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paper). The mixture was then extracted with CH2Cl2 (2 x 30 mL), and dried (MgSO4).
The solvent was then evaporated under reduced pressure. The residue was subjected to
flash column chromatography (40% ethyl acetate in petroleum spirit) to give (4chloropyridin-3-yl)(cyclobutyl)(3-nitrophenyl)methanol 61 (209 mg, 50%) as a brown
semi solid, IR (cm-1): υ 3094 (w, OH), 1525 (s, NO2), 1341 (s, NO2). 1H NMR (CDCl3),
δ: 8.93 (s, 1H, pyridine_2 H), 8.46 (d, J = 5.1 Hz, 1H, pyridine_6 H), 8.15 (s, 1H,
phenyl_2 H), 8.09 (d, J = 8.0 Hz, 1H, phenyl_6 H), 7.51 (d, J = 7.8 Hz, phenyl_4 H),
7.51 (t, J = 8.0 Hz, 1H, phenyl_5 H), 7.25 (d, J = 4.8 Hz, 1H, pyridine_5 H), 3.44 (p, J
= 8.6 Hz, 1H, cyclobutyl_CH), 3.33 (s, OH), 2.27-2.18 (m, 2H, cyclobutyl_CH2), 2.051.88 (m, 2H, cyclobutyl_CH2), 1.85-1.71 (m, 2H, cyclobutyl_CH2). 13C NMR, δ: 150.3
(phenyl C3), 149.4 (pyridine C6), 148.1 (pyridine C2), 146.7 (phenyl C1), 143.1
(pyridine C3), 136.9 (pyridine C4), 132.2 (phenyl C6), 129.1 (phenyl C5), 126.4
(pyridine C5), 122.2 (phenyl C2), 121.1 (phenyl C4), 42.9 (methanol C), 23.2
(cyclobutyl CH), 22.1 (CH2-CH2-CH2), 21.1 (CH2-CH2-CH2), 16.9 (CH2-CH2-CH2)
ppm. EI-MS m/z 318 (M+, 7), 301 (5), 263 (100%), 247 (20), 217 (16), 191 (5). HRMS
(ESI) calcd for C16H16ClN2O3 (MH+), 319.0849; found, 319.0842.

4-Chloro-3-(2-methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyridine 62

A solution of 1-(4-chloropyridin-3-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 59 (100
mg, 0.327 mmol) in conc. H2SO4 (20 mL) was stirred under N2 for 24 h at room
temperature. The mixture was then poured onto crushed ice, and neutralized with a
saturated solution of Na2CO3. The mixture was then extracted with CH2Cl2 (2 x 25 mL),
the combined organic layers were washed with brine (20 mL), dried (MgSO4), and the
solvent was concentrated under reduced pressure. The residue was subjected to a flash
column chromatography and elution with 40% ethyl acetate in petroleum spirit gave 4chloro-3-(2-methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyridine 62 (80 mg, 85%) as a
yellow oil, IR (cm-1): υ 2980 (w, C-H aliphatic), 1653 (m, C=C), 1528 (s, NO2), 1465
(w), 1347 (s, NO2). 1H NMR (CDCl3), δ: 8.49 (s, 1H, pyridine_2 H), 8.42 (d, J = 5.4
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Hz, 1H, pyridine_6 H), 8.09-8.07 (m, 2H, phenyl_2,6 H), 7.51 (d, J = 7.6 Hz, 1H,
phenyl_4 H), 7.47 (t, J = 7.6 Hz, 1H, phenyl_5 H), 7.35 (d, J = 5.4 Hz, 1H, pyridine_5
H), 1.92 (s, 3H, CH3), 1.72 (s, 3H, CH3).

13

C NMR, δ: 151.9 (phenyl C3), 149.3

(pyridine C6), 148.1 (pyridine C2), 143.6 (phenyl C1), 142.2 (phenyl C6), 138.5
(propene C1), 136.7 (pyridine C3), 135.7 (pyridine C4), 129.0 (phenyl C5), 128.7
(pyridine C5), 124.8 (phenyl C4), 124.5 (phenyl C2), 121.7 (propene C2), 22.5 (CH 3),
21.8 (CH3) ppm. EI-MS m/z 288 (M+ 35Cl, 100%), 273 (5), 241 (10), 227 (16), 204 (8),
191 (10). HRMS (ESI) calcd for C15H1435ClN2O2 (MH+), 289.0744; found, 289.0754.

4-Chloro-3-(cyclopropylidene(3-nitrophenyl)methyl)pyridine 63

Method A: a solution of 4-chloropyridin-3-yl)(cyclopropyl)(3-nitrophenyl)methanol 60
(100 mg, 0.329 mmol) in conc. H2SO4 (10 mL) was stirred under N2 for 24 h at room
temperature. The mixture was then poured onto crushed ice, and neutralized with a
saturated solution of Na2CO3. The mixture was then extracted with CH2Cl2 (2 x 25 mL),
the combined organic layers were washed with brine (15 mL), dried (MgSO4), and the
solvent was removed under reduced pressure. The residue was subjected to a flash
column chromatography and elution with 40% ethyl acetate in petroleum spirit gave the
alkene 63 (58.3 mg, 62%) as a yellow oil, IR (cm-1): υ 2990 (w, C-H aliphatic), 1676
(w, C=C), 1527 (s, NO2), 1347 (s, NO2). 1H NMR (CDCl3), δ: 8.57 (d, J = 5.1 Hz, 1H,
pyridine_6 H), 8.50 (s, 1H, pyridine_2 H), 8.17-8.07 (m, 2H, phenyl_2,4 H), 7.49-7.45
(m, 2H, phenyl_6 H, pyridine_5 H), 6.54 (t, J = 7.2 Hz, 1H, phenyl_5 H), 3.63 (t, J =
6.6 Hz, 2H, CH2-CH2), 2.52 (q, J = 6.6 Hz, 2H, CH2-CH2). 13C NMR, δ: 151.7 (phenyl
C3), 150.5 (pyridine C6), 148.5 (pyridine C2), 143.8 (phenyl C1), 141.2 (C*), 136.3
(phenyl C6), 132.2 (pyridine C4), 131.4 (phenyl C5), 129.5 (pyridine C3), 124.9
(pyridine C5), 124.0 (phenyl C4), 122.5 (phenyl C2), 121.0 (C**), 43.2 (CH 2), 32.9
(CH2) ppm. EI-MS m/z 286 (M+

35

Cl, 25), 227 (100%), 204 (10), 191 (70), 164 (60).

HRMS (ESI) calcd for C15H1235ClN2O2 (MH+), 287.0587; found, 287.0576.
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B:

Under

a

N2

atmosphere,

(4-chloropyridin-3-yl)(cyclopropyl)(3-

nitrophenyl)methanol 60 (100 mg, 0.329 mmol) was added to SOCl2 (15 mL) in a 25
mL round bottom flask. The flask was then heated at 80 ºC under N 2 atmosphere for 24
h. The mixture was cooled to room temperature, and the solution was poured onto
crushed ice (50 mL) with vigorous stirring. KOH solution (2 M) was added dropwise
until neutral solution obtained (pH paper). The mixture was then extracted with CH2Cl2
(2 x 25 mL), washed with water (2 x 20 mL), brine (20 mL) and dried (MgSO4). The
organic fraction was then concentrated under reduced pressure and the residue subjected
to flash column chromatography (40% ethyl acetate in petroleum spirit) to afford 4chloro-3-(cyclopropylidene(3-nitrophenyl)methyl)pyridine 63 (70.6 mg, 75%) as a
yellow oil. Spectral data for 63 obtained by method B are exactly the same as in method
A.

4-Chloro-3-(cyclobutylidene(3-nitrophenyl)methyl)pyridine 64

Under

a

N2

atmosphere,

a

solution of

(4-chloropyridin-3-yl)(cyclobutyl)(3-

nitrophenyl)methanol 61 (90 mg, 0.283 mmol) in SOCl2 (15 mL) was then heated at 80
ºC under N2 atmosphere for 36 h. The mixture was cooled, and the solution was poured
onto crushed ice (50 mL) with vigorous stirring. KOH solution (2 M) was added
dropwise to neutral (pH paper). The mixture was then extracted with CH2Cl2 (2 x 25
mL), the combined organic extracts were washed sequentially with water (2 x 20 mL),
brine (20 mL), and then dried (MgSO4). The solvent was removed under reduced
pressure. The resulting residue was subjected to a flash column chromatography and
elution with 40% ethyl acetate in petroleum spirit gave 4-chloro-3-(cyclobutylidene(3nitrophenyl)methyl)pyridine 64 (58.6 mg, 69%) as a brown oil, IR (cm-1): υ 2989 (w, CH aliphatic), 1657 (m, C=C), 1527 (s, NO2), 1340 (s, NO2). 1H NMR (CDCl3), δ: 8.51
(d, J = 5.1 Hz, 1H, pyridine_6 H), 8.49 (s, 1H, pyridine_2 H), 8.04 (d, J = 8.1 Hz, 1H,
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phenyl_4 H), 8.01 (s, 1H, phenyl_2 H), 7.44 (t, J = 8.1 Hz, 1H, phenyl_5 H), 7.40 (d, J
= 5.6 Hz, 1H, pyridine_5 H), 7.34 (d, J = 8.0 Hz, 1H, phenyl_6 H), 3.12 (t, J = 7.2 Hz,
2H, cyclobutyl CH2), 2.68 (t, J = 7.2 Hz, 2H, cyclobutyl CH2), 2.17 (p, J = 7.2 Hz, 2H,
CH2-CH2-CH2).

13

C NMR, δ: 152.4 (phenyl C3), 149.9 (pyridine C6), 149.2 (pyridine

C2), 148.6 (phenyl C1), 144.1 (C**), 140.3 (C*), 133.9 (phenyl C6), 133.0 (phenyl C5),
129.4 (pyridine C4), 125.7 (pyridine C3), 125.2 (pyridine C5), 121.9 (phenyl C4), 121.5
(phenyl C2), 32.9 (CH2-CH2-CH2), 31.9 (CH2-CH2-CH2), 17.4 (CH2-CH2-CH2) ppm.
EI-MS m/z 300 (M+

35

Cl, 100%), 285 (5), 253 (20), 218 (20), 164 (22). HRMS (ESI)

35

calcd for C16H14 ClN2O2 (MH+), 301.0744; found, 301.0733.

3-(Cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline 72

4-Chloro-3-(cyclobutylidene(3-nitrophenyl)methyl)pyridine 64 (100 mg, 0.333 mmol)
was added to sealed tube containing phenol (2.0 g, 21.25 mmol) and N1,N1diethylpentane-1,4-diamine 47 (105 mg, 0.666 mmol). The tube was sealed and heated
at 100 ºC for 5 min, 120 ºC for 10 min, 140 ºC for 1 h, and then at 160 ºC for 14 h. The
tube was then cooled to room temperature, the mixture was then adsorped onto silica
and subjected to a flash column chromatography and elution with 10% methanol in
CH2Cl2 gave 3-(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline 72 (46.9 mg,
43%) as a colourless oil, IR (cm-1): υ 3256 (w, NH2), 1452 (s, C-N), 1237 (w, C-O). 1H
NMR (CDCl3), δ: 8.41-8.35 (m, 2H, pyridine_2,6 H), 7.33 (t, J = 7.8 Hz, 2H,
phenoxy_3,5 H), 7.17 (t, J = 7.3 Hz, 1H, aniline_5 H), 7.06 (t, J = 7.8 Hz, 1H,
phenoxy_4 H), 6.90 (d, J = 7.8 Hz, 2H, phenoxy_2,6 H), 6.65-6.59 (m, 2H, aniline_4,6
H), 6.50 (d, J = 7.8 Hz, 1H, pyridine_5 H), 6.84 (s, 1H, aniline_2 H), 3.55 (br, NH2),
3.08 (t, J = 7.0 Hz, 2H, CH2-CH2-CH2), 2.75 (t, J = 7.0 Hz, 2H, CH2-CH2-CH2), 2.06
(p, J = 7.4 Hz, 2H, CH2-CH2-CH2).13C NMR, δ: 162.8 (phenoxy C1), 154.9 (pyridine
C4), 153.3 (pyridine C2), 150.1 (pyridine C6), 146.4 (aniline C1), 144.6 (aniline C3),
140.9 (C*), 130.2 (phenoxy C3, C5), 129.3 (phenoxy C4), 126.1 (C**), 125.2 (aniline
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C5), 120.9 (pyridine C3), 120.8 (phenoxy C2, C6), 118.5 (aniline C4), 114.5 (aniline
C2), 113.6 (pyridine C5), 111.8 (aniline C6), 33.1 (CH2), 32.1 (CH2), 17.6 (CH2-CH2CH2) ppm. EI-MS m/z 328 (M+, 100%), 313 (20), 299 (17), 235 (23), 219 (15). HRMS
(ESI) calcd for C22H21N2O (MH+), 329.1654; found, 329.1659.

4-(3-(Cyclopropylidene(3-nitrophenyl)methyl)pyridin-4-yl)morpholine 77

In a 25 mL round bottom flask fitted with a reflux condenser, 4-chloro-3(cyclopropylidene(3-nitrophenyl)methyl)pyridine 63 (100 mg, 0.349 mmol) was
dissolved in morpholine 75 (15 mL), and the mixture was heated at reflux for 48 h. The
excess morpholine was then removed by distillation under vacuum to leave a dark
brown oily residue, which was subjected to alumina column chromatography using 40%
CH2Cl2 and 60% ethyl acetate. 4-(3-(Cyclopropylidene(3-nitrophenyl)methyl)pyridin-4yl)morpholine 77 was isolated as a red oil (76.4 mg, 65%). IR (cm-1): υ 2957 (w, C-H
aliphatic), 1525 (s, NO2), 1457 (m), 1346 (s, NO2). 1H NMR (CDCl3), δ: 8.56 (d, J =
5.3 Hz, 1H, pyridine_6 H), 8.48 (s, 1H, pyridine_2 H), 8.10 (s, 1H, phenyl_2 H), 7.487.43 (m, 3H, phenyl_4,6 H, pyridine_5 H), 6.53 (t, J = 7.4 Hz, 1H, phenyl_5 H), 3.69 (t,
J = 4.3 Hz, 4H, morpholine_2,6 H), 2.42 (t, J = 7.3 Hz, 2H, cyclopropyl_2H), 2.26 (br,
apparent s, 4H, morpholine_3,5 H), 2.08 (ddd, J = 14.3, 7.3, 7.3 Hz, 2H,
cyclopropyl_2H). 13C NMR, δ: 151.7 (pyridine C6), 150.1 (phenyl C3), 148.4 (pyridine
C4), 143.7 (pyridine C2), 141.5 (C*), 134.5 (phenyl C6), 133.7 (phenyl C5), 133.3
(phenyl C1), 131.9 (phenyl C4), 129.3 (phenyl C2), 124.9 (pyridine C3), 122.1 (C**),
120.8 (pyridine C5), 66.8 (morpholine C2, C6), 57.7 (cyclopropyl CH2), 53.4
(morpholine C3, C5), 27.3 (cyclopropyl CH2) ppm. ESI-MS m/z 336.9 (M-). HRMS
(ESI) calcd for C19H19N3O3 (MH+), 338.1505; found, 338.1506.
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9.1.3. Experimental for chapter 3
2-(3-Nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84

In a 50 mL round bottom flask, 3,4-diaminobenzonitrile 82 (1.0 g, 7.519 mmol) was
added to 3-nitrobenzaldehyde 83 (1.13 g, 7.519 mmol), and the mixture was triturated
until homogenous mixture obtained. The flask was then fitted with a CaCl2 tube, and
heated in an oil bath at 90 ºC with vigorous stirring. The mixture started to melt to a
brown oily solution before the mixture solidified into dark brown gummy solid. The oil
bath temperature was then increased to 145 ºC where the brown gummy solid started to
melt to give dark red oil. After stirring of this red oil for 3 min, the mixture then
solidified to give a gummy dark red solid. The flask was then cooled to room
temperature and excess ethanol was added and the mixture was heated at 80 ºC for 10
min and filtered hot. The filtrate was concentrated under reduced pressure and the solid
residue was recrystallised from a mixture of methanol/1,4-dioxane/water (3:1:1) to give
2-(3-nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84 as a yellow crystalline solid
(1.38 g, 70%), mp: 239-240 ºC, IR (cm-1): υ 3294 (w, NH), 2224 (m, CN), 1623 (w,
C=N), 1517 (s, NO2), 1348 (s, NO2). 1H NMR (DMSO-d6), δ: 13.8 (br, NH), 9.02 (s,
1H, phenyl_2 H), 8.62 (d, J = 7.8 Hz, 1H, phenyl_4 H), 8.37 (d, J = 7.8 Hz, 1H,
phenyl_6 H), 8.21 (s, 1H, benzimidazole_4 H), 7.89 (t, J = 7.8 Hz, 1H, phenyl_5 H),
7.80 (d, J = 8.3 Hz, 1H, benzimidazole_6 H), 7.63 (d, J = 8.3 Hz, 1H, benzimidazole_7
H).

13

C NMR, δ: 152.1 (benzimidazole C2), 148.3 (phenyl C3), 135.4 (benzimdazole

C3a), 132.9 (benzimidazole C7a), 132.8 (phenyl C6), 130.8 (phenyl C1), 130.7 (phenyl
C5), 126.1 (benzimidazole C6), 124.9 (phenyl C4), 123.9 (benzimidazole C4), 121.3
(phenyl C2), 119.8 (CN), 116.6 (benzimidazole C7), 104.5 (benzimidazole C5) ppm.
ESI-MS m/z 264.1 (M+). HRMS (ESI) calcd for C14H9N4O2 (MH+), 265.0726; found,
265.0723.
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2-(3-Aminophenyl)-1H-benzo[d]imidazole-5-carbonitrile 85

To a solution of 2-(3-nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84 (200 mg,
0758 mmol) in methanol (20 mL) in a 100 mL round bottom flask, was added under a
N2 atmosphere, Raney Nickel (0.1 mol%) with vigorous stirring. Under a N 2
atmosphere, a solution of hydrazine monohydrate (75.6 mg, 1.5 mmol) in methanol (5
mL) was added dropwise over 10 min at room temperature. The mixture was then
heated at 80 ºC for 2 h, and filtered hot through a short pad of celite. Methanol and
excess hydrazine hydrate were concentrated under reduced pressure to give a brown
residue. The residue was then subjected to a flash column chromatography and elution
with 10% methanol in CH2Cl2 gave 2-(3-aminophenyl)-1H-benzo[d]imidazole-5carbonitrile 85 (141 mg, 80%) as a dark yellow solid, mp: 69-70 ºC, IR (cm-1): υ 3174
(m, NH), 2219 (m, CN), 1616 (m, C=N). 1H NMR (DMSO-d6), δ: 8.08 (s, 1H,
phenyl_2 H), 7.70 (d, J = 8.3 Hz, 1H, phenyl_4 H), 7.56 (d, J = 8.3 Hz, 1H, phenyl_6
H), 7.46 (s, 1H, benzimidazole_4 H), 7.32 (d, J = 7.2 Hz, 1H, benzimidazole_6 H), 7.19
(d, J = 8.0 Hz, 1H, phenyl_5 H), 6.72 (d, J = 7.0 Hz, 1H, benzimidazole_7 H), 5.37 (br,
NH2). 13C NMR, δ: 155.4 (benzimidazole C2), 149.2 (phenyl C3), 149.1 (benzimidazole
C7a), 140.0 (benzimidazole C3a), 129.8 (phenyl C5), 129.5 (phenyl C1), 125.4
(benzimidazole C6), 120.2 (benzimidazole C4), 116.3 (phenyl C6), 115.9 (CN), 115.5
(phenyl C4), 114.3 (benzimidazole C7), 112.2 (phenyl C2), 103.6 (benzimidazole C5)
ppm. ESI-MS m/z 233.0 (M-). HRMS (ESI) calcd for C14H11N4 (MH+), 235.0984;
found, 235.0993.
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N1,N2-Bis(3-(5-cyano-1H-benzo[d]imidazol-2-yl)phenyl)oxalamide 86

To a solution of 2-(3-aminophenyl)-1H-benzo[d]imidazole-5-carbonitrile 85 (100 mg,
0.427 mmol) in dry THF (20 mL) In an oven dried 25 mL flask, was added TEA (43
mg, 0.427 mmol) and the mixture was stirred under N2 at 0 ºC for 30 min. A solution of
oxalyl chloride (27.1 mg, 0.213 mmol) in dry THF (5 mL) was added dropwise over 15
min. The mixture was left to warm up to room temperature with stirring for 2 h. Chilled
water (10 mL) was added to the reaction mixture with vigorous stirring. The separated
solid was filtered, washed with water and methanol, and was recrystallised from DMF
to give the bis product 86 (153.8 mg, 69%) as a brown solid, mp: >250 ºC; IR (cm-1): υ
3259 (w, NH), 2224 (m, CN), 1684 (s, C=O). 1H NMR (DMSO-d6), δ: 11.08 (s, br,
oxalamide NH), 8.85 (s, 2H, phenyl_2 H), 8.18 (s, 2H, benzimidazole_6 H), 7.99-7.96
(m, 4 H, phenyl_4 H, benzimidazole_7 H), 7.78 (d, J = 8.2 Hz, 2 H, benzimidazole_6
H), 7.64-7.60 (m, 4H, phenyl_5,6 H).

13

C NMR, δ: 158.8 (CO), 153.9 (benzimidazole

C2), 141.4 (benzimidazole C7a), 139.9 (phenyl C1), 138.3 (benzimidazole C3a), 129.6
(phenyl C3), 126.5 (benzimidazole C6), 125.9 (benzimidazole C4), 123.2 (phenyl C6),
123.1 (phenyl C5), 120.7 (phenyl C4), 119.9 (CN), 119.5 (phenyl C2), 115.7
(benzimidazole C7), 104.3 (benzimidazole C5) ppm. ESI-MS m/z 521.4 (M-H). HRMS
(ESI) calcd for C30H17N8O2 (M-H), 521.1474; found, 521.1453.

9.1.4. Experimental for chapter 4
General procedure 1: synthesis of isobenzofuran-1(3H)-one derivatives 90-92:
Under a N2 atmosphere, a sealed tube was charged with the appropriate benzoic acid (1
mmol), palladium acetate (22.4 mg, 0.1 mmol), dipotassium phosphate (K2HPO4, 522.5
mg, 3 mmol) and dibromomethane (4 mL). The content of the tube was degassed by
flushing N2 through a needle for 10 min. The tube was then sealed, and heated in an oil
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bath at 140 ºC for 36 h. The tube was then allowed to cool to room temperature, the
content was diluted with CH2Cl2 (20 mL), and then filtered through celite. The filtrate
was washed with 1 M HCl (20 mL) and brine (2 x 15 mL), and was dried (MgSO 4). The
solvent was evaporated under reduce pressure and the residue was either subjected to
flash column chromatography (10% methanol in chloroform) or recrystallised from
chloroform/hexane mixture (1:3).

6-Bromo-7-methoxyisobenzofuran-1(3H)-one 90

Following the general procedure 1using 3-bromo-2-methoxybenzoic acid 87 (231 mg),
the benzofuran 90 was isolated after column chromatography, as a white solid (92 mg,
38%), mp: 102-103 ºC; IR (cm-1): υ 1752 (s, C=O), 1288 (m, C-O), 1064 (w, C-O),
1111 (w, C-Br). 1H NMR (CDCl3), δ: 7.84 (d, J = 7.9 Hz, 1H, H5), 7.06 (d, J = 7.9 Hz,
1H, H4), 5.23 (s, 2H, CH2), 4.16 (s, 3H, OCH3). 13C NMR, δ: 167.5 (C=O), 156.3 (C7),
148.3 (C3a), 139.3 (C5), 118.6 (C4), 117.9 (C7a), 117.2 (C6), 68.7 (CH 2), 62.9 (CH3)
ppm. EI-MS m/z 242 (M+ 79Br, 81Br, 30), 213 (33), 198 (100%), 183 (15). HRMS (ESI)
calcd for C9H879BrO3 (MH+), 242.9649; found, 242.9657.

6-Bromo-7-methylisobenzofuran-1(3H)-one 91

Following the general procedure 1using 3-bromo-2-methylbenzoic acid 88 (215 mg),
the benzofuran 91 was isolated after recrystallisation, as a pale yellow solid (124 mg,
55%), mp: 91-92 ºC; IR (cm-1): υ 1739 (s, C=O), 1358 (w, C-O), 1069 (w, C-Br). 1H
NMR (CDCl3), δ: 7.79 (d, J = 8.0 Hz, 1H, H5), 7.18 (d, J = 8.0 Hz, 1H, H4), 5.20 (s,
2H, CH2), 2.74 (s, 3H, CH3). 13C NMR, δ: 170.1 (C=O), 146.1 (C3a), 139.8 (C5), 137.7
(C4), 126.3 (C7), 124.7 (C7a), 120.6 (C6), 68.2 (CH2), 16.6 (CH3) ppm. EI-MS m/z 226
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(M+ 79Br, 81Br, 55), 197 (100%), 169 (30). HRMS (ESI) calcd for C9H879BrO2 (MH+),
226.9708; found, 226.9705.

5,7-Dimethoxyisobenzofuran-1(3H)-one264 92

This compound is reported but prepared in this work by a different method, following
the general procedure 1 using 2,4-dimethoxybenzoic acid 89 (182 mg). The benzofuran
92 was isolated after column chromatography as a white solid (112.5 mg, 58%).
Spectral data of the isolated benzofuran 92 are in agreement with the reported
literature.264

6-Bromo-5,7-dimethoxyisobenzofuran-1(3H)-one205* 94

In a round bottom flask (50 mL), 5,7-dimethoxyisobenzofuran-1(3H)-one 92 (150 mg,
0.773 mmol) was dissolved in glacial acetic acid (20 mL) with vigorous stirring and the
flask was cooled to -5 : 0 ºC using an ice bath. A solution of bromine (136 mg, 0.851
mmol) in glacial acetic acid (10 mL) was added dropwise over 20 min. The reaction was
allowed to warm up slowly to room temperature and was then allowed to stir for 4 h.
The formed solid was filtered and washed with dilute acetic acid, and was then
subjected to column chromatography (60% CH2Cl2 in hexane) to afford the benzofuran
94 (176.7 mg, 84%) as a white solid. It could also be recrystallised from 1,4-dioxane,
mp: 189-190 ºC; IR (cm-1): υ 1700 (s, C=O), 1316 (w, C-O), 1071 (w, C-O), 1036 (w,
C-Br). 1H NMR (CDCl3), δ: 6.46 (s, 1H, H4), 5.07 (s, 2H, CH2), 4.02 (s, 6H, OCH3).
13

C NMR, δ: 168.4 (C=O), 162.2 (C7), 159.5 (C5), 150.5 (C3a), 107.8 (C7a), 96.2 (C6),

95.1 (C4), 69.3 (CH2), 57.1 (C7-OCH3), 56.6 (C5-OCH3) ppm. EI-MS m/z 272 (M+
*

This reference reports only the elemental analysis and 1H NMR.
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Br, 40), 254 (20), 243 (30), 228 (100%), 213 (20). HRMS (ESI) calcd for

C10H1079BrO4 (MH+), 272.9762; found, 272.9754.

6-Nitroisobenzofuran-1(3H)-one208 98

This compound was prepared following the reported procedure. 208 The nitro-phthalide
98 was isolated as a yellow crystalline solid (1.08 g, 81%).
6-Aminoisobenzofuran-1(3H)-one208 99

Reduction of the nitro group of the 6-nitroisobenzofuran-1(3H)-one 98 to the 6aminoisobenzofuran-1(3H)-one 99 was achieved following the reported reduction
procedure developed in our laboratory.209 by sonicating a suspension of the nitro
derivative 98 (172 mg, 0.961 mmol) in a mixture of ethanol (2 mL), acetic acid (2 mL)
and water (1 mL) and with iron powder (0.27 g, 5 mmol) for 1 h at 35 ºC. The reaction
mixture was filtered to remove the iron residue. The filtrate was partitioned with 2 M
KOH, and the basic layer was further extracted with ethyl acetate (3 x 25 mL). The
combined organic extracts were washed with brine (2 x 25 mL) and water (3 x 50 mL),
dried (MgSO4), and concentrated under reduced pressure. The solid residue was then
crystallized from toluene to give the amino derivative 99 in 88% yield (126 mg) as a
white solid. The spectral data obtained for this compound 99 using this reduction
method are in agreement with the previously reported.208

6-Bromoisobenzofuran-1(3H)-one210 100

This compound was prepared following the reported procedure.210 The 6bromoisobenzofuran-1(3H)-one 100 was isolated as a pale yellow solid (106 mg, 74%).
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4,6-Dimethoxyindoline-2,3-dione212 102

This compound was prepared following the reported procedure. 212 The 4,6dimethoxyindole-2,3-dione 102 was obtained as a yellow solid (5.2 g, 80%).

5-Bromo-4,6-dimethoxyindoline-2,3-dione 103

In a 100 mL round bottom flask, a solution of 4,6-dimethoxyindole-2,3-dione 102 (143
mg, 0.5 mmol) in acetic acid (10 mL) was stirred at room temperature until all the isatin
was dissolved completely before being cooled to 0 ºC using an ice bath. NBromosuccinimide (97.9 mg, 0.55 mmol) was added portion wise over 15 min. After
addition of the NBS, the reaction mixture started to solidify, and the flask was removed
from the ice bath and was allowed to warm to room temperature and then stirred for 8 h.
The yellow solid was filtered from the mother liquor to which cold water (10 mL) was
added to precipitate the remaining soluble product. The combined solids were washed
with saturated NaHCO3 solution (2 x 15 mL) and with 1:1 water ethanol mixture (25
mL) and then vacuum dried. Recrystallisation from 1,4-dioxane yielded the 5-bromo4,6-dimethoxyindoline-2,3-dione 103 as a yellow solid (118 mg, 60%), mp: >250 ºC; IR
(cm-1): υ 3195 (m, NH), 1718 (s, C=O), 1264 (m, C-O). 1H NMR (DMSO-d6), δ: 11.14
(s, NH), 6.36 (s, H7), 3.99 (s, 3H, C6-OCH3), 3.94 (s, 3H, C4-OCH3).

13

C NMR, δ:

178.4 (C3), 165.5 (C2), 161.7 (C4), 160.4 (C6), 151.4 (C7a), 102.7 (C3a), 91.8 (C7),
86.2 (C5), 58.1 (C4-OCH3), 57.2 (C6-OCH3) ppm. EI-MS m/z 287 (M+ 79Br, 81Br, 40),
257 (100%), 213 (7). HRMS (ESI) calcd for C10H9N79BrNO4 (MH+), 285.9715; found,
285.9719.
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5-Bromo-7-methylindoline-2,3-dione215 106

This compound is reported by a different method than the method described here.215 In
this work, 4-bromo-2-methylaniline 104 (6.88 g, 37 mmol) was added to a 500 mL flask
and was reacted with chloral hydrate (7.35 g, 44.4 mmol), hydroxylamine hydrochloride
(9.25 g, 133 mmol), sodium sulfate (42 g, 295 mmol) in water (250 mL) and 2 M HCl
(12.5 mL), by heating the mixture at 55 ºC with vigorous stirring for 14 h. After cooling
to room temperature, the aqueous layer was decanted from the formed the gummy
residue which was further washed with cold water and dried under vacuum. The flask
was then cooled to -5 : 0 ºC using ice/salt bath before adding cold sulphuric acid (22.5
mL). The flask was allowed to warm to room temperature before heating the reaction
mixture gradually to 70 ºC where the mixture started to get darker in colour. When the
colour change became stable after almost 30 min, the reaction was heated to 80 ºC for
10 min. After cooling to room temperature, the mixture was poured onto crushed ice
(150 mL) and stirred for 1 h. The separated solid was then filtered and washed with
water (3 x 100 mL) to give a red solid of 5-bromo-7-methylindoline-2,3-dione 106 (6.65
g, 75%) and was sufficiently pure for the next step. The spectral data were consistent
with the reported literature.215

4-Methoxy-1-methyl-2-nitrobenzene216 108

This compound was synthesized following the reported procedure from 4-methyl-3nitrophenol 107.216 The 4-methoxy-1-methyl-2-nitrobenzene 108 was isolated as a
white crystalline solid (5.34 g, 80%).
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5-Methoxy-2-methylaniline217 109

The synthesis of this compound is reported by a different method. 217 In this work, it was
prepared by dissolving 4-methoxy-1-methyl-2-nitrobenzene 108 (5.1 g, 30.5 mmol) in
methanol (35 mL) under a N2 atmosphere. Raney Nickel (0.1 mol %) was added and the
mixture was vigorously stirred at room temperature until the H2 ceased to evolve.
Hydrazine monohydrate (2.0 g, 41 mmol) in methanol (10 mL) was added through a
syringe slowly over 10 min. The mixture was then heated at reflux for 4 h. The reaction
mixture was filtered hot through celite, and the filtrate was concentrated under reduced
pressure. The obtained residue was recrystallised from petroleum spirit to yield 5methoxy-2-methylaniline 109 as white solid (3.8 g, 91%). Spectral data for this aniline
derivative 109 are in agreement with the reported literature. 217

4-Methoxy-7-methylindoline-2,3-dione* 111

In a 250 mL round bottom flask, 5-methoxy-2-methylaniline 109 (2.0 g, 15 mmol) was
dissolved in anhydrous benzene (20 mL), and oxalyl chloride (4.12 g, 2.8 mL, 32.4
mmol) was added dropwise. When the HCl ceased to evolve, the reaction was heated at
reflux for 3 h. The benzene and oxalyl chloride were then removed by distillation, and
the residue was quickly suspended in dichloroethane (20 mL) and then cooled to 0 ºC in
an ice bath. Aluminium chloride (2.1 g, 15.5 mmol) as a suspension in dichloroethane
(10 mL) was added portion wise with vigorous stirring and the reaction mixture was
allowed to warm to room temperature over 3 h. The reaction mixture was then heated at
reflux for 40 min. After cooling to room temperature, the mixture was poured onto
*

This compound is commercially available but with no synthesis reference.
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crushed ice, portioned between 0.1 M HCl and ethyl actetate. The aqueous layer was
further extracted with ethyl acetate (2 x 100 mL). The combined organic layers were
washed with brine (100 mL), dried (MgSO4) and evaporated under reduced pressure.
The resulting orange solid was subjected to a flash column chromatography and elution
with 30% ethyl acetate in petroleum spirit yielded 4-methoxy-7-methylindoline-2,3dione 111 as an orange solid (0.84 g, 30%), mp: 235-236 ºC; IR (cm-1): υ 3195 (m, NH),
1635 (s, C=O), 1250 (m, C-O). 1H NMR (DMSO-d6), δ: 10.99 (s, NH), 7.36 (d, J = 8.7,
1H, H6), 6.61 (d, J = 8.7, 1H, H5), 3.83 (s, 3H, OCH3), 2.09 (s, 3H, CH3). 13C NMR, δ:
180.9 (C2), 160.1 (C3), 156.4 (C4), 149.1 (C7a), 141.8 (C6), 112.9 (C7), 106.5 (C5),
105.8 (C3a), 55.8 (OCH3), 14.6 (CH3) ppm. EI-MS m/z 191 (M+, 100%), 163 (50), 149
(10), 134 (7), 121 (7), 106 (93). HRMS (ESI) calcd for C10H10NNO3 (MH+), 192.0661;
found, 192.0653.

5-Bromo-4-methoxy-7-methylindoline-2,3-dione 112

In a 100 mL round bottom flask, 4-methoxy-7-methylindoline-2,3-dione 111 (440 mg,
2.3 mmol) was dissolved in glacial acetic acid (15 mL) and the mixture was stirred until
the solid dissolved completely. The flask was then cooled to 0 ºC using an ice bath. A
solution of bromine (405 mg, 2.5 mmol) in glacial acetic acid (5 mL) was then added
dropwise over 10 min. The flask was allowed to warm to room temperature and was
stirred for 2 h. The resulting solid was filtered and cold water (15 mL) added to the
filtrate and the resulting solid was filtered. The combined solids were washed with
saturated NaHCO3 (2 x 25 mL) and water (2 x 25 mL), and recrystallised from acetic
acid to yield 5-bromo-4-methoxy-7-methylindoline-2,3-dione 112 as an orange solid
(520.5 mg, 84%), mp: >250 ºC; IR (cm-1): υ 3162 (m, NH), 1696 (s, C=O), 1248 (w, CO). 1H NMR (DMSO-d6), δ: 11.20 (s, NH), 7.67 (s, H6), 3.97 (s, 3H, OCH 3), 2.12 (s,
3H, CH3).

13

C NMR, δ: 180.7 (C2), 159.2 (C3), 152.6 (C4), 148.9 (C7a), 142.6 (C6),

117.7 (C7), 110.1 (C3a), 108.1 (C5), 61.8 (OCH3), 14.6 (CH3) ppm. EI-MS m/z 271
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Br, 90), 241 (100%), 228 (20), 185 (80). HRMS (ESI) calcd for

C10H979BrNO3 (MH+), 269.9766; found, 269.9773.

General procedure 2: Suzuki coupling of 6-bromobenzolactone derivatives 90, 91,
94 and 100 with 3-(3-boronophenyl)propanoic acid 113:
Under a N2 atmosphere, a 25 mL flask was charged with the bromoisobenzofuran1(3H)-one

(1

equiv),

3-(3-boronophenyl)propanoic

acid

113

(1.2

equiv),

tetrakis(triphenylphosphine)palladium(0) (5 mol%) and 1,4-dioxane (5 mL). The flask
was sealed with a rubber cap. The reaction mixture was degassed by flushing N 2
through a needle for 10 min. The flask was heated in an oil bath at 85 ºC. When the
solid dissolved, a N2 degassed solution of potassium phosphate (3 equiv) in water (3
mL) was added to the reaction mixture and heating at 85 ºC continued for 4-6 h. After
cooling to room temperature, the solvent was concentrated under reduced pressure, and
2 M HCl (15 mL) was added to the residue. The suspended solid was either collected by
filtration or extracted with ethyl acetate (2 x 25 mL). The combined ethyl acetate
extracts were dried (MgSO4) and evaporated under reduced pressure. The obtained
residues were dissolved in ethanol and were subjected PLC (10% methanol in CH2Cl2,
0.5% acetic acid).

3-(3-(4-Methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 114

Following the general procedure 2 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one
90 (110 mg, 0.453 mmol), 3-(3-boronophenyl)propanoic acid 113 (105.5 mg, 0.544
mmol), tetrakis(triphenylphosphine)palladium(0) (26.2 mg, 0.023 mmol) and potassium
phosphate (288.5 mg, 1.359 mmol) and heating for 5 h, the acid 114 was isolated as a
white solid (87.5 mg, 62%), mp: 116-117 ºC; IR (cm-1): υ 2989 (m, OH), 1755 (s,
C=O), 1718 (s, C=O), 1216 (m, C-O). 1H NMR (CDCl3), δ: 10.54 (s, 1H, COOH), 7.73
(d, 1H, J = 7.5 Hz, isobenzofuran_6 H), 7.45 (s, 1H, phenyl_2 H), 7.41 (d, 1H, J = 7.7
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Hz, phenyl_4 H), 7.40-7.37 (m, 2H, phenyl_5,6 H), 7.30 (d, 1H, J = 7.5 Hz,
isobenzofuran_7 H), 5.37 (s, 2H, isobenzofuran CH2), 3.88 (s, 3H, OCH3), 2.99 (t, 2H, J
= 6.7 Hz, COOH-CH2-CH2), 2.68 (t, 2H, J = 6.7 Hz, COOH-CH2-CH2).

13

C NMR, δ:

175.6 (COOH), 168.9 (C=O), 156.9 (isobenzofuran C4), 148.4 (phenyl C1), 140.5
(isobenzofuran C7a), 137.8 (phenyl C5), 137.1 (isobenzofuran C6), 135.7 (phenyl C6),
129.5 (phenyl C3), 128.7 (phenyl C2), 127.9 (isobenzofuran C5), 127.5 (phenyl C4),
118.0 (isobenzofuran C3a), 117.1 (isobenzofuran C7), 68.9 (isobenzofuran C1), 62.7
(OCH3), 47.4 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EI-MS m/z 312 (M+,
75), 295 (20), 266 (17), 239 (100%), 223 (50), 208 (15), 195 (51). HRMS (ESI) calcd
for C18H17O5 (MH+), 313.1076; found, 313.1078. HPLC purity: 97.4%, Rt=8.245 (1%
solvent B in solvent A).

3-(3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 115

Following the general procedure 2 using 6-bromo-7-methylisobenzofuran-1(3H)-one 91
(95 mg, 0.418 mmol), 3-(3-boronophenyl)propanoic acid 113 (97.3 mg, 0.502 mmol),
tetrakis(triphenylphosphine)palladium(0) (24.2 mg, 0.021 mmol) and potassium
phosphate (266.2 mg, 1.254 mmol) and heating for 4 h, the acid 115 was isolated as a
white solid (66.8 mg, 54%), mp: 110-111 ºC; IR (cm-1): υ 2989 (m, OH), 1731 (s,
C=O), 1696 (s, C=O). 1H NMR (CDCl3), δ: 7.55 (d, 1H, J = 7.8 Hz, isobenzofuran_6
H), 7.50 (d, 1H, J = 7.3 Hz, phenyl_4 H), 7.37 (t, 1H, J = 7.3 Hz, phenyl_5 H), 7.26 (d,
1H, J = 7.3 Hz, phenyl_6 H), 7.20 (s, 1H, phenyl_2 H), 7.16 (d, 1H, J = 7.3 Hz,
isobenzofuran_7 H), 5.28 (s, 2H, isobenzofuran CH2), 3.02 (t, 2H, J = 7.3 Hz, COOHCH2-CH2), 2.74 (t, 2H, J = 7.3 Hz, COOH-CH2-CH2), 2.59 (s, 3H, CH3). 13C NMR, δ:
185.4 (COOH), 171.6 (C=O), 146.3 (phenyl C1), 143.5 (isobenzofuran C7a), 140.5
(phenyl C3), 140.3 (isobenzofuran C4), 137.6 (phenyl C2), 135.7 (isobenzofuran C5),
132.3 (phenyl C5), 129.5 (phenyl C6), 128.7 (isobenzofuran C6), 127.6 (phenyl C4),
123.8 (isobenzofuran C3a), 119.1 (isobenzofuran C7), 68.5 (isobenzofuran C1), 35.7
(COOH-CH2-CH2), 30.7 (COOH-CH2-CH2), 14.9 (CH3) ppm. EI-MS m/z 296 (M+,
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100%), 278 (54), 260 (46), 250 (80), 136 (60), 223 (40). HRMS (ESI) calcd for
C18H17O4 (MH+), 297.1127; found, 297.1129. HPLC purity: 97.9%, Rt=5.571 (1%
solvent B in solvent A).

3-(3-(4,6-Dimethoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 116

Following the general procedure 2 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)one 94 (80 mg, 0.293 mmol), 3-(3-boronophenyl)propanoic acid 113 (68.2 mg, 0.352
mmol), tetrakis(triphenylphosphine)palladium(0) (16.9 mg, 0.015 mmol) and potassium
phosphate (186.6 mg, 0.879 mmol) and heating for 6 h, the acid 116 was isolated as a
pale yellow oil in (56 mg, 56%), IR (cm-1): υ 2989 (m, OH), 1750 (s, C=O), 1739 (s,
C=O), 1208 (w, C-O). 1H NMR (CDCl3), δ: 7.33 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.18
(d, 1H, J = 7.9 Hz, phenyl_4 H), 7.12-7.10 (m, 2H, phenyl_2,6 H), 6.50 (s, 1H,
isobenzofuran_7 H), 4.98 (s, 2H, isobenzofuran CH2), 4.03 (s, 3H, isobenzofuran_4
OCH3), 3.85 (s, 3H, isobenzofuran_6 OCH3), 2.97 (t, 3H, J = 7.6 Hz, COOH-CH2CH2), 2.66 (t, 3H, J = 7.6 Hz, COOH-CH2-CH2).

13

C NMR, δ: 177.2 (COOH), 169.0

(C=O), 162.8 (isobenzofuran C6), 159.4 (isobenzofuran C4), 149.3 (phenyl C1), 140.7
(isobenzofuran C7a), 133.8 (phenyl C3), 129.3 (phenyl C2), 128.7 (phenyl C5), 127.7
(phenyl C4), 127.4 (phenyl C6), 117.5 (isobenzofuran C3a), 106.1 (isobenzofuran C5),
95.5 (isobenzofuran C7), 68.3 (isobenzofuran C1), 56.3 (isobenzofuran_6 OCH3), 56.2
(isobenzofuran_4 OCH3), 35.1 (COOH-CH2-CH2), 30.7 (COOH-CH2-CH2) ppm. EIMS m/z 342 (M+, 100), 326 (25), 296 (26). HRMS (ESI) calcd for C19H18O6 (MH+),
343.1182; found, 343.1190. HPLC purity: 98.7%, Rt=13.234 (5% solvent B in solvent
A).
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3-(3-(3-Oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 117

Following the general procedure 2 using 6-bromoisobenzofuran-1(3H)-one 100 (90 mg,
0.422 mmol), 3-(3-boronophenyl)propanoic acid 113 (98.2 mg, 0.506 mmol),
tetrakis(triphenylphosphine)palladium(0) (24.4 mg, 0.021 mmol) and potassium
phosphate (268.7 mg, 1.266 mmol) and heating for 4 h, the acid 117 was isolated as a
white solid (92.8 mg, 78%), mp: 118-119 ºC; IR (cm-1): υ 2972 (m, OH), 1743 (s,
C=O), 1699 (s, C=O). 1H NMR (CDCl3), δ: 8.11 (s, 1H, isobenzofuran_4 H), 7.90 (d,
1H, J = 8.0 Hz, phenyl_4 H), 7.55 (d, 1H, J = 7.9 Hz, phenyl_6 H), 7.47 (s, 1H,
phenyl_2 H), 7.46 (d, 1H, J = 6.2 Hz, isobenzofuran_6 H), 7.41 (t, 1H, J = 8.0 Hz,
phenyl_5 H), 7.27 (d, 1H, J = 6.7 Hz, isobenzofuran_7 H), 5.37 (s, 2H, isobenzofuran
CH2), 3.05 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.75 (t, 2H, J = 7.6 Hz, COOH-CH2CH2).

13

C NMR, δ: 178.3 (COOH), 171.4 (C=O), 145.5 (phenyl C1), 142.8

(isobenzofuran C7a), 141.4 (phenyl C2), 139.9 (isobenzofuran C5), 133.4 (phenyl C3),
129.6 (phenyl C5), 128.3 (phenyl C6), 127.6 (isobenzofuran C6), 126.7 (isobenzofuran
C3a), 125.6 (phenyl C4), 124.3 (isobenzofuran C4), 122.7 (isobenzofuran C7), 69.9
(isobenzofuran C1), 35.6 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EI-MS m/z
282 (M+, 70), 253 (20), 237 (100%), 223 (16). HRMS (ESI) calcd for C17H15O4 (MH+),
283.0970; found, 283.0974. HPLC purity: 99.6%, Rt=6.285 (2% solvent B in solvent
A).

2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile 119

Under a N2 atmosphere, an oven dried 100 mL flask was charged with 2-(3iodophenoxy)acetonitrile 124 (1.16 g, 4.479 mmol), bis(pinacolato)diboron 125 (4.55 g,
17.916
235

mmol),

potassium

acetate

(17.916

mmol,

1.76

g)

and

[1,1′-
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bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)) (32.8 mg, 1
mol%). Dry THF (50 mL) was added to the mixture, and the flask was heated at reflux
for 18 h under N2 atmosphere. The solvent was then evaporated under reduced pressure,
ethyl acetate (30 mL) was added and the mixture was sonicated for 10 min and filtered.
The filtrate was triturated with MgSO4 and charcoal (0.5 g), and filtered through a short
pad of celite. The filtrate was then concentrated under reduced pressure and the
resulting residue was recrystallised from a mixture of ethyl acetate/hexane (3:2) to give
the boronic ester 119 as a pink solid (1.1 g, 95%), mp: 40-41 ºC; IR (cm-1): υ 2980 (m,
C-H aliphatic), 2152 (m, CN), 1128 (w, C-O). 1H NMR (CDCl3), δ: 7.43 (d, 1H, J = 7.6
Hz, phenoxy_6 H), 7.39 (s, 1H, phenoxy_2 H), 7.08 (t, 1H, J = 7.9 Hz, phenoxy_5 H),
6.96 (d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.76 (s, 2H, CH2), 1.26 (s, 12H, 4CH3).

13

C

NMR, δ: 157.1 (phenoxy C1), 132.6 (phenoxy C3), 131.4 (phenoxy C5), 124.7
(phenoxy C4), 114.8 (CN), 114.6 (phenoxy C2), 94.6 (phenoxy C6), 83.7 (dioxaborolan
C4, C5), 53.9 (CH2), 25.2 (4CH3) ppm. ESI-MS m/z 259 (M+). HRMS (ESI) calcd for
C14H19BNO3 (MH+), 260.1458; found, 260.1462.

General procedure 3: Suzuki coupling of 6-bromobenzolactone derivatives 90 and
91 with (3-(cyanomethoxy)phenyl)boronic acid 118 or ester 119:
A round bottom 25 mL flask was charged with the appropriate dihydroisobenzofuran
derivative (1 equiv), (3-(cyanomethoxy)phenyl)boronic acid 118 (1 equiv) or 2-(3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile

119

(1.2

equiv),

tetrakis(triphenylphosphine)palladium(0) (5 mol%), 1,4-dioxane (10 mL) was added
and the flask was sealed with a rubber cap. The reaction mixture was degassed by
flushing N2 through a needle for 10 min. The flask was heated in an oil bath at 85 ºC.
When all the solid was dissolved, potassium phosphate (3 mmol, 636.8 mg) dissolved in
water (5 mL) was added to the reaction via a needle. The flask was then heated at 85 ºC
for 7-15 h. The solvent was concentrated under reduced pressure, and was added 1M
HCl (10 mL), the reaction mixture turned to a white turbid solution which was then
extracted with ethyl acetate (2 x 30 mL), washed with brine (2 x 10 mL) and dried
(MgSO4). The solvent was evaporated and the residue was subjected to flash column
chromatography (40% ethyl acetate in petroleum spirit).
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2-(3-(4-Methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 120

Following the general procedure 3 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one
90 (100 mg, 0.411 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (72 mg, 0.411
mmol), tetrakis(triphenylphosphine)palladium(0) (23.7 mg, 0.021 mmol) and heating
for 15 h, the acetonitrile intermediate 120 was isolated as a white solid (60.7 mg, 50%),
mp: 103-104 ºC; IR (cm-1): υ 2920 (w, C-H aliphatic), 2165 (m, CN), 1759 (s, C=O),
1212 (w, C-O). 1H NMR (CDCl3), δ: 7.74 (d, 1H, J = 7.7 Hz, isobenzofuran_6 H), 7.43
(t, 1H, J = 8.0 Hz, phenyl_5 H), 7.25-7.23 (m, 2H, phenyl_4 H, isobenzofuran_7 H),
7.19 (s, 1H, phenyl_2 H), 7.02 (d, 1H, J = 8.2 Hz, phenyl_6 H), 5.30 (s, 2H,
isobenzofuran CH2), 4.83 (s, 2H, CN-CH2), 3.90 (s, 3H, OCH3).

13

C NMR, δ: 168.5

(C=O), 156.7 (phenyl C1), 156.4 (isobenzofuran C4), 148.7 (isobenzofuran C7a), 138.7
(isobenzofuran C6), 137.4 (phenyl C5), 134.7 (isobenzofuran C5), 129.8 (phenyl C4),
124.1 (phenyl C3), 117.9 (phenyl C6), 117.1 (phenyl C2), 116.1 (CN), 115.1
(isobenzofuran C3a), 114.5 (isobenzofuran C7), 68.7 (isobenzofuran C1), 62.7 (CNCH2), 53.7 (OCH3) ppm. EI-MS m/z 295 (M+, 15), 255 (100%), 237 (13), 208 (10), 180
(16). HRMS (ESI) calcd for C17H14NO4 (MH+), 296.0914; found, 296.0913. HPLC
purity: 98.3%, Rt=16.676 (1% solvent B in solvent A).

2-(3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 121

Following the general procedure 3 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one
91 (100 mg, 0.358 mmol), 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)
acetonitrile 119 (111.4 mg, 0.430 mmol), tetrakis(triphenylphosphine)palladium(0)
(20.7 mg, 0.018 mmol) and heating for 7 h, the acetonitrile intermediate 121 was
isolated as white solid (93.4 mg, 76%), mp: 99-100 ºC; IR (cm-1): υ 2972 (w, C-H
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aliphatic), 2169 (m, CN), 1743 (s, C=O). 1H NMR (CDCl3), δ: 7.74 (d, 1H, J = 7.7 Hz,
isobenzofuran_6 H), 7.43 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.32 (d, 1H, J = 7.7 Hz,
isobenzofuran_7 H), 7.02 (d, 2H, J = 8.0 Hz, phenyl_4,6 H), 6.93 (s, 1H, phenyl_2 H),
5.28 (s, 2H, isobenzofuran CH2), 4.83 (s, 2H, CN-CH2), 2.60 (s, 3H, CH3). 13C NMR, δ:
171.4 (C=O), 156.7 (phenyl C1), 146.7 (isobenzofuran C7a), 142.8 (isobenzofuran C4),
142.1 (isobenzofuran C5), 137.6 (phenyl C3), 135.6 (phenyl C5), 130.1 (isobenzofuran
C3a), 124.4 (phenyl C4), 124.1 (isobenzofuran C6), 119.4 (isobenzofuran C7), 116.4
(phenyl C2), 115.3 (CN), 114.1 (phenyl C6), 68.6 (isobenzofuran C1), 53.9 (CN-CH2),
15.0 (CH3) ppm. EI-MS m/z 279 (M+, 90), 239 (100%), 223 (15), 195 (12), 165 (24).
HRMS (ESI) calcd for C17H14NO3 (MH+), 280.0974; found, 280.0966. HPLC purity:
98.1%, Rt=11.021 (1% solvent B in solvent A).

2-(3-Iodophenoxy)acetonitrile 124265*

A solution of 3-iodophenol 122 (2.0 g, 9.09 mmol) and NaOH (0.91 g, 22.73 mmol) in
dry DMF (25 mL) was stirred vigorously for 30 min until the solution became pale
brown. 2-Chloroacetonitrile 123 (1.03 g, 0.86 mL, 13.64 mmol) was then added
dropwise through a syringe and the mixture was further stirred for 18 h at room
temperature. The resulting brown solution was then poured onto crushed ice (100 mL),
stirred for 30 min, and the resulting oil was extracted with ethyl acetate (2 x 25 mL).
The combined organic layers were washed with water (2 x 25 mL), brine (2 x 25 mL)
and dried (MgSO4). The organic fraction was then triturated with charcoal (0.5 g) and
filtered through celite, and evaporated under reduced pressure to afford 2-(3iodophenoxy)acetonitrile 124 as a yellow oil (1.88 g, 80%), IR (cm-1): υ 2942 (m, C-H
aliphatic), 2246 (s, CN), 1203 (w, C-O). 1H NMR (CDCl3), δ: 7.37 (d, 1H, J = 7.7 Hz,
phenoxy_6 H), 7.29 (s, 1H, phenoxy_2 H), 7.02 (t, 1H, J = 7.9 Hz, phenoxy_5 H), 6.90
(d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.68 (s, 2H, CH2). 13C NMR, δ: 157.1 (phenoxy C1),
132.5 (phenoxy C5), 131.6 (phenoxy C4), 124.7 (phenoxy C2), 115.3 (CN), 114.6
*

This reference was published in 2013 after the synthesis of 124 in this work, and it only reports the 1H
NMR, 13C NMR and LRMS.
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(phenoxy C6), 94.9 (phenoxy C3), 54.0 (CH2) ppm. EI-MS m/z 259 (M+, 100%), 219
(27), 203 (5). HRMS (ESI) calcd for C8H7INO (MH+), 259.9572; found, 259.9565.

General procedure 4: synthesis of the benzolactone-tetrazole conjugates 126 and
127 using sodium azide method:
Under a N2 atmosphere, a round bottom flask (25 mL) was charged with the appropriate
acetonitrile derivative 120-121 (0.186 mmol), sodium azide (48.4 mg, 0.744 mmol),
amonium chloride (39.4 mg, 0.744 mmol), DMF (10 mL) and a catalytic amount of
glacial acetic acid (5-10 drops), and the reaction mixture was then heated at reflux for
24 h. DMF was concentrated under reduced pressure and the residue was dried by
vacuum. Ethanol was added to the resulting dry residue and the mixture was sonicated
for 10 min, filtered and the ethanol solution was concentrated and subjected to PLC
(90% CH2Cl2, 10% ethanol and 0.1% TFA) to yield the tetrazole conjugate 126 and
127.

6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-7-methoxyisobenzofuran-1(3H)-one 126

Following

the

general

procedure

4

using

2-(3-(4-methoxy-3-oxo-1,3-

dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 120 (55 mg), the tetrazole conjugate
126 was isolated as a pale yellow solid (21.4 mg, 34%), mp: 130-131 ºC; IR (cm-1): υ
3404 (w, NH), 2907 (w, C-H aliphatic), 1751 (s, C=O), 1660 (m, C=N), 1134 (w, C-O).
1

H NMR (CD3OD), δ: 7.72 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.42 (t, 1H, J = 7.9

Hz, phenyl_5 H), 7.37 (d, 1H, J = 7.7 Hz, isobenzofuran_4 H), 7.22-7.17 (m, 2H,
phenyl_2,4 H), 7.10 (d, 1H, J = 8.2 Hz, phenyl_6 H), 5.50 (s, 2H, isobenzofuran CH2),
5.34 (s, 2H, O-CH2), 3.78 (s, 3H, OCH3). 13C NMR, δ: 169.7 (C=O), 157.9 (phenyl C3),
156.5 (isobenzofuran C7), 149.6 (tetrazole C), 138.7 (isobenzofuran C3a), 137.7
(isobenzofuran C5), 135.1 (phenyl C5), 129.5 (isobenzofuran C6), 129.4 (phenyl C6),
123.0 (phenyl C1), 117.6 (phenyl C4), 117.5 (phenyl C2), 115.9 (isobenzofuran C7a),
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113.9 (isobenzofuran C4), 69.3 (isobenzofuran C3), 61.7 (tetrazole-CH2-O), 59.9
(OCH3) ppm. EI-MS m/z 338 (M+, 14), 255 (100%), 239 (10), 211 (12), 195 (11).
HRMS (ESI) calcd for C17H15N4O4 (MH+), 339.1093; found, 339.1107. HPLC purity:
96.3%, Rt=16.339 (5% solvent B in solvent A).

6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-7-methylisobenzofuran-1(3H)-one 127

Following

the

general

procedure

4

using

2-(3-(4-methyl-3-oxo-1,3-

dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 121 (51.9 mg), the final tetrazole
conjugate 127 was isolated as a pale yellow gummy solid (21 mg, 35%), IR (cm-1): υ
3392 (m, NH), 2988 (w, C-H aliphatic), 1741 (s, C=O), 1668 (m, C=N), 1212 (w, C-O).
1

H NMR (CD3OD), δ: 7.58 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.48 (d, 1H, J = 7.7

Hz, isobenzofuran_4 H), 7.44 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.12 (d, 1H, J = 7.9 Hz,
phenyl_6 H), 7.03 (s, 1H, phenyl_2 H), 6.99 (d, 1H, J = 7.5 Hz, phenyl_4 H), 5.51 (s,
2H, isobenzofuran CH2), 5.36 (s, 2H, O-CH2), 2.55 (s, 3H, CH3).

13

C NMR, δ: 170.9

(C=O), 162.4 (phenyl C3), 157.3 (tetrazole C), 147.2 (isobenzofuran C3a), 142.1
(isobenzofuran C7), 141.1 (isobenzofuran C6), 135.7 (phenyl C5), 135.4 (isobenzofuran
C5), 129.7 (phenyl C1), 122.9 (isobenzofuran C7a), 122.7 (phenyl C6), 120.8
(isobenzofuran C4), 115.8 (phenyl C2), 114.1 (phenyl C4), 68.5 (isobenzofuran C3),
59.3 (tetrazole-CH2-O), 14.4 (CH3) ppm. EI-MS m/z 322 (M+, 50), 239 (75), 223 (26),
195 (60), 165 (100%). HRMS (ESI) calcd for C 17H15N4O3 (MH+), 323.1144; found,
323.1138. HPLC purity: 98.7%, Rt=10.695 (5% solvent B in solvent A).
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5-((3-Iodophenoxy)methyl)-1H-tetrazole 128

In a round bottom 50 mL flask, a solution of 2-(3-iodophenoxy)acetonitrile 124 (1.6 g,
6.18 mmol), sodium azide (1.6 g, 24.7 mmol) and amonium chloride (1.3 g, 24.7 mmol)
in dry DMF (25 mL), containing few drops of glacial acetic acid, was heated at reflux
for 14 h under a N2 atmosphere. The solvent was then concentrated under reduced
pressure, and the resulting residue was dried under vacuum. Ethanol (25 mL) was added
to the residue and the mixture was sonicated for 10 min, filtered and ethanol was
evaporated under reduced pressure resulting in a white fluffy solid of the tetrazole
intermediate 128 (1.5 g, 80%), mp: 99-100 ºC ; IR (cm-1): υ 2995 (w, NH), 1589 (m,
C=N), 1240 (w, C-O). 1H NMR (CD3OD), δ: 7.46 (s, 1H, phenoxy_2 H), 7.39 (t, 1H, J
= 7.0 Hz, phenoxy_5 H), 7.09-7.08 (m, 2H, phenoxy_4,6 H), 5.47 (s, 2H, CH2).

13

C

NMR, δ: 159.7 (phenoxy C1), 155.3 (tetrazole C), 132.4 (phenoxy C4), 132.2 (phenoxy
C5), 125.4 (phenoxy C2), 115.3 (phenoxy C6), 94.9 (phenoxy C3), 61.1 (CH 2) ppm. EIMS m/z 302 (M+, 100%), 220 (80), 203 (10). HRMS (ESI) calcd for C8H8IN4O (MH+),
302.9743; found, 302.9734.

Potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol1-ide 129

Under a N2 atmosphere, an oven dried 100 mL flask was charged with 5-((3iodophenoxy)methyl)-1H-tetrazole 128 (960 mg, 3.179 mmol), bis(pinacolato)diboron
125 (3.2 g, 12.716 mmol), potassium acetate (1.25 g, 12.716 mmol) and PdCl2(dppf)
(23.3 mg, 1 mol%). Dry THF (30 mL) was added to the mixture, and the flask was
heated at reflux for 18 h under a N2 atmosphere. The solvent was then concentrated
under reduced pressure. Ethanol (30 mL) was added to the resulting residue and the
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mixture was further heated at reflux for 10 min, filtered hot and concentrated under
reduced pressure to afford a white solid of the boronic ester potassium salt 129 (1.1 g,
99%), mp: >250 ºC ; IR (cm-1): υ 2983 (s, C-H aliphatic), 1680 (m, C=N), 1233 (w, CO). 1H NMR (CD3OD), δ: 7.38 (s, 1H, phenoxy_2 H), 7.28 (d, 1H, J = 7.1 Hz,
phenoxy_6 H), 7.04-6.99 (m, 2H, phenoxy_4,5 H), 5.25 (s, 2H, CH2), 1.90 (s, 12H,
4CH3).

13

C NMR, δ: 178.5 (phenoxy C1), 159.5 (tetrazole C), 158.3 (phenoxy C3),

130.8 (phenoxy C5), 130.2 (phenoxy C4), 124.2 (phenoxy C6), 114.2 (phenoxy C2),
93.6 (dioxaborolan C4, C5), 61.2 (CH2), 22.6 (4CH3) ppm. ESI-MS m/z 301.1 (M-K)-.

General procedure 5: synthesis of the benzolactone-tetrazole conjugates 130 and
131 using the coupling method:
Under a N2 atmosphere, a mixture of the appropriate bromoisobenzofuran-1(3H)-one
derivative (1 mmol) and potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy)methyl)tetrazol-1-ide

129

(374

mg,

1.1

mmol),

tetrakis(triphenylphosphine)palladium(0) (80.9 mg, 7 mol%) and potassium phosphate
(636.8 mg, 3 mmol) was added to a solvent mixture of 1,4-dioxane (25 mL) and water
(10 mL) in a 50 mL round bottom flask. The reaction mixture was degassed by flushing
N2 through a needle for 10 min, the flask was then sealed with a rubber cap, heated at 85
ºC for 20-24 h. The solvent was then concentrated under reduced pressure. Saturated
NaHCO3 (25 mL) was added to the resulting residues, and the mixture sonicated for 15
min, before the turbid solution was washed with CH2Cl2 (25 mL). The aqueous layer
was filtered, cooled to 0 ºC using an ice bath, and the filtrate was then neutralized with
2 M HCl. The resulting white solid was collected by vacuum filtration, washed with
chilled methanol and dried under vacuum to afford the tetrazoles 130, 131.
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6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)-5,7-dimethoxyisobenzofuran-1(3H)-one 130

Following the general procedure 5 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)one 90 (1 mmol, 273 mg) and heating for 24 h, the final tetrazole conjugate 130 was
isolated as a white solid (195 mg, 53%), mp: charring; IR (cm-1): υ 3204 (w, NH), 1740
(s, C=O), 1614 (m, C=N), 1218 (w, C-O). 1H NMR (CD3OD), δ: 7.37 (t, 1H, J = 7.9
Hz, phenyl_5 H), 7.05 (d, 1H, J = 8.0 Hz, phenyl_6 H), 7.02 (s, 1H, phenyl_2 H), 6.98
(d, 1H, J = 7.7 Hz, phenyl_4 H), 6.78 (s, 1H, isobenzofuran_4 H), 5.48 (s, 2H,
isobenzofuran CH2), 5.09 (s, 2H, O-CH2), 4.04 (s, 3H, isobenzofuran_7 OCH3), 3.89 (s,
3H, isobenzofuran_5 OCH3).

13

C NMR, δ: 167.9 (C=O), 162.6 (isobenzofuran C5),

158.9 (phenyl C3), 157.4 (isobenzofuran C7), 153.6 (tetrazole C), 149.2 (isobenzofuran
C3a), 134.9 (phenyl C5), 129.5 (phenyl C6), 122.8 (phenyl C4), 115.9 (phenyl C10),
115.7 (phenyl C11), 114.1 (isobenzofuran C7a), 104.7 (isobenzofuran C4), 96.2
(isobenzofuran

C6),

67.8

(isobenzofuran

C3),

59.2

(tetrazole-CH2-O),

56.6

(isobenzofuran_7 OCH3), 56.1 (isobenzofuran_5 OCH3) ppm. ESI-MS m/z 367.1 (MH). HRMS (ESI) calcd for C18H15N4O5 (M-H+), 367.1042; found, 367.1038. HPLC
purity: 95.2%, Rt=18.896 (10% solvent B in solvent A).

6-(3-((1H-Tetrazol-5-yl)methoxy)phenyl)isobenzofuran-1(3H)-one 131

Following the general procedure 5 using 6-bromoisobenzofuran-1(3H)-one 91 (213 mg,
1 mmol) and heating for 20 h, the final tetrazole conjugate 131 was isolated as a white
solid (181 mg, 59%), mp: charring; IR (cm-1): υ 3195 (w, NH), 1751 (s, C=O), 1653 (m,
C=N). 1H NMR (CD3OD), δ: 8.07 (s, 1H, isobenzofuran_7 H), 7.99 (d, 1H, J = 8.0 Hz,
isobenzofuran_5 H), 7.67 (d, 1H, J = 8.0 Hz, isobenzofuran_4 H), 7.38 (t, 1H, J = 7.9
Hz, phenyl_5 H), 7.33 (s, 1H, phenyl_2 H), 7.24 (d, 1H, J = 7.5 Hz, phenyl_6 H), 7.09
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(d, 1H, J = 8.0 Hz, phenyl_4 H), 5.42 (s, 2H, isobenzofuran CH2), 5.37 (s, 2H, O-CH2).
13

C NMR, δ: 171.9 (C=O), 159.3 (phenyl C3), 146.3 (tetrazole C), 142.4 (isobenzofuran

C3a), 140.9 (isobenzofuran C6), 133.2 (phenyl C1), 129.7 isobenzofuran C5), 125.9
(phenyl C5), 122.9 (phenyl C6), 122.7 (isobenzofuran C7), 122.6 (isobenzofuran C7a),
119.7 (phenyl C2), 114.4 (isobenzofuran C4), 113.7 (phenyl C4), 69.9 (isobenzofuran
C3), 61.1 (tetrazole-CH2-O) ppm. ESI-MS m/z 307.1 (M-H). HRMS (ESI) calcd for
C16H11N4O3 (M-H+), 307.0831; found, 307.0826. HPLC purity: 98.8%, Rt=13.175 (5%
solvent B in solvent A).

5-Bromo-3-methyl-7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5-trien-8-one 133

In an oven dried 50 mL flask and under a N2 atmosphere, 2-amino-3-bromo-5methylbenzoic acid 132 (750 mg, 3.26 mmol) was dissolved in dry THF (20 mL), and
the flask was then sealed with a rubber cap with fitted with a N2 balloon, and cooled to 78 ºC. n-BuLi (4.08 mL of 2 M solution, 8.15 mmol) was added dropwise through a
needle and the mixture was stirred for 20 min at -78 ºC before adding pivaloyl chloride
(0.48 mL, 3.91 mmol) dropwise. The reaction was then allowed to warm to room
temperature and stirred for 3 h. The reaction mixture was then diluted with ethyl acetate
(10 mL) and water (10 mL), the organic layer was separated and washed with water (2 x
20 mL), brine (2 x 10 mL) and dried (MgSO4). The combined organic layers were
concentrated under reduced pressure to yield the β-lactam derivative 133 as a colourless
oil (452 mg, 47%), IR (cm-1): υ 1745 (s, C=O), 1634 (s, C=O), 1465 (w, C-N), 1059 (w,
C-Br). 1H NMR (CDCl3), δ: 7.94 (s, 1H, H4), 7.86 (s, 1H, H2), 2.45 (s, 3H, CH3), 1.42
(s, 9H, pivaloyl 3CH3).

13

C NMR, δ: 168.1 (pivaloyl C=O), 159.7 (C6), 142.3 (C=O),

140.9 (C4), 139.3 (C1), 127.4 (C2), 121.8 (C3), 117.8 (C5), 38.3 (C(CH3)3), 27.6
(pivaloyl 3CH3), 20.9 (CH3) ppm. EI-MS m/z 295 (M+, 35), 280 (100%), 253 (20), 238
(37). HRMS (ESI) calcd for C13H15BrNO2 (MH+), 296.0286; found, 296.0294.
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3-(3-(3-Methyl-8-oxo-7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5-trien-5yl)phenyl)propanoic acid 137

Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam
derivative 133 (100 mg, 0.339 mmol), 3-(3-boronophenyl)propanoic acid 113 (72.3 mg,
0.372 mmol), tetrakis(triphenylphosphine)palladium(0) (19.6 mg, 0.016 mmol) and
potassium phosphate (215.9 mg, 1.02 mmol). A mixture of 1,4-dioxane (10 mL) and
water (3 mL) was added and the reaction mixture was degassed by flushing N 2 through
a needle for 10 min. The flask was then sealed with a rubber cap, heated at 85 ºC for 18
h. The solvent was then concentrated under reduced pressure and the flask was cooled
to 0 ºC. Chilled 1 N HCl (10 mL) was added dropwise with stirring, and the resulting
solid was extracted with ethyl acetate (2 x 15 mL). The combined organic layers were
washed with water (15 mL), brine (15 mL) and dried (MgSO4) and concentrated under
reduced pressure. The resulting residue was subjected to a flash column
chromatography (50% CH2Cl2, 50% ethyl acetate and 1% acetic acid) to afford 137 as a
pale yellow oil (74.2 mg, 60%), IR (cm-1): υ 2959 (m, OH), 1696 (s, C=O), 1662 (s,
C=O), 1481 (m, C-N). 1H NMR (CDCl3), δ: 8.56 (s, 1H, COOH), 7.77 (s, 1H, H4),
7.32-7.29 (m, 2H, phenyl_5 H, H2), 7.20 (d, 1H, J = 7.5 Hz, phenyl_6 H), 7.19 (s, 1H,
phenyl_2 H), 7.15 (d, 1H, J = 7.7 Hz, phenyl_4 H), 2.97 (t, 2H, J = 7.5 Hz, COOHCH2-CH2), 2.68 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.37 (s, 3H, CH3), 1.03 (s, 9H,
pivaloyl 3CH3).

13

C NMR, δ: 178.4 (pivaloyl C=O), 176.9 (COOH), 171.9 (azabicyclo

C=O), 140.4 (phenyl C1), 140.1 (azabicyclo C6), 139.8 (phenyl C3), 136.4 (phenyl C5),
135.8 (azabicyclo C4), 133.1 (azabicyclo C2), 130.9 (azabicyclo C3), 128.8 (azabicyclo
C1), 128.7 (phenyl C2), 127.3 (phenyl C6), 126.8 (azabicyclo C5), 124.8 (phenyl C4),
39.3 (C(CH3)3), 35.8 (COOH-CH2-CH2), 30.9 (COOH-CH2-CH2), 27.2 (pivaloyl
3CH3), 21.0 (CH3) ppm. EI-MS m/z 365 (M+, 60), 350 (70), 320 (50), 299 (25), 277
(100%), 235 (26), 220 (23), 193 (52). HRMS (ESI) calcd for C22H24NO4 (MH+),
366.1705; found, 366.1717. HPLC purity: 98.9%, Rt=27.924 (3% solvent B in solvent
A).
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3'-(Cyanomethoxy)-5-methyl-2-pivalamido-[1,1'-biphenyl]-3-carboxylic acid 138

Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam
derivative 133 (100 mg, 0.339 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (66.0
mg, 0.373 mmol), tetrakis(triphenylphosphine)palladium(0) (19.6 mg, 0.016 mmol) and
potassium phosphate (215.9 mg, 1.02 mmol). A mixture of 1,4-dioxane (10 mL) and
water (3 mL) was added and the reaction mixture was degassed by flushing N2 through
a needle for 10 min. The flask was then sealed with a rubber cap, heated at 85 ºC for 12
h. The solvent was then concentrated under reduced pressure and 1 N HCl (10 mL) was
added dropwise to the resulting residue which was extracted with ethyl acetate (2 x 15
mL). The combined organic layers were washed with water (15 mL), brine (15 mL) and
dried (MgSO4). The mixture was then concentrated under reduced pressure, and the
resulting residue was subjected to a flash column chromatography and elution with 90%
CH2Cl2, 10% ethanol and 0.1% TFA yielded 138 as a pale yellow oil (59.4 mg, 48%),
IR (cm-1): υ 3328 (m, NH), 2967 (m, OH), 2200 (m, CN), 1646 (w, NH), 1411 (w, CN). 1H NMR (CDCl3), δ: 8.61 (s, 1H, COOH), 7.53 (s, 1H, phenyl_6 H), 7.32 (t, 1H, J =
7.7 Hz, phenyl_5' H), 7.15 (s, 1H, phenyl_4 H), 7.01 (d, 1H, J = 7.5 Hz, phenyl_6' H),
6.92-6.90 (m, 2H, phenyl_2', 4'), 6.47 (s, 1H, NH), 4.73 (s, 2H, CH 2), 2.28 (s, 3H, CH3),
0.97 (s, 9H, pivaloyl 3 CH3). 13C NMR, δ: 177.7 (pivaloyl C=O), 176.7 (COOH), 173.8
(C3'), 156.4 (C2), 141.7 (C5), 137.8 (C1), 135.7 (C6'), 133.2 (C4), 130.5 (C6), 129.7
(C1'), 129.6 (C6'), 123.4 (C4'), 115.6 (CN), 115.1 (C3), 113.3 (C2'), 53.5 (CH 2), 38.9
(C(CH3)3), 26.9 (pivalamido 3 CH3), 20.8 (CH3) ppm. ESI-MS m/z 365.0 (M-H).
HRMS (ESI) calcd for C21H23N2O4 (MH+), 367.1658; found, 367.1656. HPLC purity:
99.4%, Rt=17.599 (2% solvent B in solvent A).
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General procedure 6: Suzuki coupling of 5-bromoisatin derivatives 103, 106, 112
and 139 with 3-(3-boronophenyl)propanoic acid 113:
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1
equiv),

3-(3-boronophenyl)propanoic

acid

113

(1.2

equiv),

tetrakis(triphenylphosphine)palladium(0) (5 mol%) and DME (3 mL) or diglyme (3
mL), was sealed with a rubber cap. The reaction mixture was degassed by flushing N 2
through a needle for 10 min, and was then heated in an oil bath at 85 ºC. When the solid
dissolved, a N2 degassed solution of potassium phosphate (3 equiv) in water (3 mL) was
added to the reaction mixture and heating continued at 85 ºC for 4-6 h. After cooling to
room temperature, the solvent was concentrated under reduced pressure. A solution of
HCl 2 M (15 mL) was added, and the resulting suspended solid was either collected by
filtration or extracted with ethyl acetate (2 x 25 mL). The combined organic layers were
dried (MgSO4) and evaporated under reduced pressure. The combined residues were
then dissolved in ethanol and were subjected to PLC (10% methanol in CH2Cl2, 0.5%
acetic acid) to yield the isatin-acid conjugates 140-143.

3-(3-(4,6-Dimethoxy-2,3-dioxoindolin-5-yl)phenyl)propanoic acid 140

Following the general procedure 6 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 103
(100 mg, 0.349 mmol), 3-(3-boronophenyl)propanoic acid 113 (81.2 mg ,0.419 mmol),
tetrakis(triphenylphosphine)palladium(0) (20.2 mg, 0.017 mmol) and potassium
phosphate (222.2 mg, 1.047 mmol) and heating for 6 h, the acid 140 was isolated as a
yellow solid (49.5 mg, 40%), mp: 175-176 ºC; IR (cm-1): υ 3185 (m, NH), 2978 (m,
OH), 1718 (s, C=O), 1696 (s, C=O), 1290 (w, C-O). 1H NMR (DMSO-d6), δ: 12.09 (s,
1H, COOH), 10.36 (s, NH), 7.31 (t, J = 7.5 Hz, 1H, phenyl_5 H), 7.20 (d, J = 7.5 Hz,
1H, pheny_4 H), 7.08-7.06 (m, 2H, phenyl_2,6 H), 6.35 (s, 1H, isatin_7 H), 3.97 (s, 3H,
isatin_4 OCH3), 3.84 (s, 3H, isatin_C6 OCH3), 2.85 (t, J = 7.5 Hz, 2H, COOH-CH2CH2), 2.58 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2).
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(isatin C2), 166.6 (isatin C3), 161.5 (isatin C6), 160.1 (isatin C4), 149.2 (phenyl C1),
141.0 (isatin C7a), 131.2 (phenyl C3), 130.3 (phenyl C5), 128.3 (phenyl C6), 127.4
(phenyl C2), 120.9 (phenyl C4), 108.2 (isatin C7), 100.6 (isatin C5), 90.1 (isatin C3a),
56.7 (isatin_4 OCH3), 56.3 (isatin_6 OCH3), 35.0 (COOH-CH2-CH2), 30.3 (COOHCH2-CH2) ppm. EI-MS m/z 355 (M+, 40), 299 (4), 254 (100%), 191 (45). HRMS (ESI)
calcd for C19H18NO6 (MH+), 356.1134; found, 356.1116. HPLC purity: 99.3%,
Rt=35.814 (3% solvent B in solvent A).

3-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenyl)propanoic acid 141

Following the general procedure 6 using 5-bromo-7-methylindoline-2,3-dione 106 (100
mg, 0.416 mmol), 3-(3-boronophenyl)propanoic acid 113 (96.8 mg, 0.499 mmol),
tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.021 mmol) and potassium
phosphate (264.9 mg, 1.248 mmol) and heating for 4 h, the acid 141 was isolated as a
red solid (70 mg, 55%), mp: 238-239 ºC; IR (cm-1): υ 3172 (m, NH), 2989 (m, OH),
1731 (s, C=O), 1696 (s, C=O). 1H NMR (Acetone-d6), δ: 9.94 (s, NH), 7.81 (s, 1H,
isatin_4 H), 7.66 (s, 1H, phenyl_2 H), 7.60 (s, 1H, isatin_6 H), 7.50 (d, J = 7.6 Hz, 1H,
pheny_6 H), 7.40 (t, J = 7.6 Hz, 1H, phenyl_5 H), 7.29 (d, J = 7.6 Hz, 1H, phenyl_4 H),
3.03 (t, J = 7.3 Hz, 2H, COOH-CH2-CH2), 2.71 (t, J = 7.3 Hz, 2H, COOH-CH2-CH2),
2.41 (s, 3H, CH3).

13

C NMR (DMSO-d6), δ: 184.8 (COOH), 173.9 (isatin C3), 160.1

(isatin C2), 148.5 (isatin C7a), 141.7 (phenyl C3), 138.7 (phenyl C1), 137.6 (isatin C6),
134.8 (isatin C5), 128.9 (phenyl C5), 127.4 (phenyl C6), 126.5 (phenyl C2), 123.8
(phenyl C4), 122.1 (isatin C4), 119.8 (isatin C3a), 118.1 (isatin C7), 35.3 (COOH-CH2CH2), 30.4 (COOH-CH2-CH2), 15.5 (CH3) ppm. EI-MS m/z 309 (M+, 100%), 277 (25),
253 (80), 207 (79), 193 (30). HRMS (ESI) calcd for C18H16NO4 (MH+), 310.1079;
found, 310.1071. HPLC purity: 98.1%, Rt=5.339 (1% solvent B in solvent A).
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3-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenyl) propanoic acid 142

Following the general procedure 6 using 5-bromo-4-methoxy-7-methylindoline-2,3dione 112 (100 mg, 0.370 mmol), 3-(3-boronophenyl)propanoic acid 113 (86.1 mg,
0.444 mmol), tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol) and
potassium phosphate (235.6 mg, 1.11 mmol) and heating for 5 h, the acid 142 was
isolated as a red solid (60 mg, 48%), mp: 219-220 ºC; IR (cm-1): υ 3182 (m, NH), 2982
(m, OH), 1749 (s, C=O), 1692 (s, C=O), 1287 (w, C-O). 1H NMR (DMSO-d6), δ: 11.16
(s, NH), 7.40 (s, 1H, isatin_6 H), 7.13 (t, J = 7.4 Hz, 1H, phenyl_5 H), 7.26 (s, 1H,
phenyl_2 H), 7.22 (d, J = 7.4 Hz, 1H, pheny_6 H), 7.19 (d, J = 7.4 Hz, 1H, phenyl_4
H), 3.81 (s, 3H, OCH3), 2.86 (t, J = 7.4 Hz, 2H, COOH-CH2-CH2), 2.56 (t, J = 7.4 Hz,
2H, COOH-CH2-CH2), 2.41 (s, 3H, CH3).

13

C NMR, δ: 182.8 (COOH), 174.5 (isatin

C2), 160.5 (isatin C3), 154.6 (isatin C4), 149.3 (isatin C3a), 142.6 (phenyl C1), 141.5
(isatin C6), 137.4 (phenyl C3), 129.5 (phenyl C2), 129.1 (phenyl C5), 128.8 (isatin C7),
127.7 (phenyl C6), 127.3 (phenyl C4), 116.5 (isatin C5), 110.3 (isatin C3a), 62 (OCH 3),
35.9 (COOH-CH2-CH2), 31.0 (COOH-CH2-CH2), 15.6 (CH3) ppm. EI-MS m/z 339
(M+, 100%), 311 (75), 293 (10), 277 (77). HRMS (ESI) calcd for C19H18NO5 (MH+),
340.1185; found, 340.1187. HPLC purity: 99.4%, Rt=5.579 (1% solvent B in solvent
A).

3-(3-(2,3-Dioxoindolin-5-yl)phenyl)propanoic acid 143

Following the general procedure 6 using 5-bromoindoline-2,3-dione 139 (100mg, 0.442
mmol),

3-(3-boronophenyl)propanoic

acid

113

(102.9

mg,

0.530

mmol),

tetrakis(triphenylphosphine)palladium(0) (25.5 mg, 0.022 mmol) and potassium
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phosphate (281.5 mg, 1.326 mmol) and heating for 4 h, the acid 143 was isolated as an
orange solid (84.8 mg, 65%), mp: 182-183 ºC; IR (cm-1): υ 3185 (m, NH), 2989 (m,
OH), 1714 (s, C=O), 1684 (s, C=O). 1H NMR (DMSO-d6), δ: 11.14 (s, NH), 7.89 (dd, J
= 8.2, 1.8 Hz, 1H, isatin_6 H), 7.77 (d, J = 1.4 Hz, 1H, isatin_4 H), 7.53 (s, 1H,
phenyl_2 H), 7.46 (d, J = 7.6 Hz, 1H, phenyl_4 H), 7.35 (t, J = 7.5 Hz, 1H, phenyl_5
H), 7.21 (d, J = 7.5 Hz, 1H, phenyl_6 H), 6.99 (d, J = 7.9 Hz, 1H, isatin_7 H), 2.88 (t, J
= 7.6 Hz, 2H, COOH-CH2-CH2), 2.59 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2). 13C NMR,
δ: 184.9 (COOH), 174.4 (isatin C3), 160.0 (isatin C2), 150.4 (isatin C7a), 142.2 (phenyl
C3), 139.1 (phenyl C1), 136.9 (isatin C6), 135.4 (isatin C 5), 129.4 (phenyl C5), 127.9
(phenyl C6), 126.7 (phenyl C2), 124.4 (phenyl C4), 122.9 (isatin C4), 118.9 (isatin
C3a), 113.1 (isatin C7), 35.7 (COOH-CH2-CH2), 30.9 (COOH-CH2-CH2) ppm. EI-MS
m/z 295 (M+, 40), 267 (100%), 250 (95), 207 (20), 193 (25). HRMS (ESI) calcd for
C17H14NO4 (MH+), 296.0914; found, 296.0912. HPLC purity: 98.2%, Rt=7.237 (1%
solvent B in solvent A).

General procedure 7: Suzuki coupling of the 5-bromoisatin derivatives 103, 106,
112 and 139 with (3-(cyanomethoxy)phenyl)boronic acid 118:
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1
equiv),

(3-(cyanomethoxy)phenyl)boronic

acid

118

(1

equiv),

tetrakis(triphenylphosphine)palladium(0) (5 mol%), potassium phosphate (3 equiv) and
a mixture of diglyme (3 mL) and water (3 mL), and the reaction mixture was degassed
by flushing N2 through a needle for 10 min. The flask was then sealed and heated at 85
ºC for 5-9 h. After cooling to room temperature, the solvent was concentrated under
reduced pressure, and 1 N HCl (15 mL) was added. The suspended solid was either
collected by filtration or extracted with ethyl acetate (2 x 25 mL). The combined
organic layers were dried (MgSO4) and evaporated under reduced pressure. The
combined residues were adsorbed onto silica and subjected to flash column
chromatography (40% ethyl acetate in petroleum spirit) to yield the acetonitrile
derivative 144-147.
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2-(3-(4,6-Dimethoxy-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile 144

Following the general procedure 7 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 103
(40 mg, 0.139 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (24.6 mg, 0.139
mmol), tetrakis(triphenylphosphine)palladium(0) (8 mg, 0.007 mmol), potassium
phosphate (88.5 mg, 0.417 mmol) and heating for 9 h, the acetonitrile intermediate 144
could not be isolated. Analysis of the crude mixture: EI-MS m/z 338 (M+, 17), 309 (7),
382 (66), 257 (100%), 225 (25). HRMS (ESI) calcd for C18H15N2O5 (MH+), 339.0981;
found, 339.0980. This sample was collected from the reaction mixture before
purification trial. Could not purify and was not stable enough to get NMR data.

2-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile 145

Following the general procedure 7 using 5-bromo-7-methylindoline-2,3-dione 106 (100
mg, 0.416 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (73.6 mg, 0.416 mmol),
tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.021 mmol), potassium phosphate
(264.9 mg, 1.248 mmol) and heating for 5 h, the acetonitrile intermediate 145 was
isolated as a red solid (63.2 mg, 52%), mp: 208-209 ºC; IR (cm-1): υ 3185 (w, NH),
2365 (m, CN), 1750 (s, C=O), 1587 (s, C=O). 1H NMR (Acetone-d6), δ: 10.13 (s, NH),
7.83 (s, 1H, isatin_4 H), 7.68 (s, 1H, isatin_C6), 7.47 (t, J = 7.8 Hz, 1H, phenoxy_5 H),
7.40-7.38 (m, 2H, phenoxy_2,4 H), 7.09 (d, J = 8.0 Hz, 1H, phenoxy_6 H), 5.21 (s, 2H,
CH2), 2.39 (s, 3H, CH3).

13

C NMR, δ: 185.1 (isatin C3), 160.5 (phenoxy C1), 158.6

(isatin C2), 149.8 (isatin C7a), 142.4 (phenoxy C3), 138.9 (isatin C7), 136.4 (isatin C6),
131.3 (isatin C5), 123.3 (phenoxy C5), 121.8 (isatin C4), 121.2 (phenoxy C4), 119.5
(phenoxy C2), 116.7 (phenoxy C6), 115.3 (CN), 114.1 (isatin C3a), 54.7 (CH 2), 15.8
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(CH3) ppm. EI-MS m/z 292 (M+, 93), 264 (80), 236 (100%), 196 (17), 180 (11). HRMS
(ESI) calcd for C17H13N2O3 (MH+), 293.0926; found, 293.0931. HPLC purity: 97.9%,
Rt=13.070 (2.5% solvent C in solvent A).

2-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenoxy) acetonitrile 146

Following the general procedure 7 using 5-bromo-4-methoxy-7-methylindoline-2,3dione 112 (100 mg, 0.370 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (65.5 mg,
0.370 mmol), tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol),
potassium phosphate (235.6 mg, 1.11 mmol) and heating for 8 h, the acetonitrile
intermediate 146 was isolated as a red solid (41.7 mg, 35%), mp: 179-180 ºC; IR (cm-1):
υ 3190 (m, NH), 2166 (w, CN), 1706 (s, C=O), 1611 (s, C=O), 1294 (w, C-O). 1H NMR
(CD3OD), δ: 7.40 (s, 1H, isatin_6 H), 7.38 (t, J = 8.2 Hz, 1H, phenoxy_5 H), 7.12 (d, J
= 8.2 Hz, 1H, phenoxy_4 H), 7.11 (s, 1H, phenoxy_2 H), 7.01 (d, J = 8.3 Hz, 1H,
phenoxy_6 H), 5.00 (s, 2H, CH2), 3.91 (s, 3H, OCH3), 2.22 (s, 3H, CH3). 13C NMR, δ:
160.2 (isatin C3), 156.7 (phenoxy C1), 154.9 (isatin C2), 148.6 (isatin C4), 142.1 (isatin
C7a), 138.9 (isatin C6), 137.8 (phenoxy C3), 129.2 (phenoxy C5), 123.4 (isatin C5),
120.5 (isatin C7), 115.9 (phenoxy C4), 115.7 (phenoxy C6), 115.5 (phenoxy C2), 113.7
(CN), 109.5 (isatin C3a), 61.13 (CH2), 53.3 (OCH3), 13.7 (CH3) ppm. EI-MS m/z 322
(M+, 74), 294 (68), 280 (4), 254 (7), 226 (100%), 211 (11). HRMS (ESI) calcd for
C18H15N2O4 (MH+), 323.1032; found, 323.1018. HPLC purity: 99.5%, Rt=11.766 (2.5%
isopropanol in solvent A).
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2-(3-(2,3-Dioxoindolin-5-yl)phenoxy)acetonitrile 147

Following the general procedure 7 using 5-bromoindoline-2,3-dione 139 (100 mg, 0.442
mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (78.2 mg, 0.442 mmol),
tetrakis(triphenylphosphine)palladium(0) (25.5 mg, 0.022 mmol), potassium phosphate
(281.5 mg, 1.326 mmol) and heating for 5 h, the acetonitrile intermediate 147 was
isolated as a red solid (73.7 mg, 60%), mp: 205-206 ºC; IR (cm-1): υ 3168 (w, NH),
2166 (m, CN), 1732 (s, C=O), 1621 (s, C=O). 1H NMR (Acetone-d6), δ: 10.04 (s, NH),
7.95 (d, J = 8.2, 1H, phenoxy_4 H), 7.83 (s, 1H, phenoxy_2 H), 7.47 (t, J = 8.2 Hz, 1H,
phenoxy_5 H), 7.39-7.38 (m, 2H, isatin_4,7 H), 7.14 (d, J = 8.2 Hz, phenoxy_6 H),
7.09 (d, J = 8.6 Hz, 1H, isatin_6 H), 5.21 (s, 2H, CH2). 13C NMR, δ: 184.1 (isatin C3),
159.6 (phenoxy C1), 157.8 (isatin C2), 150.4 (isatin C7a), 141.5 (phenoxy C3), 137.0
(phenoxy C4), 135.7 (phenoxy C2), 130.6 (phenoxy C5), 123.1 (isatin C5), 121.0 (isatin
C7), 118.9 (phenoxy C6), 116.0 (CN), 114.6 (isatin C3a), 113.1 (isatin C4), 112.9
(isatin C6), 53.8 (CH2) ppm. EI-MS m/z 278 (M+, 46), 250 (100%), 207 (5), 182 (49).
HRMS (ESI) calcd for C16H11N2O3 (MH+), 279.0770; found, 279.0759. HPLC purity:
99.7%, Rt=20.046 (2.5% solvent C in solvent A).

9.1.5. Experimental for chapter 7
General procedure 8: synthesis of compounds 162, 164-166
A solution of 7-nitro-1,2,3,4-tetrahydroquinoline 161 (1.0 g, 5.62 mmol) in dry pyridine
(3 mL) was cooled to 0 ºC. The appropriate sulfonyl chloride (6.18 mmol) was then
added dropwise over 10 min with stirring and the mixture was then allowed to warm to
room temperature and stirred for 24 h. Cold water (20 mL) was added, the resulting
solid or oil was extracted with ethyl acetate (2 x 25 mL). The combined organic layers
were washed with 1 M HCl (2 x 20 mL), brine (10 mL) and dried (MgSO4). The solvent
was then removed under reduced pressure. The resulting residue was subjected to flash
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column chromatography and elution with 20% ethyl acetate in petroleum spirit yielded
the corresponding intermediate.

1-(Ethylsulfonyl)-7-nitro-1,2,3,4-tetrahydroquinoline 162

Following general procedure 8 using ethanesulfonyl chloride (794 mg, 6.18 mmol) gave
the intermediate 162 (1.1 g, 70%) as a yellow solid, mp: 64-65 ºC; IR (cm-1): υ 3139 (w,
C-H aromatic), 2944 (w, C-H aliphatic), 1517 (s, NO2), 1345 (m, SO2), 1333 (m, NO2),
1147 (w, C-N). 1H NMR, δ: 8.49 (s, 1H, H8), 7.86 (d, J = 8.3 Hz, 1H, H6), 7.28 (d, J =
8.3 Hz, 1H, H5), 3.83 (t, J = 6.0 Hz, 2H, H2), 3.22 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.95
(t, J = 6.5 Hz, 2H, H4), 2.07 (p, J = 6.0 Hz, 2H, H3), 1.41 (t, J = 7.5 Hz, 3H, CH3). 13C
NMR, δ: 146.7 (C8a), 137.9 (C7), 135.7 (C5), 130.4 (C4a), 118.3 (C6), 116.8 (C8), 47.1
(ethyl CH2), 46.4 (C2), 27.6 (C4), 22.1 (C3), 8.0 (CH3) ppm. EI-MS m/z 270 (M+, 55),
177 (90), 131 (100%). HRMS (ESI) calcd for C11H15N2O4S (MH+), 271.0753; found,
271.0744.

7-Nitro-1-(propylsulfonyl)-1,2,3,4-tetrahydroquinoline 164

Following general procedure 8 using propane-1-sulfonyl chloride (880.5 mg, 6.18
mmol) gave the intermediate 164 (1.28 g, 80%) as a yellow solid, mp: 79-80 ºC; IR (cm1

): υ 3128 (w, C-H aromatic), 2972 (w, C-H aliphatic), 1517 (s, NO2), 1346 (m, SO2),

1332 (m, NO2), 1143 (w, C-N). 1H NMR, δ: 8.51 (s, 1H, H8), 7.86 (d, J = 8.3 Hz, 1H,
H6), 7.28 (d, J = 8.4 Hz, 1H, H5), 3.83 (t, J = 5.8 Hz, 2H, H2), 3.13 (t, J = 7.7 Hz, 2H,
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propyl_1 CH2), 2.95 (t, J = 6.4 Hz, 2H, H4), 2.07 (p, J = 5.9 Hz, 2H, H3), 1.89 (sex, J =
7.6 Hz, 2H, propyl_2 CH2), 1.06 (t, J = 7.4 Hz, 3H, CH3).

13

C NMR, δ: 146.7 (C8a),

137.9 (C7), 135.8 (C5), 130.4 (C4a), 118.3 (C6), 116.8 (C8), 54.3 (propyl C1), 46.3
(C2), 27.6 (C4), 22.1 (C3), 17.1 (propyl C2), 12.9 (CH3) ppm. EI-MS m/z 284 (M+, 54),
178 (92), 131 (100%). HRMS (ESI) calcd for C12H17N2O4S (MH+), 285.0909; found,
285.0916.

7-Nitro-1-(thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinoline 165

Following general procedure 8 using thiophene-2-sulfonyl chloride (1.13 g, 6.18 mmol)
gave the intermediate 165 (1.52 g, 84%) as an orange solid, mp: 130-131 ºC; IR (cm-1):
υ 3139 (w, C-H aromatic), 2966 (w, C-H aliphatic), 1515 (s, NO2), 1341 (m, SO2), 1292
(m, NO2), 1160 (w, C-N). 1H NMR, δ: 8.72 (s, 1H, H8), 7.91 (d, J = 8.4 Hz, 1H, H6),
7.56 (d, J = 4.8 Hz, 1H, thiophene_5 H), 7.52 (d, J = 3.1 Hz, 1H, thiophene_3 H), 7.21
(d, J = 8.4 Hz, 1H, H5), 7.06 (t, J = 4.4 Hz, 1H, thiophene_4 H), 3.89 (t, J = 6.2 Hz, 2H,
H2), 2.66 (t, J = 6.5 Hz, 2H, H4), 1.80 (p, J = 6.2 Hz, 2H, H3).

13

C NMR, δ: 146.7

(C8a), 138.9 (thiophene C1), 137.5 (C7), 137.2 (C5), 133.0 (thiophene C3), 132.9
(C4a), 129.9 (thiophene C4), 127.6 (thiophene C5), 119.4 (C6), 119.3 (C8), 46.6 (C2),
27.3 (C4), 21.2 (C3) ppm. EI-MS m/z 324 (M+, 10), 243 (9), 214 (17), 177 (15), 131
(100%). HRMS (ESI) calcd for C13H13N2O4S2 (MH+), 325.0317; found, 325.0325.

255

Chapter 9

Experimental

7-Nitro-1-tosyl-1,2,3,4-tetrahydroquinoline 166

Following general procedure 8 using 4-methylbenzenesulfonyl chloride (1.18 g, 6.18
mmol) gave the intermediate 166 (1.64 g, 88%) as a yellow crystalline solid, mp: 133134 ºC; IR (cm-1): υ 3136 (m, C-H aromatic), 2949 (m, C-H aliphatic), 1510 (s, NO2),
1340 (m, SO2), 1334 (w, NO2), 1163 (w, C-N). 1H NMR, δ: 8.68 (s, 1H, H8), 7.87 (dd,
J = 8.4, 2.1 Hz, 1H, H6), 7.57 (d, J = 8.3 Hz, 2H, tosyl_2,6 H), 7.25 (d, J = 8.1 Hz, 2 H,
tosyl_3,5 H), 7.17 (d, J = 8.4 Hz, 1H, H5), 3.85 (t, J = 6.0 Hz, 2H, H2), 2.64 (t, J = 6.5
Hz, 2H, H4), 2.40 (s, 3H, CH3), 1.75 (p, J = 6.5 Hz, 2H, H3). 13C NMR, δ: 146.6 (C8a),
144.4 (C7), 137.8 (tosyl C4), 137.0 (tosyl C1), 136.1 (C5), 129.93 (C4a), 129.90 (tosyl
C3, C5), 127.2 (tosyl C2, C6), 118.9 (C6), 118.8 (C8), 46.3 (C2), 27.2 (C4), 21.6 (C3),
21.1 (CH3) ppm. EI-MS m/z 332 (M+, 70), 268 (46), 251 (49), 177 (70), 130 (100%).
HRMS (ESI) calcd for C16H17N2O4S (MH+), 333.0909; found, 333.0900.

General procedure 9: synthesis of compounds 163, 167-169
A solution of the appropriate sulfonamide 162, 164-166 (1 equiv) and Raney Ni (0.05
equiv) in methanol (20 mL) was stirred at room temperature under a N2 atmosphere. A
solution of hydrazine hydrate (1.2 equiv) in methanol (10 mL) was then added dropwise
and stirring continued for 10 min, after which the H2 gas ceased to evolve, and the
reaction mixture was then heated at reflux for 4-6 h. The mixture was then filtered hot
through a short pad of celite, and the filterate was concentrated under reduced pressure.
The resulting residues were recrystallised either from methanol or toluene (80-90%).
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7-Amino-1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinoline 163

Following

the

general

procedure

9

using

1-(ethylsulfonyl)-7-nitro-1,2,3,4-

tetrahydroquinoline 162 (1.1 g, 4.07 mmol), hydrazine hydrate (244 mg, 4.884 mmol)
and heating for 4 h, the amine intermediate 163 was obtained by recrystallisation from
methanol as a white solid (763 mg, 78%), mp: 65-66 ºC; IR (cm-1): υ 3358 (w, C-H
aromatic), 2943 (w, C-H aliphatic), 1323 (m, SO2), 1143 (w, C-N). 1H NMR, δ: 7.07 (s,
1H, H8), 6.88 (d, J = 8.0 Hz, 1H, H6), 6.40 (d, J = 8.0 Hz, 1H, H5), 3.78 (t, J = 6.0 Hz,
2H, H2), 3.62 (s, br, NH2), 3.10 (q, J = 7.3 Hz, 2H, ethyl CH2), 2.73 (t, J = 6.4 Hz, 2H,
H4), 1.95 (p, J = 6.0 Hz, 2H, H3), 1.33 (t, J = 7.3 Hz, 3H, CH3).

13

C NMR, δ: 145.4

(C7), 137.9 (C8a), 130.6 (C5), 118.7 (C4a), 111.7 (C6), 108.3 (C8), 46.9 (ethyl C1),
46.2 (C2), 26.7 (C4), 23.1 (C3), 8.2 (CH3) ppm. EI-MS m/z 240 (M+, 30), 147 (100%),
130 (49). HRMS (ESI) calcd for C11H17N2O2S (MH+), 241.1011; found, 241.1005.

7-Amino-1-(propylsulfonyl)-1,2,3,4-tetrahydroquinoline 167

Following

the

general

procedure

9

using

7-nitro-1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinoline 164 (1.2 g, 4.22 mmol), hydrazine hydrate (253 mg, 5.064 mmol)
and heating for 4 h, the amine intermediate 167 was obtained by recrystallisation from
methanol as an orange solid (808 mg, 75%), mp: 86-87 ºC; IR (cm-1): υ 3358 (m, NH2),
2941 (w, C-H aliphatic), 1327 (m, SO2), 1139 (m, C-N). 1H NMR, δ: 7.07 (s, 1H, H8),
6.88 (d, J = 8.1 Hz, 1H, H6), 6.40 (d, J = 7.8 Hz, 1H, H5), 3.77 (t, J = 5.8 Hz, 2H, H2),
3.65 (s, br, NH2), 3.02 (t, J = 7.4 Hz, 2H, propyl_1 CH2), 2.71 (t, J = 6.3 Hz, 2H, H4),
1.93 (p, J = 6.0 Hz, 2H, H3), 1.83 (sex, J = 7.5 Hz, 2H, propyl_2 CH2), 1.00 (t, J = 7.4
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13

C NMR, δ: 145.2 (C8), 137.6 (C8a), 130.4 (C5), 118.4 (C4a), 111.5

(C6), 108.2 (C8), 53.3 (propyl C1), 46.6 (C1), 26.5 (C4), 22.8 (C3), 17.0 (propyl C2),
13.0 (CH3) ppm. ESI-MS m/z 255.2 (M+H). HRMS (ESI) calcd for C12H19N2O2S
(MH+), 255.1167; found, 255.1156.

7-Amino-1-(thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinoline 168

Following the general procedure 9 using 7-nitro-1-(thiophen-2-ylsulfonyl)-1,2,3,4tetrahydroquinoline 165 (1.0 g, 3.09 mmol), hydrazine hydrate (185 mg, 3.708 mmol)
and heating for 6 h, the amine intermediate 168 was obtained by recrystallisation from
toluene as a yellow solid (762 mg, 84%), mp: 78-79 ºC; IR (cm-1): υ 3363 (w, NH2),
3092 (w, C-H aromatic), 2937 (w, C-H aliphatic), 1337 (m, SO2), 1153 (w, C-N). 1H
NMR, δ: 7.49 (d, J = 4.4 Hz, 1H, thiophene_5 H), 7.38 (d, J = 3.8 Hz, 1H, thiophene_3
H), 7.19 (s, 1H, H8), 6.99 (t, J = 4.5 Hz, 1H, thiophene_4 H), 6.80 (d, J = 8.0 Hz, 1H,
H5), 6.46 (dd, J = 8.0, 2.1 Hz, 1H, H6), 3.80 (t, J = 6.0 Hz, 2H, H2), 3.67 (s, br, NH2)
2.38 (t, J = 6.5 Hz, 2H, H4), 1.63 (p, J = 6.3 Hz, 2H, H3).

13

C NMR, δ: 144.9 (C7),

139.6 (C8a), 136.8 (thiophene C1), 131.9 (thiophene C3), 131.8 (C4a), 129.8 (C5),
127.2 (thiophene C4), 120.7 (thiophene C5), 112.8 (C6), 111.4 (C8), 47.1 (C2), 25.9
(C4), 21.5 (C3) ppm. EI-MS m/z 294 (M+, 47), 230 (100%), 145 (52), 130 (65). HRMS
(ESI) calcd for C13H15N2O2S2 (MH+), 295.0575; found, 295.0562.
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7-Amino-1-tosyl-1,2,3,4-tetrahydroquinoline 169

Following the general procedure 9 using 7-nitro-1-tosyl-1,2,3,4-tetrahydroquinoline 166
(1.0 g, 3.01 mmol), hydrazine hydrate (180.6 mg, 3.612 mmol) and heating for 6 h, the
amine intermediate 169 was obtained by recrystallisation from toluene as a yellow
crystalline solid (773 mg, 85%), mp: 89-90 ºC (Lit.266 m.p: 109-110 ºC); IR (cm-1): υ
3353 (w, NH2), 2949 (w, C-H aliphatic), 1339 (m, SO2), 1156 (w, C-N). 1H NMR, δ:
7.50 (d, J = 8.1 Hz, 2H, tosyl_3,5 H), 7.20 (s, 1H, H8), 7.18 (d, J = 8.1 Hz, 2H,
tosyl_2,6 H), 6.76 (d, J = 8.1 Hz, 1H, H5), 6.44 (dd, J = 8.0, 2.1 Hz, 1H, H6), 3.76 (t, J
= 5.9 Hz, 2H, H2), 3.64 (s, br, NH2), 2.37 (s, 3H, CH3), 2.33 (t, J = 6.4 Hz, 2H, H4),
1.55 (p, J = 6.1 Hz 2H, H3).

13

C NMR, δ: 144.9 (C7), 143.4 (C8a), 137.4 (tosyl C4),

136.9 (tosyl C1), 129.5 (C5), 127.13 (C4a), 127.07 (tosyl C3, C5), 120.4 (tosyl C2, C6),
112.5 (C6), 111.2 (C8), 46.7 (C2), 25.8 (C4), 21.59 (C3), 21.51 (CH 3) ppm. EI-MS m/z
302 (M+, 55), 238 (46), 147 (100%), 130 (75). HRMS (ESI) calcd for C 16H19N2O2S
(MH+), 303.1167; found, 303.1156.

General procedure 10: synthesis of compounds 160, 170-194
A solution of the appropriate amine intermediate 163, 167-169 (1 mmol) in dry pyridine
(2 mL) was cooled at 0 ºC. The appropriate sulfonyl chloride (1.2 mmol) was added
portion wise over a 10 min period with stirring. The reaction mixture was then allowed
to warm to room temperature and stirred for 6 h. Cold water (5 mL) was then added and
the resulting solid or oil was extracted with ethyl acetate (2 x 10 mL). The combined
organic layers were washed with 1 M HCl (2 x 10 mL), brine (10 mL) and dried
(MgSO4). The solvent was then concentrated under reduced pressure and the resulting
residues were subjected to flash column chromatography (30% ethylacetate in
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petroleum spirit) to yield the corresponding bis-sulfonamides 160 and 170-194 (7080%).

N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2-fluorobenzenesulfonamide 160

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 2-fluorobenzenesulfonyl chloride (233.5 mg), 160
was isolated as a colourless solid (282.6 mg, 71%), mp: 108-109 ºC; IR (cm-1): υ 3223
(m, NH), 2949 (w, C-H aliphatic), 1472 (w, C-F), 1329 (m, SO2), 1135 (w, C-N). 1H
NMR, δ: 7.86 (t, J = 6.9 Hz, 1H, benzene_4 H), 7.53 (q, J = 6.8 Hz, 1H, benzene_3 H),
7.42 (s, br, NH), 7.26-7.17 (m, 2H, benzene_5,6 H), 6.96 (d, J = 8.2 Hz, 1H,
tetrahydroquinoline_6 H), 6.92 (s, 1H, tetrahydroquinoline_8 H), 6.86 (d, J = 8.2 Hz,
1H, tetrahydroquinoline_5 H), 3.73 (t, J = 6.0 Hz, 2H, tetrahydroquinoline_2 CH2),
3.03 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.73 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4
CH2), 1.92 (p, J = 6.3 Hz, 2H, tetrahydroquinoline_3 CH2), 1.27 (t, J = 7.4 Hz, 3H,
CH3).

13

C NMR, δ: 159.6 (d, J = 254.9 Hz, benzene C2), 137.7 (tetrahydroquinoline

C8a), 135.4 (d, J = 8.4 Hz, benzene C3), 134.4 (tetrahydroquinoline C7), 131.1
(tetrahydroquinoline C5), 130.1 (benzene C5), 126.4 (d, J = 13.0 Hz, benzene C1),
125.6 (benzene C6), 124.5 (d, J = 3.7 Hz, benzene C4), 117.1 (tetrahydroquinoline
C4a),

116.7 (tetrahydroquinoline C6),

114.2 (tetrahydroquinoline

C8),

46.5

(tetrahydroquinoline C2), 46.4 (ethyl CH2), 26.7 (tetrahydroquinoline C4), 22.4
(tetrahydroquinoline C3), 8.0 (CH3) ppm. EI-MS m/z 398 (M+, 50), 305 (45), 159 (15),
145 (100%). HRMS (ESI) calcd for C17H20FN2O4S2 (MH+), 399.0849; found,
399.0862. HPLC purity: 99.4%, Rt=12.672 (20% solvent D in solvent A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-4-fluorobenzenesulfonamide 170

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg 1.0 mmol), 4-fluorobenzenesulfonyl chloride (233.5 mg), 170 was
isolated as a colourless solid (286.6 mg, 72%), mp: 90-91 ºC; IR (cm-1): υ 3276 (m,
NH), 2955 (w, C-H aliphatic), 1456 (w, C-F), 1327 (m, SO2), 1166 (w, C-N). 1H NMR,
δ: 7.84 (dd, J = 8.2, 5.2 Hz, 2H, benzene_3,5 H), 7.35 (s, 1H, tetrahydroquinoline_8 H),
7.12 (s, br, NH), 7.09 (d, J = 8.2 Hz, 2H, benzene_2,6 H), 6.99 (d, J = 8.2 Hz, 1H,
tetrahydroquinoline_5 H), 6.86 (d, J = 8.1 Hz, 1H, tetrahydroquinoline_6 H), 3.75 (t, J
= 6.0 Hz, 2H, tetrahydroquinoline_2 H), 3.05 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.76 (t, J
= 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.96 (p, J = 6.0 Hz, 2H, tetrahydroquinoline_3
H), 1.27 (t, J = 7.4 Hz, 3H, CH3). 13C NMR, δ: 165.5 (d, J = 266.4 Hz, benzene C4),
138.1 (tetrahydroquinoline C8a), 135.4 (d, J = 13.8 Hz, benzene C2, C6), 135.2
(tetrahydroquinoline C7), 130.9 (tetrahydroquinoline C4a), 130.6 (d, J = 10.1 Hz,
benzene C1), 125.8 (tetrahydroquinoline C5), 117.0 (d, J = 90.3 Hz, benzene C3, C5),
116.5

(tetrahydroquinoline

C8),

114.6

(tetrahydroquinoline

C6),

46.9

(tetrahydroquinoline C2), 46.8 (ethyl CH2), 27.0 (tetrahydroquinoline C4), 22.8
(tetrahydroquinoline C3), 8.3 (CH3) ppm. EI-MS m/z 398 (M+, 17), 305 (10), 159 (20),
145 (65), 95 (100%). HRMS (ESI) calcd for C17H20FN2O4S2 (MH+), 399.0849; found,
399.0846. HPLC purity: 97.3%, Rt=4.416 (20% solvent D in solvent A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-3-fluorobenzenesulfonamide 171

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 3-fluorobenzenesulfonyl chloride (233.5 mg), 171
was isolated as a pale yellow solid (274 mg, 69%), mp: 91-92 ºC; IR (cm-1): υ 3272 (m,
NH), 2955 (m, C-H aliphatic), 1451 (w, C-F), 1327 (m, SO2), 1144 (w, C-N). 1H NMR,
δ: 7.64 (d, J = 7.6 Hz, 1H, benzene_2 H), 7.50 (d, J = 7.6 Hz, 1H, benzene_6 H), 7.447.40 (m, 2H, benzene_4,5 H), 7.37 (s, 1H, tetrahydroquinoline_8 H), 7.21 (t, J = 8.1
Hz, 1H, benzene_5 H), 6.99 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.89 (d, J =
8.1 Hz, 1H, tetrahydroquinoline_6 H), 3.74 (t, J = 5.5 Hz, 2H, tetrahydroquinoline_2
H), 3.06 (q, J = 7.2 Hz, 2H, ethyl CH2), 2.75 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_4
H), 1.95 (p, J = 5.5 Hz, 2H, tetrahydroquinoline_3 H), 1.27 (t, J = 7.2 Hz, 3H, CH3).
13

C NMR, δ: 162.5 (d, J = 251.2 Hz, benzene C3), 141.3 (d, J = 6.5 Hz, benzene C1),

137.8 (tetrahydroquinoline C8a), 135.1 (tetrahydroquinoline C7), 131.2 (d, J = 7.5 Hz,
benzene C5), 130.8 (tetrahydroquinoline C5), 125.8 (tetrahydroquinoline C4a), 123.5
(d, J = 3.7 Hz, benzene C6), 120.4 (d, J = 21.4 Hz, benzene C4), 117.5
(tetrahydroquinoline

C6),

115.0

(d,

J

=

25.1

Hz,

benzene

C2),

114.7

(tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 46.7 (ethyl CH 2), 26.9
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 8.2 (CH 3) ppm. EI-MS m/z
398 (M+, 33), 305 (33), 159 (10), 145 (80), 118 (60), 95 (100%). HRMS (ESI) calcd for
C17H20FN2O4S2 (MH+), 399.0849; found, 399.0837. HPLC purity: 99.3%, Rt=10.956
(20% solvent D in solvent A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2,6-difluorobenzenesulfonamide
172

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 2,6-difluorobenzenesulfonyl chloride (255 mg), 172
was isolated as a white solid (295 mg, 71%), mp: 118-119 ºC; IR (cm-1): υ 3245 (m,
NH), 2942 (w, C-H aliphatic), 1467 (w, C-F), 1318 (m, SO2), 1139 (w, C-N). 1H NMR
(CD3OD), δ: 7.62-7.54 (m, 1H, benzene_4 H), 7.47 (s, 1H, tetrahydroquinoline_8 H),
7.07 (t, J = 9.0 Hz,

2H, benzene_3,5 H), 7.02 (d, J = 8.2 Hz,

1H,

tetrahydroquinoline_5 H), 6.87 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.71 (t, J
= 5.8 Hz, 2H, tetrahydroquinoline_2 H), 3.09 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.75 (t, J
= 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.93 (p, J = 6.4 Hz, 2H, tetrahydroquinoline_3
H), 1.23 (t, J = 7.3 Hz, 3H, CH3). 13C NMR (CD3OD), δ: 160.0 (dd, J = 256.5, 3.8 Hz,
benzene C2, C6), 139.5 (tetrahydroquinoline C8a), 137.9 (tetrahydroquinoline C7),
135.2 (t, J = 10.9 Hz, benzene C1), 130.2 (benzene C4), 125.7 (tetrahydroquinoline
C5), 117.1 (tetrahydroquinoline C4a), 116.5 (tetrahydroquinoline C6), 114.0
(tetrahydroquinoline C8), 113.0 (dd, J = 23.3, 3.4 Hz, benzene C3, C5), 46.4
(tetrahydroquinoline C2), 46.0 (ethyl CH2), 26.4 (tetrahydroquinoline C4), 22.4
(tetrahydroquinoline C3), 7.0 (CH3) ppm. EI-MS m/z 416 (M+, 30), 323 (27), 177 (20),
145 (100%), 118 (82). HRMS (ESI) calcd for C17H19F2N2O4S2 (MH+), 417.0754;
found, 417.0742. HPLC purity: 99.3%, Rt=18.012 (15% solvent D in solvent A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2,3,4,5,6-pentafluoro
benzenesulfonamide 173

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (319.8
mg), 173 was isolated as a white solid (348 mg, 74%), mp: 122-123 ºC; IR (cm-1): υ
3201 (m, NH), 2947 (w, C-H aliphatic), 1464 (m, C-F), 1324 (m, SO2), 1143 (w, C-N).
1

H NMR, δ: 7.39 (s, br, NH), 7.32 (s, 1H, tetrahydroquinoline_8 H), 7.06 (d, J = 8.2 Hz,

1H, tetrahydroquinoline_5 H), 6.92 (dd, J = 8.5, 1.9 Hz, 1H, tetrahydroquinoline_6 H),
3.74 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2), 3.12 (q, J = 7.4 Hz, 2H, ethyl CH2),
2.79 (t, J = 6.6 Hz, 2H, tetrahydroquinoline_4 H), 1.97 (p, J = 6.1 Hz, 2H,
tetrahydroquinoline_3 H), 1.34 (t, J = 7.4 Hz, 3H, CH3). 13C NMR, δ: 145.1 (ddd, J =
259.2, 12.1, 4.7 Hz, benzene C4), 144.6 (dt, J = 263.3, 13.1 Hz, benzene C2, C6), 138.3
(dt, J = 258.6, 12.1 Hz, benzene C3, C5), 138.2 (tetrahydroquinoline C8a), 137.5 (d, J
= 117.2 Hz, benzene C1), 133.4 (tetrahydroquinoline C7), 131.2 (tetrahydroquinoline
C5), 127.2 (tetrahydroquinoline C4a), 117.8 (tetrahydroquinoline C6), 115.0
(tetrahydroquinoline C8), 47.2 (tetrahydroquinoline C2), 46.7 (ethyl CH 2), 27.0
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 8.2 (CH 3) ppm. 19F NMR, δ: 136.6 (2F), -145.0, -158.6 (2F). ESI-MS m/z 469.2 (M-H). HRMS (ESI) calcd for
C17H16F5N2O4S2 (MH+), 471.0472; found, 471.0452. HPLC purity: 95.3%, Rt=6.211
(20% solvent D in solvent A).
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4-Bromo-N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2-fluoro
benzenesulfonamide 174

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 4-bromo-2-fluorobenzenesulfonyl chloride (328.2
mg), 174 was isolated as a red solid (328 mg, 69%), mp: 138-139 ºC; IR (cm-1): υ 3244
(w, NH), 2967 (w, C-H aliphatic), 1471 (w, C-F), 1314 (m, SO2), 1130 (w, C-N). 1H
NMR, δ: 7.73 (t, J = 7.9 Hz, 1H, benzene_3 H), 7.40-7.37 (m, 3H, benzene_5,6,
tetrahydroquinoline_8 H), 6.99 (d, J = 8.1 Hz, 1H, tetrahydroquinoline_5 H), 6.87 (s,
br, NH), 6.84 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.74 (t, J = 5.7 Hz, 2H,
tetrahydroquinoline_2 H), 3.03 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.75 (t, J = 6.4 Hz, 2H,
tetrahydroquinoline_4 H), 1.94 (p, J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.29 (t, J
= 7.3 Hz, 3H, CH3).

13

C NMR, δ: 157.5 (d, J = 259.6 Hz, benzene C2), 138.0

(tetrahydroquinoline C8a), 134.1 (tetrahydroquinoline C7), 132.3 (tetrahydroquinoline
C5), 130.7 (tetrahydroquinoline C4a), 129.0 (d, J = 9.3 Hz, benzene C6), 128.2 (d, J =
3.7 Hz, benzene C5), 126.2 (d, J = 14.0 Hz, benzene C1), 126.1 (benzene C5), 120.8 (d,
J = 24.2 Hz, benzene C3), 117.3 (tetrahydroquinoline C6), 114.5 (tetrahydroquinoline
C8), 46.6 (tetrahydroquinoline C2, ethyl CH2), 26.9 (tetrahydroquinoline C4), 22.5
(tetrahydroquinoline C3), 8.1 (CH3) ppm. EI-MS m/z 476 (M+79Br, 9), 385 (8), 237
(11), 189 (6), 173 (12), 145 (100%). HRMS (ESI) calcd for C 17H1979BrFN2O4S2 (MH+),
476.9959; found, 476.9958. HPLC purity: 97.4%, Rt=6.907 (20% solvent D in solvent
A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)thiophene-2-sulfonamide 175

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), thiophene-2-sulfonyl chloride (219 mg), 175 was
isolated as a red solid (247 mg, 64%), mp: 80-81 ºC; IR (cm-1): υ 3276 (w, NH), 2942
(m, C-H aliphatic), 1332 (m, SO2), 1123 (w, C-N). 1H NMR, δ: 7.58 (d, J = 3.5 Hz, 1H,
thiophene_5 H), 7.54 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.38 (s, 1H,
tetrahydroquinoline_8 H), 7.04-7.01 (m, 2H, thiophene_4 H, tetrahydroquinoline_5 H),
6.91 (d, J = 7.5 Hz, 1H, tetrahydroquinoline_6 H), 6.65 (s, br, NH), 3.76 (t, J = 6.0 Hz,
2H, tetrahydroquinoline_2 H), 3.06 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.78 (t, J = 6.4 Hz,
2H, tetrahydroquinoline_4 H), 1.94 (p, J = 6.0 Hz, 2H, tetrahydroquinoline_3 H), 1.30
(t, J = 7.5 Hz, 3H, CH3). 13C NMR, δ: 139.4 (thiophene C2), 137.5 (tetrahydroquinoline
C8a), 134.9 (tetrahydroquinoline C7), 133.1 (tetrahydroquinoline C5), 132.4 (thiophene
C4), 130.5 (thiophene C3), 127.4 (thiophene C5), 125.6 (tetrahydroquinoline C4a),
117.2

(tetrahydroquinoline

C6),

114.4

(tetrahydroquinoline

C8),

46.5

(tetrahydroquinoline C2), 46.4 (ethyl CH2), 26.7 (tetrahydroquinoline C4), 22.4
(tetrahydroquinoline C3), 7.9 (CH3) ppm. EI-MS m/z 386 (M+, 20), 322 (20), 293 (11),
229 (29), 145 (96), 118 (100%), 99 (33). HRMS (ESI) calcd for C 15H19N2O4S3 (MH+),
387.0507; found, 387.0504. HPLC purity: 97.5%, Rt=5.716 (20% solvent D in solvent
A).
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5-Bromo-N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)thiophene-2-sulfonamide
176

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 5-bromothiophene-2-sulfonyl chloride (313.8 mg),
176 was isolated as red solid (315 mg, 68%), mp: 82-83 ºC; IR (cm-1): υ 3192 (w, NH),
2958 (m, C-H aliphatic), 1326 (m, SO2), 1152 (w, C-N), 635 (w, C-Br). 1H NMR, δ:
7.41 (d, J = 1.5 Hz, 1H, tetrahydroquinoline_8 H), 7.33 (d, J = 4.1 Hz, 1H, thiophene_4
H), 7.27 (s, br, NH), 7.04 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.98 (d, J = 3.9
Hz, 1H, thiophene_3 H), 6.94 (dd, J = 8.4, 1.6 Hz, 1H, tetrahydroquinoline_6 H), 3.77
(t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.10 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.79
(t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.98 (p, J = 5.9 Hz, 2H,
tetrahydroquinoline_3 H), 1.31 (t, J = 7.4 Hz, 3H, CH3). 13C NMR, δ: 140.2 (thiophene
C2), 137.7 (tetrahydroquinoline C8a), 134.5 (tetrahydroquinoline C7), 133.3 (thiophene
C4), 130.7 (tetrahydroquinoline C5), 130.5 (thiophene C3), 125.9 (tetrahydroquinoline
C4a), 120.3 (tetrahydroquinoline C6), 117.3 (thiophene C5), 114.4 (tetrahydroquinoline
C8), 46.5 (tetrahydroquinoline C2, ethyl CH2), 26.8 (tetrahydroquinoline C4), 22.5
(tetrahydroquinoline C3), 8.0 (CH3) ppm. EI-MS m/z 466 (M+ 79Br, 81Br, 10), 400 (12),
321 (12), 307 (11), 227 (35), 145 (97), 118 (100%), 91 (32). HRMS (ESI) calcd for
C15H1879BrN2O4S3 (MH+), 464.9612; found, 464.9617. HPLC purity: 98.0%, Rt=3.968
(20% solvent D in solvent A).
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5-Chloro-N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl) thiophene-2-sulfonamide
177

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 5-chlorothiophene-2-sulfonyl chloride (260.4 mg),
177 was isolated as a yellow oil (277 mg, 66%), IR (cm-1): υ 3195 (w, NH), 2941 (w, CH aliphatic), 1328 (s, SO2), 1155 (w, C-N). 1H NMR, δ: 7.48 (s, br, NH), 7.43 (s, 1H,
tetrahydroquinoline_8 H), 7.38 (d, J = 3.8 Hz, 1H, thiophene_4 H), 7.04 (d, J = 8.3 Hz,
1H, tetrahydroquinoline_5 H), 6.94 (d, J = 7.9 Hz, 1H, tetrahydroquinoline_6 H), 6.83
(d, J = 3.8 Hz, 1H, thiophene_3 H), 3.77 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H),
3.12 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.79 (t, J = 6.3 Hz, 2H, tetrahydroquinoline_4 H),
1.97 (p, J = 5.8 Hz, 2H, tetrahydroquinoline_3 H), 1.30 (t, J = 7.3 Hz, 3H, CH3). 13C
NMR,

δ:

137.7

(thiophene

C2),

137.5

(tetrahydroquinoline

C8a),

137.4

(tetrahydroquinoline C7), 134.6 (thiophene C3), 132.7 (thiophene C4), 130.7
(tetrahydroquinoline C5), 126.9 (tetrahydroquinoline C4a), 125.9 (thiophene C5), 117.3
(tetrahydroquinoline C6), 114.4 (tetrahydroquinoline C8), 46.6 (tetrahydroquinoline C2,
ethyl CH2), 26.8 (tetrahydroquinoline C4), 22.5 (tetrahydroquinoline C3), 8.0 (CH 3)
ppm. EI-MS m/z 420 (M+

35

Cl, 10), 356 (12), 263 (30), 227 (27), 181 (24), 145 (97),

118 (100%). HRMS (ESI) calcd for C15H1835ClN2O4S3 (MH+), 421.0117; found,
421.0107. HPLC purity: 99.6%, Rt=7.798 (20% solvent D in solvent A).
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N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-4-methylbenzenesulfonamide 178

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride (228.7 mg), 178
was isolated as a colourless solid (287 mg, 73%), mp: 74-75 ºC; IR (cm-1): υ 3274 (m,
NH), 2939 (w, C-H aliphatic), 1320 (s, SO2), 1124 (w, C-N). 1H NMR, δ: 7.71 (d, J =
7.5 Hz, 2H, benzene_2,6 H), 7.33 (s, 1H, tetrahydroquinoline_8 H), 7.23 (d, J = 7.9 Hz,
2H, benzene_3,5 H), 6.98 (d, J = 5.5 Hz, 1H, tetrahydroquinoline_5 H), 6.87 (d, J = 5.5
Hz, 1H, tetrahydroquinoline_6), 6.85 (s, br, NH), 3.74 (t, J = 5.5 Hz, 2H,
tetrahydroquinoline_2 H), 3.03 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.75 (t, J = 6.4 Hz, 2H,
tetrahydroquinoline_4 H), 2.37 (s, 3H, p-CH3), 1.94 (p, J = 6.1 Hz,
tetrahydroquinoline_3 H), 1.27 (t, J = 7.1 Hz, 3H, CH3).
(tetrahydroquinoline C8a),

137.9 (benzene

C4),

13

2H,

C NMR, δ: 144.1

136.6 (benene C1),

135.5

(tetrahydroquinoline C7), 130.8 (tetrahydroquinoline C5), 130.0 (benzene C3, C5),
127.8 (benzene C2, C6), 125.4 (tetrahydroquinoline C4a), 117.3 (tetrahydroquinoline
C6), 114.3 (tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 46.7 (ethyl CH 2),
27.1 (tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 21.9 (benzene_4 CH 3),
8.3 (CH3) ppm. EI-MS m/z 394 (M+, 15), 301 (9), 237 (5), 145 (90), 118 (55), 91
(100%). HRMS (ESI) calcd for C18H23N2O4S2 (MH+), 395.1099; found, 395.1096.
HPLC purity: 98.9%, Rt=10.216 (20% solvent D in solvent A).

N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)ethanesulfonamide 179

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), ethanesulfonyl chloride (154.2 mg), 179 was isolated
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as a colourless oil (199 mg, 60%), IR (cm-1): υ 3260 (m, NH), 2943 (w, C-H aliphatic),
1322 (s, SO2), 1139 (w, C-N).

1

H NMR, δ: 7.50 (d, J = 1.7 Hz, 1H,

tetrahydroquinoline_8 H), 7.32 (s, br, NH), 7.06 (d, J = 8.2 Hz, 1H,
tetrahydroquinoline_5 H), 6.98 (dd, J = 8.2, 1.9 Hz, 1H, tetrahydroquinoline_6 H), 3.78
(t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.21 (q, J = 7.4 Hz, 2H, ethylsulfonyl
CH2), 3.15 (q, J = 7.4 Hz, 2H, ethanesulfonamide CH2), 2.80 (t, J = 6.5 Hz, 2H,
tetrahydroquinoline_4 H), 2.00 (p, J = 6.4 Hz, 2H, tetrahydroquinoline_3 H), 1.36 (t, J
= 7.3 Hz, 3H, ethylsulfonyl CH3), 1.35 (t, J = 7.4 Hz, 3H, ethanesulfonamide CH3). 13C
NMR, δ: 137.8 (tetrahydroquinoline C8a), 135.6 (tetrahydroquinoline C7), 130.6
(tetrahydroquinoline C5), 124.9 (tetrahydroquinoline C4a), 116.0 (tetrahydroquinoline
C6), 113.5 (tetrahydroquinoline C8), 46.9 (tetrahydroquinoline C2), 46.5 (ethylsulfonyl
CH2),

45.9

(ethanesulfonamide

CH2),

26.6

(tetrahydroquinoline

C4),

22.6

(tetrahydroquinoline C3), 8.1 (ethylsulfonyl CH3), 8.0 (ethanesulfonamide CH3) ppm.
ESI-MS m/z 331.1(M-H). HRMS (ESI) calcd for C13H20N2O4S2 (M-H), 331.0786;
found, 331.0795. HPLC purity: 99.6%, Rt=10.071 (25% solvent D in solvent A).

N-(1-(Ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2,2,2-trifluoroethanesulfonamide
180

Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin7-amine 163 (240 mg, 1.0 mmol), 2,2,2-trifluoroethane-1-sulfonyl chloride (219 mg),
180 was isolated as a pale yellow solid (247 mg, 64%), mp: 78-79 ºC; IR (cm-1): υ 3236
(m, NH), 2951 (m, C-H aliphatic), 1244 (w, C-F), 1322 (s, SO2), 1126 (w, C-N). 1H
NMR, δ: 7.16 (s, 1H, tetrahydroquinoline_8 H), 7.24 (s, br, NH), 7.11 (d, J = 8.2 Hz,
1H, tetrahydroquinoline_5 H), 6.99 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.85
(q, J = 8.8 Hz, 2H, CF3CH2), 3.79 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.19
(q, J = 7.4 Hz, 2H, ethyl CH2), 2.83 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.02
(p, J = 5.5 Hz, 2H, tetrahydroquinoline_3 H), 1.36 (t, J = 7.4 Hz, 3H, CH3). 13C NMR,
δ:

138.3
270

(tetrahydroquinoline

C8a),

134.1

(tetrahydroquinoline

C7),

131.3
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(tetrahydroquinoline C5), 126.8 (tetrahydroquinoline C4a), 121.8 (q, J = 276.5 Hz,
CF3), 117.3 (tetrahydroquinoline C6), 114.9 (tetrahydroquinoline C8), 52.6 (q, J = 31.7
Hz,

CF3CH2),

47.2

(tetrahydroquinoline

C2),

46.8

(ethyl

CH2),

27.1

(tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 8.3 (CH3) ppm. ESI-MS m/z
385.1 (M-H). HRMS (ESI) calcd for C13H18F3N2O4S2 (MH+), 387.0660; found,
387.0664. HPLC purity: 99.9%, Rt=8.931 (20% solvent D in solvent A).

4-Methyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide
181

O
S

H
N

O S O
N

O

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride
(228.7 mg), 181 was isolated as a pale yellow solid (310 mg, 76%), mp: 112-113 ºC; IR
(cm-1): υ 3276 (w, NH), 2976 (m, C-H aliphatic), 1320 (s, SO2), 1125 (w, C-N). 1H
NMR, δ: 7.72 (d, J = 7.8 Hz, 2H, benzene_2,6 H), 7.54 (s, br, NH), 7.42 (s, 1H,
tetrahydroquinoline_8 H), 7.20 (d, J = 7.9 Hz, 2H, benzene_3,5 H), 6.95 (d, J = 8.0
Hz, 1H, tetrahydroquinoline_5 H), 6.86 (d, J = 8.0 Hz, 1H, tetrahydroquinoline_6 H),
3.72 (t, J = 5.6 Hz, 2H, tetrahydroquinoline_2 H), 2.99 (t, J = 7.4 Hz, 2H, propyl_1 H),
2.72 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.34 (s, 3H, p-CH3), 1.92 (p, J = 5.7
Hz, 2H, tetrahydroquinoline_3 H), 3.74 (sex, J = 7.4 Hz, 2H, propyl_2 H), 0.97 (t, J =
7.3 Hz, 3H, propyl_3 H). 13C NMR, δ: 143.9 (tetrahydroquinoline C8a), 137.8 (benzene
C4), 136.5 (benzene C1), 135.6 (tetrahydroquinoline C7), 130.6 (tetrahydroquinoline
C5), 129.8 (benzene C3, C5), 127.6 (benzene C2, C6), 125.1 (tetrahydroquinoline C4a),
116.9

(tetrahydroquinoline

C6),

114.0

(tetrahydroquinoline

C8),

53.9

(tetrahydroquinoline C2), 46.6 (propyl C1), 26.9 (tetrahydroquinoline C4), 22.7
(tetrahydroquinoline C3), 21.7 (benzene_4 CH3), 17.2 (propyl C2), 13.2 (propyl C3)
ppm. EI-MS m/z 408 (M+, 48), 301 (46), 237 (10), 145 (100%), 118 (45), 91 (81).
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HRMS (ESI) calcd for C19H25N2O4S2 (MH+), 409.1256; found, 409.1258. HPLC purity:
99.9%, Rt=6.809 (20% solvent D in solvent A).

4-Isopropyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide
182

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 4-isopropylbenzenesulfonyl
chloride (555.7 mg), 182 was isolated as pale yellow solid (344 mg, 79%), mp: 108-109
ºC; IR (cm-1): υ 3273 (m, NH), 2967 (m, C-H aliphatic), 1324 (s, SO2), 1126 (w, C-N).
1

H NMR, δ: 7.77 (d, J = 8.2 Hz, 2H, benzene_2,6 H), 7.42 (s, 1H,

tetrahydroquinoline_8 H), 7.28 (d, J = 8.0 Hz, 2H, benzene_3,5 H), 7.21 (s, br, NH),
6.96 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.85 (d, J = 8.2 Hz, 1H,
tetrahydroquinoline_6 H), 3.74 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.02 (t, J
= 7.6 Hz, 2H, propyl_1 H), 2.95-2.89 (m, 1H, CH(CH3)2), 2.74 (t, J = 6.4 Hz, 2H,
tetrahydroquinoline_4 H), 1.94 (p, J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.77 (sex,
J = 7.6 Hz, 2H, propyl_2 H), 1.22 (d, J = 6.8 Hz, 6H, CH(CH3)2), 0.98 (t, J = 7.5 Hz,
3H, propyl_3 H).

13

C NMR, δ: 154.5 (benzene C4), 137.7 (tetrahydroquinoline C8a),

136.8 (benzene C1), 135.5 (tetrahydroquinoline C7), 130.5 (tetrahydroquinoline C5),
127.6 (benzene C3, C5), 127.2 (benzene C2, C6), 124.9 (tetrahydroquinoline C4a),
116.6

(tetrahydroquinoline

C6),

113.8

(tetrahydroquinoline

C8),

53.9

(tetrahydroquinoline C2), 46.5 (propyl C1), 34.2 (CH(CH3)2), 26.8 (tetrahydroquinoline
C4), 23.7 (CH(CH3)2), 22.6 (tetrahydroquinoline C3), 17.1 (propyl C2), 13.1 (propyl
C3) ppm. EI-MS m/z 436 (M+, 33), 329 (30), 265 (8), 145 (100%), 119 (60), 91 (47).
HRMS (ESI) calcd for C21H29N2O4S2 (MH+), 437.1569; found, 437.1550. HPLC purity:
99.4%, Rt=5.180 (15% solvent D in solvent A).
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N-(1-(Propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-[1,1'-biphenyl]-4-sulfonamide*
183

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), [1,1'-biphenyl]-4-sulfonyl
chloride (303.2 mg), 183 was isolated as a reddish white solid (362 mg, 77%), mp: 118119 ºC; IR (cm-1): υ 3265 (m, NH), 2971 (w, C-H aliphatic), 1325 (s, SO2), 1125 (w, CN). 1H NMR, δ: 7.90 (d, J = 8.3 Hz, 2H, H2, H6), 7.57 (d, J = 8.3 Hz, 2H, H3, H5),
7.50 (d, J = 7.5 Hz, 2H, H8, H12), 7.46 (d, J = 1.3 Hz, 1H, tetrahydroquinoline_8 H),
7.42 (s, br, NH), 7.40 (d†, J = 7.7 Hz, 2H, H9, H11), 7.36 (t, J = 7.0 Hz, 1H, H10), 6.97
(d, J = 8.3 Hz, 1H, tetrahydroquinoline_5 H), 6.90 (dd, J = 8.2, 1.4 Hz, 1H,
tetrahydroquinoline_6 H), 3.71 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 3.00 (t, J
= 7.6 Hz, 2H, propyl _1 H), 2.70 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.91 (p,
J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.72 (sex, J = 7.6 Hz, 2H, propyl_2 H), 0.90
(t, J = 7.5 Hz, 3H, propyl_3 H).

13

C NMR, δ: 145.9 (C7), 139.4 (C4), 138.2

(tetrahydroquinoline C8a), 138.0 (C1), 135.6 (tetrahydroquinoline C7), 130.7 (C3, C5),
129.2 (tetrahydroquinoline C5),

128.7 (C2, C6),

128.2 (C9,

C11),

127.8

(tetrahydroquinoline C4a), 127.5 (C10), 125.5 (C8, C12), 117.1 (tetrahydroquinoline
C6), 114.4 (tetrahydroquinoline C8), 54.1 (tetrahydroquinoline C2), 46.7 (propyl C1),
27.0 (tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 17.3 (propyl C2), 13.1
(propyl C3) ppm. EI-MS m/z 470 (M+, 45), 363 (33), 299 (29), 253 (10), 207 (11), 145
(100%), 118 (62), 91 (31). HRMS (ESI) calcd for C24H27N2O4S2 (MH+), 471.1412;
found, 471.1407. HPLC purity: 98.8%, Rt=6.716 (20% solvent D in solvent A).

*

Numbering of the 1,1'-biphenyl carbons doesn’t correspond to the compound name.
† Apparent doublet.
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2-Fluoro-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide
184

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2-fluorobenzenesulfonyl chloride
(233.5 mg), 184 was isolated as red solid (284 mg, 69%), mp: 102-103 ºC; IR (cm-1): υ
3245 (w, NH), 2958 (m, C-H aliphatic), 1472 (w, C-F), 1331 (s, SO2), 1126 (w, C-N).
1

H NMR, δ: 7.55 (t, J = 7.6 Hz, 1H, benzene_4 H), 7.53 (q, J = 7.4 Hz, 1H, benzene_3

H), 7.42 (s, 1H, tetrahydroquinoline_8 H), 7.23-7.17 (m, 2H, benzene_5,6 H), 6.97 (d, J
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.94 (s, br, NH), 6.86 (d, J = 8.2 Hz, 1H,
tetrahydroquinoline_6 H), 3.72 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 2.95 (t, J
= 7.7 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.92 (p, J
= 6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.75 (sex, J = 7.7 Hz, 2H, propyl_2 H), 0.99
(t, J = 7.6 Hz, 3H, propyl_3 H).

13

C NMR, δ: 159.0 (d, J = 254.96 Hz, benzene C2),

137.9 (tetrahydroquinoline C8a), 135.6 (d, J = 8.38 Hz, benzene C4), 134.6
(tetrahydroquinoline C7), 131.3 (tetrahydroquinoline C5), 130.7 (tetrahydroquinoline
C4a), 127.1 (d, J = 13.07 Hz, benzene C1), 125.9 (tetrahydroquinoline C6), 124.7 (d, J
= 3.77 Hz, benzene C6), 117.3 (benzene C5), 117.1 (d, J = 20.47 Hz, benzene C3),
114.5 (tetrahydroquinoline C8), 53.9 (tetrahydroquinoline C2), 46.6 (propyl C1), 27.0
(tetrahydroquinoline C4), 22.6 (tetrahydroquinoline C3), 17.2 (propyl C2), 13.2 (propyl
C3) ppm. EI-MS m/z 412 (M+, 42), 305 (44), 145 (100%), 118 (60). HRMS (ESI) calcd
for C18H22FN2O4S2 (MH+), 413.1005; found, 413.1000. HPLC purity: 99.7%, Rt=8.117
(20% solvent D in solvent A).
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N-(1-(Propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)thiophene-2-sulfonamide 185

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), thiophene-2-sulfonyl chloride
(219 mg), 185 was isolated as an orange solid (268 mg, 67%), mp: 96-97 ºC; IR (cm-1):
υ 3288 (w, NH), 2976 (w, C-H aliphatic), 1335 (s, SO2), 1125 (w, C-N). 1H NMR, δ:
7.58 (d, J = 3.7 Hz, 1H, thiophene_5 H), 7.52 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.43
(s, 1H, tetrahydroquinoline_8 H), 7.18 (s, br, NH), 7.03 (d, J = 7.9 Hz, 1H,
tetrahydroquinoline_5 H), 7.00 (t, J = 4.2 Hz, 1H, thiophene_4), 6.92 (d, J = 8.1 Hz,
1H, tetrahydroquinoline_6), 3.75 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.02 (t, J
= 7.8 Hz, 2H, propyl_1 H), 2.77 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.96 (p, J
= 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.78 (sex, J = 7.6 Hz, 2H, propyl_2 H), 1.00
(t, J = 7.5 Hz, 3H, propyl_3 H).

13

C NMR, δ: 139.6 (thiophene C2), 137.6

(tetrahydroquinoline C8a), 134.8 (tetrahydroquinoline C7), 133.1 (thiophene C4), 132.4
(tetrahydroquinoline C5), 130.5 (thiophene C3), 127.4 (thiophene C5), 125.6
(tetrahydroquinoline C4a), 117.3 (tetrahydroquinoline C6), 114.5 (tetrahydroquinoline
C8), 53.7 (tetrahydroquinoline C2), 46.4 (propyl C1), 26.8 (tetrahydroquinoline C4),
22.5 (tetrahydroquinoline C3), 17.0 (propyl C2), 12.9 (propyl C3) ppm. EI-MS m/z 400
(M+, 24), 335 (25), 293 (17), 229 (61), 145 (100%), 118 (76). HRMS (ESI) calcd for
C16H21N2O4S3 (MH+), 401.0663; found, 401.0646. HPLC purity: 99.9%, Rt=8.586
(20% solvent D in solvent A).

275

Chapter 9

Experimental

2-Methyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide
186

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2-methylbenzenesulfonyl chloride
(228.7 mg), 186 was isolated as an orange oil (302 mg, 74%), IR (cm-1): υ 3244 (m,
NH), 2936 (m, C-H aliphatic), 1326 (s, SO2), 1130 (w, C-N). 1H NMR, δ: 7.98 (d, J =
7.7 Hz, 1H, benzene_6 H), 7.41 (t, J = 7.7 Hz, 1H, benzene_5 H), 7.35 (d, J = 2.0 Hz,
1H, tetrahydroquinoline_8 H), 7.27-7.24 (m, 3H, NH, benzene_3,4 H), 6.93 (d, J = 8.2
Hz, 1H, tetrahydroquinoline_5 H), 6.81 (dd, J = 8.2, 2.0 Hz, 1H, tetrahydroquinoline_6
H), 3.70 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.94 (t, J = 7.9 Hz, 2H, propyl_1
H), 2.70 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.65 (s, 3H, o-CH3), 1.90 (p, J =
6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.72 (sex, J = 7.6 Hz, 2H, propyl_2 H), 0.96 (t, J
= 7.4 Hz, 3H, propyl_3 H).

13

C NMR, δ: 137.8 (benzene C1), 137.7

(tetrahydroquinoline C8a), 137.5 (benzene C2), 135.4 (benzene C4), 133.2 (benzene
C5), 132.8 (tetrahydroquinoline C7), 130.7 (benzene C3), 130.4 (tetrahydroquinoline
C5), 126.4 (benzene C6), 124.9 (tetrahydroquinoline C4a), 116.2 (tetrahydroquinoline
C6), 113.5 (tetrahydroquinoline C8), 53.8 (tetrahydroquinoline C2), 46.6 (propyl C1),
26.9 (tetrahydroquinoline 4), 22.7 (tetrahydroquinoline C3), 20.6 (benzene_2 CH 3),
17.2 (propyl C2), 13.2 (propyl C3) ppm. EI-MS m/z 408 (M+, 40), 301 (36), 237 (10),
145 (96), 118 (55), 91 (100%). HRMS (ESI) calcd for C 19H25N2O4S2 (MH+), 409.1256;
found, 409.1252. HPLC purity: 99.7%, Rt=6.298 (20% solvent D in solvent A).
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3-Methyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide
187

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 3-methylbenzenesulfonyl chloride
(228.7 mg), 187 was isolated as a yellow oil (306 mg, 75%), IR (cm-1): υ 3256 (m, NH),
2934 (m, C-H aliphatic), 1324 (s, SO2), 1123 (m, C-N). 1H NMR, δ: 7.69 (s, 1H,
benzene_2 H), 7.61 (d, J = 6.4 Hz, 1H, benzene_6 H), 7.38 (s, 1H,
tetrahydroquinoline_8 H) 7.31-7.28 (m, 2H, benzene_4,5 H), 7.22 (s, br, NH), 6.96 (d, J
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.86 (dd, J = 8.2, 1.8 Hz, 1H,
tetrahydroquinoline_6 H), 3.72 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_2 H), 2.98 (t, J
= 7.6 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.6 Hz, 2H, tetrahydroquinoline_4 H), 2.34 (s,
3H, m-CH3), 1.92 (p, J = 6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.74 (sex, J = 7.6 Hz,
2H, propyl_2 H), 0.97 (t, J = 7.6 Hz, 3H, propyl_3 H).

13

C NMR, δ: 139.3

(tetrahydroquinoline C8a), 139.0 (benzene C3), 137.5 (benzene C1), 135.3
(tetrahydroquinoline C7), 133.7 (benzene C4), 130.4 (tetrahydroquinoline C5), 128.8
(benzene C5), 127.7 (tetrahydroquinoline C4a), 124.9 (benzene C6), 124.5 (benzene
C2),

116.8

(tetrahydroquinoline

C6),

113.9

(tetrahydroquinoline

C8),

53.7

(tetrahydroquinoline C2), 46.4 (propyl C1), 26.7 (tetrahydroquinoline C4), 22.5
(tetrahydroquinoline C3), 21.2 (benzene_3 CH3), 17.0 (propyl C2), 12.9 (propyl C3)
ppm. EI-MS m/z 408 (M+, 43), 301 (37), 237 (11), 145 (100%), 118 (60), 91 (95).
HRMS (ESI) calcd for C19H25N2O4S2 (MH+), 409.1256; found, 409.1236. HPLC purity:
99.5%, Rt=6.382 (20% solvent D in solvent A).
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2,4-Dimethyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7yl)benzenesulfonamide 188

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2,4-dimethylbenzenesulfonyl
chloride (245.5 mg), 188 was isolated as an orange oil (320 mg, 76%), IR (cm-1): υ 3277
(m, NH), 2973 (m, C-H aliphatic), 1322 (s, SO2), 1139 (m, C-N). 1H NMR, δ: 7.88 (d, J
= 8.0 Hz, 1H, benzene_6 H), 7.35 (d, J = 2.0 Hz 1H, tetrahydroquinoline_8 H), 7.33 (s,
1H, benzene_3 H), 7.06 (s, br, NH), 7.05 (d, J = 8.0 Hz, 1H, benzene_5 H), 6.92 (d, J =
8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.80 (dd, J = 8.5, 2.0 Hz, 1H,
tetrahydroquinoline_6 H), 3.72 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.95 (t, J
= 7.7 Hz, 2H, propyl_1 H), 2.71 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.61 (s,
3H, benzene_2 CH3), 2.31 (s, 3H, benzene_4 CH3),

1.91 (p, J = 6.0 Hz,

2H,

tetrahydroquinoline_3 H), 1.75 (sex, J = 7.7 Hz, 2H, propyl_2 H), 0.97 (t, J = 7.5 Hz,
3H, propyl_3 H).

13

C NMR, δ: 143.9 (benzene C1), 137.8 (benzene C2), 137.3

(tetrahydroquinoline C8a), 135.6 (benzene C4), 134.8 (benzene C5), 133.5
(tetrahydroquinoline C7), 130.6 (benzene C6), 130.6 (tetrahydroquinoline C5), 127.0
(tetrahydroquinoline C4a), 124.7 (benzene C3), 116.0 (tetrahydroquinoline C6), 113.3
(tetrahydroquinoline C8), 53.8 (tetrahydroquinoline C2), 46.6 (propyl C1), 26.9
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 21.5 (benzene_2 CH3), 20.5
(benzene_4 CH3), 17.2 (propyl C2), 13.2 (propyl C3) ppm. EI-MS m/z 422 (M+, 32),
315 (26), 251 (29), 145 (100%), 118 (33), 105 (30), 91 (17). HRMS (ESI) calcd for
C20H27N2O4S2 (MH+), 423.1412; found, 423.1399. HPLC purity: 99.9%, Rt=5.799
(20% solvent D in solvent A).
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3,5-Dimethyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7yl)benzenesulfonamide 189

Following

the

general

procedure

10

using

1-(propylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 3,5-dimethylbenzenesulfonyl
chloride (245.5 mg), 189 was isolated as an orange oil (324 mg, 77%), IR (cm-1): υ 3246
(m, NH), 2968 (m, C-H aliphatic), 1324 (s, SO2), 1146 (w, C-N). 1H NMR, δ: 7.48 (s,
2H, benzene_2,6 H), 7.42-7.40 (m, 2H, tetrahydroquinoline_8 H, benzene_4 H), 7.11 (s,
br, NH), 6.95 (d, J = 8.3 Hz, 1H, tetrahydroquinoline_5 H), 6.85 (dd, J = 8.2, 1.70 Hz,
1H, tetrahydroquinoline_6 H), 3.72 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.99
(t, J = 7.7 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.29
(s, 6H, benzene_3,5 CH3), 1.92 (p, J = 6.0 Hz, 2H, tetrahydroquinoline_3 H), 1.75
(sex, J = 7.6 Hz, 2H, propyl_2 H), 0.97 (t, J = 7.5 Hz, 3H, propyl_1 H).

13

C NMR, δ:

138.9 (tetrahydroquinoline C8a), 138.8 (benzene C3, C5), 137.5 (benzene C1), 135.3
(tetrahydroquinoline C7), 134.5 (benzene C4), 130.3 (tetrahydroquinoline C5), 124.9
(tetrahydroquinoline C4a), 124.7 (benzene C2, C6), 116.5 (tetrahydroquinoline C6),
113.6 (tetrahydroquinoline C8), 53.6 (tetrahydroquinoline C2), 46.3 (propyl C1), 26.6
(tetrahydroquinoline C4), 22.5 (tetrahydroquinoline C3), 21.1 (benzene_3,5 CH 3), 16.9
(propyl C2), 12.9 (propyl C3) ppm. EI-MS m/z 422 (M+, 40), 315 (38), 251 (20), 207
(17), 145 (100%), 118 (27), 105 (29). HRMS (ESI) calcd for C20H27N2O4S2 (MH+),
423.1412; found, 423.1396. HPLC purity: 99.9%, Rt=5.503 (20% solvent D in solvent
A).
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2,3,4,5,6-Pentamethyl-N-(1-(propylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)
benzenesulfonamide 190

Following

the

general

tetrahydroquinolin-7-amine

procedure
167

10

(254

using
mg,

1-(propylsulfonyl)-1,2,3,41.0

mmol),

2,3,4,5,6-

pentamethylbenzenesulfonyl chloride (296 mg), 190 was isolated as a yellow solid (371
mg, 80%), mp: 128-129 ºC; IR (cm-1): υ 3266 (m, NH), 2937 (m, C-H aliphatic), 1315
(s, SO2), 1130 (w, C-N). 1H NMR, δ: 7.21 (s, 1H, tetrahydroquinoline_8 H), 6.92 (d, J
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.92 (s, br, NH), 6.70 (d, J = 8.2, 1H,
tetrahydroquinoline_6 H), 3.71 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 2.84 (t, J
= 7.8 Hz, 2H, propyl_1 H), 2.71 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.58 (s,
6H, benzene_2,6 CH3), 2.24 (s, 3H, benzene_4 CH3), 2.21 (s, 6H, benzene_3,5 CH3),
1.91 (p, J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.67 (sex, J = 7.6 Hz, 2H, propyl_2
H), 0.93 (t, J = 7.4 Hz, 3H, propyl_3 H).

13

C NMR, δ: 139.8 (benzene C2, C6), 137.5

(tetrahydroquinoline C8a), 135.9 (benzene C3, C5), 135.4 (benzene C4), 134.9
(tetrahydroquinoline C7), 134.4 (tetrahydroquinoline C5), 130.4 (tetrahydroquinoline
C4a), 124.6 (benzene C1), 116.4 (tetrahydroquinoline C6), 113.6 (tetrahydroquinoline
C8), 53.4 (tetrahydroquinoline C2), 46.4 (propyl C1), 26.8 (tetrahydroquinoline C4),
22.5 (tetrahydroquinoline C3), 19.0 (benzene_2,6 CH3), 17.8 (benzene_3,5 CH3), 17.1
(benzene_4 CH3), 16.9 (propyl C2), 12.9 (propyl C3) ppm. EI-MS m/z 464 (M+, 29),
293 (66), 254 (16), 147 (100%). HRMS calcd for C23H33N2O4S2 (MH+), 465.1882;
found, 465.1881. HPLC purity: 99.9%, Rt=5.024 (15% solvent D in solvent A).
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N-(1-(Thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)thiophene-2-sulfonamide
191

Following

the

general

procedure

10

using

1-(thiophen-2-ylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 168 (294 mg, 1.0 mmol), thiophene-2-sulfonyl chloride
(219 mg), 191 was isolated as a white solid (264 mg, 60%), mp: 108-109 ºC; IR (cm-1):
υ 3259 (m, NH), 2965 (w, C-H aliphatic), 1339 (s, SO2), 1122 (w, C-N). 1H NMR, δ:
7.60 (d, J = 3.4 Hz, 1H, thiophen-2-yl_5 H), 7.55 (d, J = 4.9 Hz, 1H, thiophene_5 H),
7.50 (d, J = 4.9 Hz, 2H, thiophen-2-yl_3 H, thiophene_3 H), 7.35 (d, J = 3.3 Hz, 1H,
thiophen-2-yl_4 H), 7.26 (s, br, NH), 7.06-6.96 (m, 3H, tetrahydroquinoline_5,6 H,
thiophene_4 H), 6.76 (s, 1H, tetrahydroquinoline_8H), 3.79 (t, J = 5.8 Hz, 2H,
tetrahydroquinoline _2 H), 2.46 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.66 (p, J
= 6.0 Hz, 2H, tetrahydroquinoline _3 H). 13C NMR, δ: 139.5 (tetrahydroquinoline C8a),
139.2 (thiophene C1), 136.9 (thiophen-2-yl C1), 134.6 (tetrahydroquinoline C7), 133.3
(tetrahydroquinoline C5), 132.5 (thiophene C4), 132.4 (thiophen-2-yl C3), 132.3
(thiophene C3), 130.1 (thiophen-2-yl C4), 128.0 (thiophen-2-yl C5), 127.5 (thiophene
C5), 127.4 (tetrahydroquinoline C4a), 118.9 (tetrahydroquinoline C6), 117.7
(tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 26.4 (tetrahydroquinoline C4),
21.3 (tetrahydroquinoline C5) ppm. EI-MS m/z 440 (M+, 29), 376 (26), 312 (38), 229
(80), 145 (100%), 118 (78), 91 (55). HRMS (ESI) calcd for C17H17N2O4S4 (MH+),
441.0071; found, 441.0068. HPLC purity: 99.9%, Rt=9.126 (20% solvent D in solvent
A).
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4-Methyl-N-(1-(thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)
benzenesulfonamide 192

S
O H
N
S
O

Following

the

O S O
N

general

procedure

10

using

1-(thiophen-2-ylsulfonyl)-1,2,3,4-

tetrahydroquinolin-7-amine 168 (294 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride
(228.7 mg), 192 was isolated as a yellow solid (291 mg, 65%), mp: 119-120 ºC; IR (cm1

): υ 3236 (m, NH), 2948 (w, C-H aliphatic), 1318 (s, SO2), 1129 (w, C-N). 1H NMR, δ:

7.74 (d, J = 8.1 Hz, 2H, benzene_2,6 H), 7.50 (s, 1H, tetrahydroquinoline_8 H), 7.48 (d,
J = 4.8 Hz, 1H, thiophene_5 H), 7.28 (d, J = 3.1 Hz, 1H, thiophene_3 H), 7.23 (d, J =
8.0 Hz, 2H, benzene_3,5 H), 6.97-6.91 (m, 3H, tetrahydroquinoline_5,6 H, thiophene_4
H), 6.89 (s, br, NH), 3.77 (t, J = 6.1 Hz, 2H, tetrahydroquinoline_2 H), 2.43 (t, J = 6.4
Hz, 2H, tetrahydroquinoline_4 H), 2.36 (s, 3H, p-CH3), 1.65 (p, J = 6.1 Hz, 2H,
tetrahydroquinoline_3 H).

13

C NMR, δ: 143.8 (tetrahydroquinoline C8a), 139.2

(thiophene C2), 136.8 (benzene C4), 136.2 (benzene C1), 135.0 (tetrahydroquinoline
C7), 132.3 (tetrahydroquinoline C5), 132.1 (thiophene C3), 129.9 (thiophene C4), 129.5
(thiophene C5), 127.3 (benzene C3, C5), 127.3 (tetrahydroquinoline C4a), 127.2
(benzene C2, C6), 118.3 (tetrahydroquinoline C6), 117.2 (tetrahydroquinoline C8), 46.8
(tetrahydroquinoline C2), 26.3 (tetrahydroquinoline C4), 21.6 (tetrahydroquinoline C3),
21.3 (benzene_4 CH3) ppm. EI-MS m/z 448 (M+, 24), 384 (17), 319 (26), 229 (99), 146
(100%), 118 (53), 91 (80). HRMS (ESI) calcd for C20H21N2O4S3 (MH+), 449.0663;
found, 449.0645. HPLC purity: 99.8%, Rt=7.260 (20% solvent D in solvent A).

282

Chapter 9

Experimental

N-(1-Tosyl-1,2,3,4-tetrahydroquinolin-7-yl)thiophene-2-sulfonamide 193

Following the general procedure 10 using 1-tosyl-1,2,3,4-tetrahydroquinolin-7-amine
169 (302 mg, 1.0 mmol), thiophene-2-sulfonyl chloride (219 mg), 193 was isolated as a
pale yellow solid (287 mg, 64%), mp: 68-69 ºC; IR (cm-1): υ 3255 (m, NH), 2951 (w,
C-H aliphatic), 1329 (s, SO2), 1132 (w, C-N). 1H NMR, δ: 7.60 (d, J = 3.8 Hz, 1H,
thiophene_5 H), 7.55 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.51 (d, J = 1.7 Hz, 1H,
tetrahydroquinoline_8 H), 7.41 (d, J = 8.0 Hz, 2H, tosyl_2,6 H), 7.18 (d, J = 8.1 Hz,
2H, tosyl_3,5 H), 7.02 (t, J = 4.0 Hz, 1H, thiophene_4 H), 7.00 (dd, J = 7.9, 1.7 Hz, 1H,
tetrahydroquinoline_6 H), 6.92 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.83 (s,
br, NH), 3.75 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_2 H), 2.42 (t, J = 6.6 Hz, 2H,
tetrahydroquinoline_4 H), 2.38 (s, 3H, p-CH3), 1.59 (p, J = 6.2 Hz, 2H,
tetrahydroquinoline_3

H).

13

C

NMR,

δ:

143.8

(thiophene

C2),

139.5

(tetrahydroquinoline C8a), 137.5 (tosyl C4), 136.5 (tetrahydroquinoline C7), 134.5
(tosyl C1), 133.3 (tetrahydroquinoline C5), 132.4 (thiophene C4), 129.9 (thiophene C3),
129.7 (tosyl C3, C5), 127.6 (thiophene C5), 127.4 (tosyl C2, C6), 127.1
(tetrahydroquinoline C4a), 118.5 (tetrahydroquinoline C6), 117.5 (tetrahydroquinoline
C8),

46.5

(tetrahydroquinoline

C2),

26.3

(tetrahydroquinoline

C4),

21.6

(tetrahydroquinoline C3), 21.3 (CH3) ppm. EI-MS m/z 448 (M+, 16), 320 (19), 229
(18), 207 (22), 145 (100%) 118 (60), 91 (85). HRMS (ESI) calcd for C20H21N2O4S3
(MH+), 449.0663; found, 449.0655. HPLC purity: 98.9%, Rt=19.993 (15% solvent D in
solvent A).
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4-Methyl-N-(1-tosyl-1,2,3,4-tetrahydroquinolin-7-yl)benzenesulfonamide 194

Following the general procedure 10 using 1-tosyl-1,2,3,4-tetrahydroquinolin-7-amine
169 (302 mg, 1 mmol), 4-methylbenzenesulfonyl chloride (228.7 mg), 194 was isolated
as a white solid (296 mg, 65%), mp: 148-149 ºC; IR (cm-1): υ 3232 (m, NH), 2921 (w,
C-H aliphatic), 1326 (s, SO2), 1157 (w, C-N). 1H NMR, δ: 7.75 (d, J = 8.1 Hz, 2H,
benzene_2,6 H), 7.51 (d, J = 2.1 Hz, 1H, tetrahydroquinoline_8 H), 7.37 (d, J = 8.1 Hz,
2H, benzene_3,5 H), 7.23 (d, J = 8.1 Hz, 2H, tosyl_2,6 H), 7.14 (d, J = 8.1 Hz, 2H,
tosyl_3,5 H), 7.01 (s, br, NH), 6.93 (dd, J = 8.0, 1.9 Hz, 1H, tetrahydroquinoline_6 H),
6.86 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 3.73 (t, J = 5.9 Hz, 2H,
tetrahydroquinoline_2 H), 2.39-2.36 (m, 5H, tetrahydroquinoline_4 H, benzene_4 CH3),
2.35 (s, 3H, tosyl_CH3), 1.57 (p, J = 5.9 Hz, 2H, tetrahydroquinoline_3 H).

13

C NMR,

δ: 143.7, 143.6, 137.4, 136.5, 136.2, 134.9, 129.9 (tetrahydroquinoline C5), 129.7,
129.6, 127.5, 127.1, 126.9 (tetrahydroquinoline C6), 117.9 (tetrahydroquinoline C8),
116.9,

46.5

(tetrahydroquinoline

C2),

26.2

(tetrahydroquinoline

C4),

21.6

(tetrahydroquinoline C3), 21.5 (benzene_4 CH3), 21.3 (tosyl_CH3) ppm. EI-MS m/z 456
(M+, 30), 327 (27), 301 (33), 237 (24), 207 (19), 145 (100%), 118 (37), 91 (73). HRMS
(ESI) calcd for C23H25N2O4S2 (MH+), 457.1256; found, 457.1242. HPLC purity: 99.4%,
Rt=13.965 (15% solvent D in solvent A).

9.2. In Silico experiments
9.2.1. CHIKV non-structural protein 2 (nsP2)
The CHIKV nsP2 crystal structure (PDB: 3TRK) was used for the virtual screening
study. The virtual screening study was performed on both nsP2 sites (the domain C
site_1 and the domain N site_2) using the Life chemicals cysteine protease inhibitors
library (28,960 compounds). This cysteine protease inhibitors library was designed
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using Ligand based approach – first, a set of 585 compounds active in assays related to
cysteine proteases was assembled. And then, Life Chemicals collection was searched
for compounds similar to the reference dataset using MDL public keys and the
Tanimoto similarity cut-off of 85% to generate a library of 28,960 compounds. Omega2
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com),235,

236

was

used to generate multiple conformers for each compound in the cysteine protease
inhibitors library, using the default settings, generating 3,349,162 conformers. The
binding sites were prepared for docking using Fred receptor setup software (OpenEye
Scientific Software, Santa Fe, NM. http://www.eyesopen.com). The binding sites were
detected using the molecular detection method within Fred receptor setup software,
where the method detection uses multiple molecular probes rather than a single carbon
probe to determine areas of the protein where docking is likely to occur. These probes
are docked using a shape based potential, and regions where multiple probes dock are
considered favourable. This type of site based detection is slow, it can take several
minutes, but detects few sites that are in general of higher quality than atomic probe
detection method.
For the C domain site_1, the binding site detected within the C domain had a
size of 8321 Å3, an inner contour of 119 Å3 and an outer contour of 2023 Å3. For the N
domain site_2, the binding site had a box size of 9394 Å3, an inner contour of 69 Å3 and
an outer contour of 2748 Å3. As a blind docking, no constraints were enabled within
these sites, with any of the amino acid residues.
Fast exhaustive virtual screening was performed using FRED v2.2.5 (OpenEye
Scientific Software, Santa Fe, NM. http://www.eyesopen.com). During the docking
calculations, chemgauss3 scoring functions was enabled. After the docking calculations,
the poses returned were scored and ranked with a Gaussian shape function
independently by the five available scoring functions (PLP, Chemgauss3, Chemscore,
OEChemscore, and Screenscore) and by a consensus of all. The top ranked poses from
the exhaustive docking were then optimized using systematic solid body optimization
by

chemgauss3.

VIDA

v4.2.0

(OpenEye

Scientific

Software,

Santa

Fe,

NM. http://www.eyesopen.com) was used to visualise the docked poses within the
receptor active site, and to inspect the critical interacting residues in each pocket with
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the individual docked poses. Top 25 hits were then recorded for each of the two sites
(Tables 5.1, 5.4).
The top 25 docked poses ranked in each of the two binding sites (site_1, site_2)
were then extracted as PDB files, and were processed with AutoDock Tools 1.5.6rc3
(ADT) graphical interface.173 The Gasteiger charges were computed and the nonpolar
hydrogen atoms were merged, torsion angles were defined, they were then saved as
pdbqt files for Autodock calculations. The crystal structure 3TRK was used by ADT to
setup the binding sites. For the C domain site_1, the grid box x, y and z coordinates
were 11.779, 31.511 and 29.546, respectively. The grid spacing was set to 0.375 Å. The
grid box size was set to 42 x 42 x 42 points in x, y, and a z direction. For the N domain
site_2, the grid box x, y and z coordinates were 3.366, 28.678 and 21.482 respectively.
The grid box size was set to 42 x 42 x 42 points in x, y, and a z direction, with grid
spacing of 0.375 Å. AutoGrid 4.2 algorithm was used to evaluate the binding energies
between the inhibitors and the enzyme and to generate the energy maps for the docking
run. Fifty runs were generated by using Autodock 4.2 Lamarckian genetic algorithm173
for the searches. Cluster analysis was performed on docked results, with a root-meansquare tolerance of 1.0, 2.0 and 3.0 Å, the docked poses were ranked according to the
binding energies and ligand efficiencies, and finally the five lowest energy poses
(Tables 5.2, 5.3, 5.5, 5.6) were selected as the resultant complexes with the enzymes.
The complexes were then typed with the CHARMm forcefield with Discovery Studio
3.5 software (Accelrys Software Inc.: San Diego, CA, 2012) to relax the obtained poses
within the enzyme pockets, and visualized.

9.2.2. CHIKV envelope proteins
9.2.2.1. Identification of novel binding sites
Both the crystal structure of the immature complex (PDB file: 3N4095) and the mature
complex (PDB file: 3N4295) were used. Binding sites within the receptors were detected
using the Discovery Studio 3.5 software (Accelrys Software Inc.: San Diego, CA,
2012). The algorithm is based on a grid search and "eraser" algorithm which derives
binding sites from cavities in the structure of the receptor. The binding site found is
displayed as a set of points. The volume of each cavity is defined as the product of
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number of site points and the cube of the grid spacing. Six main sites were detected in
both the immature and the mature crystal structures and only one site were detected in
the mature crystal structure that is not present in the immature form (Figure 6.2). Table
1 shows the identified sites with their characters. Suitable cavities were then checked
further based on functionality, presence of hydrophobic residues, presence of charged
residues and solvent accessibility.
9.2.2.2. Virtual screening with the CHIKV envelope proteins
Two chemical compounds libraries were used; The NCI set library of 265,242
compounds and the Life chemicals protein-protein interactions inhibitors library of
31,143 compounds. The databases were filtered with the drug-likeness-index; limit the
range for Molecular Weight < 500, calculated octanol–water partition coefficient (clogP
< 5), and hydrogen bond donors, and acceptors (OH’s and NH’s < 5; N’s and O’s <
10),231

using

Filter

v2.0.2

(OpenEye

Scientific

Software,

Santa

Fe,

NM. http://www.eyesopen.com), producing 55,841 compounds from the NCI library
and 4,124 compounds from the Life Chemicals library. Fast exhaustive virtual screening
was performed using FRED v2.2.5 (OpenEye Scientific Software, Santa Fe,
NM. http://www.eyesopen.com). FRED is a fast and effective docking application
whose performance is significantly more reliable, i.e. lower variance, than most other
programs.232, 233 FRED performs a systematic, exhaustive, nonstochastic examination of
all possible poses within the protein active site, filters for shape complementarily 234 and
pharmacophoric features before selecting and optimizing poses using the Chemgauss
scoring function. Omega2 (Systematic high-throughput conformer generation, OpenEye
Scientific Software, Santa Fe, NM. http://www.eyesopen.com),235,

236

was used to

generate multiple conformers for each compound in the database libraries using the
default settings. Omega2 takes into account the ﬂexibility of a molecule by generating
all representative conformers. For the NCI library, 2,312,012 conformers were
generated, and 334,064 conformers were generated from the Life Chemicals
compounds. The work-flow diagram is shown in (Figure 6.3), the life chemical library
was screened on site 2 (light green, Figure 6.2) in both of the immature and the mature
glycoproteins. The NCI set compounds were screened on site 4 (blue, Figure 6.2) of the
two envelope protein forms. The binding sites were prepared for docking using Fred
receptor
287

setup

software

(OpenEye
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NM. http://www.eyesopen.com). The grid boxes were determined based on the x, y and
z co-ordinates given in Table 1. For site 2 in the 3N40 receptor, the box size was set to
6153 Å3 and was assigned an inner contour of 99 Å3 and an outer contour of 1886 Å3.
Site 4 in the 3N40 receptor has a box size of 6580 Å3 and was assigned an inner contour
of 116 Å3 and an outer contour of 1071 Å3. Site 2 in 3N42 receptor has a box size of
7578 Å3 and was assigned an inner contour of 66 Å3 and an outer contour of 1816 Å3.
Site 4 in 3N42 receptor was assigned a box size of 6482 Å3, an inner contour of 45 Å3
and an outer contour of 1547 Å3. No constraints were enabled in any of the prepared
receptors. During the docking calculations, both chemgauss3 and shapeguass scoring
functions were enabled. After the docking calculations, the poses returned were scored
and ranked with a Gaussian shape function independently by the five available scoring
functions (PLP, Chemgauss3, Chemscore, OEChemscore, and Screenscore) and by a
consensus of all. The top ranked poses from the exhaustive docking were then
optimized using systematic solid body optimization by chemgauss3. VIDA v4.2.0
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com) was used to
visualise the docked poses within the receptor active site, and to inspect the critical
interacting residues in each pocket with the individual docked poses. Top 20 hits were
then recorded for each of the four sites (Tables 6.2, 6.5, 6.8, 6.11).
The top 20 docked poses ranked in each of the four binding sites were then
extracted as PDB files, and were processed with AutoDock Tools 1.5.6rc3 (ADT)
graphical interface.173 The Gasteiger charges were computed and the nonpolar hydrogen
atoms were merged, torsion angles were defined, they were then saved as pdbqt files for
Autodock calculations. Crystal structures (3N40, 3N42) were used by AutoDock Tools
1.5.6rc3 to setup the receptor binding sites. The grid box co-ordinates in each site were
determined based on the co-ordinates in Table 6.1. The grid box size was set to 46 x 46
x 46 points in x, y, and a z direction in each of the four sites and a grid spacing of 0.375
Å was used. AutoGrid 4.2 algorithm was used to evaluate the binding energies between
the inhibitors and the enzyme and to generate the energy maps for the docking run. Fifty
runs were generated by using Autodock 4.2 Lamarckian genetic algorithm173 for the
searches. Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 2.0 Å, the docked poses were ranked according to the binding energies and
ligand efficiencies, and finally the five lowest energy poses (Tables 6.3, 6.4, 6.6, 6.7,
6.9, 6.10, 6.12, 6.13) were selected as the resultant complexes with the enzymes. The
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complexes were then typed with the CHARMm forcefield with Discovery Studio 3.5
software (Accelrys Software Inc.: San Diego, CA, 2012) to relax the obtained poses
within the enzyme pockets, and visualized.

9.2.3. CHIKV non-structural protein 3 (nsP3)
9.2.3.1. Virtual screening with Autodock Vina
The CHIKV nsP3 macro domain crystal structure was downloaded from the protein
data bank (RCSB), PDB code: 3GPO.80 Autodock Tools 1.5.6rc3 (ADT) graphical
interface173 was used to prepare the receptor, where waters were removed, non-polar
hydrogens were merged and polar hydrogens were added. The Kollman charges were
added and the Gasteiger charges were calculated for the receptor. The grid box coordinates were determined according to the co-crystallized ligand (ADPribose) where x,
y and z values were 29.642, 29.232 and 21.592, respectively. The grid box size was set
to 32 x 32 x 32 Å, with a grid spacing of 0.375 Å. The receptor was then saved as a
pdbqt file, and was ready for the virtual screening run.
The NCI Diversity Set III 1990 compounds’ library was downloaded from the
NCI website (http://cactus.nci.nih.gov/download/nci/). Compounds were energy
minimized using the Uff forcefield267 embedded within the Open Babel of PyRx
(Scripps research institute, http://pyrx.sourceforge.net/), with 100,000 steps where the
minimization stopped when the energy difference was less than 0.001. The minimized
structures were then converted to the pdbqt format using Autodock Tools 1.5.6rc3
(ADT).173
Autodock Vina was used to dock each compound in the library within the nsP3
binding site, using an exhaustiveness (number of runs) value of 125. The docked poses
were then ranked according to the Vina binding energies (Kcal/mol). Top poses ranked
that achieved better binding energies than the co-crystallized ligand (ADP-ribose), were
extracted, complexed with the receptor (nsP3). The complexes were then typed with the
CHARMm forcefield with Discovery Studio 3.5 software (Accelrys Software Inc.: San
Diego, CA, 2012) to relax the obtained poses within the enzyme pocket, and visualized.
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9.2.3.2. Re-ranking using Autodock 4
The Autodock Vina hit list poses (Table 3.1) were extracted as pdbqt files by (ADT).
The CHIKV nsP3 receptor that was prepared for Autodock Vina was re-used for
Autodock 4. AutoGrid 4.2 algorithm was used to evaluate the binding energies between
the inhibitors and the enzyme and to generate the energy maps for the docking run. Fifty
runs were generated by using Autodock 4.2 Lamarckian genetic algorithm173 for the
searches. Cluster analysis was performed on docked results, with a root-mean-square
tolerance of 1.0, 2.0 and 3.0 Å, the docked poses were ranked according to the binding
energies and ligand efficiencies, and finally, the survived lowest energy poses (Table
3.2) were selected as the resultant complexes with the enzyme. The complexes were
then typed with the CHARMm forcefield with Discovery Studio 3.5 software (Accelrys
Software Inc.: San Diego, CA, 2012) to relax the obtained poses within the enzyme
pocket, and visualized.

9.3. Biological evaluation
9.3.1. Anti-Chikungunya evaluations
Currently, the synthetic compounds 114-117, 120, 121, 126, 127, 130, 131, 137, 138,
140-143 and 145-147, along with the CHIKV nsP2 data base searching hits (Tables 5.3
and 5.6) are being evaluated for their anti-CHIKV activity including virus-cell-based
CPE reduction and cytotoxicity assays (with the standard deviations). Testing is being
conducted at Rega Institute for Medical Research, University of Leuven (KU Leuven),
Belgium, with Prof. Johan Neyts and Dr. Peiter Leyssen.
The NCI hits (Table 3.1) are being evaluated against the CHIKV by Professor Suresh
Mahalingam, Emerging Viruses and Inflammation Research Group, Institute for
Glycomics, Griffith University, Gold Coast, QLD, Australia, 4222.
9.3.2. Trypanocidal activity evaluation
9.3.2.1. Initial screen
The bis-sulfonamide compounds 160, 170-194 were resuspended in the appropriate
volume of 100% DMSO to give a stock solution of 21 mM. Initially all compounds
290

Chapter 9

Experimental

were screened at doses of 10.43 µM and 1.4 µM against T. b. brucei, to give an
indication of the compounds trypanocidal activity. The compounds were screened once
against two separate trypanosome populations, designated culture A and culture B.
Compounds with >80% activity at 10.43 µM and >50% activity at 1.4 µM were
classified as active. Using these selection criteria, active compounds were selected for
IC50 and selectivity index (SI) determination.

9.3.2.2. Assay controls
Positive in-plate controls in wells G2-O23 contained 0.417% final DMSO
concentration. The in-plate controls were used to calculate the activity of compounds
whilst taking into account any plate-to-plate variability in the signal of the assay. Two
types of external control plates were included for each trypanosome population. To
calculate the assay Z’, a plate containing minimum and maximum assay signals was
used. For calculation of the minimum signal, or 100% inhibition of cell growth, 36.45
μM final concentration puromycin was placed in half of the plate. To calculate the
maximum signal, 0.42% DMSO was placed in the second half of the plate. The Z’
prime was 0.57 and 0.72 for culture A and B respectively.
As a measure of the sensitivity of each assay, a plate containing dose response
dilutions of the reference compounds pentamidine, diminazene aceturate and puromycin
was used. Puromycin gave IC50 values of 54.78 nM and 73.69 nM for culture A and B,
respectively. Pentamidine exhibited an IC50 value of 1.6 nM and 2.44 nM for culture A
and B respectively. Diminazene aceturate had an IC50 value of 103.8 nM and 155.2 nM.
9.3.2.3. IC50 and selectivity index determination
The compounds were screened against T. b. brucei and HEK 293 in 20 point dose CRC
format. The highest dose of 83.33 μM was only used in the HEK293 assay. This
allowed the selectivity index of the compounds to be estimated. The compounds were
screened in duplicate against two separate cultures (designated A and B) of both T.
brucei and HEK 293. The IC50 and SI was determined for compounds with greater than
>80% activity at 41.67 μM in the T. b. brucei assay. The SI of the compound was
determined where possible by directly comparing the IC50 values between the two
assays. If this was not possible, an estimated IC50 value was calculated by comparing
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the dose at which the compound was active >50% in the T. brucei assay and the lowest
dose at which there was no activity (<50%) in the HEK293 assay.
Assay controls: Positive in-plate controls in column 23 (rows B-O) contained 0.417%
final DMSO concentration. The in-plate controls were used to calculate the activity of
compounds whilst taking into account any plate-to-plate variability in the signal of the
assay. Two types of external control plates were included for each of the two cell
populations in the T. b. brucei and HEK 293 assay. To calculate the assay Z’, a plate
containing minimum and maximum assay signals was used. For calculation of the
minimum signal, or 100% inhibition of cell growth, 36.45 μM final puromycin was
placed in half of the plate. To calculate the maximum signal, 0.42% DMSO was placed
in the second half of the plate. The Z’ prime was 0.63 and 0.72 for culture A and B in
the T. brucei assay respectively. In the HEK 293 assay the Z’ prime was 0.69 for culture
A and 0.56 for culture B. As a measure of the sensitivity of each assay, a plate
containing dose response dilutions of the reference compounds pentamidine,
diminazene aceturate and puromycin was used. In the T. brucei assay Puromycin gave
IC50 values of 43.6 nM and 47.62 nM for culture A and B, respectively. Pentamidine
exhibited an IC50 value of 1.58 nM and 1.78 nM for culture A and B respectively.
Diminazene aceturate had an IC50 value of 94.6 nM and 88.9 nM. In the HEK 293
assay, Puromycin gave IC50 values of 165.3 nM and 225.7 nM for culture A and B,
respectively. Pentamidine and diminazene aceturate exhibited no activity in the HEK
293 assay.
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